Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1r_wp271

Request ID: cder_mpl1r_wp271_nsdp_v01

Requester: Center for Drug Evaluation and Research (CDER)

Request Description: In this report, we counted and described individuals in the Sentinel Distributed Database (SDD) with evidence of coronavirus disease 2019 (COVID-19) vaccinations. We identified individuals with at least one COVID-19 vaccination and calculated the timing between doses, overall and by brand. We additionally identified individuals with at least two COVID-19 vaccinations and characterized the timing between doses. We finally identified individuals with evidence of a booster COVID-19 vaccination.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 13.0.1

Data Source: We distributed this request to 14 Sentinel Data Partners (DPs) on May 17, 2024. The study period included data from November 1, 2020, to the January 31, 2024. Please see Appendix A for a list of available data dates for each Data Partner.

Study Design: We identified individuals of all ages in the Sentinel Distributed Database who received COVID-19 vaccines. This is a Type 2 analysis in the Query Request Package (QRP) documentation. We conducted these analyses in four separate runs:

Run 1: We examined patients who received at least one COVID-19 vaccine overall and stratified by age group, sex, year, calendar month, geographic region, and year-month-age group. We characterized the demographic and clinical characteristics of this cohort. We also summarized the time interval between the first and second doses.

Run 2: We examined patients who received at least two COVID-19 vaccines overall and stratified by sex, U.S. State and territory, and year-month-age group. We characterized the demographic and clinical characteristics of this cohort. We also summarized the time interval between the first and second doses.

Run 3: We examined patients who received at least one COVID-19 vaccine by vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax, or unspecified]) or by data source (only immunization information systems [IIS] data, only claims data, or both IIS and claims data). We summarized the time interval between first and second doses for all possible combinations of brand or data source.

Run 4: We examined the number of patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021. We defined boosters using four different cohorts:

Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
Cohort 2: Individuals with a history of an immunocompromising condition, and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
Cohort 3: Individuals without a history of an immunocompromising condition, and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

We examined the overall patient count in each cohort. Cohort 1 was further stratified by sex, geographic region, and year-month-age group. For this cohort, we additionally described the demographic and clinical characteristics.

Exposures of Interest: Our exposure of interest was any brand and type of COVID-19 vaccine administered or dispensed in any care setting in the United States (Pfizer-BioNTech, Moderna, Janssen, Novavax, or unspecified). These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, National Drug Codes (NDCs), and IIS Vaccine Administered Code Set (CVX)[1] codes. Please see Appendix B for a list of non-proprietary and proprietary names of medical products, Appendix B.1 for a list of NDCs, and Appendix C for a list of procedure codes used to define exposures in this request.
We included only the first valid index date during the query period for each patient; cohort re-entry was not allowed. If more than one vaccine code appeared on the index day, the patient still only contributed one exposure episode, but all codes were taken into account for brand and data source analyses. Additional details on exposures and index dates for each run are defined below:

Overview for Request: cder_mpl1r_wp271

Run 1: The index date was the date of the first COVID-19 vaccine. The first COVID-19 vaccination was identified as the first instance without any previous COVID-19 vaccination records.
Run 2: The index date was the date of the first COVID-19 vaccine. The first COVID-19 vaccination was identified as the first instance without any previous COVID-19 vaccination records. Individuals were also required to have evidence of a second dose at least four days after the index date.
Run 3: The index date was the date of the first COVID-19 vaccine with a given brand or data source for a given cohort. The first COVID-19 vaccination was identified as the first instance without any previous COVID-19 vaccination records. We included 16 cohorts based on brand combinations for first and second dose (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for first and second dose (Only IIS-Only IIS, Only IIS-IIS&Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS&Claims, Only Claims-Only IIS, IIS&Claims-Only IIS, IIS&Claims-Only Claims, and IIS&Claims-IIS&Claims).
Run 4: The index date was the date of the COVID-19 vaccine booster. The COVID-19 vaccine booster was defined as any COVID-19 vaccine observed after September 1, 2021, with two prior vaccine codes (for all and non-immunocompromised cohorts) or three prior vaccine codes (for immunocompromised cohorts) more than four days apart.

Cohort Eligibility Criteria: We required members to have medical and drug coverage for a minimum of 183 days before the index date; gaps in coverage of up to 45 days were allowed and considered continuous enrollment. Individuals of the following ages were included in the cohorts: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years.

Inclusion/Exclusion Criteria: In Runs 1, 2, and 3 we excluded evidence of any prior COVID-19 vaccination records before the index date. This was to ensure that the first dose index date was date of the first ever COVID-19 vaccination record to occur. In Run 2, we added an inclusion criteria so that individuals were also required to have received a second COVID-19 vaccine dose at least four days after their first dose. We also excluded patients that had a duplicate vaccine code in the days 1-4 after the index event. This was to remove competing censoring events when evaluating the timing between the first and second dose (see Follow-up Time section below).
For Run 4, we had different inclusion criteria requirements for each of the four cohorts. For the overall booster cohort (cohort 1), we required patients to have two previous COVID-19 vaccine codes at least 4 days apart, at least 4 days before the index dose. For the immunocompromised cohort (cohort 2), we required patients to have three previous COVID-19 vaccine codes at least 4 days apart, at least 4 days before the index dose. We also required patients to have evidence of an immunocompromising condition in their enrollment history. We defined immunocompromised as any evidence of HIV/AIDS, hematological malignancy, treatment-independent immune deficiencies, dialysis, chemotherapeutic agents/diagnoses and procedures, immunosuppressant therapeutic agents/diagnoses and procedures, steroid diagnoses and procedures, organ transplant diagnoses and procedures, or solid malignancies. For the non-immunocompromised cohort (cohort 3), we required patients to have two previous COVID-19 vaccine codes at least 4 days apart, at least 4 days before the index dose. We also required patients to not have any evidence of an immunocompromising condition in their enrollment history. For the booster-specific code cohort (cohort 4), we did not have any additional inclusion or exclusion criteria. Please see Appendix D for a list of the codes used to define the inclusion and exclusion criteria.

Follow-up Time: For all cohorts where we evaluated the timing between first and second COVID-19 vaccine doses, any COVID-19 vaccine codes that occurred within 1-4 days after the index date were defined as duplicate first dose codes and subsequently ignored when assessing timing to second dose. Therefore, follow-up began on day 5 after the index dispensing and continued until the first occurrence of any of the following: 1) evidence of a second dose; 2) disenrollment; 3) death; 4) the end of the data provided by each Data Partner; or 5) the end of the query period.

Overview for Request: cder_mpl1r_wp271

Baseline Characteristics: Baseline characteristics were included for the cohorts in Run 1, Run 2, and the overall booster cohort from Run 4. We described demographic characteristics (such as sex, age, race, and ethnicity) and calendar year of the index date. We also assessed clinical characteristics in the 183 days prior to and including the index date. These characteristics included health conditions associated with severe COVID-19 outcomes (reactive airway disease and lung diseases, other chronic respiratory diseases, sickle cell disease, liver disease, tuberculosis, cystic fibrosis, congenital or acquired heart disease, lung cancer, breast cancer, colorectal cancer, prostate cancer, endometrial cancer, other cancer, asthma, chronic obstructive pulmonary disease [COPD] and bronchiectasis, diabetes, chronic kidney disease, hypertension, acute myocardial infarction, atrial fibrillation, heart failure, ischemic heart disease, stroke/transient ischemic attack, history of cardiac arrest, history of coronary angioplasty or bypass, Alzheimer's disease/dementia, depression, bipolar or other depressive mood disorders, attention-deficit/hyperactivity disorder, alcohol abuse or dependence, drug abuse or dependence, obesity, smoking, and immunocompromised [HIV/AIDS, hematological malignancy, treatment-dependent immune deficiencies, dialysis, chemotherapeutic agents, immunosuppressant treatments, steroids, organ transplant, or solid malignancies) and other general health indicators (hyperlipidemia, rheumatoid arthritis/osteoarthritis, acquired hypothyroidism, glaucoma, osteoporosis, anemia, benign prostatic hyperplasia, hip/pelvic fracture, cataracts, and Parkinson's disease/secondary parkinsonism). We assessed evidence of cerebral palsy, spinal cord injuries, and down syndrome in patients' entire available history. We further evaluated COVID-19 diagnoses and related treatments (including lopinavir/ritonavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ivermectin, dexamethasone, other corticosteroids, inhaled corticosteroids, Paxlovid, baricitinib, tocilizumab, bamlanivimab, casirivimab/imdevimab, bamlanivimab/etesevimab, sotrovimab, non-steroidal anti-inflammatory drugs, and antidepressants) in the 183 days before and including the index date, and separately in the 183 days after the index date. We reported additional details about the index COVID-19 vaccine at the index date, such as brand (Pfizer-BioNTech, Moderna, Janssen, Novavax, or unspecified), COVID-19 vaccine code type (CVX codes or NDC/CPT-4/HCPCS codes), monovalent or bivalent (only in Pfizer-BioNTech, Moderna vaccines), and percentage of duplicated codes in the 1-4 days after the index date. We used International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, CPT-4 procedure codes, and NDCs to define the clinical characteristics and treatments. Please see Appendix E for a list of diagnosis and procedure codes used to define baseline characteristics in this request, Appendix F for a list of non-proprietary and proprietary names of medical products.

Please refer to Appendices G and H for the specifications of parameters used in this request and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[1] Schneider, Karen L et al. "Use of Immunization Information Systems in Ascertainment of COVID-19 Vaccinations for Claims-Based Vaccine Safety and Effectiveness Studies." JAMA Network open vol. 6,5 e2313512. 1 May. 2023, doi:10.1001/jamanetworkopen.2023.13512

Sentinel

Table of Contents

Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
	Patient Characteristics Tables
Table 1 r01	Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024
Table 1 r02	Aggregated Characteristics of Patients With At Least TwoCoronavirus Disease 2019 (COVID-19) Vaccines in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024
Table 1 r04	Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024
	Summary of Exposures of Interest
Table 2 r01	Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024
Table 2 r02	Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024
Table 2 r03	Summary of Exposures of Interest (Combinations of Brand of Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024
Table 2 r04	Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024
	Stratified Tables for Run 1 (At Least One COVID-19 Vaccine)
Table 3a r01	Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Sex
Table 3b r01	Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group
Table 3c_r01	Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Year
Table 3d r01	Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Year and Month
Table 3e r01	Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory
Table 3f r01	Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month
	Stratified Tables for Run 2 (At Least Two COVID-19 Vaccines)
Table 3a r02	Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Sex
Table 3b r02	Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory
Table 3c r02	Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month
	Stratified Tables for Run 4 (Booster COVID-19 Vaccine)
Table 3a r04	Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Sex
Table 3b r04	Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory
Table 3c r04	Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

Table of Contents

Interval Time Between the First and Second Vaccine

Table 4 r01 Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Table 4 r02 Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Table 4 r03 Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code Distribution Tables for Runs 1 (At Least One COVID-19 Vaccine) and 2 (At Least Two COVID-19 Vaccines)

Table 5a r01 Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Table 5a r02 Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Table 5b r01 Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Table 5b r02 Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Cohort Attrition Tables

Table 6 r01 Summary of Patient-Level Cohort Attrition (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Table 6 r02 Summary of Patient-Level Cohort Attrition (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Table 6 r03 Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One Coronavirus disease

Table 6 r04 Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines) in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024

Appendices

Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 17, 2024)

Appendix B List of Non-proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Appendix C List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Appendix D List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Appendix E List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Appendix F Technical Specifications Used for this Request

Appendix G r01 Specifications Defining Parameters for Baseline Characteristics for run01 in this Request

Appendix G r02 Specifications Defining Parameters for Baseline Characteristics for run02 in this Request

Appendix G r04 Specifications Defining Parameters for Baseline Characteristics for run04 in this Request

Appendix H Design Diagram Used for this Request

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.
Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.
Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.
Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.
Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.
Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.
Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.
Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).
Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.
Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.
Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.
Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.
Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1 r01. Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination[1] the Sentinel Distributed Database

	With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Unique patients	38,575,376	N/A
Demographic Characteristics		
Age (Years)	57.1	16.4
Age Group (Years)		
0-6 months	19,444	0.1%
7-59 months	252,552	0.7%
5-11 years	1,049,954	2.7%
12-15 years	967,134	2.5%
16-39 years	7,103,637	18.4%
40-64 years	10,145,602	26.3%
≥ 65 years	19,037,053	49.4%
Sex		
Female	21,192,498	54.9%
Male	17,382,878	45.1%
Race[3]		
American Indian or Alaska Native	121,745	0.3%
Asian	1,436,122	3.7%
Black or African American	2,470,027	6.4%
Multi-racial	459,856	1.2%
Native Hawaiian or Other Pacific Islander	67,549	0.2%
Unknown	11,217,510	29.1%
White	22,802,567	59.1%
Hispanic origin		
Yes	1,076,741	2.8%
No	23,581,349	61.1%
Unknown	13,917,286	36.1%
Year		
2020	*****	*****
2021	33,971,705	88.1%
2022	3,869,270	10.0%
2023	326,245	0.8%
2024	*****	*****

Table 1 r01. Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination[1] the Sentinel Distributed Database

	With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	
COVID-19 Vaccination		
Duplicated COVID-19 vaccine records *(having evidence of days with any COVID-19 vaccine codes 1-4 after the index date [not including the index])*	233,258	0.6%
COVID-19 Vaccine Brand for the First Observed Record		
Pfizer at index	21,480,531	55.7%
Moderna at index	15,409,521	39.9%
Jannsen at index	1,694,574	4.4%
Novavax at index	4,546	0.0%
Unspecified at index	101,747	0.3%
Other (including Janssen, Novavax, or Unspecified) at index	1,796,746	4.7%
Having both Pfizer and Moderna at the index	39,348	0.1%
Having both Pfizer and Other at the index	36,498	0.1%
Having both Moderna and Other at the index	35,715	0.1%
Having both Pfizer and Moderna 1-4 days after the index	604	0.0%
Having both Pfizer and Other 1-4 days after the index	149	0.0%
Having both Moderna and Other 1-4 days after the index	132	0.0%
Only Pfizer at index	21,404,824	55.5%
Only Moderna at index	15,334,597	39.8%
Only Jannsen at index	1,680,266	4.4%
Only Novavax at index	4,388	0.0%
Only Unspecified at index	35,916	0.1%
Only Other (including Janssen, Novavax, or Unspecified) at index	1,724,672	4.5%
COVID-19 Vaccine Code Type for the First Observed Record		
Insurance claims data (National Drug Codes[NDC]/Current Procedural Terminology[CPT]/Healthcare Common Procedure Coding System [HCPCS] codes) at index	34,905,903	90.5%
State-based Immunization Information Systems (IIS) (Vaccine Administered Code Set [CVX] codes) at index	8,027,823	20.8%
Having both IIS and insurance claims data at index	4,358,350	11.3%
COVID-19 Vaccine Code Type for the First Observed Record		
Only Insurance claims data at index	30,547,553	79.2%
Only IIS data at index	3,669,473	9.5%

Table 1 r01. Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination[1] the Sentinel Distributed Database

	With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	
Having both insurance claims and IIS data 1-4 days after the index	21,278	0.1%
COVID-19 Vaccine for the First Observed Record; Monovalent or Bivalent (only Pfizer and Moderna)		
Monovalent at index	35,340,762	91.6%
Bivalent at index	1,523,475	3.9%
Having both Monovalent and Bivalent at index date	13,533	0.0%
Only Monovalent at index date	35,327,229	91.6%
Only Bivalent at index date	1,509,942	3.9%
Monovalent and Bivalent 4 days of index	109	0.0%
COVID-19 Vaccine for the First Observed Record; Whether the "dose1" is Mentioned in the Code Description		
COVID-19 Vaccine Dose 1	19,695,558	51.1%
COVID-19 Vaccine for the Second Observed Record; Whether the "dose2" is Mentioned in the Code Description		
COVID-19 Vaccine Dose 2	14,675,301	38.0%
Total Number of Observed Days with Records for the COVID-19 Vaccination after Index, Including the First Record		
With at least one COVID-19 vaccine codes	38,575,376	100.0%
With at least two COVID-19 vaccine codes in two separate days	30,342,790	78.7%
With at least three COVID-19 vaccine codes in three separate days	17,528,409	45.4%
With one COVID-19 vaccine	8,232,586	21.3%
With two COVID-19 vaccine in two separate days	12,814,381	33.2%
With three COVID-19 vaccine in three separate days	9,565,864	24.8%
With ≥4 COVID-19 vaccine codes in ≥4 separate days	7,962,545	20.6%
Health Characteristics		
Reactive Airway and Lung Diseases	8,683	0.0%
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	1,564,650	4.1%
Sickle Cell Disease	21,499	0.1%
Liver disease (severe/moderate)	1,341,493	3.5%
Tuberculosis	25,474	0.1%
Cystic fibrosis	8,739	0.0%
Congenital or Acquired Heart Disease	226,117	0.6%
Lung Cancer	173,622	0.5%
Breast Cancer	651,175	1.7%
Colorectal Cancer	182,445	0.5%

Table 1 r01. Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination[1] the Sentinel Distributed Database

	With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	
Prostate Cancer	582,189	1.5%
Endometrial Cancer	62,131	0.2%
Other cancer	2,869,416	7.4%
Asthma	898,754	2.3%
Chronic obstructive pulmonary disease (COPD) and Bronchiectasis	1,535,395	4.0%
Diabetes types 1 and/or 2	5,082,760	13.2%
Chronic Kidney Disease	2,807,500	7.3%
Hypertension	10,523,519	27.3%
Acute Myocardial Infarction	114,736	0.3%
Atrial Fibrillation	1,883,587	4.9%
Heart Failure	1,969,486	5.1%
Ischemic Heart Disease	4,055,176	10.5%
Stroke/Transient Ischemic Attack (TIA)	501,948	1.3%
History of Cardiac Arrest	22,398	0.1%
History of Coronary Angioplasty or Bypass	1,068,457	2.8%
Alzheimer's Disease and related conditions	1,203,547	3.1%
Depression	4,800,729	12.4%
Bipolar or Other Depressive Mood Disorders	804,743	2.1%
Attention-deficit/hyperactivity disorder (ADHD)	755,803	2.0%
History of Cerebral palsy	792,384	2.1%
History of Spinal cord injuries	502,498	1.3%
History of Down syndrome	50,008	0.1%
Alcohol Abuse or Dependence	486,970	1.3%
Drug Abuse or Dependence	578,811	1.5%
Obesity/overweight	7,251,735	18.8%
Smoking	3,839,053	10.0%
Immunocompromised	8,622,903	22.4%
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)	113,928	0.3%
Hematological Malignancy	434,780	1.1%
Treatment-Independent Immune Deficiencies	311,897	0.8%
Dialysis	209,067	0.5%
Chemo Therapeutic Agents	1,045,485	2.7%

Table 1 r01. Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination[1] the Sentinel Distributed Database

	With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	
Immunosuppressant Therapeutic Agents	979,284	2.5%
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	3,954,124	10.3%
Organ Transplant Diagnoses and Procedures	163,047	0.4%
Solid Malignancies	4,044,591	10.5%
Hyperlipidemia	8,675,527	22.5%
Rheumatoid Arthritis/Osteoarthritis	3,831,171	9.9%
Acquired Hypothyroidism	2,796,822	7.3%
Glaucoma	2,579,483	6.7%
Osteoporosis	1,065,809	2.8%
Anemia	1,955,354	5.1%
Benign Prostatic Hyperplasia	1,101,445	2.9%
Hip/Pelvic Fracture	132,495	0.3%
Cataract	3,999,011	10.4%
Parkinsons Disease and Secondary Parkinsonism	240,238	0.6%
Comorbidity score		
Charlson/Elixhauser combined comorbidity score[4]	0.9	1.9
Medical Product Use		
Pre-Index		
COVID-19 diagnosis	1,958,234	5.1%
Lopinavir/Ritonavir	639	0.0%
Remdesivir	112,503	0.3%
Hydroxychloroquine	282,749	0.7%
Chloroquine	645	0.0%
Azithromycin	1,540,281	4.0%
Ivermectin	45,888	0.1%
Dexamethasone	1,665,469	4.3%
Other Corticosteroids	5,329,422	13.8%
Inhaled Corticosteroids	1,753,866	4.5%
Paxlovid	57,403	0.1%
Baricitinib	4,282	0.0%
Tocilizumab	13,681	0.0%
Bamlanivimab	37,824	0.1%
Casirivimab/Imdevimab	40,298	0.1%

Table 1 r01. Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination[1] the Sentinel Distributed Database

	With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	
Pre-Index		
Bamlanivimab/Etesevimab	6,269	0.0%
Sotrovimab	2,228	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	4,721,971	12.2%
Antidepressants	8,325,257	21.6%
Post-Index		
COVID-19 diagnosis	1,251,524	3.2%
Lopinavir/Ritonavir	501	0.0%
Remdesivir	36,594	0.1%
Hydroxychloroquine	269,712	0.7%
Chloroquine	739	0.0%
Azithromycin	1,545,668	4.0%
Ivermectin	27,168	0.1%
Dexamethasone	1,622,776	4.2%
Other Corticosteroids	5,483,445	14.2%
Inhaled Corticosteroids	1,726,847	4.5%
Paxlovid	90,490	0.2%
Baricitinib	3,119	0.0%
Tocilizumab	13,852	0.0%
Bamlanivimab	5,623	0.0%
Casirivimab/Imdevimab	40,081	0.1%
Bamlanivimab/Etesevimab	7,469	0.0%
Sotrovimab	11,258	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	4,543,175	11.8%
Antidepressants	8,371,547	21.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.8	10.5
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.3	7.6
Mean number of filled prescriptions	11.2	13.8
Mean number of generics dispensed	4.9	4.2
Mean number of unique drug classes dispensed	4.6	3.9

Table 1 r01. Aggregated Characteristics of Patients with At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination[1] the Sentinel Distributed Database

With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1 r02. Aggregated Characteristics of Patients With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Sentinel Distributed Database (SDD) from

	With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Unique patients	30,109,785	N/A
Demographic Characteristics		
Age (Years)	57.3	16.6
Age Group (Years)		
0-6 months	16,228	0.1%
7-59 months	211,618	0.7%
5-11 years	880,159	2.9%
12-15 years	837,253	2.8%
16-39 years	5,280,627	17.5%
40-64 years	7,838,777	26.0%
≥ 65 years	15,045,123	50.0%
Sex		
Female	16,639,352	55.3%
Male	13,470,433	44.7%
Race[3]		
American Indian or Alaska Native	95,890	0.3%
Asian	1,164,974	3.9%
Black or African American	1,851,060	6.1%
Multi-racial	371,108	1.2%
Native Hawaiian or Other Pacific Islander	47,860	0.2%
Unknown	8,299,925	27.6%
White	18,278,968	60.7%
Hispanic origin		
Yes	836,410	2.8%
No	18,838,343	62.6%
Unknown	10,435,032	34.7%
Year		
2020	365,336	1.2%
2021	28,440,942	94.5%
2022	1,275,963	4.2%
2023	27,544	0.1%
2024	0	0.0%

Table 1 r02. Aggregated Characteristics of Patients With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Sentinel Distributed Database (SDD) from

COVID-19 Vaccination		
COVID-19 Vaccine Brand for the First Observed Record		
Pfizer at index	17,118,506	56.9%
Moderna at index	12,247,161	40.7%
Jannsen at index	752,491	2.5%
Novavax at index	2,897	0.0%
Unspecified at index	73,539	0.2%
Other (including Janssen, Novavax, or Unspecified) at index	826,953	2.7%
Having both Pfizer and Moderna at the index	32,313	0.1%
Having both Pfizer and Other at the index	26,654	0.1%
Having both Moderna and Other at the index	23,971	0.1%
Only Pfizer at index	17,059,642	56.7%
Only Moderna at index	12,190,980	40.5%
Only Jannsen at index	744,699	2.5%
Only Novavax at index	2,793	0.0%
Only Unspecified at index	26,979	0.1%
Only Other (including Janssen, Novavax, or Unspecified) at index	776,431	2.6%
COVID-19 Vaccine Code Type for the First Observed Record		
Insurance claims data (National Drug Codes[NDC]/Current Procedural Terminology[CPT]/Healthcare Common Procedure Coding System [HCPCS] codes) at index	26,840,080	89.1%
State-based Immunization Information Systems (IIS) (Vaccine Administered Code Set [CVX] codes) at index	7,099,567	23.6%
Having both IIS and insurance claims data at index	3,829,862	12.7%
Only Insurance claims data at index	23,010,218	76.4%
Only IIS data at index	3,269,705	10.9%
COVID-19 Vaccine for the First Observed Record; Monovalent or Bivalent (only Pfizer and Moderna)		
Monovalent at index	29,278,292	97.2%
COVID-19 Vaccine for the First Observed Record; Monovalent or Bivalent (only Pfizer and Moderna)		
Bivalent at index	57,235	0.2%
Having both Monovalent and Bivalent at index date	2,173	0.0%
Only Monovalent at index	29,276,119	97.2%
Only Bivalent at index	55,062	0.2%
COVID-19 Vaccine for the First Observed Record; Whether the "dose1" is Mentioned in the Code Description		
COVID-19 Vaccine Dose 1	18,113,228	60.2%

Table 1 r02. Aggregated Characteristics of Patients With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Sentinel Distributed Database (SDD) from

COVID-19 Vaccine for the Second Observed Record; Whether the "dose2" is Mentioned in the Code Description		
COVID-19 Vaccine Dose 2	14,631,284	48.6%
Total Number of Observed records for the COVID-19 Vaccination after Index, Including the First Record		
With at least one COVID-19 vaccine codes	30,109,785	100.0%
With at least two COVID-19 vaccine codes in two separate days	30,109,532	100.0%
With at least three COVID-19 vaccine codes in three separate days	17,330,727	57.6%
With one COVID-19 vaccine[4]	253	0.0%
With two COVID-19 vaccine in two separate days	12,778,805	42.4%
With three COVID-19 vaccine in three separate days	7,816,859	26.0%
With ≥4 COVID-19 vaccine codes in ≥4 separate days	7,816,859	26.0%
Health Characteristics		
Reactive Airway and Lung Diseases	6,752	0.0%
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	1,184,410	3.9%
Sickle Cell Disease	15,876	0.1%
Liver disease (severe/moderate)	1,024,089	3.4%
Tuberculosis	19,033	0.1%
Cystic fibrosis	6,669	0.0%
Congenital or Acquired Heart Disease	177,920	0.6%
Lung Cancer	132,478	0.4%
Breast Cancer	521,401	1.7%
Colorectal Cancer	141,075	0.5%
Prostate Cancer	459,347	1.5%
Endometrial Cancer	49,334	0.2%
Other cancer	2,265,882	7.5%
Asthma	700,065	2.3%
Chronic obstructive pulmonary disease (COPD) and Bronchiectasis	1,158,214	3.8%
Diabetes types 1 and/or 2	3,908,665	13.0%
Chronic Kidney Disease	2,133,897	7.1%
Hypertension	8,168,955	27.1%
Acute Myocardial Infarction	84,091	0.3%
Atrial Fibrillation	1,473,333	4.9%
Heart Failure	1,492,352	5.0%
Ischemic Heart Disease	3,141,732	10.4%
Stroke/Transient Ischemic Attack (TIA)	385,622	1.3%
History of Cardiac Arrest	16,823	0.1%

Table 1 r02. Aggregated Characteristics of Patients With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Sentinel Distributed Database (SDD) from

History of Coronary Angioplasty or Bypass	824,131	2.7%
Alzheimer's Disease and related conditions	925,464	3.1%
Depression	3,681,263	12.2%
Bipolar or Other Depressive Mood Disorders	610,923	2.0%
Attention-deficit/hyperactivity disorder (ADHD)	566,873	1.9%
History of Cerebral palsy	613,861	2.0%
History of Spinal cord injuries	391,233	1.3%
History of Down syndrome	39,122	0.1%
Alcohol Abuse or Dependence	357,665	1.2%
Drug Abuse or Dependence	414,116	1.4%
Obesity/overweight	5,512,773	18.3%
Smoking	2,920,348	9.7%
Immunocompromised	6,709,728	22.3%
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)	86,296	0.3%
Hematological Malignancy	346,265	1.2%
Treatment-Independent Immune Deficiencies	235,940	0.8%
Dialysis	153,092	0.5%
Chemo Therapeutic Agents	822,439	2.7%
Immunosuppressant Therapeutic Agents	782,992	2.6%
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	3,002,863	10.0%
Organ Transplant Diagnoses and Procedures	128,399	0.4%
Solid Malignancies	3,203,312	10.6%
Hyperlipidemia	6,753,328	22.4%
Rheumatoid Arthritis/Osteoarthritis	2,972,421	9.9%
Acquired Hypothyroidism	2,192,278	7.3%
Glaucoma	2,059,675	6.8%
Osteoporosis	852,484	2.8%
Anemia	1,498,151	5.0%
Benign Prostatic Hyperplasia	853,864	2.8%
Hip/Pelvic Fracture	100,803	0.3%
Cataract	3,190,157	10.6%
Parkinsons Disease and Secondary Parkinsonism	188,392	0.6%
Comorbidity score		
Charlson/Elixhauser combined comorbidity score[5]	0.9	1.9

Table 1 r02. Aggregated Characteristics of Patients With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Sentinel Distributed Database (SDD) from

Medical Product Use		
Pre-Index		
COVID-19 diagnosis	1,514,183	5.0%
Lopinavir/Ritonavir	540	0.0%
Remdesivir	93,110	0.3%
Hydroxychloroquine	223,561	0.7%
Chloroquine	482	0.0%
Azithromycin	1,136,816	3.8%
Ivermectin	35,171	0.1%
Dexamethasone	1,274,693	4.2%
Other Corticosteroids	4,076,775	13.5%
Inhaled Corticosteroids	1,376,612	4.6%
Paxlovid	5,741	0.0%
Baricitinib	3,122	0.0%
Tocilizumab	11,093	0.0%
Bamlanivimab	34,711	0.1%
Casirivimab/Imdevimab	25,555	0.1%
Bamlanivimab/Etesevimab	4,161	0.0%
Sotrovimab	1,196	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	3,641,782	12.1%
Pre-Index		
Antidepressants	6,463,681	21.5%
Post-Index		
COVID-19 diagnosis	867,577	2.9%
Lopinavir/Ritonavir	440	0.0%
Remdesivir	21,641	0.1%
Hydroxychloroquine	214,740	0.7%
Chloroquine	575	0.0%
Azithromycin	1,136,390	3.8%
Ivermectin	20,824	0.1%
Dexamethasone	1,257,110	4.2%
Other Corticosteroids	4,314,569	14.3%
Inhaled Corticosteroids	1,372,747	4.6%
Paxlovid	35,542	0.1%
Baricitinib	1,678	0.0%

Table 1 r02. Aggregated Characteristics of Patients With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Sentinel Distributed Database (SDD) from

Tocilizumab	11,334	0.0%
Bamlanivimab	4,665	0.0%
Casirivimab/Imdevimab	28,172	0.1%
Bamlanivimab/Etesevimab	5,010	0.0%
Sotrovimab	7,071	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	3,585,501	11.9%
Antidepressants	6,605,729	21.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.9	10.4
Mean number of emergency room encounters	0.1	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.4	7.6
Mean number of filled prescriptions	11.2	13.8
Mean number of generics dispensed	4.8	4.1
Mean number of unique drug classes dispensed	4.6	3.8

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]In the covariate "Total number of observed records for the COVID-19 vaccination" after index, a small number of patients are recorded as having received only one COVID-19 vaccine. However, our cohort inclusion criteria require at least two COVID-19 vaccines (including index and after). This discrepancy arises because the assessment of covariates requires that claims occur during a valid enrollment span. For this query, both medical and drug coverage enrollment were necessary, meaning that any claim made during the enrollment period with only medical coverage, for instance, was not counted. This is the case for those few patients. Our cohort inclusion criteria consider all claims without restricting to those occurring during enrollment, which is why these patients are included in our cohort but not in our covariate.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

N/A: Not Applicable

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Sentinel Distributed Database (SDD) from September

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Unique patients	19,510,553	N/A
Demographic Characteristics		
Age (Years)	61.3	15.7
Age Group (Years)		
0-6 months	91	0.0%
7-59 months	109,649	0.6%
5-11 years	291,472	1.5%
12-15 years	330,263	1.7%
16-39 years	2,678,909	13.7%
40-64 years	4,884,301	25.0%
≥ 65 years	11,215,868	57.5%
Sex		
Female	10,938,777	56.1%
Male	8,571,776	43.9%
Race[3]		
American Indian or Alaska Native	61,491	0.3%
Asian	904,767	4.6%
Black or African American	1,119,329	5.7%
Multi-racial	242,514	1.2%
Native Hawaiian or Other Pacific Islander	28,123	0.1%
Unknown	4,316,653	22.1%
White	12,837,676	65.8%
Hispanic origin		
Yes	503,709	2.6%
No	12,875,083	66.0%
Unknown	6,131,761	31.4%
Year		
2021	12,117,840	62.1%
2022	6,900,040	35.4%
2023	492,673	2.5%
2024	0	0.0%
COVID-19 Vaccination		

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Sentinel Distributed Database (SDD) from September

COVID-19 Vaccine Booster Brand		
Pfizer at index	11,064,325	56.7%
Moderna at index	8,464,238	43.4%
COVID-19 Vaccine Booster Code Type		
Insurance claims data (National Drug Codes[NDC]/Current Procedural Terminology[CPT]/Healthcare Common Procedure Coding System [HCPCS] codes) at index	17,886,689	91.7%
State-based Immunization Information Systems (IIS) (Vaccine Administered Code Set [CVX] codes) at index	5,038,330	25.8%
COVID-19 Vaccine Booster; Monovalent or Bivalent (only Pfizer and Moderna)		
Monovalent at index	16,249,941	83.3%
Bivalent at index	3,281,886	16.8%
COVID-19 Vaccine Booster; Whether the "Booster" or "Bivalent" is Mentioned in the Code Description		
Booster or Bivalent COVID-19 Vaccine based on code description	10,251,524	52.5%
Total Number of Observed Records for the COVID-19 Vaccination Before Index, Including the Booster Record		
With at least one COVID-19 vaccine codes	19,510,553	100.0%
With at least two COVID-19 vaccine codes in two separate days	19,164,423	98.2%
With at least three COVID-19 vaccine codes in three separate days	713,527	3.7%
With one COVID-19 vaccine[4]	346,130	1.8%
With two COVID-19 vaccine in two separate days	18,450,896	94.6%
With three COVID-19 vaccine in three separate days	569,126	2.9%
With ≥4 COVID-19 vaccine codes in ≥4 separate days	144,401	0.7%
Health Characteristics		
Reactive Airway and Lung Diseases	5,121	0.0%
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	883,040	4.5%
Sickle Cell Disease	9,078	0.0%
Liver disease (severe/moderate)	743,525	3.8%
Tuberculosis	14,011	0.1%
Cystic fibrosis	4,286	0.0%
Congenital or Acquired Heart Disease	125,577	0.6%
Lung Cancer	100,902	0.5%
Breast Cancer	403,554	2.1%
Colorectal Cancer	100,977	0.5%
Prostate Cancer	363,470	1.9%
Endometrial Cancer	37,833	0.2%

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Sentinel Distributed Database (SDD) from September

Other cancer	1,798,217	9.2%
Asthma	481,929	2.5%
Chronic obstructive pulmonary disease (COPD) and Bronchiectasis	789,380	4.0%
Diabetes types 1 and/or 2	2,793,671	14.3%
Chronic Kidney Disease	1,567,214	8.0%
Hypertension	5,899,889	30.2%
Acute Myocardial Infarction	50,954	0.3%
Atrial Fibrillation	1,114,506	5.7%
Heart Failure	1,073,456	5.5%
Ischemic Heart Disease	2,292,146	11.7%
Stroke/Transient Ischemic Attack (TIA)	265,172	1.4%
History of Cardiac Arrest	11,814	0.1%
History of Coronary Angioplasty or Bypass	589,921	3.0%
Alzheimer's Disease and related conditions	637,079	3.3%
Depression	2,516,173	12.9%
Bipolar or Other Depressive Mood Disorders	381,553	2.0%
Attention-deficit/hyperactivity disorder (ADHD)	344,213	1.8%
History of Cerebral palsy	418,995	2.1%
History of Spinal cord injuries	295,529	1.5%
History of Down syndrome	23,776	0.1%
Alcohol Abuse or Dependence	235,163	1.2%
Drug Abuse or Dependence	245,317	1.3%
Obesity/overweight	3,883,388	19.9%
Smoking	1,991,185	10.2%
Immunocompromised	5,009,665	25.7%
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)	61,399	0.3%
Hematological Malignancy	269,623	1.4%
Treatment-Independent Immune Deficiencies	186,763	1.0%
Dialysis	98,810	0.5%
Chemo Therapeutic Agents	600,550	3.1%
Immunosuppressant Therapeutic Agents	623,967	3.2%
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	2,151,278	11.0%
Organ Transplant Diagnoses and Procedures	94,520	0.5%
Solid Malignancies	2,519,557	12.9%

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Sentinel Distributed Database (SDD) from September		
Hyperlipidemia	5,009,138	25.7%
Rheumatoid Arthritis/Osteoarthritis	2,276,194	11.7%
Acquired Hypothyroidism	1,583,624	8.1%
Glaucoma	1,681,629	8.6%
Osteoporosis	692,509	3.5%
Anemia	1,076,919	5.5%
Benign Prostatic Hyperplasia	647,442	3.3%
Hip/Pelvic Fracture	69,000	0.4%
Cataract	2,580,537	13.2%
Parkinsons Disease and Secondary Parkinsonism	143,900	0.7%
Comorbidity score		
Charlson/Elixhauser combined comorbidity score[5]	1.0	2.0
Medical Product Use		
Pre-Index		
COVID-19 diagnosis	824,156	4.2%
Lopinavir/Ritonavir	227	0.0%
Remdesivir	16,978	0.1%
Hydroxychloroquine	152,921	0.8%
Chloroquine	422	0.0%
Azithromycin	823,038	4.2%
Ivermectin	10,346	0.1%
Dexamethasone	881,775	4.5%
Other Corticosteroids	3,067,556	15.7%
Pre-Index		
Inhaled Corticosteroids	962,261	4.9%
Paxlovid	152,518	0.8%
Baricitinib	1,479	0.0%
Tocilizumab	8,525	0.0%
Bamlanivimab	154	0.0%
Casirivimab/Imdevimab	38,208	0.2%
Bamlanivimab/Etesevimab	5,244	0.0%
Sotrovimab	4,303	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	2,415,053	12.4%
Antidepressants	4,467,366	22.9%
Post-Index		

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Sentinel Distributed Database (SDD) from September

COVID-19 diagnosis	1,040,696	5.3%
Lopinavir/Ritonavir	128	0.0%
Remdesivir	17,718	0.1%
Hydroxychloroquine	149,248	0.8%
Chloroquine	419	0.0%
Azithromycin	941,489	4.8%
Ivermectin	4,543	0.0%
Dexamethasone	874,402	4.5%
Other Corticosteroids	2,968,449	15.2%
Inhaled Corticosteroids	955,714	4.9%
Paxlovid	232,247	1.2%
Baricitinib	1,383	0.0%
Tocilizumab	8,661	0.0%
Bamlanivimab	88	0.0%
Casirivimab/Imdevimab	11,467	0.1%
Bamlanivimab/Etesevimab	4,338	0.0%
Sotrovimab	13,310	0.1%
Non-steroidal anti-inflammatory drugs (NSAIDs)	2,260,849	11.6%
Antidepressants	4,421,494	22.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.7	10.8
Mean number of emergency room encounters	0.2	0.6
Health Service Utilization Intensity Metrics		
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.6	7.3
Mean number of filled prescriptions	12.0	14.2
Mean number of generics dispensed	5.3	4.2
Mean number of unique drug classes dispensed	5.0	3.9

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Sentinel Distributed Database (SDD) from September

[1]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

This table presents baseline characteristics for Cohort 1 only. Baseline tables for Cohorts 2, 3, and 4 were not produced.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]In the covariate "Total number of observed records for the COVID-19 vaccination" before index, a small number of patients are recorded as having received only one COVID-19 vaccine. However, our cohort inclusion criteria require at least two COVID-19 vaccines prior to the index date. This discrepancy arises because the assessment of covariates requires that claims occur during a valid enrollment span. For this query, both medical and drug coverage enrollment were necessary, meaning that any claim made during the enrollment period with only medical coverage, for instance, was not counted. This is the case for those few patients. Our cohort inclusion criteria consider all claims without restricting to those occurring during enrollment, which is why these patients are included in our cohort but not in our covariate.

[5]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not Applicable

Table 2 r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	38,575,376	146,209,200	2,638.37

[1] The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 2 r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines	30,109,785	38,716,649	7,776.96

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility.

Table 2 r03. Summary of Exposures of Interest (Combinations of Brand of Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

	Number of Patients with Only the First Component of the Combination[2]	Number of Exposure Episodes with First and Second Components of Combination[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
Coronavirus Disease 2019 (COVID-19) Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	21,480,531	16,967,289	146,209,200	1,469.16
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	15,409,521	11,956,511	146,209,200	1,053.94
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	1,694,574	186,679	146,209,200	115.90
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	106,283	45,906	146,209,200	7.27
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	21,480,531	1,395,619	146,209,200	1,469.16
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	15,409,521	1,883,481	146,209,200	1,053.94
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	21,480,531	70,218	146,209,200	1,469.16
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	21,480,531	16,741	146,209,200	1,469.16
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	15,409,521	19,971	146,209,200	1,053.94
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	15,409,521	62,948	146,209,200	1,053.94
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	1,694,574	353,510	146,209,200	115.90
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	1,694,574	336,449	146,209,200	115.90
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	1,694,574	6,101	146,209,200	115.90
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	106,283	34,741	146,209,200	7.27

Table 2 r03. Summary of Exposures of Interest (Combinations of Brand of Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

	Number of Patients with Only the First Component of the Combination[2]	Number of Exposure Episodes with First and Second Components of Combination[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	106,283	43,638	146,209,200	7.27
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	106,283	2,158	146,209,200	7.27
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	30,221,690	22,806,991	137,800,681	2,193.15
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	1,947,898	1,605,596	109,404,496	178.05
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS	30,547,553	125,712	146,201,735	2,089.41
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims	3,669,473	376,045	146,186,684	251.01
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	30,547,553	236,587	146,201,735	2,089.41
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	3,669,473	1,473,864	146,186,684	251.01
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)	4,358,350	740,334	8,028,304	5,428.73
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	4,358,350	500,044	8,028,304	5,428.73
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	4,358,350	3,624,130	8,028,304	5,428.73

Table 2 r03. Summary of Exposures of Interest (Combinations of Brand of Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

	Number of Patients with Only the First Component of the Combination[2]	Number of Exposure Episodes with First and Second Components of Combination[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines, categorized by the combination of vaccine brand and data source.

[4]***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the Code Type cohorts. For this cohort, the Code Type of interest was used to define the cohorts. Specifically, the Claims Code Type was defined using Healthcare Common Procedure Coding System (HCPCS) codes, Current Procedural Terminology, Fourth Edition (CPT-4) codes, and National Drug Codes (NDCs). The Immunization Information Systems (IIS) Code Type was defined using Vaccine Administered Code Set (CVX) codes.

Table 2 r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine [3]	19,510,553	34,598,324	5,639.16
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised) [4,5]	5,976,552	13,473,878	4,435.66
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised) [4,6]	7,772,502	16,032,849	4,847.86
With Booster COVID-19 Vaccine (Booster Specific Code) [7]	21,414,387	84,151,328	2,544.75

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] ***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[3] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[4] Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[5] The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[6] The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[7] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

Table 3a r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Sex

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
Female	21,192,498	77,370,200	2,739.10
Male	17,382,878	68,839,000	2,525.15

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 3b r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
0-6 months	19,444	1,291,970	150.50
7-59 months	252,552	10,750,517	234.92
5-11 years	1,049,954	17,223,866	609.59
12-15 years	967,134	10,395,255	930.36
16-39 years	7,103,637	43,590,709	1,629.62
40-64 years	10,145,602	35,352,112	2,869.87
≥ 65 years	19,037,053	33,463,237	5,688.95

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 3c r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Year

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
2020	408,153	119,810,281	34.07
2021	33,971,705	64,406,304	5,274.59
2022	3,869,270	31,537,240	1,226.89
2023	*****	28,637,885	*****
2024	*****	320,558	*****

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3d r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD)			
	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
2020			
November	5,638	116,641,594	0.48
December	402,515	118,967,569	33.83
2021			
January	4,064,681	56,429,491	720.31
February	4,884,004	51,751,984	943.73
March	6,763,629	46,918,547	1,441.57
April	4,507,821	40,064,696	1,125.14
May	1,901,834	35,454,678	536.41
June	820,095	33,441,989	245.23
July	906,084	34,815,282	260.25
August	1,480,552	34,149,365	433.55
September	1,379,418	32,174,160	428.73
October	2,236,756	31,261,608	715.50
November	2,939,262	28,708,915	1,023.82
December	2,087,569	26,561,013	785.95
2022			
January	894,084	21,407,356	417.65
February	259,148	20,209,248	128.23
March	154,069	20,157,874	76.43
April	282,005	20,169,396	139.82
May	223,473	20,019,900	111.63
June	201,128	19,924,865	100.94
July	291,155	23,088,568	126.10
August	177,120	23,289,849	76.05
September	306,352	22,636,175	135.34
October	496,466	23,135,456	214.59
November	348,704	22,266,489	156.60
December	235,566	23,045,010	102.22
2023			
January	110,597	21,244,561	52.06
February	50,686	20,845,371	24.32

Table 3d r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD)			
	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
March	42,065	21,155,855	19.88
April	30,812	21,335,378	14.44
May	28,425	17,382,035	16.35
June	18,095	17,459,513	10.36
July	13,599	15,396,104	8.83
August	17,738	15,850,041	11.19
September	7,512	15,569,150	4.82
October	6,695	11,163,683	6.00
November	*****	321,531	*****
December	*****	331,462	*****
2024			
January	*****	320,558	*****

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3e r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
AK	50,497	319,552	1,580.24
AL	345,476	854,399	4,043.50
AR	302,277	1,457,916	2,073.35
AZ	764,890	3,523,007	2,171.13
CA	3,937,483	17,654,480	2,230.30
CO	1,115,305	3,535,846	3,154.28
CT	648,257	2,064,417	3,140.15
DC	110,551	412,034	2,683.06
DE	153,740	479,719	3,204.79
FL	2,182,400	5,699,916	3,828.83
FM	0	*****	0.00
GA	1,474,373	5,657,019	2,606.27
GU	3,624	28,798	1,258.42
HI	234,415	722,722	3,243.50
IA	434,428	1,434,694	3,028.02
ID	129,702	637,854	2,033.41
IL	1,418,754	5,596,424	2,535.11
IN	1,158,114	3,941,734	2,938.08
KS	316,956	1,108,590	2,859.09
KY	963,572	2,316,331	4,159.91
LA	436,744	2,613,847	1,670.89
MA	841,613	1,941,052	4,335.86
MD	941,854	3,046,728	3,091.36
ME	323,073	849,442	3,803.36

Table 3e r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
MH	0	15	0.00
MI	733,327	3,830,956	1,914.21
MN	1,027,974	3,073,035	3,345.14
MO	825,437	3,064,796	2,693.29
MP	3,330	9,522	3,497.16
MS	265,222	1,326,755	1,999.03
MT	89,823	464,407	1,934.14
NC	1,159,847	4,373,581	2,651.94
ND	72,190	248,639	2,903.41
NE	231,465	565,261	4,094.83
NH	234,044	673,465	3,475.22
NJ	1,099,582	3,535,143	3,110.43
NM	150,209	1,058,085	1,419.63
NV	303,930	1,456,216	2,087.12
NY	2,068,652	9,151,330	2,260.49
OH	1,707,924	6,727,778	2,538.62
OK	295,363	809,570	3,648.39
OR	629,905	2,197,639	2,866.28
PA	1,298,795	5,278,436	2,460.57
PR	11,680	956,788	122.08
PW	0	*****	0.00
RI	87,737	453,032	1,936.66
SC	548,780	1,306,947	4,198.95
SD	85,472	282,050	3,030.38

Table 3e r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
TN	728,041	4,397,907	1,655.43
TX	2,268,878	10,599,805	2,140.49
UT	216,353	606,251	3,568.70
VA	1,853,341	5,213,044	3,555.20
VI	2,735	36,451	750.32
VT	69,300	266,232	2,602.99
WA	955,690	3,533,915	2,704.34
WI	746,808	2,739,016	2,726.56
WV	164,094	944,480	1,737.40
WY	51,991	180,541	2,879.73
Invalid	290,732	814,249	3,570.55
Missing	8,616	137,330	627.39

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]American Samoa counts are included in the “Other” category.

[3] Due to data partners' data privacy restrictions, any data smaller than 25 has not been included (i.e., is regarded as 0). As a result, the sum of the numbers across all states is slightly smaller than the total number of patients.

[4] Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
0-6 months			
0-6 months, 2020			
November	0	281,667	0.00
December	0	410,912	0.00
0-6 months, 2021			
January	*****	55,909	*****
February	*****	48,738	*****
March	*****	48,384	*****
April	11	45,861	2.40
May	*****	43,391	*****
June	*****	40,934	*****
July	*****	44,364	*****
August	*****	51,493	*****
September	*****	47,321	*****
October	*****	57,131	*****
November	*****	49,999	*****
December	*****	59,897	*****
0-6 months, 2022			
January	*****	48,280	*****
February	*****	40,566	*****
March	*****	41,292	*****
April	*****	39,578	*****
May	*****	37,543	*****
June	478	34,869	137.08

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
July	1,693	38,666	437.85
August	1,767	44,083	400.83
September	1,822	38,822	469.32
October	2,000	47,042	425.15
November	1,908	39,742	480.10
December	1,942	48,373	401.46
0-6 months, 2023			
0-6 months			
January	1,759	44,578	394.59
February	1,502	38,098	394.25
March	1,418	38,528	368.04
April	994	36,321	273.67
May	573	24,914	229.99
June	490	23,262	210.64
July	444	26,287	168.90
August	417	30,974	134.63
September	143	25,534	56.00
October	22	21,844	10.07
November	0	794	0.00
December	0	1,247	0.00
0-6 months, 2024			
January	0	1,252	0.00
7-59 months			
7-59 months, 2020			

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
November	11	8,671,788	0.01
December	12	8,776,828	0.01
7-59 months, 2021			
January	85	1,525,361	0.56
February	66	1,509,312	0.44
March	193	1,515,255	1.27
April	286	1,514,029	1.89
May	279	1,508,373	1.85
June	215	1,496,640	1.44
July	207	1,601,836	1.29
August	191	1,601,826	1.19
September	184	1,567,117	1.17
October	197	1,574,070	1.25
November	463	1,551,344	2.98
7-59 months			
December	297	1,581,160	1.88
7-59 months, 2022			
January	220	1,243,136	1.77
February	80	1,225,954	0.65
March	106	1,238,044	0.86
April	96	1,241,047	0.77
May	108	1,240,574	0.87
June	42,265	1,231,866	343.10
July	77,129	1,303,289	591.80

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
August	42,649	1,208,440	352.93
September	23,555	1,137,381	207.10
October	18,019	1,128,246	159.71
November	14,709	1,085,746	135.47
December	10,105	1,103,679	91.56
7-59 months, 2023			
January	6,635	999,236	66.40
February	3,813	980,640	38.88
March	3,550	992,161	35.78
April	1,932	992,584	19.46
May	1,089	695,510	15.66
June	959	693,962	13.82
July	1,032	782,827	13.18
August	1,207	783,242	15.41
September	364	767,041	4.75
October	244	568,197	4.29
November	0	24,617	0.00
December	0	25,084	0.00
7-59 months, 2024			
January	0	24,620	0.00
5-11 years			
5-11 years, 2020			
November	68	14,449,075	0.05
December	63	14,662,773	0.04

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
5-11 years, 2021			
January	273	2,697,677	1.01
February	144	2,668,854	0.54
March	333	2,677,737	1.24
April	533	2,676,412	1.99
May	1,021	2,670,428	3.82
June	709	2,660,256	2.67
July	624	2,847,965	2.19
August	870	2,858,094	3.04
September	534	2,814,966	1.90
October	522	2,824,738	1.85
November	544,030	2,789,802	1,950.07
December	208,012	2,279,461	912.55
5-11 years, 2022			
January	108,109	1,593,875	678.28
February	30,802	1,470,022	209.53
March	15,881	1,455,955	109.08
April	11,239	1,451,128	77.45
May	13,389	1,449,434	92.37
June	17,953	1,442,906	124.42
July	21,691	1,610,945	134.65
August	19,384	1,593,987	121.61
September	8,725	1,552,558	56.20
October	9,381	1,576,620	59.50

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
November	13,186	1,540,398	85.60
December	8,591	1,585,065	54.20
5-11 years, 2023			
5-11 years			
January	4,258	1,450,062	29.36
February	2,358	1,429,685	16.49
March	2,154	1,451,637	14.84
April	1,436	1,460,051	9.84
May	817	1,019,398	8.01
June	810	1,021,840	7.93
July	779	1,185,804	6.57
August	947	1,194,992	7.92
September	216	1,177,771	1.83
October	112	875,817	1.28
November	0	37,617	0.00
December	0	38,105	0.00
5-11 years, 2024			
January	0	37,244	0.00
12-15 years			
12-15 years, 2020			
November	23	8,461,138	0.03
December	43	8,596,247	0.05
12-15 years, 2021			
January	354	1,724,111	2.05

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
February	182	1,705,871	1.07
March	571	1,712,790	3.33
April	1,093	1,711,877	6.38
May	357,259	1,709,204	2,090.21
June	132,089	1,349,050	979.13
July	111,920	1,313,893	851.82
August	128,778	1,216,824	1,058.31
September	53,440	1,086,620	491.80
October	26,510	1,052,096	251.97
November	23,959	1,025,111	233.72
12-15 years			
December	22,925	1,031,152	222.32
12-15 years, 2022			
January	38,894	775,879	501.29
February	11,716	729,959	160.50
March	5,911	730,773	80.89
April	4,277	734,453	58.23
May	4,726	736,723	64.15
June	5,091	736,342	69.14
July	6,088	846,541	71.92
August	4,903	848,100	57.81
September	3,736	830,865	44.97
October	5,922	847,338	69.89
November	5,839	826,009	70.69

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
December	4,257	856,485	49.70
12-15 years, 2023			
January	1,972	784,594	25.13
February	1,006	773,616	13.00
March	956	787,147	12.15
April	698	792,791	8.80
May	395	552,957	7.14
June	423	555,347	7.62
July	437	662,160	6.60
August	446	669,056	6.67
September	138	659,941	2.09
October	157	488,719	3.21
November	0	18,641	0.00
December	0	19,050	0.00
12-15 years, 2024			
January	0	18,643	0.00
16-39 years			
16-39 years, 2020			
November	255	32,830,861	0.08
December	87,649	33,771,945	25.95
16-39 years, 2021			
January	303,822	11,658,948	260.59
February	259,922	11,180,845	232.47
March	1,131,789	10,972,078	1,031.52

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
April	1,712,719	9,818,108	1,744.45
May	595,497	8,075,683	737.40
June	262,179	7,440,217	352.38
July	292,213	7,767,497	376.20
August	441,420	7,456,157	592.02
September	271,757	6,831,071	397.82
October	200,967	6,664,907	301.53
November	275,689	6,353,592	433.91
December	412,902	6,351,268	650.11
16-39 years, 2022			
January	243,540	4,989,033	488.15
February	75,956	4,663,565	162.87
March	42,538	4,689,868	90.70
April	30,671	4,722,920	64.94
May	30,041	4,751,669	63.22
June	24,988	4,771,093	52.37
July	29,501	5,768,800	51.14
August	23,158	5,862,624	39.50
September	63,393	5,642,015	112.36
October	91,223	5,836,215	156.31
November	73,542	5,606,544	131.17
December	53,033	5,922,058	89.55
16-39 years, 2023			
16-39 years			

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
January	24,525	5,455,104	44.96
February	11,757	5,341,129	22.01
March	10,611	5,478,166	19.37
April	7,308	5,547,065	13.17
May	4,572	3,940,616	11.60
June	3,546	3,958,313	8.96
July	3,246	4,567,265	7.11
August	4,096	4,645,725	8.82
September	1,786	4,521,105	3.95
October	1,812	3,096,348	5.85
November	*****	116,977	*****
December	*****	121,567	*****
16-39 years, 2024			
January	*****	116,550	*****
40-64 years			
40-64 years, 2020			
November	980	26,647,267	0.37
December	151,704	27,181,597	55.81
40-64 years, 2021			
January	654,987	14,692,342	445.80
February	641,020	13,845,344	462.99
March	2,657,669	13,190,874	2,014.78
April	1,899,995	10,478,971	1,813.15
May	568,365	8,532,132	666.15

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
June	244,928	7,923,852	309.10
July	295,314	8,240,804	358.36
August	439,674	8,005,642	549.21
September	283,525	7,428,425	381.68
October	312,355	7,255,365	430.52
November	489,258	6,857,419	713.47
40-64 years			
December	553,785	6,585,300	840.94
40-64 years, 2022			
January	237,400	5,384,929	440.86
February	66,024	5,060,387	130.47
March	36,762	5,040,945	72.93
April	42,579	5,044,409	84.41
May	40,194	5,029,744	79.91
June	31,172	5,026,867	62.01
July	52,004	6,038,068	86.13
August	30,156	6,119,235	49.28
September	71,690	5,949,244	120.50
October	122,203	6,088,844	200.70
November	87,327	5,859,280	149.04
December	61,238	6,081,543	100.69
40-64 years, 2023			
January	27,344	5,544,972	49.31
February	12,072	5,426,531	22.25

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
March	9,745	5,503,004	17.71
April	6,477	5,541,835	11.69
May	3,976	4,187,324	9.50
June	2,783	4,202,136	6.62
July	2,500	4,478,587	5.58
August	3,625	4,655,665	7.79
September	2,255	4,578,803	4.92
October	*****	3,175,337	*****
November	*****	93,326	*****
December	0	96,473	0.00
40-64 years, 2024			
January	*****	92,707	*****
≥ 65 years			
≥ 65 years, 2020			
November	4,301	26,043,468	1.65
December	163,044	26,352,014	61.87
≥ 65 years, 2021			
January	3,105,158	24,269,000	1,279.48
February	3,982,667	20,975,301	1,898.74
March	2,973,069	16,991,760	1,749.71
April	893,184	13,987,050	638.58
May	379,408	13,077,355	290.13
June	179,968	12,682,388	141.90
July	205,804	13,164,333	156.33

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
August	469,617	13,122,452	357.87
September	769,975	12,553,162	613.37
October	1,696,204	11,984,194	1,415.37
November	1,605,859	10,219,463	1,571.37
December	889,642	8,808,306	1,010.00
≥ 65 years, 2022			
January	265,915	7,475,723	355.70
February	74,564	7,114,713	104.80
March	52,868	7,066,595	74.81
April	193,141	7,037,543	274.44
May	135,011	6,878,770	196.27
June	79,181	6,783,029	116.73
July	103,049	7,599,725	135.60
August	55,103	7,729,265	71.29
September	133,431	7,596,947	175.64
October	247,718	7,722,780	320.76
November	152,193	7,412,150	205.33
December	96,400	7,554,872	127.60
≥ 65 years, 2023			
≥ 65 years			
January	44,104	7,062,470	62.45
February	18,178	6,946,501	26.17
March	13,631	7,007,879	19.45
April	11,967	7,062,069	16.95

Table 3f. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
May	17,003	7,035,202	24.17
June	9,084	7,077,047	12.84
July	5,161	3,775,990	13.67
August	7,000	3,955,518	17.70
September	2,610	3,920,858	6.66
October	*****	2,996,826	*****
November	*****	31,642	*****
December	0	32,153	0.00
≥ 65 years, 2024			
January	0	31,639	0.00

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Sex

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
Female	16,639,352	21,271,177	7,822.49
Male	13,470,433	17,445,472	7,721.45

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 3b r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Member[4]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
AK	37,560	50,554	7,429.68
AL	255,276	346,336	7,370.76
AR	252,141	303,152	8,317.31
AZ	598,416	767,167	7,800.34
CA	3,235,721	3,951,548	8,188.49
CO	889,257	1,124,105	7,910.80
CT	493,182	649,993	7,587.50
DC	86,409	111,024	7,782.91
DE	126,214	154,128	8,188.91
FL	1,506,098	2,188,441	6,882.06
FM	0	0	NaN
GA	1,114,637	1,480,359	7,529.50
GU	2,016	3,644	5,532.38
HI	194,609	235,586	8,260.64
IA	364,121	435,333	8,364.19
ID	104,911	129,926	8,074.67
IL	1,131,764	1,422,733	7,954.86
IN	967,653	1,162,764	8,322.01
KS	234,637	317,822	7,382.65
KY	794,647	970,189	8,190.64
LA	341,935	438,122	7,804.56
MA	706,629	842,870	8,383.61
MD	700,803	946,741	7,402.27
ME	259,297	324,428	7,992.44
MH	0	0	NaN

Table 3b r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Member[4]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
MI	580,802	735,438	7,897.36
MN	852,428	1,032,773	8,253.78
MO	619,175	828,742	7,471.26
MP	2,739	3,334	8,215.36
MS	171,931	266,679	6,447.11
MT	60,951	89,952	6,775.95
NC	888,016	1,163,594	7,631.67
ND	57,160	72,312	7,904.64
NE	166,145	232,105	7,158.18
NH	158,812	234,915	6,760.40
NJ	913,128	1,102,514	8,282.23
NM	111,086	150,684	7,372.12
NV	229,636	305,338	7,520.71
NY	1,625,586	2,075,593	7,831.91
OH	1,340,357	1,713,530	7,822.20
OK	207,048	296,306	6,987.64
OR	518,532	632,520	8,197.88
PA	1,032,869	1,301,546	7,935.71
PR	8,970	11,714	7,657.50
PW	0	0	NaN
RI	62,963	87,980	7,156.51
SC	431,495	551,410	7,825.30
SD	64,038	85,652	7,476.53
TN	500,119	729,473	6,855.89
TX	1,667,303	2,276,514	7,323.93

Table 3b r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Member[4]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
UT	151,400	217,069	6,974.74
VA	1,458,115	1,863,386	7,825.08
VI	2,120	2,744	7,725.95
VT	48,030	69,458	6,914.97
WA	769,008	958,868	8,019.96
WI	605,123	749,620	8,072.40
WV	104,431	164,573	6,345.57
WY	39,828	52,047	7,652.31
Invalid	257,119	292,650	8,785.89
Missing	5,384	8,651	6,223.56

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2] American Samoa counts are included in the “Other” category.

[3] Due to data partners' data privacy restrictions, any data smaller than 25 has not been included (i.e., is regarded as 0). As a result, the sum of the numbers across all states is slightly smaller than the total number of patients.

[4] Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*NaN: Not a number

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
0-6 months			
0-6 months, 2020			
November	0	5,289	0.00
December	0	6,545	0.00
0-6 months, 2021			
January	*****	6,725	*****
February	*****	5,584	*****
March	*****	5,279	*****
April	11	5,070	21.70
May	*****	4,834	*****
June	*****	4,320	*****
July	*****	4,793	*****
August	*****	6,309	*****
September	*****	5,818	*****
October	*****	7,616	*****
November	*****	6,575	*****
December	*****	7,877	*****
0-6 months, 2022			
January	*****	7,801	*****
February	*****	6,506	*****
March	*****	6,840	*****
April	*****	6,646	*****
May	*****	6,407	*****
June	452	6,068	744.89

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
July	1,562	6,197	2,520.57
August	1,659	6,275	2,643.82
September	1,696	5,323	3,186.17
October	1,841	6,129	3,003.75
November	1,730	4,721	3,664.48
December	1,618	5,141	3,147.25
0-6 months, 2023			
January	1,603	4,515	3,550.39
February	1,297	3,124	4,151.73
March	1,025	2,520	4,067.46
April	523	1,698	3,080.09
May	466	1,330	3,503.76
June	353	936	3,771.37
July	241	726	3,319.56
August	*****	517	*****
September	*****	132	*****
October	*****	29	*****
November	0	0	NaN
December	0	0	NaN
0-6 months, 2024			
January	0	0	NaN
7-59 months			
7-59 months, 2020			
November	*****	251,442	*****

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
December	*****	251,407	*****
7-59 months, 2021			
January	73	247,161	2.95
February	59	242,693	2.43
March	167	240,781	6.94
April	235	237,471	9.90
May	238	233,708	10.18
June	175	228,778	7.65
July	169	244,305	6.92
August	148	241,799	6.12
September	143	234,755	6.09
October	143	233,775	6.12
November	382	228,161	16.74
December	200	229,490	8.71
7-59 months, 2022			
January	156	227,495	6.86
February	57	224,579	2.54
March	84	226,821	3.70
April	67	227,747	2.94
May	76	228,486	3.33
June	39,822	228,179	1,745.21
July	70,165	202,875	3,458.53
August	37,241	124,607	2,988.68
September	19,502	81,211	2,401.40

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
October	14,162	58,655	2,414.46
November	10,906	40,081	2,720.99
December	6,494	26,729	2,429.57
7-59 months, 2023			
January	4,359	17,521	2,487.87
February	2,378	11,511	2,065.85
March	1,742	8,434	2,065.45
April	641	5,281	1,213.79
May	536	3,849	1,392.57
June	468	3,089	1,515.05
July	403	2,715	1,484.35
August	180	1,636	1,100.24
September	*****	519	*****
October	*****	223	*****
November	0	0	NaN
December	0	0	NaN
7-59 months, 2024			
January	0	0	NaN
5-11 years			
5-11 years, 2020			
November	55	868,218	0.63
December	60	879,300	0.68
5-11 years, 2021			
January	256	876,636	2.92

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
February	134	870,933	1.54
March	299	874,620	3.42
April	465	875,967	5.31
May	933	875,964	10.65
June	650	874,859	7.43
July	568	950,333	5.98
August	785	958,206	8.19
September	459	951,616	4.82
October	451	964,362	4.68
November	515,305	958,251	5,377.56
December	165,705	415,372	3,989.32
5-11 years, 2022			
January	89,582	214,084	4,184.43
February	24,889	112,039	2,221.46
March	12,957	89,147	1,453.44
April	9,506	80,253	1,184.50
May	10,140	76,003	1,334.16
June	11,456	68,852	1,663.86
July	12,356	76,205	1,621.42
August	9,744	59,510	1,637.37
September	3,962	43,777	905.04
October	3,032	39,109	775.27
November	2,603	28,707	906.75
December	1,529	18,554	824.08

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
5-11 years, 2023			
January	1,067	11,328	941.91
February	552	7,559	730.26
March	441	5,841	755.01
April	141	4,024	350.40
May	29	2,742	105.76
June	28	2,126	131.70
July	*****	1,919	*****
August	*****	1,135	*****
September	0	263	0.00
October	0	103	0.00
November	0	0	NaN
December	0	0	NaN
5-11 years, 2024			
January	0	0	NaN
12-15 years			
12-15 years, 2020			
November	22	807,102	0.27
December	38	820,288	0.46
12-15 years, 2021			
January	327	821,990	3.98
February	178	819,718	2.17
March	535	827,528	6.47
April	1,009	832,745	12.12

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
May	344,564	836,126	4,120.96
June	119,777	480,869	2,490.84
July	103,390	391,138	2,643.31
August	116,269	290,662	4,000.14
September	46,105	173,491	2,657.49
October	23,234	135,206	1,718.41
November	20,914	117,725	1,776.51
December	17,166	103,342	1,661.09
12-15 years, 2022			
January	21,798	83,028	2,625.38
February	6,308	44,071	1,431.33
March	3,067	35,402	866.34
April	2,495	31,669	787.84
May	2,542	29,095	873.69
June	2,151	25,327	849.29
July	2,044	29,350	696.42
August	1,427	25,485	559.94
September	522	21,870	238.68
October	433	19,673	220.10
November	334	13,461	248.12
December	170	8,971	189.50
12-15 years, 2023			
January	164	5,297	309.61
February	101	3,600	280.56

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
March	105	2,839	369.85
April	40	2,021	197.92
May	*****	1,400	*****
June	*****	1,084	*****
July	*****	1,105	*****
August	*****	671	*****
September	*****	254	*****
October	0	129	0.00
November	0	0	NaN
December	0	0	NaN
12-15 years, 2024			
January	0	0	NaN
16-39 years			
16-39 years, 2020			
November	242	5,812,997	0.42
December	74,502	5,980,123	124.58
16-39 years, 2021			
January	286,160	5,979,737	478.55
February	244,708	5,684,332	430.50
March	1,053,235	5,524,211	1,906.58
April	1,559,524	4,448,616	3,505.64
May	496,779	2,790,213	1,780.43
June	213,006	2,234,847	953.11
July	244,220	2,212,232	1,103.95

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
August	360,951	1,961,004	1,840.64
September	206,921	1,523,323	1,358.35
October	124,913	1,322,217	944.72
November	124,890	1,116,646	1,118.44
December	119,456	904,354	1,320.90
16-39 years, 2022			
January	71,282	523,849	1,360.74
February	23,460	307,855	762.05
March	13,428	256,042	524.45
April	10,753	230,008	467.51
May	10,129	213,074	475.37
June	8,611	198,707	433.35
July	9,137	301,378	303.17
August	6,597	312,971	210.79
September	4,746	297,191	159.70
October	3,944	251,233	156.99
November	2,905	159,360	182.29
December	1,936	104,154	185.88
16-39 years, 2023			
January	1,564	59,814	261.48
February	1,060	38,422	275.88
March	967	29,253	330.56
April	360	20,367	176.76
May	95	13,956	68.07

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
June	62	10,250	60.49
July	49	10,137	48.34
August	*****	7,079	*****
September	*****	3,105	*****
October	*****	1,492	*****
November	0	*****	0.00
December	0	*****	0.00
16-39 years, 2024			
January	0	0	NaN
40-64 years			
40-64 years, 2020			
November	938	8,940,529	1.05
December	134,156	9,129,820	146.94
40-64 years, 2021			
January	625,238	9,018,690	693.27
February	609,975	8,360,421	729.60
March	2,490,756	7,788,687	3,197.92
April	1,712,937	5,163,197	3,317.59
May	462,617	3,311,299	1,397.09
June	193,954	2,777,912	698.20
July	247,197	2,784,827	887.66
August	354,194	2,532,434	1,398.63
September	207,470	2,094,223	990.68
October	189,529	1,887,276	1,004.25

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
November	238,227	1,552,948	1,534.03
December	183,771	1,103,049	1,666.03
40-64 years, 2022			
January	68,639	593,493	1,156.53
February	20,387	379,245	537.57
March	11,858	331,701	357.49
April	17,989	308,338	583.42
May	16,212	278,409	582.31
June	11,506	253,856	453.25
July	19,306	400,401	482.17
August	8,709	385,334	226.01
September	3,929	362,585	108.36
October	3,787	303,955	124.59
November	2,188	177,971	122.94
December	1,281	110,869	115.54
40-64 years, 2023			
January	790	58,371	135.34
February	511	33,996	150.31
March	401	24,413	164.26
April	153	16,328	93.70
May	59	10,628	55.51
June	29	7,729	37.52
July	36	9,908	36.33
August	27	7,933	34.04

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
September	*****	4,267	*****
October	*****	*****	*****
November	0	*****	0.00
December	0	*****	0.00
40-64 years, 2024			
January	0	*****	0.00
≥ 65 years			
≥ 65 years, 2020			
November	4,222	17,402,133	2.43
December	151,079	17,671,168	85.49
≥ 65 years, 2021			
January	3,021,587	17,576,038	1,719.15
February	3,875,162	14,471,205	2,677.84
March	2,797,630	10,574,324	2,645.68
April	770,686	7,662,578	1,005.78
May	307,819	6,825,845	450.96
June	144,420	6,486,026	222.66
July	173,506	6,633,594	261.56
August	374,691	6,531,905	573.63
September	571,346	6,056,012	943.44
October	1,149,011	5,361,721	2,142.99
November	910,418	3,583,102	2,540.87
December	312,385	2,082,685	1,499.91
≥ 65 years, 2022			

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
January	80,905	1,285,815	629.21
February	25,637	1,048,296	244.56
March	24,669	998,033	247.18
April	126,941	959,658	1,322.77
May	79,472	785,133	1,012.21
June	40,739	673,342	605.03
July	48,212	781,748	616.72
August	19,237	728,866	263.93
September	13,926	682,270	204.11
October	11,745	555,689	211.36
November	4,925	303,551	162.25
December	2,488	185,752	133.94
≥ 65 years, 2023			
January	1,125	101,637	110.69
February	520	62,821	82.77
March	308	48,389	63.65
April	136	38,854	35.00
May	67	26,168	25.60
June	18	12,953	13.90
July	49	15,483	31.65
August	30	10,688	28.07
September	*****	4,032	*****
October	*****	*****	*****
November	0	*****	0.00

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 Coronavirus disease 2019 [COVID-19])[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus disease 2019 (COVID-19) Vaccines			
December	0	0	NaN
≥ 65 years, 2024			
January	0	0	NaN

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 3a r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Sex

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
Female	10,938,777	19,067,560	5,736.85
Male	8,571,776	15,530,764	5,519.22
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[4,5]			
Female	3,465,408	7,775,134	4,457.04
Male	2,511,144	5,698,744	4,406.49
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[4,6]			
Female	4,147,758	8,371,622	4,954.55
Male	3,624,744	7,661,227	4,731.28
With Booster COVID-19 Vaccine (Booster Specific Code)[7]			
Female	12,024,121	44,390,136	2,708.74
Male	9,390,266	39,761,192	2,361.67

Table 3a r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Sex

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] ***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[3] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[4] Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[5] The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[6] The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[7] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
AK	22,151	40,803	5,428.77
AL	132,889	283,617	4,685.51
AR	160,935	275,192	5,848.10
AZ	381,131	701,909	5,429.92
CA	2,349,838	3,794,052	6,193.48
CO	549,309	1,004,988	5,465.83
CT	370,274	622,210	5,950.95
DC	57,741	94,218	6,128.45
DE	92,513	142,769	6,479.91
FL	816,678	1,659,767	4,920.44
FM	0	0	NaN
GA	611,222	1,302,877	4,691.33
GU	253	2,073	1,220.45
HI	128,841	208,962	6,165.76
IA	264,959	394,510	6,716.15
ID	64,852	114,215	5,678.06
IL	816,939	1,332,594	6,130.44
IN	622,577	1,087,715	5,723.71
KS	141,848	256,697	5,525.89
KY	471,609	891,185	5,291.93
LA	183,503	378,356	4,850.01
MA	545,686	818,795	6,664.50
MD	452,534	792,429	5,710.72
ME	174,853	284,605	6,143.71

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
MH	0	0	NaN
MI	400,065	666,070	6,006.35
MN	606,872	994,001	6,105.35
MO	335,792	678,954	4,945.73
MP	349	2,833	1,231.91
MS	69,929	187,316	3,733.21
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
MT	35,326	66,687	5,297.28
NC	600,177	1,076,473	5,575.40
ND	38,921	62,596	6,217.81
NE	97,785	184,074	5,312.27
NH	92,339	176,667	5,226.73
NJ	651,627	1,069,490	6,092.88
NM	75,775	128,879	5,879.55
NV	143,727	277,612	5,177.26
NY	1,167,971	1,942,408	6,013.01
OH	861,822	1,510,309	5,706.26
OK	107,938	230,087	4,691.18
OR	309,760	581,061	5,330.94
PA	772,933	1,234,299	6,262.12
PR	5,714	9,232	6,189.34
PW	0	0	NaN
RI	38,208	68,426	5,583.84
SC	266,782	487,445	5,473.07
SD	40,107	69,234	5,792.96

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
TN	202,885	546,582	3,711.89
TX	927,649	1,933,892	4,796.80
UT	77,849	176,618	4,407.76
VA	923,776	1,645,252	5,614.80
VI	1,130	2,226	5,076.37
VT	30,395	51,954	5,850.37
WA	545,028	906,203	6,014.41
WI	407,586	689,214	5,913.78
WV	50,285	114,698	4,384.12
WY	24,524	42,900	5,716.55
Invalid	184,353	294,220	6,265.82
Missing	2,028	5,874	3,452.50
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[6,7]			
AK	5,946	13,459	4,417.86
AL	34,704	107,496	3,228.40
AR	59,075	129,485	4,562.30
AZ	128,339	278,004	4,616.44
CA	686,381	1,402,887	4,892.63
CO	139,680	326,942	4,272.32
CT	109,588	247,820	4,422.08
DC	15,897	32,036	4,962.23
DE	35,407	70,489	5,023.05
FL	240,455	679,994	3,536.13
FM	0	0	NaN
GA	168,388	471,112	3,574.27

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
GU	33	176	1,875.00
HI	38,144	78,642	4,850.33
IA	106,477	192,735	5,524.53
ID	22,182	46,138	4,807.75
IL	283,713	576,172	4,924.10
IN	198,574	439,814	4,514.95
KS	45,413	104,691	4,337.81
KY	147,970	371,640	3,981.54
LA	49,005	150,452	3,257.19
MA	196,307	359,744	5,456.85
MD	130,218	297,166	4,382.00
ME	56,195	111,999	5,017.46
MH	0	0	NaN
MI	136,199	295,163	4,614.37
MN	179,883	347,311	5,179.31
MO	98,598	244,120	4,038.92
MP	36	218	1,651.38
MS	14,712	57,438	2,561.37
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[6,7]			
MT	11,279	25,923	4,350.96
NC	194,192	451,298	4,302.97
ND	13,839	27,572	5,019.22
NE	25,343	66,948	3,785.48
NH	20,644	64,949	3,178.49
NJ	203,358	456,843	4,451.38

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
NM	23,994	51,383	4,669.64
NV	41,004	100,038	4,098.84
NY	353,320	787,748	4,485.19
OH	292,511	639,462	4,574.33
OK	30,098	87,102	3,455.49
OR	77,311	173,400	4,458.54
PA	278,534	575,411	4,840.61
PR	2,130	4,828	4,411.76
PW	0	0	NaN
RI	12,335	28,055	4,396.72
SC	91,867	218,673	4,201.11
SD	12,832	29,862	4,297.10
TN	51,017	160,331	3,181.98
TX	255,306	674,737	3,783.79
UT	17,278	50,751	3,404.46
VA	274,248	634,514	4,322.17
VI	310	819	3,785.10
VT	9,199	20,927	4,395.76
WA	159,896	306,282	5,220.55
WI	126,713	253,084	5,006.76
WV	12,314	40,034	3,075.89
WY	8,900	19,043	4,673.63
Invalid	48,970	89,625	5,463.88
Missing	280	893	3,135.50
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[6,8]			

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
AK	10,595	21,510	4,925.62
AL	38,060	97,826	3,890.58
AR	45,136	95,555	4,723.56
AZ	141,259	329,257	4,290.24
CA	1,135,722	2,076,657	5,468.99
CO	265,626	552,018	4,811.91
CT	160,504	312,679	5,133.19
DC	29,079	53,511	5,434.21
DE	29,637	55,043	5,384.34
FL	201,254	557,034	3,612.96
FM	0	0	NaN
GA	204,101	531,965	3,836.74
GU	100	1,359	735.84
HI	59,213	108,922	5,436.28
IA	95,182	162,907	5,842.72
ID	23,938	50,493	4,740.86
IL	322,768	620,334	5,203.13
IN	242,359	491,834	4,927.66
KS	48,335	104,129	4,641.84
KY	150,810	339,511	4,441.98
LA	49,963	125,664	3,975.92
MA	228,279	391,850	5,825.67
MD	184,817	378,112	4,887.89
ME	75,478	140,716	5,363.85
MH	0	0	NaN

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
MI	143,579	279,863	5,130.33
MN	310,965	584,540	5,319.82
MO	120,450	296,491	4,062.52
MP	160	1,628	982.80
MS	18,709	62,576	2,989.80
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[6,8]			
MT	12,320	26,539	4,642.22
NC	213,790	459,229	4,655.41
ND	14,344	27,531	5,210.13
NE	39,180	86,045	4,553.43
NH	33,024	75,883	4,351.96
NJ	256,581	500,227	5,129.29
NM	30,891	60,234	5,128.50
NV	59,482	138,842	4,284.15
NY	490,841	940,883	5,216.81
OH	300,292	631,154	4,757.82
OK	30,024	78,975	3,801.71
OR	158,967	339,365	4,684.25
PA	281,340	532,288	5,285.48
PR	1,203	2,353	5,112.62
PW	0	0	NaN
RI	12,732	28,034	4,541.63
SC	72,302	166,551	4,341.13
SD	13,105	26,286	4,985.54
TN	59,080	198,239	2,980.24

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
TX	343,855	877,985	3,916.41
UT	33,888	93,600	3,620.51
VA	363,629	750,128	4,847.56
VI	394	912	4,320.18
VT	11,306	20,998	5,384.32
WA	282,749	527,538	5,359.78
WI	187,942	369,228	5,090.13
WV	14,705	39,636	3,710.01
WY	7,451	15,207	4,899.72
Invalid	109,773	190,815	5,752.85
Missing	1,227	4,160	2,949.52
With Booster COVID-19 Vaccine (Booster Specific Code)[9]			
AK	32,264	108,064	2,985.64
AL	163,660	784,214	2,086.93
AR	153,924	611,925	2,515.41
AZ	415,007	1,791,650	2,316.34
CA	2,370,766	7,737,065	3,064.17
CO	590,432	2,262,574	2,609.56
CT	391,027	1,333,077	2,933.27
DC	59,040	198,642	2,972.18
DE	102,186	261,297	3,910.72
FL	1,187,209	5,264,255	2,255.23
FM	0	*****	0.00
GA	581,992	3,663,929	1,588.44
GU	548	26,868	203.96

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
HI	83,492	402,898	2,072.29
IA	289,688	784,601	3,692.17
ID	71,957	306,695	2,346.21
IL	907,794	2,879,362	3,152.76
IN	617,242	2,491,069	2,477.82
KS	196,813	708,060	2,779.61
KY	436,851	2,043,333	2,137.93
LA	187,522	1,132,957	1,655.16
MA	617,769	1,355,219	4,558.44
MD	551,346	1,719,402	3,206.61
ME	190,593	609,242	3,128.36
MH	0	*****	0.00
MI	439,867	1,526,019	2,882.45
MN	634,204	2,038,500	3,111.13
MO	397,670	2,068,916	1,922.12
MP	336	9,287	361.80
MS	121,451	716,917	1,694.07
With Booster COVID-19 Vaccine (Booster Specific Code)[9]			
MT	61,788	225,134	2,744.50
NC	673,098	2,654,636	2,535.56
ND	47,388	156,421	3,029.52
NE	134,551	483,364	2,783.64
NH	154,677	485,705	3,184.59
NJ	622,848	1,995,467	3,121.31
NM	97,447	322,444	3,022.14

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
NV	164,429	796,212	2,065.14
NY	1,243,430	3,875,154	3,208.72
OH	912,973	4,012,107	2,275.54
OK	168,793	714,260	2,363.19
OR	294,566	1,216,595	2,421.23
PA	854,728	2,566,159	3,330.77
PR	7,292	17,715	4,116.29
PW	0	*****	0.00
RI	55,902	160,971	3,472.80
SC	310,727	1,244,495	2,496.81
SD	61,430	171,555	3,580.78
TN	303,520	2,981,849	1,017.89
TX	1,082,019	5,849,548	1,849.75
UT	106,203	552,536	1,922.10
VA	934,909	3,756,444	2,488.81
VI	1,207	7,044	1,713.52
VT	52,834	121,144	4,361.26
WA	586,914	1,850,161	3,172.23
WI	427,113	1,679,954	2,542.41
WV	89,695	447,214	2,005.64
WY	30,492	122,737	2,484.34
Invalid	138,326	725,200	1,907.42
Missing	2,428	123,046	197.32

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] American Samoa counts are included in the "Other" category.

[3] Due to data partners' data privacy restrictions, any data smaller than 25 has not been included (i.e., is regarded as 0). As a result, the sum of the numbers across all states is slightly smaller than the total number of patients.

[4]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[5]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[6]Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[7]The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[8]The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[9]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
*NaN: Not a number

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
0-6 months			
0-6 months, 2021			
September	*****	50	*****
October	*****	53	*****
November	*****	47	*****
December	*****	60	*****
0-6 months, 2022			
January	*****	58	*****
February	*****	52	*****
March	*****	63	*****
April	*****	60	*****
May	*****	56	*****
June	*****	58	*****
July	*****	132	*****
August	*****	293	*****
September	*****	244	*****
October	*****	183	*****
November	*****	121	*****
December	*****	123	*****
0-6 months, 2023			
January	*****	102	*****
February	*****	79	*****

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
March	*****	63	*****
April	*****	114	*****
May	*****	83	*****
June	0	80	0.00
July	0	74	0.00
August	*****	87	*****
September	0	48	0.00
0-6 months			
October	0	23	0.00
November	0	0	NaN
December	0	0	NaN
0-6 months, 2024			
January	0	0	NaN
7-59 months			
7-59 months, 2021			
September	151	983	1,536.11
October	174	1,014	1,715.98
November	145	994	1,458.75
December	184	1,202	1,530.78
7-59 months, 2022			
January	97	1,126	861.46
February	104	1,101	944.60
March	102	1,096	930.66

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
April	109	1,077	1,012.07
May	104	1,031	1,008.73
June	112	1,014	1,104.54
July	290	37,802	76.72
August	515	106,994	48.13
September	22,062	139,648	1,579.83
October	22,450	143,001	1,569.92
November	14,772	133,175	1,109.22
December	11,012	136,665	805.77
7-59 months, 2023			
January	10,995	123,765	888.38
February	7,053	116,192	607.01
March	6,830	113,575	601.36
April	4,548	108,061	420.87
7-59 months			
May	2,640	74,803	352.93
June	2,125	71,385	297.68
July	1,299	69,815	186.06
August	1,182	65,610	180.16
September	270	62,564	43.16
October	324	41,908	77.31
November	0	2,197	0.00
December	0	2,156	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
7-59 months, 2024			
January	0	2,052	0.00
5-11 years			
5-11 years, 2021			
September	131	2,611	501.72
October	185	2,697	685.95
November	1,620	19,273	840.55
December	6,017	529,381	113.66
5-11 years, 2022			
January	3,428	633,439	54.12
February	1,851	698,049	26.52
March	1,303	723,445	18.01
April	546	726,985	7.51
May	28,207	729,084	386.88
June	57,924	698,584	829.16
July	38,026	655,422	580.18
August	33,580	607,363	552.88
September	14,282	568,488	251.23
October	21,001	551,640	380.70
November	36,290	525,447	690.65
December	21,874	492,159	444.45
5-11 years			
5-11 years, 2023			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
January	9,262	430,750	215.02
February	4,576	415,303	110.18
March	3,987	407,291	97.89
April	2,542	396,648	64.09
May	1,513	286,816	52.75
June	1,237	280,344	44.12
July	814	274,535	29.65
August	877	262,962	33.35
September	170	256,658	6.62
October	229	181,227	12.64
November	0	8,032	0.00
December	0	7,951	0.00
5-11 years, 2024			
January	0	7,706	0.00
12-15 years			
12-15 years, 2021			
September	2,062	681,704	30.25
October	1,173	711,243	16.49
November	1,213	711,746	17.04
December	2,882	727,873	39.59
12-15 years, 2022			
January	150,314	665,676	2,258.07
February	37,656	522,165	721.15

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
March	18,051	490,484	368.02
April	9,734	472,012	206.22
May	14,335	463,991	308.95
June	17,113	448,949	381.18
July	13,782	440,562	312.83
12-15 years			
August	10,520	416,327	252.69
September	7,213	403,773	178.64
October	12,823	398,355	321.90
November	12,731	382,433	332.89
December	8,695	371,615	233.98
12-15 years, 2023			
January	3,424	333,756	102.59
February	1,646	325,781	50.52
March	1,485	322,610	46.03
April	962	317,112	30.34
May	606	232,635	26.05
June	620	229,402	27.03
July	419	226,672	18.48
August	388	218,275	17.78
September	160	214,850	7.45
October	256	158,110	16.19
November	0	8,524	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
December	0	8,442	0.00
12-15 years, 2024			
January	0	8,186	0.00
16-39 years			
16-39 years, 2021			
September	42,136	4,614,046	91.32
October	160,599	4,779,893	335.99
November	475,580	4,730,180	1,005.42
December	895,507	4,442,248	2,015.89
16-39 years, 2022			
January	482,243	3,345,085	1,441.65
February	129,316	2,883,975	448.40
16-39 years			
March	68,209	2,786,812	244.76
April	42,561	2,713,820	156.83
May	41,403	2,669,315	155.11
June	33,721	2,611,134	129.14
July	29,871	2,601,420	114.83
August	21,699	2,484,690	87.33
September	48,289	2,463,519	196.02
October	69,396	2,482,457	279.55
November	53,292	2,426,361	219.64
December	37,236	2,416,690	154.08

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
16-39 years, 2023			
January	16,960	2,183,750	77.66
February	7,512	2,140,141	35.10
March	6,702	2,126,255	31.52
April	4,533	2,096,256	21.62
May	3,029	1,574,001	19.24
June	2,447	1,551,350	15.77
July	1,755	1,470,872	11.93
August	2,052	1,392,572	14.74
September	1,214	1,363,865	8.90
October	1,634	969,438	16.86
November	13	63,708	2.04
December	0	63,462	0.00
16-39 years, 2024			
January	0	60,976	0.00
40-64 years			
40-64 years, 2021			
September	129,219	6,818,686	189.51
October	536,895	6,909,591	777.03
40-64 years			
November	1,192,349	6,588,959	1,809.62
December	1,377,303	5,639,215	2,442.37
40-64 years, 2022			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
January	539,110	4,040,750	1,334.18
February	153,024	3,515,020	435.34
March	84,630	3,378,238	250.52
April	101,765	3,358,318	303.02
May	86,740	3,325,687	260.82
June	60,928	3,266,784	186.51
July	59,436	3,302,999	179.95
August	32,893	3,201,803	102.73
September	107,113	3,207,640	333.93
October	167,635	3,249,921	515.81
November	106,915	3,141,300	340.35
December	69,467	3,111,339	223.27
40-64 years, 2023			
January	30,462	2,824,180	107.86
February	12,903	2,769,556	46.59
March	10,382	2,748,850	37.77
April	7,185	2,714,743	26.47
May	5,201	2,115,396	24.59
June	3,643	2,089,716	17.43
July	1,880	1,792,899	10.49
August	2,611	1,736,044	15.04
September	1,942	1,715,060	11.32
October	2,627	1,286,191	20.42

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
November	43	75,230	5.72
December	0	75,087	0.00
40-64 years, 2024			
40-64 years			
January	0	72,625	0.00
≥ 65 years			
≥ 65 years, 2021			
September	823,900	11,332,180	727.04
October	2,576,207	10,861,564	2,371.86
November	2,538,515	8,621,606	2,944.36
December	1,353,673	6,332,270	2,137.74
≥ 65 years, 2022			
January	432,816	4,824,189	897.18
February	149,793	4,404,253	340.11
March	120,547	4,287,448	281.16
April	354,938	5,065,581	700.69
May	217,825	5,321,649	409.32
June	119,098	5,350,606	222.59
July	109,898	5,590,961	196.56
August	58,261	5,585,798	104.30
September	647,264	5,785,344	1,118.80
October	827,973	5,776,882	1,433.25
November	381,751	5,252,080	726.86

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
December	209,911	5,089,267	412.46
≥ 65 years, 2023			
January	86,541	4,697,124	184.24
February	31,595	4,606,521	68.59
March	22,862	4,576,292	49.96
April	36,490	4,545,459	80.28
May	71,050	4,482,528	158.50
June	32,480	4,406,389	73.71
July	4,034	1,302,869	30.96
≥ 65 years			
≥ 65 years			
September	1,888	1,280,453	14.74
October	*****	923,198	*****
November	*****	38,869	*****
December	0	38,960	0.00
≥ 65 years, 2024			
January	0	38,425	0.00
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[4,5]			
0-6 months			
0-6 months, 2021			
September	0	0	NaN
October	0	*****	0.00
November	0	*****	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
December	0	*****	0.00
0-6 months, 2022			
January	0	*****	0.00
February	0	*****	0.00
March	0	*****	0.00
April	0	*****	0.00
May	*****	*****	*****
June	*****	*****	*****
July	0	*****	0.00
August	0	*****	0.00
September	0	*****	0.00
October	0	*****	0.00
November	0	*****	0.00
December	0	*****	0.00
0-6 months, 2023			
January	0	*****	0.00
February	0	*****	0.00
0-6 months			
March	0	*****	0.00
April	0	*****	0.00
May	0	*****	0.00
June	0	*****	0.00
July	0	*****	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
August	0	*****	0.00
September	0	*****	0.00
October	0	*****	0.00
November	0	0	NaN
December	0	0	NaN
0-6 months, 2024			
January	0	0	NaN
7-59 months			
7-59 months, 2021			
September	21	55	3,818.18
October	15	64	2,343.75
November	23	81	2,839.51
December	23	101	2,277.23
7-59 months, 2022			
January	11	93	1,182.80
February	15	103	1,456.31
March	20	119	1,680.67
April	29	130	2,230.77
May	19	134	1,417.91
June	24	133	1,804.51
July	21	166	1,265.06
August	13	233	557.94
September	48	2,823	170.03

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
October	55	7,222	76.16
7-59 months			
November	42	9,595	43.77
December	51	11,582	44.03
7-59 months, 2023			
January	65	12,394	52.44
February	36	13,423	26.82
March	99	14,419	68.66
April	125	14,960	83.56
May	121	11,301	107.07
June	85	11,287	75.31
July	47	11,198	41.97
August	63	10,850	58.06
September	17	10,762	15.80
October	131	7,688	170.40
November	0	136	0.00
December	0	141	0.00
7-59 months, 2024			
January	0	141	0.00
5-11 years			
5-11 years, 2021			
September	17	88	1,931.82
October	21	118	1,779.66

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
November	104	364	2,857.14
December	269	1,830	1,469.95
5-11 years, 2022			
January	196	2,417	810.92
February	86	2,762	311.37
March	87	3,076	282.83
April	46	3,148	146.12
May	160	7,877	203.12
5-11 years			
June	311	20,238	153.67
July	249	29,152	85.41
August	196	36,233	54.09
September	97	39,051	24.84
October	2,669	43,104	619.20
November	5,072	48,224	1,051.76
December	3,047	48,390	629.68
5-11 years, 2023			
January	1,217	44,568	273.07
February	555	44,496	124.73
March	496	45,066	110.06
April	303	45,233	66.99
May	235	33,549	70.05
June	197	33,624	58.59

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
July	143	33,502	42.68
August	175	32,806	53.34
September	56	32,704	17.12
October	128	24,490	52.27
November	0	688	0.00
December	0	693	0.00
5-11 years, 2024			
January	0	682	0.00
12-15 years			
12-15 years, 2021			
September	127	2,988	425.03
October	107	3,214	332.92
November	95	3,433	276.73
December	146	4,116	354.71
12-15 years, 2022			
12-15 years			
January	1,004	36,018	278.75
February	341	45,410	75.09
March	200	49,269	40.59
April	149	50,475	29.52
May	246	52,680	46.70
June	304	55,533	54.74
July	273	58,360	46.78

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
August	180	58,771	30.63
September	3,664	59,161	619.33
October	5,776	57,689	1,001.23
November	4,931	53,796	916.61
December	3,152	50,875	619.56
12-15 years, 2023			
January	1,071	45,261	236.63
February	417	44,307	94.12
March	391	44,174	88.51
April	201	43,554	46.15
May	161	32,646	49.32
June	165	32,477	50.81
July	130	32,125	40.47
August	127	31,288	40.59
September	57	30,961	18.41
October	151	23,391	64.55
November	0	1,189	0.00
December	0	1,174	0.00
12-15 years, 2024			
January	0	1,142	0.00
16-39 years			
16-39 years, 2021			
16-39 years			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
September	1,628	52,258	311.53
October	2,881	103,829	277.48
November	6,345	251,605	252.18
December	10,027	502,554	199.52
16-39 years, 2022			
January	6,808	627,210	108.54
February	3,098	661,627	46.82
March	2,599	683,919	38.00
April	4,550	695,908	65.38
May	6,944	707,021	98.21
June	6,123	711,342	86.08
July	6,053	712,879	84.91
August	3,347	700,899	47.75
September	46,759	705,768	662.53
October	64,234	680,610	943.77
November	47,119	628,926	749.20
December	29,846	601,024	496.59
16-39 years, 2023			
January	12,107	537,333	225.32
February	4,119	528,771	77.90
March	3,359	532,134	63.12
April	2,077	531,062	39.11
May	1,588	423,639	37.48

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
June	1,213	424,009	28.61
July	735	403,982	18.19
August	1,133	392,530	28.86
September	*****	390,187	*****
October	1,343	286,683	46.85
November	*****	11,775	*****
16-39 years			
December	0	11,850	0.00
16-39 years, 2024			
January	*****	11,662	*****
40-64 years			
40-64 years, 2021			
September	5,441	191,323	284.39
October	13,511	455,726	296.47
November	25,656	1,066,564	240.55
December	27,901	1,750,199	159.42
40-64 years, 2022			
January	15,821	1,941,181	81.50
February	10,706	2,005,282	53.39
March	19,197	2,042,153	94.00
April	138,599	2,070,609	669.36
May	129,370	1,980,479	653.23
June	84,779	1,883,236	450.18

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
July	85,303	1,836,192	464.56
August	38,615	1,751,165	220.51
September	124,977	1,755,745	711.82
October	203,015	1,723,483	1,177.93
November	130,939	1,570,271	833.86
December	81,255	1,493,930	543.90
40-64 years, 2023			
January	32,755	1,342,078	244.06
February	12,670	1,318,041	96.13
March	9,516	1,320,189	72.08
April	6,449	1,316,422	48.99
May	4,967	1,080,499	45.97
June	3,268	1,078,923	30.29
40-64 years			
July	1,707	928,460	18.39
August	2,525	909,446	27.76
September	2,144	908,909	23.59
October	3,678	689,783	53.32
November	26	29,031	8.96
December	0	29,148	0.00
40-64 years, 2024			
January	0	28,622	0.00
≥ 65 years			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
≥ 65 years, 2021			
September	8,676	610,874	142.03
October	24,764	2,428,648	101.97
November	28,848	4,338,535	66.49
December	16,294	5,325,108	30.60
≥ 65 years, 2022			
January	14,373	5,491,285	26.17
February	28,784	5,580,770	51.58
March	110,041	5,626,779	195.57
April	1,052,233	5,727,285	1,837.23
May	641,276	4,845,002	1,323.58
June	312,296	4,295,141	727.09
July	282,236	4,101,135	688.19
August	126,285	3,870,562	326.27
September	353,560	4,139,282	854.16
October	579,493	4,469,675	1,296.50
November	316,750	4,199,817	754.20
December	177,584	4,089,596	434.23
≥ 65 years, 2023			
January	74,384	3,832,780	194.07
≥ 65 years			
February	27,187	3,795,650	71.63
March	19,924	3,809,078	52.31
April	57,065	3,825,081	149.19

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
May	126,223	3,812,732	331.06
June	54,561	3,727,636	146.37
July	3,384	917,336	36.89
August	4,079	914,559	44.60
September	1,894	919,130	20.61
October	*****	609,978	*****
November	*****	24,536	*****
December	0	24,765	0.00
≥ 65 years, 2024			
January	0	24,652	0.00
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[4,6]			
0-6 months			
0-6 months, 2021			
September	*****	45	*****
October	*****	48	*****
November	*****	44	*****
December	*****	55	*****
0-6 months, 2022			
January	*****	50	*****
February	*****	49	*****
March	*****	60	*****
April	*****	56	*****
May	*****	53	*****

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
June	*****	54	*****
July	*****	127	*****
August	*****	283	*****
0-6 months			
September	*****	229	*****
October	*****	169	*****
November	*****	114	*****
December	*****	115	*****
0-6 months, 2023			
January	*****	96	*****
February	*****	74	*****
March	*****	57	*****
April	*****	107	*****
May	*****	77	*****
June	0	70	0.00
July	0	66	0.00
August	*****	77	*****
September	0	40	0.00
October	0	17	0.00
November	0	0	NaN
December	0	0	NaN
0-6 months, 2024			
January	0	0	NaN

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
7-59 months			
7-59 months, 2021			
September	117	792	1,477.27
October	147	828	1,775.36
November	119	811	1,467.32
December	150	977	1,535.31
7-59 months, 2022			
January	79	905	872.93
February	88	890	988.76
March	85	881	964.81
7-59 months			
April	88	860	1,023.26
May	86	824	1,043.69
June	94	814	1,154.79
July	248	32,339	76.69
August	436	91,675	47.56
September	18,834	119,330	1,578.31
October	18,840	121,845	1,546.23
November	12,482	112,638	1,108.15
December	9,307	114,974	809.49
7-59 months, 2023			
January	9,274	103,700	894.31
February	6,037	97,109	621.67

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
March	5,920	94,671	625.32
April	3,947	89,549	440.76
May	2,296	61,687	372.20
June	1,877	58,588	320.37
July	1,139	57,365	198.55
August	1,029	53,673	191.72
September	231	50,950	45.34
October	263	33,725	77.98
November	0	1,954	0.00
December	0	1,915	0.00
7-59 months, 2024			
January	0	1,818	0.00
5-11 years			
5-11 years, 2021			
September	83	1,852	448.16
October	131	1,918	683.00
November	1,161	14,474	802.13
5-11 years			
December	4,503	413,821	108.82
5-11 years, 2022			
January	2,474	494,340	50.05
February	1,346	543,791	24.75
March	932	563,936	16.53

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
April	384	566,118	6.78
May	22,068	566,639	389.45
June	45,481	540,602	841.30
July	29,112	508,004	573.07
August	25,971	470,819	551.61
September	11,148	439,148	253.86
October	16,312	424,657	384.12
November	28,187	402,691	699.97
December	17,005	375,145	453.29
5-11 years, 2023			
January	7,156	325,867	219.60
February	3,556	312,986	113.62
March	3,184	305,903	104.09
April	2,039	296,433	68.78
May	1,245	212,523	58.58
June	984	206,626	47.62
July	632	201,807	31.32
August	667	191,962	34.75
September	131	186,535	7.02
October	165	127,734	12.92
November	0	6,193	0.00
December	0	6,120	0.00
5-11 years, 2024			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
January	0	5,907	0.00
12-15 years			
12-15 years, 2021			
September	1,319	519,037	25.41
October	778	540,280	14.40
November	774	538,697	14.37
December	1,879	550,161	34.15
12-15 years, 2022			
January	114,658	506,881	2,262.03
February	28,834	396,176	727.81
March	13,772	371,373	370.84
April	7,332	356,341	205.76
May	10,858	349,397	310.76
June	12,908	336,914	383.12
July	10,287	331,431	310.38
August	7,987	312,478	255.60
September	5,610	302,177	185.65
October	9,831	297,400	330.56
November	9,789	284,516	344.06
December	6,653	275,143	241.80
12-15 years, 2023			
January	2,618	245,324	106.72
February	1,270	238,679	53.21

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
March	1,136	235,595	48.22
April	760	230,684	32.95
May	470	168,133	27.95
June	462	165,131	27.98
July	327	162,778	20.09
August	293	155,610	18.83
September	123	152,565	8.06
October	190	108,674	17.48
12-15 years			
November	0	6,395	0.00
December	0	6,294	0.00
12-15 years, 2024			
January	0	6,079	0.00
16-39 years			
16-39 years, 2021			
September	22,699	3,203,960	70.85
October	99,488	3,309,837	300.58
November	313,852	3,259,155	962.99
December	623,662	3,061,552	2,037.08
16-39 years, 2022			
January	337,761	2,301,853	1,467.34
February	90,660	1,961,924	462.10
March	47,090	1,889,452	249.23

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
April	28,488	1,829,310	155.73
May	27,367	1,789,694	152.91
June	22,150	1,738,926	127.38
July	19,684	1,730,369	113.76
August	14,208	1,633,900	86.96
September	32,511	1,609,100	202.04
October	46,654	1,618,152	288.32
November	35,909	1,573,357	228.23
December	25,310	1,559,965	162.25
16-39 years, 2023			
January	11,377	1,398,216	81.37
February	4,948	1,358,966	36.41
March	4,438	1,343,647	33.03
April	2,983	1,315,246	22.68
May	1,963	983,356	19.96
16-39 years			
June	1,652	962,223	17.17
July	1,159	914,700	12.67
August	1,321	849,005	15.56
September	755	823,912	9.16
October	950	548,244	17.33
November	13	46,119	2.82
December	0	45,752	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
16-39 years, 2024			
January	0	43,758	0.00
40-64 years			
40-64 years, 2021			
September	39,951	3,258,538	122.60
October	220,504	3,300,603	668.07
November	541,548	3,146,236	1,721.26
December	671,644	2,704,466	2,483.46
40-64 years, 2022			
January	261,978	1,903,341	1,376.41
February	71,742	1,623,632	441.86
March	37,530	1,549,454	242.21
April	42,534	1,525,976	278.73
May	37,228	1,501,201	247.99
June	26,191	1,461,705	179.18
July	24,629	1,481,394	166.26
August	13,594	1,420,345	95.71
September	46,409	1,413,368	328.36
October	72,901	1,433,149	508.68
November	46,996	1,377,222	341.24
December	30,421	1,358,580	223.92
40-64 years, 2023			
40-64 years			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
January	13,256	1,217,763	108.86
February	5,545	1,180,122	46.99
March	4,490	1,161,870	38.64
April	3,060	1,135,246	26.95
May	2,008	861,950	23.30
June	1,476	842,354	17.52
July	832	752,701	11.05
August	1,069	713,444	14.98
September	845	696,802	12.13
October	1,015	480,507	21.12
November	25	39,666	6.30
December	0	39,421	0.00
40-64 years, 2024			
January	0	37,778	0.00
≥ 65 years			
≥ 65 years, 2021			
September	195,372	3,515,647	555.72
October	751,823	3,394,871	2,214.58
November	770,414	2,709,988	2,842.87
December	430,158	2,009,474	2,140.65
≥ 65 years, 2022			
January	133,472	1,493,920	893.43
February	42,622	1,338,837	318.35

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
March	30,017	1,291,089	232.49
April	84,398	1,468,642	574.67
May	56,566	1,527,988	370.20
June	31,960	1,516,701	210.72
July	29,277	1,598,505	183.15
August	16,381	1,579,405	103.72
≥ 65 years			
September	152,977	1,614,909	947.28
October	207,633	1,648,735	1,259.35
November	97,869	1,513,783	646.52
December	53,836	1,470,510	366.10
≥ 65 years, 2023			
January	22,003	1,332,790	165.09
February	8,272	1,287,470	64.25
March	6,012	1,263,070	47.60
April	10,132	1,235,951	81.98
May	19,352	1,200,626	161.18
June	8,693	1,161,642	74.83
July	1,453	445,054	32.65
August	1,831	434,102	42.18
September	707	423,595	16.69
October	*****	276,591	*****
November	*****	12,779	*****

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
December	0	12,748	0.00
≥ 65 years, 2024			
January	0	12,421	0.00
With Booster COVID-19 Vaccine (Booster Specific Code)[7]			
0-6 months			
0-6 months, 2021			
September	0	47,391	0.00
October	0	57,216	0.00
November	*****	50,073	*****
December	*****	59,995	*****
0-6 months, 2022			
January	0	48,378	0.00
February	0	40,654	0.00
0-6 months			
March	*****	41,412	*****
April	0	39,690	0.00
May	*****	37,646	*****
June	*****	34,988	*****
July	*****	39,596	*****
August	*****	45,988	*****
September	*****	40,390	*****
October	*****	48,760	*****
November	*****	41,240	*****

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
December	*****	50,077	*****
0-6 months, 2023			
January	*****	46,079	*****
February	19	39,452	4.82
March	*****	39,890	*****
April	213	37,645	56.58
May	616	25,491	241.65
June	509	23,552	216.12
July	471	26,594	177.11
August	450	31,317	143.69
September	133	25,702	51.75
October	*****	21,895	*****
November	0	794	0.00
December	0	1,247	0.00
0-6 months, 2024			
January	0	1,252	0.00
7-59 months			
7-59 months, 2021			
September	*****	1,568,737	*****
October	*****	1,575,880	*****
7-59 months			
November	157	1,553,326	1.01
December	*****	1,583,489	*****

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
7-59 months, 2022			
January	76	1,245,448	0.61
February	22	1,228,351	0.18
March	29	1,240,510	0.23
April	17	1,243,583	0.14
May	27	1,243,175	0.22
June	190	1,234,571	1.54
July	277	1,354,008	2.05
August	200	1,337,286	1.50
September	195	1,305,843	1.49
October	238	1,321,631	1.80
November	207	1,290,383	1.60
December	5,726	1,326,655	43.16
7-59 months, 2023			
January	10,873	1,204,513	90.27
February	7,256	1,177,442	61.63
March	7,245	1,184,896	61.14
April	6,146	1,178,268	52.16
May	5,459	822,534	66.37
June	4,106	812,854	50.51
July	2,780	898,087	30.95
August	2,673	890,422	30.02
September	603	868,671	6.94

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
October	15	638,069	0.24
November	0	27,409	0.00
December	0	27,814	0.00
7-59 months, 2024			
7-59 months			
January	0	27,211	0.00
5-11 years			
5-11 years, 2021			
September	88	2,819,352	0.31
October	70	2,829,364	0.25
November	224,980	2,795,368	804.83
December	80,463	2,617,208	307.44
5-11 years, 2022			
January	43,235	2,003,798	215.77
February	12,822	1,934,668	66.27
March	6,375	1,941,016	32.84
April	4,368	1,943,466	22.48
May	8,488	1,944,845	43.64
June	18,753	1,934,784	96.93
July	18,681	2,127,381	87.81
August	17,493	2,091,366	83.64
September	7,991	2,039,398	39.18
October	23,424	2,058,715	113.78

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
November	42,530	1,991,598	213.55
December	26,438	2,009,867	131.54
5-11 years, 2023			
January	11,697	1,815,471	64.43
February	5,828	1,782,033	32.70
March	5,126	1,800,065	28.48
April	3,571	1,801,853	19.82
May	2,108	1,226,868	17.18
June	1,986	1,226,156	16.20
July	1,600	1,389,543	11.51
August	1,857	1,395,063	13.31
5-11 years			
September	343	1,374,051	2.50
October	31	1,011,958	0.31
November	0	47,732	0.00
December	0	48,160	0.00
5-11 years, 2024			
January	0	47,019	0.00
12-15 years			
12-15 years, 2021			
September	144	1,814,032	0.79
October	82	1,820,259	0.45
November	480	1,797,224	2.67

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
December	855	1,820,772	4.70
12-15 years, 2022			
January	50,634	1,486,819	340.55
February	22,456	1,412,484	158.98
March	12,123	1,395,073	86.90
April	6,782	1,380,796	49.12
May	8,025	1,370,367	58.56
June	9,695	1,353,642	71.62
July	9,313	1,474,076	63.18
August	7,343	1,447,747	50.72
September	21,642	1,411,604	153.31
October	34,978	1,397,622	250.27
November	31,664	1,327,664	238.49
December	20,960	1,327,340	157.91
12-15 years, 2023			
January	7,692	1,194,398	64.40
February	3,382	1,167,609	28.97
March	2,915	1,173,256	24.85
12-15 years			
April	1,886	1,168,360	16.14
May	1,118	808,274	13.83
June	1,243	803,541	15.47
July	982	904,869	10.85

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
August	930	900,924	10.32
September	186	884,674	2.10
October	33	652,138	0.51
November	0	30,335	0.00
December	0	30,602	0.00
12-15 years, 2024			
January	0	29,799	0.00
16-39 years			
16-39 years, 2021			
September	1,903	12,212,066	1.56
October	26,150	12,316,639	21.23
November	102,445	12,079,724	84.81
December	196,692	12,302,777	159.88
16-39 years, 2022			
January	132,828	10,602,949	125.27
February	71,042	10,294,544	69.01
March	42,721	10,347,824	41.29
April	29,124	10,348,315	28.14
May	30,225	10,335,135	29.24
June	27,436	10,279,957	26.69
July	27,691	11,313,539	24.48
August	20,096	11,181,905	17.97
September	268,415	10,823,516	247.99

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
October	373,755	10,738,265	348.06
November	282,338	10,103,440	279.45
16-39 years			
December	189,953	10,215,235	185.95
16-39 years, 2023			
January	77,800	9,230,530	84.29
February	30,021	9,003,779	33.34
March	24,980	9,111,282	27.42
April	16,558	9,123,677	18.15
May	11,035	6,592,315	16.74
June	8,640	6,567,887	13.15
July	6,687	7,071,434	9.46
August	8,204	7,017,904	11.69
September	2,442	6,836,194	3.57
October	254	4,785,869	0.53
November	25	218,436	1.14
December	0	222,636	0.00
16-39 years, 2024			
January	0	213,886	0.00
40-64 years			
40-64 years, 2021			
September	7,143	15,435,753	4.63
October	125,255	15,532,565	80.64

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
November	373,923	15,231,872	245.49
December	450,619	15,129,590	297.84
40-64 years, 2022			
January	195,430	13,311,802	146.81
February	86,505	12,927,250	66.92
March	58,372	12,879,199	45.32
April	132,239	12,822,540	103.13
May	123,128	12,673,846	97.15
June	90,378	12,522,944	72.17
40-64 years			
July	92,787	13,586,928	68.29
August	50,779	13,483,108	37.66
September	480,536	13,180,013	364.59
October	746,962	12,858,841	580.89
November	478,647	11,886,039	402.70
December	307,156	11,742,372	261.58
40-64 years, 2023			
January	122,009	10,518,875	115.99
February	46,915	10,246,366	45.79
March	35,414	10,276,768	34.46
April	22,225	10,251,107	21.68
May	13,418	7,819,829	17.16
June	9,545	7,791,928	12.25

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
July	6,259	7,716,291	8.11
August	8,868	7,786,299	11.39
September	3,122	7,670,590	4.07
October	626	5,540,924	1.13
November	63	229,756	2.74
December	0	232,647	0.00
40-64 years, 2024			
January	0	224,799	0.00
≥ 65 years			
≥ 65 years, 2021			
September	465,882	25,634,033	181.74
October	2,645,966	25,420,866	1,040.86
November	3,146,933	22,652,364	1,389.23
December	1,736,908	19,841,957	875.37
≥ 65 years, 2022			
January	477,978	17,205,131	277.81
≥ 65 years			
February	162,310	16,553,276	98.05
March	189,347	16,451,665	115.09
April	1,007,657	16,296,031	618.35
May	593,931	15,327,000	387.51
June	337,685	14,760,223	228.78
July	333,486	15,517,247	214.91
August	159,113	15,420,972	103.18
September	753,148	15,130,909	497.75

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
October	1,118,655	14,691,219	761.44
November	592,280	13,453,019	440.26
December	342,753	13,246,126	258.76
≥ 65 years, 2023			
January	145,857	12,220,185	119.36
February	55,413	11,959,333	46.33
March	40,044	11,997,728	33.38
April	37,353	12,016,669	31.08
May	55,302	11,879,887	46.55
June	27,832	11,863,799	23.46
July	9,417	5,713,862	16.48
August	12,429	5,865,294	21.19
September	3,498	5,815,780	6.01
October	*****	4,340,053	*****
November	*****	113,891	*****
December	0	114,627	0.00
≥ 65 years, 2024			
January	0	113,179	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] ***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[3] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[4] Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[5] The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[6] The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[7] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
*NaN: Not a number

Table 4 r01. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

			Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]			
			1-10 days		11-17 days	
	Total Number of Patients with At Least One COVID-19 Vaccine	Total Number of Patients with Two COVID-19 Vaccines[3]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccination	38,575,376	30,279,682	192,933	0.6%	9,947,271	32.9%

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days.

Table 4 r01. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines2							
18-21 days		22-24 days		25-27 days		28-40 days	
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
2,498,914	8.3%	8,180,901	27.0%	1,719,393	5.7%	1,390,191	4.6%

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days.

Table 4 r01. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines2												
41-50 days		51-60 days		61+ days		Distribution of At-Risk Time in Days, by Episode						
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
146,080	0.5%	97,528	0.3%	6,106,471	20.2%	1	17	24	28	1,015	66.6	100.0

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days.

Table 4 r02. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

			Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]			
			1-10 days		11-17 days	
	Total Number of Patients with At Least Two COVID-19 Vaccines	Total Number of Patients with Two COVID-19 Vaccines[3]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccination	30,109,785	30,070,466	176,125	0.6%	9,905,438	32.9%

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days. A small subset of patients do not appear to have received their second COVID-19 vaccine and thus are not included in the calculation of the time interval between the first and second COVID-19 vaccines. This is despite our cohort inclusion criteria requiring at least two COVID-19 vaccines. This discrepancy arises because to assess the time between the first and second COVID-19 vaccinations, the second vaccination is considered as one of the "end of follow-up" points. For a small number of patients, an earlier "end of follow-up" point, such as disenrollment/re-enrollment, occurred before the second vaccine. Consequently, the follow-up ended at this point and did not extend until the second vaccine was observed.

Table 4 r02. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

18-21 days		22-24 days		25-27 days		28-40 days	
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
2,462,168	8.2%	8,135,967	27.1%	1,686,872	5.6%	1,379,441	4.6%

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days. A small subset of patients do not appear to have received their second COVID-19 vaccine and thus are not included in the calculation of the time interval between the first and second COVID-19 vaccines. This is despite our cohort inclusion criteria requiring at least two COVID-19 vaccines. This discrepancy arises because to assess the time between the first and second COVID-19 vaccinations, the second vaccination is considered as one of the "end of follow-up" points. For a small number of patients, an earlier "end of follow-up" point, such as disenrollment/re-enrollment, occurred before the second vaccine. Consequently, the follow-up ended at this point and did not extend until the second vaccine was observed.

Table 4 r02. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

41-50 days		51-60 days		61+ days		Distribution of At-Risk Time in Days, by Episode						
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
145,113	0.5%	96,880	0.3%	6,082,462	20.2%	1	17	24	28	1,015	66.8	100.1

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days. A small subset of patients do not appear to have received their second COVID-19 vaccine and thus are not included in the calculation of the time interval between the first and second COVID-19 vaccines. This is despite our cohort inclusion criteria requiring at least two COVID-19 vaccines. This discrepancy arises because to assess the time between the first and second COVID-19 vaccinations, the second vaccination is considered as one of the "end of follow-up" points. For a small number of patients, an earlier "end of follow-up" point, such as disenrollment/re-enrollment, occurred before the second vaccine. Consequently, the follow-up ended at this point and did not extend until the second vaccine was observed.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

			Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]	
			1-10 days	
	Number of Patients with Only the First Component of the Combination[3]	Number of Exposure Episodes with First and Second Components of Combination [4]	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	21,480,531	16,967,289	91,260	0.5%
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	15,409,521	11,956,511	71,603	0.6%
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	1,694,574	186,679	9,663	5.2%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	106,283	45,906	296	0.6%
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	21,480,531	1,395,619	5,667	0.4%
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	15,409,521	1,883,481	6,745	0.4%
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	21,480,531	70,218	724	1.0%
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	21,480,531	16,741	798	4.8%
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	15,409,521	19,971	919	4.6%
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	15,409,521	62,948	667	1.1%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

			Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]	
			1-10 days	
	Number of Patients with Only the First Component of the Combination[3]	Number of Exposure Episodes with First and Second Components of Combination [4]	Number of Episodes	Percent of Total Episodes
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	1,694,574	353,510	825	0.2%
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	1,694,574	336,449	918	0.3%
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	1,694,574	6,101	370	6.1%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	106,283	34,741	1,343	3.9%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	106,283	43,638	2,222	5.1%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	106,283	2,158	588	27.2%
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	30,221,690	22,806,991	112,494	0.5%
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	1,947,898	1,605,596	8,894	0.6%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

			Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]	
			1-10 days	
	Number of Patients with Only the First Component of the Combination[3]	Number of Exposure Episodes with First and Second Components of Combination [4]	Number of Episodes	Percent of Total Episodes
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	30,547,553	125,712	9,035	7.2%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	3,669,473	376,045	16,429	4.4%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	30,547,553	236,587	1,652	0.7%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	3,669,473	1,473,864	9,412	0.6%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)	4,358,350	740,334	7,496	1.0%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	4,358,350	500,044	1,668	0.3%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	4,358,350	3,624,130	2,711	0.1%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

			Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]	
			1-10 days	
	Number of Patients with Only the First Component of the Combination[3]	Number of Exposure Episodes with First and Second Components of Combination [4]	Number of Episodes	Percent of Total Episodes

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines2									
11-17 days		18-21 days		22-24 days		25-27 days		28-40 days	
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccine Brand for the First and Second Observed Records									
9,882,819	58.2%	2,232,867	13.2%	1,261,845	7.4%	315,268	1.9%	422,520	2.5%
47,267	0.4%	256,697	2.1%	6,910,638	57.8%	1,396,929	11.7%	959,149	8.0%
2,012	1.1%	788	0.4%	1,062	0.6%	702	0.4%	1,061	0.6%
12,518	27.3%	3,580	7.8%	12,101	26.4%	5,861	12.8%	3,588	7.8%
13,403	1.0%	4,599	0.3%	15,835	1.1%	5,373	0.4%	7,192	0.5%
18,340	1.0%	8,315	0.4%	11,448	0.6%	4,029	0.2%	6,352	0.3%
11,042	15.7%	2,984	4.2%	1,772	2.5%	682	1.0%	1,633	2.3%
1,052	6.3%	357	2.1%	254	1.5%	155	0.9%	510	3.0%
384	1.9%	231	1.2%	870	4.4%	264	1.3%	621	3.1%
1,104	1.8%	691	1.1%	8,643	13.7%	2,411	3.8%	2,235	3.6%
376	0.1%	173	0.0%	1,005	0.3%	603	0.2%	654	0.2%
1,571	0.5%	876	0.3%	350	0.1%	193	0.1%	485	0.1%
135	2.2%	81	1.3%	37	0.6%	51	0.8%	84	1.4%
871	2.5%	576	1.7%	8,338	24.0%	3,045	8.8%	2,409	6.9%
10,847	24.9%	3,878	8.9%	2,115	4.8%	940	2.2%	1,357	3.1%
162	7.5%	81	3.8%	52	2.4%	64	3.0%	136	6.3%
COVID-19 Vaccine Code Type for the First and Second Observed Records									
7,001,859	30.7%	1,728,714	7.6%	6,091,438	26.7%	1,217,199	5.3%	946,335	4.1%
624,457	38.9%	155,529	9.7%	478,981	29.8%	115,183	7.2%	109,101	6.8%
6,389	5.1%	16,302	13.0%	5,549	4.4%	17,613	14.0%	6,082	4.8%
8,730	2.3%	7,274	1.9%	6,799	1.8%	6,669	1.8%	7,057	1.9%
31,579	13.3%	18,982	8.0%	26,966	11.4%	15,250	6.4%	9,694	4.1%
77,088	5.2%	35,976	2.4%	55,408	3.8%	29,825	2.0%	28,728	1.9%
69,620	9.4%	28,545	3.9%	61,895	8.4%	20,752	2.8%	21,977	3.0%
50,090	10.0%	17,461	3.5%	48,251	9.6%	9,867	2.0%	10,534	2.1%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

1,513,513	41.8%	383,665	10.6%	978,700	27.0%	214,182	5.9%	199,591	5.5%

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Sentinel

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

41-50 days		51-60 days		61+ days		Distribution of At-Risk Time in Days, by Episode						
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
COVID-19 Vaccine Brand for the First and Second Observed Records												
76,463	0.5%	50,600	0.3%	2,633,647	15.5%	1	17	17	24	1,011	54.2	91.2
66,067	0.6%	41,663	0.3%	2,206,498	18.5%	1	24	24	29	1,041	64.7	93.2
469	0.3%	1,243	0.7%	169,679	90.9%	1	196	227	250	861	208.7	78.1
535	1.2%	546	1.2%	6,881	15.0%	1	17	24	28	990	52.9	82.3
2,582	0.2%	2,263	0.2%	1,338,705	95.9%	1	244	335	529	1,042	374.7	179.7
2,513	0.1%	2,714	0.1%	1,823,025	96.8%	1	274	394	592	1,111	422.0	186.9
709	1.0%	519	0.7%	50,153	71.4%	1	30	249	354	1,108	259.8	209.7
306	1.8%	315	1.9%	12,994	77.6%	1	76	230	280	964	207.7	142.2
316	1.6%	338	1.7%	16,028	80.3%	1	105	243	283	1,024	216.9	135.2
621	1.0%	602	1.0%	45,974	73.0%	1	40	257	346	1,078	261.9	200.1
293	0.1%	531	0.2%	349,050	98.7%	1	220	244	285	961	278.2	117.3
239	0.1%	543	0.2%	331,274	98.5%	1	225	261	408	997	321.8	152.1
42	0.7%	47	0.8%	5,254	86.1%	1	191	242	341	992	277.3	186.8
331	1.0%	295	0.8%	17,533	50.5%	1	24	69	249	1,000	150.0	155.3
400	0.9%	371	0.9%	21,508	49.3%	1	17	52	252	1,018	154.1	173.6
41	1.9%	59	2.7%	975	45.2%	1	8	39	202	584	94.9	102.6
COVID-19 Vaccine Code Type for the First and Second Observed Records												
99,522	0.4%	66,866	0.3%	5,542,564	24.3%	1	17	24	41	1,015	76.3	107.7
10,755	0.7%	6,693	0.4%	96,003	6.0%	1	17	22	24	1,009	34.2	56.4
1,500	1.2%	1,200	1.0%	62,042	49.4%	1	21	53	270	1,043	176.2	200.9
2,485	0.7%	2,179	0.6%	318,423	84.7%	1	225	286	533	1,061	340.0	217.4
1,358	0.6%	845	0.4%	130,261	55.1%	1	24	204	272	1,065	184.3	178.3
6,286	0.4%	4,537	0.3%	1,226,604	83.2%	1	216	261	326	1,018	275.9	168.5
5,259	0.7%	3,903	0.5%	520,887	70.4%	1	27	240	299	1,043	241.7	200.4
2,080	0.4%	1,644	0.3%	358,449	71.7%	1	26	252	412	1,020	272.9	213.4
22,116	0.6%	14,570	0.4%	295,082	8.1%	1	17	20	24	948	40.1	72.4

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5,127,770	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3,705,112	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,239,263	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,918,442	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,809,054	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,692,895	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,433,293	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,264,569	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	949,905	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	774,753	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	657,458	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	617,701	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	565,458	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	538,914	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	535,881	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	479,400	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	446,834	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	434,488	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	411,199	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	390,420	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	335,746	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	290,257	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	268,676	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	235,690	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	228,806	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	223,037	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	220,130	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	202,658	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	202,117	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	192,393	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	179,471	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	176,415	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	168,019	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	166,478	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	159,599	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	145,041	OA
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	131,325	AV
0001a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	129,776	OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	125,909	OA
208	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	122,581	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	121,014	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	118,114	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	117,999	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	114,987	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	109,755	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	107,150	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	103,796	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	100,079	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	92,944	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV		OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	92,011	AV
0011a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	89,159	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	85,270	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	74,420	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	71,183	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	71,046	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	70,266	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	70,016	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	68,485	AV
0001a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	67,584	AV
0004a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	67,126	AV
207	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	64,368	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
208	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	63,987	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	63,887	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	63,701	AV
208	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	61,175	OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	60,965	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	56,392	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	55,029	AV
80777027399		Procedure	ND		AV
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	53,610	OA
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	53,083	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	52,845	OA
208	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	51,302	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	49,541	OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	48,740	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	47,142	OA
0011a		Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	46,938	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	46,064	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	41,791	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	39,761	AV
208		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	38,808	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	38,595	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	38,378	AV
208	Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	37,485	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	36,182	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	36,077	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	33,094	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	30,208	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	30,147	AV
0003a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	28,900	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	28,121	OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	27,663	AV
208	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	27,265	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	27,201	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	26,704	AV
0004a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	26,573	AV
0012a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	25,939	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24,561	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24,438	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	24,327	AV
0013a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	23,646	AV
0002a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	22,345	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	22,174	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	22,153	AV
0004a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	20,531	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	20,321	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	19,469	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18,438	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	17,554	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	17,228	AV
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0001a	Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	17,179	OA
0071a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	16,997	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	15,750	OA
91300	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	15,512	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	15,037	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	15,013	AV
0064a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	14,716	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13,444	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	13,344	AV
0003a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	13,278	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	12,425	OA
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	11,088	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	11,086	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	10,931	AV
91300	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
59267100002	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	10,302	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10,198	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10,194	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	9,619	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9,541	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9,241	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9,160	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	9,110	AV
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	9,103	OA
91300		Procedure	C4		AV
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8,755	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	8,660	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	8,377	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	8,368	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	8,190	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8,134	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	8,062	AV
59267100001		Procedure	ND		AV
0004a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	8,053	OA
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	7,935	OA
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	7,509	OA
207		Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7,266	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7,234	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7,043	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular	Procedure	C4	6,975	OA
0001a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,938	OA
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6,856	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6,766	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6,715	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	6,694	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	6,630	AV
208	Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6,372	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	6,150	AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,127	OA
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,034	OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5,822	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	5,795	AV
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5,699	OA
91300		Procedure	C4		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	5,661	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5,654	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5,622	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5,506	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	5,398	OA
91301	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
80777027399	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
207	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		AV
	(Sars-Cov-2) (Coronavirus Disease [covid-19])				
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,				
	100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,				
	Lnp, Preservative Free, 100 Mcg/0.5ml Or				
	50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or				
	50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022 Rescinded				
	Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	5,342	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0003a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	C4		AV
	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For				
	Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,				
	Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular				
	Injection Of Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein,				
	Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	5,324	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0002a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	5,297	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	5,241	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	5,215	AV
0002a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4,983	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4,922	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4,798	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4,786	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	4,736	AV
0002a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4,722	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	4,700	OA
91301	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	4,492	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	4,395	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4,349	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4,236	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4,210	AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	4,173	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	4,112	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4,080	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	3,942	AV
0012a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3,911	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	3,887	OA
0064a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,866	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,848	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,846	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,815	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular	Procedure	C4	3,781	AV
0001a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3,773	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,772	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,631	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,533	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3,515	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3,489	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3,438	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	3,430	AV
80777027399		Procedure	ND		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	3,408	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3,390	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3,362	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	3,353	OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3,167	OA
91301		Procedure	C4		AV
0011a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,157	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,139	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,134	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,086	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,032	OA
91301		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,020	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3,012	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,966	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,953	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2,781	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	2,759	AV
207	Lnp, Preservative Free, 100 Mcg/0.5ml Or	Procedure	CV		OA
0011a	50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	2,737	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	2,650	OA
208	Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2,616	OA
0071a		Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	2,569	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2,513	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2,472	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2,471	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,437	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	2,409	AV
59267100002		Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,392	OA
91301	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2,358	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,326	AV
0012a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,311	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	2,307	AV
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,301	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,301	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2,282	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,264	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2,231	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2,220	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,193	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2,169	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2,169	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,139	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2,121	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,119	OA
91300	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
59267100002	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,106	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,097	OA
0013a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,095	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,083	AV
0013a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,004	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a		Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1,989	OA
0071a		Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1,989	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,981	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,972	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,962	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,949	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,932	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1,928	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1,925	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,910	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1,905	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,897	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,892	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,874	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0003a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	1,856	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1,842	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	1,834	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-	Procedure	CV	1,797	OA
0071a	Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,794	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-	Procedure	CV	1,774	OA
0071a	Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,771	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1,766	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	1,760	OA
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,705	OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,700	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1,698	OA
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-	Procedure	CV	1,672	OA
0071a	Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,665	OA
0011a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	1,656	OA
0012a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,645	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,644	AV
80777027399		Procedure	ND		AV
0001a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1,627	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,575	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,570	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,552	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,552	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	1,538	AV
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,533	OA
0004a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1,526	OA
0012a		Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1,521	AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,511	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,468	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,467	OA
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		OA
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,439	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,439	OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,427	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,417	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,410	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,359	OA
207	Lnp, Preservative Free, 100 Mcg/0.5ml Or	Procedure	CV		OA
0011a	50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular	Procedure	C4	1,347	OA
0011a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,340	AV
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0004a	Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1,325	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,322	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1,275	ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,268	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,259	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,258	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1,257	OA
208		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,244	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1,227	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1,187	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,178	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1,161	OA
0013a		Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1,161	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,156	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0013a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1,149	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1,146	AV
208		Procedure	CV		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,124	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1,069	OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	1,068	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,047	OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1,038	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1,024	OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	994	OA
0001a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	969	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	966	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	947	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	936	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	926	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	920	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	918	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	914	OA
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	910	OA
0011a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	ND	900	AV
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	885	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	882	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	859	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	859	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	854	OA
0004a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	844	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	844	AV
207	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	834	OA
208	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	828	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	822	OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	811	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	809	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	808	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	804	AV
207	Lnp, Preservative Free, 100 Mcg/0.5ml Or	Procedure	CV		OA
0064a	50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrnaspik	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription	N/A	803	N/A
208	Sarscov2covid19vaccinemrnaspik	Procedure	CV		OA
0124a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	802	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	796	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	796	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	793	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	790	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	788	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	787	OA
0064a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	777	OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	773	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	767	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	765	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	762	OA
0064a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	760	OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0012a	Immunization Administration By Intramuscular	Procedure	C4	751	OA
0012a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	749	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	745	AV
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0001a	Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	743	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult	Procedure	CV		OA
	Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	743	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	743	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	742	OA
0001a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	741	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	740	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	733	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	729	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	708	OA
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	707	IS
0001a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	705	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	700	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	700	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	697	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	687	OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	683	OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	683	AV
207	Lnp, Preservative Free, 100 Mcg/0.5ml Or	Procedure	CV		OA
0011a	50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	683	ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	679	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	666	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	664	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	658	OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular	Procedure	C4	651	OA
0004a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	641	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	634	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	634	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	632	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	630	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	626	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	625	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	617	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	614	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	613	AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	605	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	586	OA
0064a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	586	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4	578	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	575	N/A
0002a	Immunization Administration By	Procedure	C4	572	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	568	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	561	AV
0012a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	561	AV
0031a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	560	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	557	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	556	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	553	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	550	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	549	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	549	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	539	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	536	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	528	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	520	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	513	AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	511	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	510	OA
	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	507	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0002a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	505	N/A
aspik	Immunization Administration By	Procedure	C4		OA
0001a	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	505	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	504	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	502	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	501	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	495	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	495	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	495	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	490	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	484	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	479	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	478	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	477	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	476	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	476	OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	472	IS
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		IS
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	472	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserv				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	467	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	467	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	466	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	460	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	459	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	454	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	453	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	450	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	444	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	436	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	426	OA
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	422	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	422	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	411	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	410	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	409	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	409	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	407	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	407	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	398	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	397	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	387	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo oster 208	Covid19mrnalnpsbivalentbooster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	386	N/A OA
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	385	N/A OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	385	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	384	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	381	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	379	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	378	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	372	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	371	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	367	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	366	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	365	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	362	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	360	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	357	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	353	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	353	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By	Procedure	C4	352	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	351	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	348	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	348	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	347	AV
59267100002		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	342	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	339	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	339	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	335	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	333	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	332	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	331	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	329	IS
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	327	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	325	IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	324	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	323	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	323	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	321	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	321	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	319	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	318	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	316	OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	314	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	314	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	314	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	309	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	305	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	303	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	301	OA
0071a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	298	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	297	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	296	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	296	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	293	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	292	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	291	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	291	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	291	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	288	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	288	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	283	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	281	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4	280	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	279	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	279	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	279	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	278	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	278	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	277	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	276	OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	276	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	274	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	274	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	270	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	270	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	270	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	269	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	268	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	267	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	265	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	264	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	263	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	261	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	260	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	259	OA
0002a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	258	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	257	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	257	AV
207		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	257	IS
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	252	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	251	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	251	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	250	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	250	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	250	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	249	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	248	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	246	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	245	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	243	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	243	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	243	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	242	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	240	OA
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	240	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	240	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	239	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	238	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	238	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	237	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	235	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	235	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	234	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	233	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	232	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	231	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	230	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	226	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	225	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	225	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	224	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
59267100001	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	224	OA
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	223	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	222	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	222	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	222	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	222	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	221	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	220	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	219	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	217	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208 0001a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	217	N/A OA OA
Sarscov2covid19vaccinevectorno207	Sarscov2covid19vaccinevectorno COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	216	N/A OA
Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos	Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos	Prescription Prescription	N/A N/A	214	N/A N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	213	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	213	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	212	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	212	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	212	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	211	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	211	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	211	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	210	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a		Procedure	C4	209	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	209	N/A OA
208 0071a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	208	OA AV
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	208	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	208	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	207	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	207	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	206	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	206	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	206	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	204	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	203	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	202	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	202	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	201	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	201	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	200	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	199	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	199	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	198	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	196	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	196	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	195	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	194	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208		Procedure	CV	194	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	194	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	193	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	192	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	191	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	191	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	190	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	190	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	190	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	190	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	189	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	189	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	189	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	188	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	187	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	187	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	187	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	185	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	185	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	184	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	184	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	182	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	182	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	181	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	180	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	180	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	179	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	178	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	178	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	177	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	176	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	176	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	176	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	174	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	174	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	174	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	173	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	173	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	173	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	171	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	170	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	170	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	170	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	170	ED
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	169	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	169	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	168	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	168	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	167	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	166	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	165	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	165	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	164	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	164	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	164	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	164	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	163	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	162	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	162	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	160	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	160	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	159	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	158	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	158	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	157	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	156	OA
0071a		Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	156	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	153	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	152	OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	152	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	151	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	150	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	150	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	150	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	150	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	149	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	149	OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	149	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	148	AV
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	148	N/A
oster	Immunization Administration By	Procedure	C4		AV
0124a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	146	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	146	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	145	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a		Procedure	C4	145	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	143	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	143	N/A
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a					
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	143	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	142	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	142	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	141	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	140	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	140	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	140	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA
0011a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	139	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	139	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	139	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	139	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	139	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription	N/A	139	N/A
05mldos	Covid19mrnalnpspf100mcg05mldos	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	138	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	138	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	137	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	137	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	136	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	135	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	133	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	133	AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	133	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	132	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	132	OA
59267100002		Procedure	ND		AV
0003a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	131	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	131	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	131	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	130	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	129	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	128	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	128	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	127	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	127	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	127	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	126	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	126	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	126	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	126	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	126	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	125	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	125	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	124	OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	124	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	124	OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	123	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	123	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	123	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	123	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	122	N/A
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	122	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	122	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	122	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	121	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	121	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	120	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	120	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	120	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	119	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	119	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	119	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	119	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	118	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	118	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	118	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	117	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	117	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	116	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0124a	Immunization Administration By	Procedure	C4	116	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	116	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	114	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	114	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	113	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	113	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	113	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	113	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0064a	Immunization Administration By	Procedure	C4	112	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	111	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	111	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	111	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	111	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	111	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	111	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	110	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	110	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	109	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	109	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	109	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	109	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	108	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	108	OA
0031a	Immunization Administration By	Procedure	C4	108	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	108	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	108	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	108	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	108	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	107	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	107	ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	107	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	106	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	105	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	105	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	105	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	105	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	105	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	105	OA
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	104	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	104	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	103	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	103	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	103	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	103	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	102	N/A
aspik	Immunization Administration By	Procedure	C4		OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	101	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	101	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	101	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	101	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	100	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	100	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	99	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	99	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	99	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	99	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	99	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	98	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	98	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	97	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	97	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	97	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	97	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	96	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	96	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	96	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	96	OA
0031a	Immunization Administration By	Procedure	C4	95	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	94	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	94	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	94	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	94	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	93	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	93	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	93	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	93	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	92	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	92	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	92	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4	92	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	92	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	92	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	92	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	91	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	91	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	90	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	90	AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300		Procedure	C4	90	OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	90	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	90	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	89	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	89	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	88	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	88	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	88	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	88	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	87	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	86	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	86	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	85	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	85	OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	85	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	85	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	85	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	85	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	85	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	84	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	84	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	84	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	84	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	84	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	83	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	83	IS
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	83	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	83	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	82	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	82	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	82	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	82	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	82	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	81	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	81	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	81	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	81	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	81	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	80	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	80	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	80	OA
0013a	Immunization Administration By	Procedure	C4	80	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	79	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	79	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	78	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	78	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	77	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	77	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	77	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	77	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	76	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	76	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	76	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	76	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	75	AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0064a		Procedure	C4		AV
0071a		Procedure	C4	75	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	75	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	75	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	74	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By	Procedure	C4	74	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	74	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	74	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	74	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	74	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	74	ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	73	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	73	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	73	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
Sarscov2covid19vaccinevect	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Sarscov2covid19vaccinevectorno	Prescription	N/A	72	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	72	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	72	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	72	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	71	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	71	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	71	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	71	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0003a		Procedure	C4	71	OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	71	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	70	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	70	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0001a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	70	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	70	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	70	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	69	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	69	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	69	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	69	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	69	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	69	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	68	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	68	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	68	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	67	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	67	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	66	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	66	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	66	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	66	IS
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		IS
0001a	Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	66	AV
212		Procedure	CV		OA
0011a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	66	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	65	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	65	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	65	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	65	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	65	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	65	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo oster 208	Covid19mrnalnpsbivalentbooster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	65	N/A OA
Sarscov2covid19vaccinemrn aspik 91300 0001a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	64	N/A AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	64	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	64	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	63	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	63	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	63	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	63	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	63	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	62	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	62	AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	62	IS
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	61	N/A
91300208	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
91300208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	61	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	61	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	61	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	61	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	61	IS
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	61	OA
0003a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	61	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	60	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	60	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	60	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	60	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	60	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	60	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	60	OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	60	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	60	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	60	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	59	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	59	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	59	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	59	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	59	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	58	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	58	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	58	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0031a	Immunization Administration By	Procedure	C4	58	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	57	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	57	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	57	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	57	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	57	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	57	OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	57	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	57	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	57	OA
Covid19mrnalnpspf10mcg02mldose 0071a	Covid19mrnalnpspf10mcg02mldose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	56	N/A AV
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	56	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	56	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	56	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV
208		Procedure	CV	56	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	56	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	55	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	55	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	55	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4	55	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	55	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	55	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	54	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	54	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	54	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	54	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	54	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	54	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	54	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	53	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	53	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	53	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	53	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	53	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	53	OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	53	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	52	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	52	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	52	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	52	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	52	N/A
orno	Immunization Administration By	Procedure	C4		OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	52	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	52	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	52	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	52	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	52	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	51	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	51	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	51	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	51	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	51	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	51	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	50	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	50	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	50	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	50	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	50	AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	50	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	49	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	49	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	49	N/A
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	49	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	49	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	49	AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	49	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	49	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	49	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	49	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	49	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	49	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208 0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV C4	49	OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	48	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	48	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	48	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	48	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	48	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	48	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	48	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	48	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	48	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	48	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	48	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	47	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	47	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	47	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	47	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	47	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	47	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	47	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	47	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	46	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	46	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	46	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	46	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	46	AV
0124a	Immunization Administration By	Procedure	C4	46	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	46	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	46	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	46	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	46	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	46	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	46	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	46	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	46	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	45	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	45	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	45	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	45	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	45	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	45	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	45	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	45	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	45	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	45	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	44	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	44	N/A
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	44	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	44	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	44	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	44	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	44	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	44	AV
0012a	Immunization Administration By	Procedure	C4	44	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	44	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	44	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	43	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	43	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	43	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	43	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	43	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	43	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207		Procedure	CV	43	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	43	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	43	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	42	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	42	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	42	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	42	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	42	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	42	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	42	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	42	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	41	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	41	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	41	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	41	OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	41	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	41	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	41	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	41	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	41	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	41	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	41	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	40	ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	40	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	40	AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	40	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4	40	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	40	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	40	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	40	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	40	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	39	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	39	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	39	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	39	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	39	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	39	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	39	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4	39	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	39	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	39	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	39	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	39	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	39	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	39	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	38	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	38	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	38	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	38	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	38	IP
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	38	IP
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	38	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	38	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	38	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	38	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	38	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	38	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	38	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	38	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	38	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	37	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	37	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	37	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	37	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	37	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	37	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	37	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	37	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	37	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
0064a	Immunization Administration By	Procedure	C4	36	OA
0064a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 0064a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	36	N/A AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	36	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	36	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	36	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	36	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0002a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	36	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	36	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	36	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	36	N/A
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	36	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	ED
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	36	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	36	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	36	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	36	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	36	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	36	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	35	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	35	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	35	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	35	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	35	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	35	OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4	35	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	35	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	35	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	35	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	35	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	35	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	34	OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	34	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	34	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	34	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	34	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	34	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	34	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	34	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	34	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	34	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	34	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	34	OA
0011a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	34	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	34	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	34	IP
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	34	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	34	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	34	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	34	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	34	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	33	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	33	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	33	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	33	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	33	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	33	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	33	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	33	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	33	OA
207	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	33	OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	33	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	33	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	33	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	IP
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	32	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	32	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	32	AV
0124a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	32	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	32	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	32	OA
208		Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	32	OA
0001a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	32	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	32	OA
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	31	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	31	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	31	OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a		Procedure	C4	31	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	31	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	31	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	31	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	31	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	31	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	31	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	31	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	31	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By	Procedure	C4	31	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	31	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	31	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	31	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	31	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	30	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	30	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	30	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	30	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	30	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	30	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	30	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	30	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	30	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	30	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	30	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	30	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	30	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	30	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	30	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	30	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	30	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	30	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	30	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	30	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	30	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	30	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	29	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	29	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	29	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	29	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	29	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	29	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	29	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	29	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	29	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	29	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	29	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	29	AV
0011a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	29	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	29	IP
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	28	OA
0064a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	28	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	28	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	28	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	28	ED
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	28	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	28	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	28	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	28	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	28	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	28	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	28	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	27	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	27	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	27	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	27	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	27	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	27	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	27	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	27	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	27	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	27	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	27	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	26	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	26	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	26	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	26	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	26	OA
0002a	Immunization Administration By	Procedure	C4	26	IP
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	26	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	26	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	26	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	26	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	26	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	26	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	26	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	26	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	26	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	26	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	26	IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	26	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	26	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	26	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	26	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	26	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	26	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	25	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	25	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	25	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	25	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	25	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	25	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	25	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	25	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	25	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV
0012a	Immunization Administration By	Procedure	C4	25	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0031a	Immunization Administration By	Procedure	C4	25	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	25	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	25	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	25	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	25	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	25	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	25	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	25	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	25	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	24	AV
207		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	24	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24	N/A
aspik	Immunization Administration By	Procedure	C4		OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	24	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	24	OA
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	24	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	24	OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	24	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	24	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	24	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	24	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	24	OA
207	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	24	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	24	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	23	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	23	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	23	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	23	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	23	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	23	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	23	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	23	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein,	Procedure	ND		AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	23	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	23	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	23	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	IP
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	23	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	23	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	23	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4	23	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	23	ED
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	23	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	23	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	23	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	23	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	23	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	23	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	23	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	23	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	23	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208 0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	23	OA AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	23	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	23	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	23	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	22	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	22	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	22	N/A
Sarscov2covid19vaccinemrnaspik80777027399	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	22	N/A AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	22	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	22	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	22	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	22	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	22	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	22	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	22	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	22	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	22	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	22	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
0031a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	22	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	22	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	21	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	21	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	21	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	21	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	21	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	21	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	21	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	21	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	21	OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	21	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	21	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	20	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	20	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	20	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	20	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0124a	Immunization Administration By Intramuscular Injection Of Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	20	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	20	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	20	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	20	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	20	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	20	AV
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	20	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	20	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	20	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	20	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	20	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	20	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	20	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	20	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	20	IP
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	20	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	19	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik212	Sarscov2covid19vaccinemrnaspik COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	19	N/A OA
Sarscov2covid19vaccinemrnaspik0003a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	19	N/A OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	19	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	19	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	19	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4	19	ED
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	19	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	19	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	19	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	19	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0003a		Procedure	C4		AV
91300		Procedure	C4	19	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	19	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	19	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		AV
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	19	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	19	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	19	OA
0004a	Dose;	Procedure	C4		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	19	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	19	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	18	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	18	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	18	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	18	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	18	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	18	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	18	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	18	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	18	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	18	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	18	OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	18	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	18	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	18	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	18	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	18	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	18	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	18	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	18	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	18	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	18	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	18	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	18	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	18	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	18	IP
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	18	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	18	AV
0011a	Immunization Administration By	Procedure	C4	18	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	18	AV
0011a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	18	IS
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	17	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	17	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	17	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik					
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	17	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	17	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	17	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	17	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	17	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	17	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	17	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	17	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0013a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	17	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	17	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	17	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	17	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	17	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	17	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	17	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	17	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	17	AV
0004a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0003a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	17	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	16	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	16	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	16	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	16	N/A OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	16	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	16	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	16	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	16	OA
0002a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	16	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	16	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	16	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	16	OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	16	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	16	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	16	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	16	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	16	IS
0012a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		IS
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	15	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	15	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	15	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	15	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	15	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	15	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	15	N/A
orno	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	15	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	ED
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	15	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	15	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	15	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	15	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	IS
0002a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By	Procedure	C4	15	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	15	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	15	OA
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	15	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	15	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	15	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	15	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	15	OA
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	15	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	15	IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	15	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	14	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	14	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	14	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	14	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	14	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	14	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	14	AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	14	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	14	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	14	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immuni				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	14	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301		Procedure	C4	14	AV
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	14	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	14	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	14	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	14	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	14	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	14	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	14	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	14	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	14	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	IS
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
0013a	Immunization Administration By	Procedure	C4	14	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	14	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	14	N/A
05mldos					
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	13	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	13	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	13	AV
0071a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	13	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	13	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	13	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	13	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	13	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	13	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	13	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	13	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	13	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	ND		AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	13	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	13	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	13	OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
0011a	Immunization Administration By	Procedure	C4	13	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	13	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	13	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	13	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	13	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	13	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	13	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	13	IP
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	12	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	12	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	12	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	12	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12	N/A
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	12	OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	12	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	12	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	12	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	12	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	12	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	12	N/A OA
Sarscov2covid19vaccinevectorno 91300	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	12 12	N/A IP
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	C4 C4	12	AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	12	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	12	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	12	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	12	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	12	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	12	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	12	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0003a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	12	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	12	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	12	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	IS
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	12	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	12	IP
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	11	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	11	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	11	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	OA
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	11	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	11	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	11	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	11	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	11	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	11	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	11	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	11	N/A AV
0031a					
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	ED
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	11	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	11	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	11	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	11	AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	11	N/A
0012a	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	11	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0011a	Immunization Administration By	Procedure	C4	11	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	11	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	11	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	11	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	11	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	11	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	11	OA
0012a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	11	OA
0013a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	11	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	11	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	11	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	11	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	10	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100001	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0124a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	10	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	10	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	10	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	IP
59267100002		Procedure	ND		IP
59267100001		Procedure	ND		IP
0001a		Procedure	C4		IP
91300		Procedure	C4	10	IS
0001a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	10	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	10	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	AV
0011a					
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA
59267100001		Procedure	ND		OA
0003a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	IS
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respira				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
05mldos	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	10	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	ED
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	10	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	10	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	10	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	10	OA
0031a		Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	10	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	10	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	10	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
0003a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	10	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	OA
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	10	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	IS
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	10	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	9	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	9	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	9	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	9	N/A AV
0124a	Immunization Administration By	Procedure	C4	9	IS
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	9	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	9	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	9	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	9	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	IS
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	9	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	9	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	9	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0012a	Immunization Administration By	Procedure	C4	9	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	9	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	9	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	9	OA
0011a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	9	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	9	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	9	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	9	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	IP
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	8	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
0124a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	8	N/A
COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations		Procedure	CV		OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a					
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	8	N/A
COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations		Procedure	CV		OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	8	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	8	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	8	AV
218		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Ad	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
0001a		Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	8	OA
0001a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	8	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	8	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	8	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
0012a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0003a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	8	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	7	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	7	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	AV
0064a	Immunization Administration By	Procedure	C4	7	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	7	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	7	OA
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	7	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	7	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	7	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	7	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	7	N/A AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0124a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By	Procedure	C4	7	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	7	N/A OA
Sarscov2covid19vaccinevectorno 0011a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	7	N/A AV
208 0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	7	OA IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300		Procedure	C4	7	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	7	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	7	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	7	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	7	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4	7	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	7	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	7	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	7	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	7	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By	Procedure	C4	7	ED
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	7	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	7	OA
207		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	7	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	7	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	7	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	IS
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	7	IS
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
0064a	Immunization Administration By	Procedure	C4	6	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0071a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		OA
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
80777027399	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	IP
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster	Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	6	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300		Procedure	C4	6	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
207	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	6	OA
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6	IP
207		Procedure	CV		OA
0011a		Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	6	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4	6	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	ED
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	6	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0002a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	6	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	6	OA
207		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	6	OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	6	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	6	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	6	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
0012a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
0013a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	6	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				OA
0004a	Immunization Administration By	Procedure	C4	6	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
0011a	Immunization Administration By	Procedure	C4	6	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	6	IP
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	6	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
0064a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	5	AV
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	5	OA
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	5	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	5	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	5	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a		Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	5	OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinemrnaspik 59267100001 0003a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A ND C4	5	N/A AV AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	5	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	5	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	5	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	5	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	IP
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	IP
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	IS
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	IS
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	IS
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IS
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	5	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	5	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0003a		Procedure	C4		AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	IP
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5	IP
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5	ED
207		Procedure	CV		OA
0011a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Ad				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	AV
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5	OA
0031a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	OA
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	5	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0012a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0013a	Immunization Administration By	Procedure	C4	5	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By	Procedure	C4	5	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	5	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	5	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	5	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	5	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	5	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0004a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208 0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	5	OA AV
212 0031a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure Procedure	CV C4	5	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	5	N/A
2mldose	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0012a	Immunization Administration By	Procedure	C4	5	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
0004a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4	5	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	5	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 0064a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	4	N/A AV
Sarscov2covid19vaccinemrn aspik 80777027399 0064a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure Procedure	N/A ND C4	4	N/A AV AV
Sarscov2covid19vaccinemrn aspik 207 0064a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure Procedure	N/A CV C4	4	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0064a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	4	N/A
oster	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	4	N/A
2mldose	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001		Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik 212	Sarscov2covid19vaccinemrnaspik COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	4	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0003a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
59267100001		Procedure	ND		AV
0124a		Procedure	C4		AV
91300		Procedure	C4	4	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	4	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a		Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By	Procedure	C4	4	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	4	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	4	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	4	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	4	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91301	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	4	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	4	N/A OA AV
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	4	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	IP
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		IP
0001a	Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IS
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0011a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Res	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
207		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	4	AV
218		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0013a		Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
207	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	4	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Ad	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
207		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
208		Procedure	CV		OA
0012a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	4	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	4	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	ED
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		ED
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	4	ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0031a	Immunization Administration By	Procedure	C4	4	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By	Procedure	C4	4	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
59267100001	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0003a	Dose;	Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By	Procedure	C4	4	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	OA
208		Procedure	CV		OA
0002a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	4	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	4	OA
0013a		Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	4	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0012a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	4	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	4	IP
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
0012a	Immunization Administration By	Procedure	C4	4	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	4	AV
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0013a	Immunization Administration By	Procedure	C4	4	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	ED
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	4	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	4	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 80777027399	Covid19mrnalnpspf100mcg05mldos Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	4	N/A AV
Covid19mrnalnpspf10mcg02 2mldose 80777027399	Covid19mrnalnpspf10mcg02mldose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	4	N/A AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	3	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0064a	Immunization Administration By	Procedure	C4	3	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	3	OA
0064a		Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	3	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	3	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	3	AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	3	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	3	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	3	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	3	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	3	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Se				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	3	N/A AV
Sarscov2covid19vaccinemrnaspik 0002a 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	3	N/A AV AV
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrn aspik 208 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	3	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 207	Sarscov2covid19vaccinemrnaspik COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	3	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 80777027399 208	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A ND CV	3	N/A AV OA
Sarscov2covid19vaccinemrnaspik 0124a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Prescription Procedure	N/A C4	3 3	N/A IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	3	IS
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By	Procedure	C4	3	IS
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0124a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	Immunization Administration By	Procedure	C4		AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	IP
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0001a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	IP
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IP
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	IP
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	IS
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	IS
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		IS
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
0002a		Procedure	C4		IS
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	ED
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4	3	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Di	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster D				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
212		Procedure	CV		OA
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	IS
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		IS
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro	Procedure	C4	3	AV
80777027399		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	ED
0004a	Immunization Administration By	Procedure	C4	3	ED
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
0011a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
212	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0004a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	3	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0031a	Immunization Administration By	Procedure	C4	3	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0013a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0003a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207 0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	3	OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0003a	Dose;	Procedure	C4		AV
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0003a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0012a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0013a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0003a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0003a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0013a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0013a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
0013a	Immunization Administration By	Procedure	C4	3	IS
0003a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0003a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	3	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0064a	Immunization Administration By	Procedure	C4	3	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo oster 0004a	Covid19mrnalnpsbivalentbooster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	3	N/A AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
Covid19mrnalnpspf100mcg 05mldos 0011a	Covid19mrnalnpspf100mcg05mldos Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	3	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	3	AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	3	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	3	IP
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	3	ED
0013a	Immunization Administration By	Procedure	C4	3	IS
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	3	IS
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	3	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	3	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	IP
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	2	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0064a	Dose;	Procedure	C4		AV
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0071a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	2	AV
207		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	AV
0064a		Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	2	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	2	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	2	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a	Immunization Administration By	Procedure	C4	2	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	2	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0064a	Immunization Administration By	Procedure	C4	2	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By	Procedure	C4	2	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	IP
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 0071a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
0001a	Through 11 Yrs), Pfizer Tris-Sucrose	Procedure	C4		AV
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	2	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	2	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	2	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	2	N/A AV
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	2	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik 59267100002 0002a 0001a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A ND C4 C4	2	N/A AV AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A AV
Sarscov2covid19vaccinemrnaspik 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik 59267100001 0002a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A ND C4	2	N/A AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212		Procedure	CV		OA
208					
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV		OA
0124a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0124a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Immunization Administration By	Procedure	C4		AV
0124a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By	Procedure	C4	2	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0124a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By	Procedure	C4	2	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA
0124a	Immunization Administration By	Procedure	C4	2	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91300	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	2	N/A OA
Sarscov2covid19vaccinevectorno 91301 0011a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A C4 C4	2	N/A AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 207 0031a	Sarscov2covid19vaccinevectorno COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 207	Sarscov2covid19vaccinevectorno COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212		Procedure	CV		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0004a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A AV
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	2	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IP
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		IP
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		IP
0001a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IP
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IP
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IS
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IS
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	IS
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	2	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	ED
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immuni	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mc				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserva				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respirato				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0002a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respirato				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0013a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0003a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a		Procedure	C4		AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunizati	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administrati	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0012a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute R				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	2	AV
59267100001		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0002a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
207		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein,	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	2	AV
212		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	2	AV
212		Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0003a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
208	Covid-19 Vaccine, Mrna, Spike Protein-Lnp, Preservative Free, 30 Mcg/0.3 Ml Dosage	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
212		Procedure	CV		OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	IP
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IP
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IP
0011a		Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IP
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IS
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IS
0011a		Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
207		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0012a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
208		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
59267100001		Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0012a		Procedure	C4		AV
0012a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0013a		Procedure	C4		AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
208		Procedure	CV		OA
0011a		Procedure	C4		OA
91301		Procedure	C4	2	OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
207		Procedure	CV		OA
0012a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	ED
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	ED
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		ED
0001a		Procedure	C4	2	AV
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0002a	Immunization Administration By	Procedure	C4	2	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		AV
0001a	Pfizer Adult Primary Series And Ic Dose	Procedure	C4		AV
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	2	AV
0003a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	2	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By	Procedure	C4	2	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	AV
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	2	AV
0003a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0002a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0031a	Immunization Administration By	Procedure	C4	2	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV	2	OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
207 0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	2	OA
0013a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
207		Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0003a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
0003a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		AV
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0004a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0012a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	2	IS
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0031a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	2	OA
0011a		Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	2	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0031a	Immunization Administration By	Procedure	C4	2	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0031a	Immunization Administration By	Procedure	C4	2	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	2	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0012a	Immunization Administration By	Procedure	C4	2	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	2	IS
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0012a	Immunization Administration By	Procedure	C4	2	ED
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	ED
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0012a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0012a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0013a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0031a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	IS
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	ED
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	1	ED
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA
0064a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	ED
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	1	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua	Procedure	C4		AV
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	1	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0064a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	AV
0071a		Procedure	C4		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0064a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0012a	Immunization Administration By	Procedure	C4		AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0013a	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
Sarscov2covid19vaccinevect orno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By	Procedure	C4	1	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0124a	Immunization Administration By	Procedure	C4	1	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By	Procedure	C4	1	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0064a		Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0064a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Synd				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
208		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservat	Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0064a		Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0064a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0004a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	1	AV
0013a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0012a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0012a	fda Eua	Procedure	C4		AV
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0004a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	1	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0071a	Immunization Administration By	Procedure	C4	1	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0064a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0003a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By	Procedure	C4	1	OA
0013a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0004a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Immunization Administration By	Procedure	C4		OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	1	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
91300		Procedure	C4	1	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100001	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
0001a	Through 11 Yrs), Pfizer Tris-Sucrose	Procedure	C4		AV
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0071a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0071a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0071a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0013a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By	Procedure	C4	1	AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrnaspik 0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn	Immunization Administration By	Procedure	C4		AV
aspik	Intramuscular Injection Of Severe Acute				
0031a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
aspik	0.5 Ml;				
212	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
aspik	0.5 Ml;				
212	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn	Immunization Administration By	Procedure	C4		AV
aspik	Intramuscular Injection Of Severe Acute				
0031a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
207	Reconstituted, For Intr	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acu				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respira				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027399	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0013a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0013a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208 0001a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
0001a	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		OA
0001a	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		IP
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IP
0002a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik0002a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0012a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
Covid19mrnalnpspf100mcg	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
05mldos	Dose Or 50 Mcg/0.25ml Dose;				
207	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208 0004a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208 0004a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0031a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik 0003a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A
Covid19mrnalnpsbivalentbooster					
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0013a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0013a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik0013a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik0013a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A ED
Sarscov2covid19vaccinemrnaspik80777027399	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	1	N/A AV
Sarscov2covid19vaccinemrnaspik0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
0124a	Immunization Administration By	Procedure	C4	1	IP
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By	Procedure	C4	1	IS
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By	Procedure	C4	1	IS
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	IS
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0124a	Immunization Administration By	Procedure	C4	1	IS
0064a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0012a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED
0124a	Immunization Administration By	Procedure	C4	1	ED
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0124a		Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0124a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0124a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
208		Procedure	CV		OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
208		Procedure	CV		OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV		OA
0124a		Procedure	C4		AV
91300		Procedure	C4	1	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
208		Procedure	CV		OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0124a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0124a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Immunization Administration By	Procedure	C4		AV
0124a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0124a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0124a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0124a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0124a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo oster 0124a	Covid19mrnalnpsbivalentbooster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Prescription Procedure	N/A C4	1	N/A AV
Covid19mrnalnpsbivalentbo oster 0124a	Covid19mrnalnpsbivalentbooster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Prescription Procedure	N/A C4	1	N/A AV
0124a	Immunization Administration By	Procedure	C4	1	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a		Procedure	C4		OA
0011a		Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By	Procedure	C4	1	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0124a	Immunization Administration By	Procedure	C4	1	OA
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91301	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0001a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinevectorno 0001a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 212 207	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
0031a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
0031a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos 212	Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Prescription Procedure	N/A N/A CV	1	N/A N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 218	Sarscov2covid19vaccinevectorno COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 0013a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinevectorno 80777027399	Sarscov2covid19vaccinevectorno Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	1	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	IP
59267100002		Procedure	ND		IP
59267100001		Procedure	ND		IP
208		Procedure	CV		OA
0001a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	IP
59267100002		Procedure	ND		IP
59267100001		Procedure	ND		IP
208		Procedure	CV		OA
0001a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		IP
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		IP
0004a		Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0001a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
0002a		Procedure	C4		IS
0001a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		IS
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	1	IS
0002a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IS
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		IS
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	ND		ED
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
91300	Spike Protein, Preservative Free, 100	Procedure	C4		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
207	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Ln				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Pri				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Pri				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0002a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Y				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0002a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0003a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Ad				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0002a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Us				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0012a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
208	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mc				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster D				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0012a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0002a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0002a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0002a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserva				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0002a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Us				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0013a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0003a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), M				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
212		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein,	Procedure	ND		AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300		Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a		Procedure	C4		AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0001a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coro	Procedure	C4	1	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Di	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a		Procedure	C4		AV
0003a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Synd				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
0004a		Procedure	C4		AV
91300		Procedure	C4	1	AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0002a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0002a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0002a		Procedure	C4		AV
91300		Procedure	C4	1	AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
0002a		Procedure	C4		AV
91300		Procedure	C4	1	AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0004a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade	Procedure	ND		AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
212		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
0003a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100002		Procedure	ND		AV
0002a		Procedure	C4		AV
91300		Procedure	C4	1	OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
212		Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0003a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
0004a		Procedure	C4		AV
91300		Procedure	C4	1	OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Mode				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dos				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0002a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Mode				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
0013a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0003a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immuni				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0003a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0004a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0031a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0031a		Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0031a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
212		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0013a		Procedure	C4		OA
0004a		Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	OA
218		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		IS
0002a		Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0002a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		IS
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
0004a		Procedure	C4		OA
91300		Procedure	C4	1	OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	IP
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		IP
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		ED
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		ED
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		ED
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	ED
207		Procedure	CV		OA
0013a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		ED
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	ED
207		Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		ED
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0031a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		OA
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		OA
80777027399		Procedure	ND		AV
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administ	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus D	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	ND		AV
0011a		Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Int	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
218		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Adminis	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
212		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservat	Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV
0013a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0013a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
218		Procedure	CV		OA
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0013a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0013a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respirat	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		ED
0013a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0012a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4	1	OA
80777027399		Procedure	ND		OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207		Procedure	CV		OA
0003a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		IS
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0013a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		OA
0012a		Procedure	C4		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		OA
0012a		Procedure	C4		OA
0012a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose	Procedure	C4		AV
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		AV
0001a	Pfizer Adult Primary Series And Ic Dose	Procedure	C4		AV
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		ED
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	1	OA
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2	Procedure	C4		AV
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0012a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Synd	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0012a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	1	IP
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0013a	Immunization Administration By	Procedure	C4	1	IP
0003a	Intramuscular Injection Of Severe Acute	Procedure	C4		IP
0002a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IP
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
0064a	Immunization Administration By	Procedure	C4	1	IP
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0003a	Immunization Administration By	Procedure	C4	1	IS
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0002a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0012a	Immunization Administration By	Procedure	C4	1	IS
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0064a	Immunization Administration By	Procedure	C4	1	IS
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
0002a	Pfizer Adult Primary Series And Ic Dose	Procedure	C4		AV
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		AV
0002a	Pfizer Adult Primary Series And Ic Dose	Procedure	C4		AV
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0002a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Prote				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0002a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0002a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0002a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0012a	Dose;	Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0002a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0002a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0003a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By	Procedure	C4	1	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0002a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4	1	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0012a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0013a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
	Immunization Administration By	Procedure	C4		AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0002a		Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0002a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0002a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0002a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By	Procedure	C4	1	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Immunization Administration By	Procedure	C4		OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0003a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0003a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1	OA
0012a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0013a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0003a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0003a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Covid19mrnalnpsbivalentbo oster 207	Covid19mrnalnpsbivalentbooster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Covid19mrnalnpsbivalentbo oster 207	Covid19mrnalnpsbivalentbooster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0012a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0012a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0012a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0012a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0013a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0013a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
0013a	Pfizer Adult Primary Series And Ic Dose	Procedure	C4		AV
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0031a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0013a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		IS
0011a	fda Eua	Procedure	C4		IS
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IS
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0012a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0012a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0012a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	OA
207		Procedure	CV		OA
0013a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208 0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV C4	1	OA AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0012a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0003a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0003a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0003a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose;	Procedure	C4		AV
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster 208	Covid19mrnalnpsbivalentbooster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
208 0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	1	OA IS
Covid19mrnalnpsbivalentbooster 208	Covid19mrnalnpsbivalentbooster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0011a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By	Procedure	C4	1	IP
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	IP
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IP
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0013a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0004a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	1	OA
0031a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0003a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
212	Dose, Tris-Sucrose;	Procedure	CV		OA
0031a	fda Eua (5 Yrs	Procedure	C4		OA
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
0003a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0003a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0004a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0013a	0.5 Ml;	Procedure	C4		AV
0013a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	IS
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	ED
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0012a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0003a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A
Covid19mrnalnpsbivalentbo	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
oster	Dose, Tris-Sucrose;				
218	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0013a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0013a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0031a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0003a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0003a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0003a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Immunization Administration By	Procedure	C4		AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0013a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0013a	Immunization Administration By	Procedure	C4	1	OA
0013a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0003a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0011a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0003a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0004a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0004a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0011a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0012a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0013a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Immunization Administration By	Procedure	C4		OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0012a	Immunization Administration By	Procedure	C4	1	IP
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0011a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	ED
0012a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		ED
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0013a	Immunization Administration By	Procedure	C4	1	ED
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0013a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0013a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4		AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	1	AV
0031a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	1	AV
0013a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 0011a	Covid19mrnalnpspf100mcg05mldos Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	1	N/A AV
Covid19mrnalnpspf100mcg 05mldos 0011a	Covid19mrnalnpspf100mcg05mldos Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	1	N/A AV
Covid19mrnalnpspf100mcg 05mldos 80777027399 0011a	Covid19mrnalnpspf100mcg05mldos Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A ND C4	1	N/A AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0013a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0013a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	ED
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By	Procedure	C4	1	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0012a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0031a	Immunization Administration By	Procedure	C4	1	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	OA
0013a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0012a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	IS
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0013a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0013a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	1	OA
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0031a	Immunization Administration By	Procedure	C4	1	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0002a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0002a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0002a	Immunization Administration By	Procedure	C4	0	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
207	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208		Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0004a	Immunization Administration By	Procedure	C4	0	IS
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	0	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0064a	Immunization Administration By	Procedure	C4	0	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	0	IS
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0064a	Immunization Administration By	Procedure	C4	0	IS
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	ED
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV	0	OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV	0	OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By	Procedure	C4	0	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	0	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
212	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0031a	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	C4		AV
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0013a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
212	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0031a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
212	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0031a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0013a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0013a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
0031a	Immunization Administration By	Procedure	C4	0	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0031a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	0	OA
0031a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0031a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	ED
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	0	AV
208		Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	0	AV
208		Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose 218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	ED
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0013a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0002a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0013a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0013a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0013a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos 207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0002a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0003a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218 0004a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV C4	0	OA AV
218 0011a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV C4	0	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	0	OA
0003a		Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	0	OA
0003a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0003a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0003a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose					
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose					
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218 0002a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV C4	0	OA AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
oster	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0003a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By	Procedure	C4	0	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	ED
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose 218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212 0031a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure Procedure	CV C4	0	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	0	AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	OA
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	OA
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By	Procedure	C4	0	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0012a	Immunization Administration By	Procedure	C4	0	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0012a	Immunization Administration By	Procedure	C4	0	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	0	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0013a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	OA
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0031a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	0	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.

[4]Encounter Care Setting is defined as AV, OA, ED, IP, or IS: AV stands for Ambulatory Visit; OA refers to Other Ambulatory Visit; ED means Emergency Department; IP denotes Inpatient Hospital Stay; and IS represents Non-Acute Institutional Stay.
N/A stands for Not Applicable.

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,792,304	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3,540,562	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,071,304	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,799,095	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,610,578	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,177,448	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,038,704	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	877,251	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	773,370	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	593,065	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	530,412	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	482,688	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	463,690	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	461,409	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	414,361	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	385,065	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	346,934	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	321,249	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	255,719	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	235,267	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	202,044	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	201,609	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	175,452	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	163,490	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	143,688	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	140,960	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	134,136	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	130,028	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	124,559	OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	123,428	AV
0001a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	119,209	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	116,056	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	115,887	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	109,370	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	100,495	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	99,068	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	97,481	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	97,442	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	97,385	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	90,695	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	87,455	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	84,940	AV
0011a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	84,697	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	83,895	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	83,559	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	80,240	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	77,690	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	69,911	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	69,278	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	69,111	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	66,412	AV
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	65,867	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	65,469	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	65,103	AV
0001a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	63,596	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	62,667	AV
208	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	60,175	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
208	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	56,723	OA
207		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	55,284	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	54,691	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	52,985	OA
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	52,313	OA
208	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	51,422	AV
80777027399		Procedure	ND		AV
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	48,895	OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	47,544	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	46,511	OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45,428	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	45,413	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	43,934	OA
0071a		Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	42,014	AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	41,157	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	39,370	AV
208	Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	37,586	AV
208	Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	37,543	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	37,041	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	36,972	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	34,277	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	32,753	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV		OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	31,091	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	30,576	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	27,771	OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	27,629	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27,226	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	26,784	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	26,728	AV
207	Lnp, Preservative Free, 100 Mcg/0.5ml Or	Procedure	CV		OA
0011a	50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	24,922	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24,120	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	22,181	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	21,930	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	20,543	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	20,168	AV
207		Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20,072	OA
207		Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	19,195	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	18,133	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17,491	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	17,410	AV
207		Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	16,878	AV
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0001a	Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	16,686	AV
207	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	C4		AV
	100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	16,458	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	16,166	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15,596	OA
91300		Procedure	C4		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr

Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	14,849	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
80777027310	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
207	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	C4		AV
	Lnp, Preservative Free, 100 Mcg/0.5ml Or				
	50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or				
	50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or				
	50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022 Rescinded				
	Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular				
	Injection Of Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Co				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	14,409	AV
0003a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,				
	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For				
	Intr				
	Immunization Administration By Intramuscular				
	Injection Of Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein,				
	Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	14,247	AV
0002a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	14,072	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
80777027310	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13,703	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	12,757	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12,709	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12,343	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12,310	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	11,905	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	10,894	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	10,877	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10,833	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	10,204	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10,067	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10,061	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	10,017	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	9,385	AV
208	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	8,991	AV
91300	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8,931	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8,309	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8,155	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8,138	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	8,085	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	7,888	OA
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult				
	Primary Series And Ic Dose Original Formulation. Eua				
	8/31/2022 Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	7,774	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
218	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7,745	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7,656	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	7,475	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6,845	OA
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	6,804	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular	Procedure	C4	6,735	OA
0001a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	6,661	AV
0004a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	6,603	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	6,580	AV
208	Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6,542	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,511	AV
218	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0071a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6,337	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,308	OA
80777027310	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6,124	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,097	OA
218	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,092	AV
218	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	6,048	OA
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	5,983	OA
80777027310	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5,749	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	5,729	AV
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5,628	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5,544	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	5,376	OA
91301	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
80777027399	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
80777027310	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	ND		AV
207	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	CV		OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	5,194	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	5,147	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4,898	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	4,865	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	4,743	OA
91301	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
80777027399	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
207	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	4,726	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	4,673	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	4,643	AV
91301	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
80777027310	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
207	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		AV
	(Sars-Cov-2) (Coronavirus Disease [covid-19])				
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,				
	100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or				
	50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or				
	50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022 Rescinded				
	Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscu				
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	4,499	OA
0071a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,				
	10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-				
	Suc				
	Immunization Administration By Intramuscular				
	Injection Of Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein,				
	Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4,397	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	4,392	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4,254	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	4,239	AV
218	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4,177	OA
0011a	Immunization Administration By Intramuscular	Procedure	C4	4,073	OA
0011a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	4,063	AV
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0001a	Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	3,768	OA
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	3,626	OA
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	C4		OA
	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,562	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	3,497	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3,480	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,444	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	3,402	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
80777027310	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
207	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3,375	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	3,371	AV
0064a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	3,317	AV
207		Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	3,308	OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	3,293	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
80777027310	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
207	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	3,239	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0071a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	3,127	OA
91301		Procedure	C4		AV
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3,102	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,038	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	3,006	OA
91301		Procedure	C4		AV
80777027310	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	2,927	OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,916	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2,893	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2,850	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,771	OA
80777027310	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	2,714	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2,596	OA
208		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,550	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	2,549	OA
0011a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2,474	AV
0002a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,450	OA
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular	Procedure	C4	2,399	AV
0001a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,341	OA
91301	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2,337	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,336	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	2,330	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,307	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,264	AV
80777027310	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0011a	100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,257	OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	2,229	OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,208	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,198	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2,194	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2,182	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2,177	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	2,167	AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	ND		AV
0004a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2,106	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2,105	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	2,078	AV
91300	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
59267100002	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,987	OA
0071a		Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,987	OA
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		OA
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,978	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1,913	OA
0071a		Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,900	OA
207		Procedure	CV		OA
Sarscov2covid19vaccinevectorno	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Sarscov2covid19vaccinevectorno	Prescription	N/A	1,899	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular	Procedure	C4	1,894	AV
0011a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,856	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	1,855	OA
91307		Procedure	C4		AV
0071a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,854	OA
91307	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
218	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0071a	10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,847	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	1,837	AV
91307		Procedure	C4		OA
0071a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1,832	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,825	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	ND	1,813	AV
0064a	50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,811	AV
0003a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,802	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1,768	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,752	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0002a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,746	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0003a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,742	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,739	OA
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,723	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,717	OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,716	AV
218	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0071a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,675	AV
218	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	CV		OA
0071a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	1,674	AV
91307		Procedure	C4		OA
0071a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	1,658	OA
0002a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,646	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0012a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,619	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,615	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,607	OA
0001a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,592	OA
0011a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,573	OA
91307	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
218	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0071a	10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,550	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1,536	OA
0064a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,532	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,531	OA
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,523	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,523	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,459	OA
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		OA
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,458	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,441	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,432	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,421	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0001a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	1,405	OA
0012a	50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,398	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,395	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
0001a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,376	OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,359	AV
0064a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1,354	OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,324	OA
207	Lnp, Preservative Free, 100 Mcg/0.5ml Or	Procedure	CV		OA
0011a	50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,316	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,256	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,244	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,243	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1,226	OA
208		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,208	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,197	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		AV
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	1,186	AV
0064a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1,179	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
207	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular	Procedure	C4	1,131	OA
0011a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	1,130	AV
80777027310		Procedure	ND		AV
0012a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,117	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,111	AV
91307	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
218	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0071a	10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	1,110	OA
0013a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1,072	AV
0064a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,058	AV
59267100002		Procedure	ND		AV
0004a		Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1,052	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,035	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,024	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,016	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,014	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	969	OA
0001a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	952	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	950	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	932	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	922	OA
0064a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	911	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	900	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	899	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	846	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	845	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	836	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	833	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	829	AV
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	828	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	813	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	811	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	811	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	801	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	787	OA
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0001a	Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	786	AV
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0004a	Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	785	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	782	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	767	OA
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	758	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	758	OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	754	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91307	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	738	OA
0071a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	736	AV
208	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	CV		OA
0001a	Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	735	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	723	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	722	OA
0004a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	720	AV
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	713	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	691	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	690	OA
0003a	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4		OA
	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,				
	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For				
	Intr				
	Immunization Administration By Intramuscular				
	Injection Of Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein,				
	Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	685	OA
0001a	Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml	Procedure	C4		OA
	Dose				
	Immunization Administration By Intramuscular				
	Injection Of Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein,				
	Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	673	AV
207	Lnp, Preservative Free, 100 Mcg/0.5ml Or	Procedure	CV		OA
0011a	50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or				
	50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022 Rescinded				
	Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular				
	Injection Of Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein,				
	Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	657	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	655	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	651	OA
0011a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	651	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	648	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	648	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	636	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	636	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	630	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	630	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular	Procedure	C4	623	OA
0012a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	622	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	619	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	606	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	582	AV
80777027310	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0013a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	581	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	580	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	576	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	569	AV
208	Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	567	AV
59267100001	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	ND		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	554	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
59267100001	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	ND		AV
208	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	CV		OA
0001a	Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				
0011a	Immunization Administration By Intramuscular	Procedure	C4	551	AV
0001a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	549	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	539	AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	536	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	533	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	527	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208		Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	518	IS
0001a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	516	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	506	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	506	AV
59267100002	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
208	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free,	Procedure	CV		OA
0002a	30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For	Procedure	C4		AV
0001a	Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	505	OA
91301		Procedure	C4		AV
80777027399	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	ND		AV
207		Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	501	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	500	OA
0013a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	497	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	494	AV
0001a	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	482	OA
207		Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	478	OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	472	OA
0001a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	471	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	469	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	468	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	468	OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	458	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	457	AV
80777027310		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	452	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	451	OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	440	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	439	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a		Procedure	C4		AV
0002a		Procedure	C4	431	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular	Procedure	C4	430	AV
0064a	Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	430	OA
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	429	OA
207		Procedure	CV		OA
0011a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	426	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	418	OA
0011a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	410	OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	CV	408	OA
0064a	50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	403	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	400	ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	C4	398	AV
207	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	387	AV
0013a	Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein,	Procedure	ND	383	IS
0001a	Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	376	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	373	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	366	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult	Procedure	C4		AV
0001a	Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2	Procedure	C4	363	AV
80777027399	(Sars-Cov-2) (Coronavirus Disease [covid-19])	Procedure	ND		AV
0013a	Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	359	OA
0064a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	359	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	355	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	348	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	347	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	347	OA
59267100002		Procedure	ND		AV
0004a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	344	OA
0011a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	341	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	338	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	338	OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	337	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	329	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	326	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	323	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	322	OA
0071a		Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	322	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	321	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	317	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	317	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	316	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	313	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	313	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0031a	Immunization Administration By	Procedure	C4	308	OA
0031a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	306	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	302	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	300	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	299	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	297	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	295	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	294	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	291	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	291	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	290	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	288	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	286	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	282	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	280	IS
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	279	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	276	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	275	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	274	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	273	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	272	OA
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	272	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	270	AV
0012a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	269	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	269	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	269	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	266	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	266	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	264	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	264	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	262	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	259	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	258	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	256	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	256	OA
0002a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	256	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	255	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	254	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	251	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	251	AV
80777027310	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	251	IS
207		Procedure	CV		OA
0011a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	250	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	250	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	250	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	248	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	245	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	245	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	244	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	244	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	244	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	244	AV
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	243	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	242	OA
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	242	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	242	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	242	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	241	AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	239	AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	238	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	234	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	233	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	232	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	228	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	228	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	228	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	227	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	226	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	224	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	224	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	224	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	222	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	222	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	222	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	221	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	219	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	219	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	216	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	215	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	215	IS
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	214	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	214	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	213	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	207	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	207	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	206	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	205	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	202	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	202	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	201	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	201	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	199	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	196	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	196	N/A
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	196	IS
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	196	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	195	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	194	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	192	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	191	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	191	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	189	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	188	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	187	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	187	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	186	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	185	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0004a	Immunization Administration By	Procedure	C4	185	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	185	OA
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	184	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	184	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	183	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	183	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	182	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	182	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	181	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	181	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	178	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	178	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	177	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0003a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	176	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	175	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	173	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	173	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	173	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	172	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	172	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	169	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	169	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4	169	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	169	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	167	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	167	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	167	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	166	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	166	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	166	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	165	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	163	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	161	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	160	IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	160	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	159	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	159	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	159	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	157	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	157	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	156	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Prescription Procedure	N/A CV	155	N/A OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	155	OA
0071a	Immunization Administration By	Procedure	C4	154	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription	N/A	153	N/A
0071a	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	151	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	151	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	151	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	150	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	150	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	149	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	149	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	149	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	149	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	148	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	147	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	147	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	146	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	144	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	144	OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	143	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	143	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	140	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	139	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	139	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	138	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	138	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	138	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	136	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	135	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	134	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	133	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	132	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	131	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	130	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	130	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	129	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	129	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	129	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	129	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	128	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	128	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	127	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	126	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	126	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	126	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	126	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	125	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	125	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	125	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	125	OA
0003a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	123	N/A OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	123	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	122	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	122	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	122	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	121	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	120	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	120	AV
Sarscov2covid19vaccinemrnaspik	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription	N/A	120	N/A
208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	120	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	119	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	119	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	118	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	118	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	117	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	116	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	116	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	115	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	115	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	115	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	115	N/A OA
Sarscov2covid19vaccinemrnaspik 212	Sarscov2covid19vaccinemrnaspik COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	114	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	113	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	113	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	113	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	112	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	112	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	112	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	110	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	108	N/A
orno	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
Covid19mrnalnpspf100mcg 05mldos					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	108	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	108	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	107	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	107	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	107	OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	106	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	106	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	104	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	103	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	103	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	103	OA
0001a		Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	102	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	102	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	102	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	101	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	101	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	101	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	100	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	100	OA
207		Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	100	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	99	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	99	AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	99	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	99	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	98	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	98	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	98	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	98	OA
0011a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	97	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	97	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	97	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	97	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	97	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	97	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	96	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	96	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	96	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	95	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	95	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	95	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	94	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	94	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	94	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	93	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	93	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	93	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	93	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	93	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	91	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	91	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	91	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0004a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	91	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	90	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	90	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	90	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0003a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	90	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	89	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	89	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	89	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	88	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	88	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	87	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	87	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0031a	Immunization Administration By	Procedure	C4	87	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	87	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	86	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	85	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	84	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	84	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0002a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	84	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	84	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	84	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	84	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	83	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	83	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	83	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	83	AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	83	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	83	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	83	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
59267100001	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	83	AV
208	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	82	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	82	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	82	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	82	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	81	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	81	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	81	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	80	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	79	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	79	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	79	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	79	OA
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	78	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	77	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	77	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	77	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	76	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	76	OA
0004a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	75	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	75	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	75	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	74	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	74	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	74	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	74	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	74	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	74	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	73	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	73	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	73	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	73	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	73	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	73	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	72	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	72	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	72	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	72	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	72	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	72	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	72	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	71	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	71	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	71	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	71	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	70	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	70	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	70	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	70	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	70	AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	70	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	70	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	69	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	69	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a		Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	69	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	69	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	69	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	69	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	69	N/A
05mldos 207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	68	N/A
Sarscov2covid19vaccinemrn aspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	68	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	68	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	68	IS
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	68	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	67	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	67	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	67	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	66	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	66	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	66	N/A
aspik	Immunization Administration By	Procedure	C4		OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	66	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	65	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	65	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	65	IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	64	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV	64	OA
0003a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	63	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	63	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	63	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	63	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	63	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	62	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	62	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	62	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	61	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	61	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	61	OA
207	Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	61	OA
0013a	Immunization Administration By	Procedure	C4	61	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	60	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	60	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	60	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a		Procedure	C4		AV
207		Procedure	CV	60	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	60	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	60	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	59	OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	59	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	59	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301		Procedure	C4	59	OA
80777027399		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	59	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	58	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	58	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	58	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	58	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	58	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	58	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	58	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	58	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	58	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	57	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	57	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	57	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	57	AV
207		Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 0064a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	56	N/A AV
Sarscov2covid19vaccinemrn aspik 91300 0001a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	56	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	56	AV
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	56	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	56	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	56	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	56	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	56	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	56	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	55	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	55	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	55	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	55	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	54	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	54	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	54	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	54	AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0013a		Procedure	C4		AV
0031a		Procedure	C4	54	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	53	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	53	OA
0002a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	52	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	52	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	52	AV
80777027310		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	52	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	51	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	51	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	51	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
218	Immunization Administration	Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	51	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	51	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	51	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	50	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	50	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	50	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	50	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	50	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	50	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	50	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	49	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	49	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	49	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	49	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	48	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	48	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	47	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	47	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	47	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	47	OA
208		Procedure	CV		OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	47	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	47	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	47	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	47	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	46	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	46	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	46	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	46	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	46	AV
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	46	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	46	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	46	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	45	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	45	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	45	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	45	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	45	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	45	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	45	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	45	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	45	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	45	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	45	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	45	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	44	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	44	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	44	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	44	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	44	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	44	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	44	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	43	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	43	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	43	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	43	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	43	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	43	AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	43	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	43	OA
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	42	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	42	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0002a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	42	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	42	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0031a	Immunization Administration By	Procedure	C4	42	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	42	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	41	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	41	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	41	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	41	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4	41	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	41	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	41	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	41	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	41	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0013a	Immunization Administration By	Procedure	C4	41	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	40	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	40	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	40	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	40	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	40	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	40	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	40	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	40	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	40	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	40	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	40	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	40	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	40	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	40	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	40	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	39	ED
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	39	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	39	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	39	OA
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	39	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	39	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	39	OA
0001a	Dose;	Procedure	C4		ED
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	39	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	39	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	38	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	38	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	38	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	38	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	38	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	38	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	38	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	37	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	37	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	37	IS
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	37	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	37	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	37	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	37	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	37	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	37	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	37	IS
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IS
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	37	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	37	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	37	IS
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	36	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	36	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	36	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0003a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	36	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	36	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	36	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	36	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	36	OA
0002a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	36	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	36	ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	35	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0071a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	35	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	35	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	35	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	35	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	35	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	35	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	35	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	35	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	35	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	34	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	34	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	34	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	34	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	34	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	34	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	34	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	34	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	34	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	34	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	34	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	34	OA
0001a		Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	34	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	34	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	34	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	33	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	33	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	33	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	33	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	33	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	33	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	33	OA
0011a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	33	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	33	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	33	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	33	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	33	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	33	IS
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	32	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	32	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	32	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	32	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	32	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	32	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	32	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	32	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	32	AV
59267100001		Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	32	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	32	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	32	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	32	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	32	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	32	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	32	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	32	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	32	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	32	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	31	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	31	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	31	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	31	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	31	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	31	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	31	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	31	OA
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	31	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	31	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	31	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	30	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	30	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	30	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	30	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	30	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	30	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	30	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	29	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	29	N/A
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	29	IS
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		IS
0001a	Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	29	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	29	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	29	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	29	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	29	OA
207		Procedure	CV		OA
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	29	OA
80777027310		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	29	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	29	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	29	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	29	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	29	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	28	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	28	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	28	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	28	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	28	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	28	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	28	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	28	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	28	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	28	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	28	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	28	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	28	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	28	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	28	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	28	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	27	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	27	OA
Sarscov2covid19vaccinemrnaspik	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Sarscov2covid19vaccinemrnaspik	Prescription	N/A	27	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 0003a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	27	N/A AV
Sarscov2covid19vaccinevect orno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	27	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	27	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	27	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	27	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	27	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	26	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	26	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	26	OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	26	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	26	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	26	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	26	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	26	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	26	OA
208		Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	26	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	26	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	25	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	25	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	25	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	25	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	25	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	25	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	25	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	25	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	25	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	IS
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	25	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	ED
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a		Procedure	C4	24	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	24	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F					
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	24	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	24	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	24	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	24	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	24	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	24	OA
207	Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	24	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	24	OA
207	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	24	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	23	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	23	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	23	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	23	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein,	Procedure	ND		AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	23	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	23	AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	23	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	23	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	23	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	23	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	23	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	23	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	23	N/A
2mldose 207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	23	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	23	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	23	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	22	N/A OA
Sarscov2covid19vaccinemrnaspik212	Sarscov2covid19vaccinemrnaspik COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure Procedure	N/A CV CV	22	N/A OA OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	22	N/A
Sarscov2covid19vaccinevectorno0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	22	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	22	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	22	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	22	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	22	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	22	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	22	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	22	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	22	IS
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	21	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
91305	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	21	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	21	N/A
orno	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	21	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	21	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	21	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	21	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	21	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	21	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	21	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	21	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	21	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	21	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	21	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	20	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	20	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	20	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	20	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	20	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	20	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	20	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	20	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	20	AV
0001a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0012a	Immunization Administration By	Procedure	C4	20	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	20	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	20	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	20	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	20	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	20	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	20	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	20	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	20	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	20	AV
0011a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	19	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	19	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	19	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	19	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	19	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0002a	Immunization Administration By	Procedure	C4	19	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	19	OA
59267100001 208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
		Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	19	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	19	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	19	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	19	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	19	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	19	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	19	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	19	OA
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	19	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	19	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	19	ED
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	19	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	18	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	18	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	18	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	18	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	18	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	18	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	18	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	18	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	18	OA
0002a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	18	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	18	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	18	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	18	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	18	AV
0011a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	18	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	18	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	17	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	17	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	17	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV
80777027399		Procedure	ND		AV
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	17	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	17	OA
80777027310		Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	17	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	17	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	17	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	17	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	17	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	16	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	16	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a		Procedure	C4	16	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	16	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0002a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	16	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	16	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	16	N/A OA
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	16	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
0002a	Immunization Administration By	Procedure	C4	16	IP
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	16	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscu	Procedure	ND		AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By I	Procedure	C4	16	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	16	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	16	OA
0002a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	16	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	16	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	16	AV
0004a	Immunization Administration By	Procedure	C4	16	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	16	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	16	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	16	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	16	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	16	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	16	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	16	OA
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	16	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	15	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	15	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV
0071a					
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	15	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	15	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	15	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	15	AV
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	15	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	15	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	15	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	15	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	15	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	15	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	15	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	15	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	15	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	15	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	15	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	14	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	14	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	14	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	14	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	14	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	14	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immuni				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	14	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	14	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	14	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	14	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	14	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	14	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	14	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	14	IP
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	14	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	13	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	13	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	13	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	13	N/A
orno					
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	ND		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	13	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	13	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	13	OA
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By I	Procedure	C4	13	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	13	AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	13	AV
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	13	OA
207		Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	13	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	13	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	13	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	13	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	13	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	13	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	12	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	12	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	12	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0001a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	12	N/A AV
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	12	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	12	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	IP
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	12	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310 0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
218		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	12	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs	Procedure	C4		OA
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	12	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
218	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	12	OA
218	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	12	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	12	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	12	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	12	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	12	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	12	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	12	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	12	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	12	IS
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0013a	Immunization Administration By	Procedure	C4	12	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	12	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	12	OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	12	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	11	OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	11	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	11	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	11	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	11	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	11	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	11	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	OA
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	11	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-C				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0001a	Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	ND		AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By I	Procedure	C4	11	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	11	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	11	ED
0001a		Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	11	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	11	AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	11	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	11	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	11	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	11	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	11	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	11	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	11	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	10	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	10	N/A
2mldose	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
aspik	Immunization Administration By	Procedure	C4		OA
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA
218		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respira				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	10	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA
0003a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA
0004a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	OA
80777027399		Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	10	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	10	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	10	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	10	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	10	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0012a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	10	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	IS
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	10	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	10	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	10	OA
0012a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	10	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				
0071a	Immunization Administration By	Procedure	C4	9	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	9	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208		Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Sarscov2covid19vaccinemrnaspik0003a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	9	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	9	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	ED
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0004a					
0001a					
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0001a					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By I	Procedure	C4	9	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	9	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	9	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	9	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By	Procedure	C4	9	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	9	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
207	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	9	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	9	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	9	OA
0011a		Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	9	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	9	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	9	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	9	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	9	N/A
0064a	Immunization Administration By	Procedure	C4	8	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
218	Immunization Administration	Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinemrnaspik0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	8	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91300	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	8	N/A OA
Sarscov2covid19vaccinevectorno 208	Sarscov2covid19vaccinevectorno COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinevectorno 91300	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	8	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	8	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	OA
0011a		Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Ad	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0013a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	8	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
0011a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	8	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	8	OA
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
0011a	Immunization Administration By	Procedure	C4	8	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	8	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	8	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	8	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	8	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	8	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	8	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	8	IP
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	8	IP
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	8	AV
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	7	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	7	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	7	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	7	OA
0071a		Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
aspik					
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	7	N/A OA
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	7	N/A OA
Sarscov2covid19vaccinevectorno 212 208	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	7	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	7	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	7	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscu				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	7	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	7	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
80777027310	Covid19mrnalnpspf100mcg05mldos	Prescription	ND		AV
0013a	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	7	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	7	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	7	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0012a	Immunization Administration By	Procedure	C4	7	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0011a	Immunization Administration By	Procedure	C4	7	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	7	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	7	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		AV
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	7	OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	7	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	AV
0004a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	7	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	7	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	7	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	7	IS
0012a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		IS
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	OA
0012a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	6	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrn aspik 208 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	6	N/A OA OA
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	6	N/A OA AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	6	N/A
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	6	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	6	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	6	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
207	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	IS
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	ED
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	6	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	6	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	6	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	IS
0002a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By	Procedure	C4	6	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	6	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	6	AV
207		Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0004a	Dose;	Procedure	C4		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	6	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	6	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	6	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	IP
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	6	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	5	OA
207		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	5	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
91307		Procedure	C4		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
218	Immunization Administration	Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	5	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik 59267100001	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Prescription Procedure	N/A ND	5	N/A OA
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	5	N/A AV
Sarscov2covid19vaccinemrnaspik 0013a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	5	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	5	N/A OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinevectorno 0011a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	5	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	IP
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	IS
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IS
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	ED
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, M				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0002a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	5	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	OA
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	5	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Ad	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	ED
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0012a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	5	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	5	OA
0002a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	5	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	5	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0003a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	5	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	5	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	5	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	5	IS
0012a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	5	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	4	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	4	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	4	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	4	OA
0071a		Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
aspik		Procedure	C4		AV
208		Procedure	C4		AV
0001a					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	4	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
Sarscov2covid19vaccinemrnaspik208 0002a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	4	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	4	N/A AV
Sarscov2covid19vaccinevectorno 91300 59267100001 0001a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A C4 ND C4	4	N/A AV AV AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	4	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	IP
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		IP
0001a		Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	IP
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	IS
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	4	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-C				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0011a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	4	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Mode				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original For	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	4	OA
208		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Ad	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0013a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4	4	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By I	Procedure	C4	4	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	4	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0003a	Immunization Administration By	Procedure	C4	4	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	4	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	4	OA
0003a		Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	4	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	4	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	4	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	4	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	4	OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0011a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0003a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0003a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	4	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0013a	Immunization Administration By	Procedure	C4	4	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0004a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0012a	Immunization Administration By	Procedure	C4	4	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	IP
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	4	IS
0013a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	4	IS
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	4	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By	Procedure	C4	3	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	3	AV
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2	Procedure	C4		AV
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0064a	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	D				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	3	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By	Procedure	C4	3	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Se				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 80777027399 208	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A ND CV	3	N/A AV OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212	Sarscov2covid19vaccinemrnaspik COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 59267100002 0003a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A ND C4	3	N/A AV AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	3	N/A AV
Sarscov2covid19vaccinemrnaspik 80777027399	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	3	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	3	N/A OA AV
Sarscov2covid19vaccinevectorno 80777027399	Sarscov2covid19vaccinevectorno Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	3	N/A AV
Sarscov2covid19vaccinevectorno 59267100001 0001a	Sarscov2covid19vaccinevectorno Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A ND C4	3	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
208		Procedure	CV		OA
0001a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	IP
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	IS
59267100001		Procedure	ND		IS
0001a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	ED
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	ED
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Di	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
59267100001		Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	3	AV
80777027399		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	OA
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	IP
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	ED
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike	Procedure	C4		AV
0011a	Use	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	3	AV
212		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4	3	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4	3	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-L	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0013a		Procedure	C4		OA
91301		Procedure	C4	3	OA
80777027399		Procedure	ND		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By	Procedure	C4	3	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0011a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By	Procedure	C4	3	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
59267100001	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0013a	Immunization Administration By	Procedure	C4	3	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	3	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	3	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0002a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
Covid19mrnalnpspf100mcg05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription	N/A	3	N/A
Covid19mrnalnpspf100mcg05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0003a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	3	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0003a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0003a	Dose;	Procedure	C4		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	3	OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0012a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0012a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0004a		Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	3	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	OA
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	3	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	3	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Immunization Administration By	Procedure	C4		AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0012a	Immunization Administration By	Procedure	C4	3	AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	3	AV
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	3	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	OA
0013a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	3	OA
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027310	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	IS
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	2	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0064a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	2	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	2	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0071a	Original For	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0071a	Original For	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	AV
218		Procedure	CV		OA
207		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		AV
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	2	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
aspik					
Covid19mrnalnpspf100mcg					
05mldos					
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0003a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription	N/A	2	N/A
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a		Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription	N/A	2	N/A
0031a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription	N/A	2	N/A
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A OA
Sarscov2covid19vaccinemrnaspik207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	2	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91300	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	2	N/A OA
Sarscov2covid19vaccinevectorno 91301	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 207	Sarscov2covid19vaccinevectorno COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinevectorno 212 207	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		IP
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IP
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0001a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0002a	Dose;	Procedure	C4		IS
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IS
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100002	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
59267100001	Use	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserva				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100002	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immuni	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	CV		OA
0001a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original For	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	2	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunizati				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administrati				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0012a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute R				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0002a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein,	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immuni	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster D				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0011a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
208		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0013a		Procedure	C4		OA
0003a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IP
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IP
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		ED
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		ED
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	ED
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		ED
0011a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301		Procedure	C4		AV
80777027310		Procedure	ND		OA
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use

COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
207		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
208		Procedure	CV		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0013a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	2	OA
80777027310		Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
207		Procedure	CV		OA
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-L	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		ED
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		ED
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0031a	Immunization Administration By	Procedure	C4	2	ED
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		AV
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		AV
0001a	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
59267100001	Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	CV		OA
0011a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0003a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0012a	Immunization Administration By	Procedure	C4	2	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0013a	Immunization Administration By	Procedure	C4	2	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	2	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	2	ED
218		Procedure	CV		OA
91307		Procedure	C4	2	OA
91307		Procedure	C4		AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	2	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
208		Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		OA
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0031a	Immunization Administration By	Procedure	C4	2	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0002a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	2	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		IP
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0003a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	2	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IP
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0031a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0003a	Dose;	Procedure	C4		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	2	AV
208		Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	2	AV
208		Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0012a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0031a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0003a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	IS
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0012a	Immunization Administration By	Procedure	C4	2	IP
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	ED
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0012a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	2	OA
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0011a	Respiratory Syndrome Coronavirus 2	Procedure	C4		AV
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	2	OA
0013a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	ED
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0064a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0013a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0064a		Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0064a		Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Synd	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscu	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscu	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0064a	Immunization Administration By	Procedure	C4	1	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0064a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a		Procedure	C4		AV
0012a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos					
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
207		Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0071a	Immunization Administration By	Procedure	C4	1	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0003a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
0071a		Procedure	C4		IP
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		ED
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	ED
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a		Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
218	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0002a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0003a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0071a	Original For	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0071a	Original For	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a					
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91307	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0071a	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	ND		AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	ND		AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4		AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	ND		AV
0071a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a		Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4		OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0071a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0013a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0071a		Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrnaspik	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
aspik	0.5 Ml;				
212	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn	Immunization Administration By	Procedure	C4		AV
aspik	Intramuscular Injection Of Severe Acute				
0031a	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
207	Reconstituted, For Intr	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respira				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027399	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik0002a 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	1	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik					
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
0001a	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		OA
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		OA
0001a	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0002a	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription	N/A	1	N/A
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription	N/A	1	N/A
207		Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription	N/A	1	N/A
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrn aspik 207 0012a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
Covid19mrnalnpspf100mcg	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
05mldos	Dose Or 50 Mcg/0.25ml Dose;				
207	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrn aspik 207	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrn aspik 218 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinemrn aspik 208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik2080004a	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik 0003a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 59267100002 0004a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A ND C4	1	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0012a		Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0013a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 80777027399	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	1	N/A AV
Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf10mcg02mldose	Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf10mcg02mldose	Prescription Prescription	N/A N/A	1	N/A N/A
Sarscov2covid19vaccinevectorno 91300 0001a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	1	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0031a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevect orno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 0001a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinevectorno 0001a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
0031a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 208 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure Procedure	N/A CV CV C4	1	N/A OA OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
Covid19mrnalnpspf100mcg	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
05mldos	0.5 Ml;				
212	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 218	Sarscov2covid19vaccinevectorno COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0004a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 80777027399	Sarscov2covid19vaccinevectorno Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	1	N/A AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		IP
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
208		Procedure	CV		OA
0001a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		IP
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		IP
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		IP
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		IS
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		IS
0001a		Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		IS
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IS
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		IS
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
208		Procedure	CV		OA
0003a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		ED
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
91300	Spike Protein, Preservative Free, 100	Procedure	C4		OA
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
207	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Ln				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Pri				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Pri				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0003a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
218	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Y				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0011a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0002a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0003a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spi				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0012a	Use	Procedure	C4		AV
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose.				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0002a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Seri				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0012a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
208	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100002	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
59267100001	Use	Procedure	ND		AV
208	Severe Acute Respiratory Syndrome	Procedure	CV		OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0012a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0002a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0002a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0002a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respirato				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
208	Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0013a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0003a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), M				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4	1	OA
91300		Procedure	C4		AV
80777027399		Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein,	Procedure	ND		AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0002a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0002a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0002a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Prote				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a		Procedure	C4		AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a		Procedure	C4		AV
0002a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
59267100002		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-C				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-C				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0003a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Di	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0004a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a		Procedure	C4		AV
0003a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Synd				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		OA
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0002a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0002a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0002a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
59267100001		Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
208		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0002a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 M				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0031a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0031a		Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0031a	Spike Protein, Preservative Free, 30	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4	1	OA
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
212		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		IS
0002a		Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218		Procedure	CV		OA
0002a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administra				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0003a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
212		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0003a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
0031a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
0003a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		IP
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IP
0011a		Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	IP
0012a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IS
0011a		Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		IS
0012a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
91301	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	ND		AV
80777027310		Procedure	ND		ED
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscu	Procedure	ND		ED
0011a		Procedure	C4		AV
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		ED
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		ED
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	ED
207		Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	ED
80777027310		Procedure	ND		ED
207		Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		ED
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		ED
0012a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	ED
0031a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		AV
80777027310	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
80777027310	Use	Procedure	ND		OA
207	Severe Acute Respiratory Syndrome	Procedure	CV		OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0031a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0012a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		OA
80777027399		Procedure	ND		AV
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administ	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
212		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0013a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0002a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Mono				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By I	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		OA
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Corona				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By I	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0013a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
208		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
208		Procedure	CV		OA
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	ND		AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0003a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
59267100002		Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
59267100001		Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0012a		Procedure	C4		AV
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0013a		Procedure	C4		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0012a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0012a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0012a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0013a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0013a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0013a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	ND		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By I	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respirat	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
80777027399		Procedure	ND		AV
0011a		Procedure	C4		OA
91301		Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	OA
212		Procedure	CV		OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		ED
0013a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	OA
80777027310		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
207		Procedure	CV		OA
0012a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	OA
212		Procedure	CV		OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		IP
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		IS
207		Procedure	CV		OA
0011a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		IS
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0012a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
208		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
208		Procedure	CV		OA
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0011a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		ED
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0012a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
208		Procedure	CV		OA
0001a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
208		Procedure	CV		OA
0001a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	ED
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		ED
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	ED
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2	Procedure	C4		OA
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose	Procedure	C4		AV
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		AV
0001a	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		ED
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0001a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0001a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
59267100001	Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	C4		AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
59267100001	Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0012a	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	C4		AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND		AV
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
	Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
59267100001	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	C4		OA
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Synd				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0012a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0002a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0013a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
Covid19mrnalnpspf10mcg02mldose	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0003a	Immunization Administration By	Procedure	C4	1	IP
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IP
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By	Procedure	C4	1	IS
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0064a	Immunization Administration By	Procedure	C4	1	IS
0004a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0002a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0064a	Immunization Administration By	Procedure	C4	1	IS
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0002a		Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
0002a	Pfizer Adult Primary Series And Ic Dose	Procedure	C4		AV
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0002a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0002a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Prote				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0002a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0002a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0002a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0012a	Dose;	Procedure	C4		AV
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0002a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0002a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0011a	Immunization Administration By	Procedure	C4	1	OA
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0002a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0002a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0002a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0002a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0012a	Immunization Administration By	Procedure	C4	1	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0013a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0003a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
218	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
207		Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0012a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0003a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0012a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0012a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0031a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0013a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0012a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	1	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IP
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		IS
0011a	fda Eua	Procedure	C4		IS
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	1	OA
207		Procedure	CV		OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	1	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0012a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
207		Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0013a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0012a	Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0004a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0004a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0004a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0003a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0003a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
0003a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0004a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0004a		Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0011a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0013a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
212		Procedure	CV		OA
0031a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0003a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0012a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0013a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0013a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	IS
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IS
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IS
0003a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	IS
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
218	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0012a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0013a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0013a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0031a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0003a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0003a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0003a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0003a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0011a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0013a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0003a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0003a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	AV
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0003a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0012a	Immunization Administration By	Procedure	C4	1	OA
0003a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0012a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0004a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0064a	Immunization Administration By	Procedure	C4	1	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0004a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0012a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IP
0012a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	1	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0013a	Immunization Administration By	Procedure	C4	1	IS
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	IS
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		IS
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		IS
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
0011a	Immunization Administration By	Procedure	C4	1	ED
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	ED
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0013a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0012a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0013a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0013a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0013a	Immunization Administration By	Procedure	C4	1	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a					
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	OA
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0013a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0031a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	IP
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	1	IS
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IS
0012a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	IS
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0012a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0012a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0012a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
0012a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0013a	Immunization Administration By	Procedure	C4	1	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	IS
0031a					OA
0013a					IS
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	1	AV
0013a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0013a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0031a	Immunization Administration By	Procedure	C4	1	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0031a	Immunization Administration By	Procedure	C4	1	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	IP
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		OA
80777027310	Dose Or 50 Mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	ED
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0031a	Immunization Administration By	Procedure	C4	1	AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (COVID-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0002a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100002		Procedure	ND		AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	0	AV
59267100001		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	0	AV
80777027310		Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	0	AV
80777027399		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0002a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	0	AV
59267100001		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	0	AV
59267100001		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	0	OA
0011a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0064a	Immunization Administration By	Procedure	C4	0	IS
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	0	AV
59267100002		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	0	OA
0011a		Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	0	AV
0002a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	0	OA
0031a	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
80777027399		Procedure	ND	0	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
212	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0031a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose				
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
212	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0031a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0031a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	0	AV
0031a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
0011a	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By	Procedure	C4	0	AV
0012a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
212		Procedure	CV		OA
0011a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0031a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
0003a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0002a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	ED
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0013a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By	Procedure	C4	0	AV
0013a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0013a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0013a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0013a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	0	OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0012a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0012a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0012a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0013a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0003a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0003a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0003a	Immunization Administration By	Procedure	C4	0	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0011a	Immunization Administration By	Procedure	C4	0	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0012a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0012a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	OA
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0012a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0013a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna,	Procedure	ND	0	OA
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0031a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.

[4]Encounter Care Setting is defined as AV, OA, ED, IP, or IS: AV stands for Ambulatory Visit; OA refers to Other Ambulatory Visit; ED means Emergency Department; IP denotes Inpatient Hospital Stay; and IS represents Non-Acute Institutional Stay.
N/A stands for Not Applicable.

Table 5b r01. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8,572,226
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6,896,887
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6,555,800
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4,058,491
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,604,209
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,206,571
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2,200,804

Table 5b r01. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,797,482
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,338,476
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,017,853
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	824,046
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	818,620
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	714,465
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	686,745
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	609,261
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	550,313

Table 5b r01. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	472,554
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	466,793
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	439,514
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	422,196
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	386,053
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	375,202
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	363,379

Table 5b r01. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	349,002
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	337,011

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.

Table 5b r02. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8,206,974
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6,588,373
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5,120,865
208	COVID-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3,855,416
207	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,438,485
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,007,469

Table 5b r02. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,236,751
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,194,829
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	915,617
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	608,410
0003a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	603,286
59267100001	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	541,436
0013a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	435,108

Table 5b r02. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	387,737
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	359,493
218	COVID-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	357,600
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	341,402
59267100002	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	301,961
0002a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	300,326
80777027399	Sars-Cov-2 (COVID-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	290,238

Table 5b r02. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
212	COVID-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	252,649
0012a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	237,414
80777027310	COVID-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	222,005
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	209,603
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	193,402

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.
N/A stands for Not Applicable.

Table 6 r01. Summary of Patient-Level Cohort Attrition (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

	With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine	
	Remaining	**Excluded**
Members Meeting Enrollment and Demographic Requirements		
Enrolled at any point during the query period	231,611,185	N/A
Had required coverage type (medical and/or drug coverage)	171,205,067	60,406,118
Enrolled during specified age range	171,179,418	25,649
Had requestable medical charts	171,179,418	0
Met demographic requirements (sex, race, and Hispanic origin)	171,127,440	51,978
Members with a Valid Index Event		
Had any cohort-defining claim during the query period	46,173,851	124,953,589
Claim recorded during specified age range	46,173,723	128
Episode defining index claim recorded during the query period	46,173,723	0
Members with Required Pre-Index History		
Had sufficient pre-index continuous enrollment	41,779,825	4,393,898
Met inclusion and exclusion criteria[2]	38,575,376	3,204,449
Evidence of any prior COVID-19 vaccination	N/A	3,204,449
Met event incidence criteria	38,575,376	0
Had sufficient post-index continuous enrollment	38,575,376	0
Had index episode of at least required length	38,575,376	0
Had index episode longer than blackout period	38,575,376	0
Did not have an event during blackout period	38,575,376	0
Final Cohort		
Number of members	38,575,376	N/A
Number of episodes	38,575,376	N/A

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

N/A: Not Applicable

Table 6 r02. Summary of Patient-Level Cohort Attrition (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

	With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccine	
	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements		
Enrolled at any point during the query period	231,611,185	N/A
Had required coverage type (medical and/or drug coverage)	171,205,067	60,406,118
Enrolled during specified age range	171,179,418	25,649
Had requestable medical charts	171,179,418	0
Met demographic requirements (sex, race, and Hispanic origin)	171,127,440	51,978
Members with a Valid Index Event		
Had any cohort-defining claim during the query period	46,173,851	124,953,589
Claim recorded during specified age range	46,173,723	128
Episode defining index claim recorded during the query period	46,173,723	0
Members with Required Pre-Index History		
Had sufficient pre-index continuous enrollment	41,779,825	4,393,898
Met inclusion and exclusion criteria[2]	30,109,785	11,670,040
Evidence of COVID-19 vaccine 1-4 days after the index (duplicated)	N/A	274,314
Evidence of any prior COVID-19 vaccination	N/A	3,437,705
No evidence of second COVID-19 vaccination	N/A	11,660,748
Met event incidence criteria	30,109,785	0
Members with Required Post-Index Follow-Up		
Had sufficient post-index continuous enrollment	30,109,785	0
Had index episode of at least required length	30,109,785	0
Had index episode longer than blackout period	30,109,785	0
Did not have an event during blackout period	30,109,785	0
Final Cohort		
Number of members	30,109,785	N/A
Number of episodes	30,109,785	N/A

Table 6 r02. Summary of Patient-Level Cohort Attrition (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD) from November 1, 2020 to January 31, 2024

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

	With a first Pfizer Coronavirus Disease 2019 (COVID-19) vaccine followed by a second Pfizer Coronavirus disease 2019 (COVID-19) vaccine (Pfizer-Pfizer combination)		With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	231,611,185	N/A	231,611,185	N/A
Had required coverage type (medical and/or drug coverage)	171,205,067	60,406,118	171,205,067	60,406,118
Enrolled during specified age range	171,179,418	25,649	171,179,418	25,649
Had requestable medical charts	171,179,418	0	171,179,418	0
Met demographic requirements (sex, race, and Hispanic origin)	171,127,440	51,978	171,127,440	51,978
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	28,448,483	142,678,957	20,377,523	150,749,917
Claim recorded during specified age range	28,448,378	105	20,377,492	31
Episode defining index claim recorded during the query period	28,448,378	0	20,377,492	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	25,668,326	2,780,052	18,586,631	1,790,861
Met inclusion andexclusion criteria[2]	21,480,531	4,187,795	15,409,521	3,177,110
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand	N/A	4,187,795	N/A	3,177,110
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	21,480,531	0	15,409,521	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	21,480,531	0	15,409,521	0
Had index episode of at least required length	21,480,531	0	15,409,521	0
Had index episode longer than blackout period	21,480,531	0	15,409,521	0

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

Did not have an event during blackout period	21,480,531	0	15,409,521	0
Final Cohort				
Number of members	21,480,531	N/A	15,409,521	N/A
Number of episodes	21,480,531	N/A	15,409,521	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Sentinel

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)		With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)		With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	
Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
Members Meeting Enrollment and Demographic Requirements							
231,611,185	N/A	231,611,185	N/A	231,611,185	N/A	231,611,185	N/A
171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118
171,179,418	25,649	171,179,418	25,649	171,179,418	25,649	171,179,418	25,649
171,179,418	0	171,179,418	0	171,179,418	0	171,179,418	0
171,127,440	51,978	171,127,440	51,978	171,127,440	51,978	171,127,440	51,978
Members with a Valid Index Event							
2,008,294	169,119,146	252,316	170,875,124	28,448,483	142,678,957	20,377,523	150,749,917
*****	*****	*****	*****	28,448,378	105	20,377,492	31
*****	*****	*****	*****	28,448,378	0	20,377,492	0
Members with Required Pre-Index History							
1,755,937	252,352	230,671	21,643	25,668,326	2,780,052	18,586,631	1,790,861
1,694,574	61,363	106,283	124,388	21,480,531	4,187,795	15,409,521	3,177,110
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	61,363	N/A	124,388	N/A	4,187,795	N/A	3,177,110
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
1,694,574	0	106,283	0	21,480,531	0	15,409,521	0
Members with Required Post-Index Follow-Up							
1,694,574	0	106,283	0	21,480,531	0	15,409,521	0
1,694,574	0	106,283	0	21,480,531	0	15,409,521	0
1,694,574	0	106,283	0	21,480,531	0	15,409,521	0
1,694,574	0	106,283	0	21,480,531	0	15,409,521	0
Final Cohort							

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

1,694,574	N/A	106,283	N/A	21,480,531	N/A	15,409,521	N/A
1,694,574	N/A	106,283	N/A	21,480,531	N/A	15,409,521	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)		With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)		With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)		With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	
Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
Members Meeting Enrollment and Demographic Requirements							
231,611,185	N/A	231,611,185	N/A	231,611,185	N/A	231,611,185	N/A
171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118
171,179,418	25,649	171,179,418	25,649	171,179,418	25,649	171,179,418	25,649
171,179,418	0	171,179,418	0	171,179,418	0	171,179,418	0
171,127,440	51,978	171,127,440	51,978	171,127,440	51,978	171,127,440	51,978
Members with a Valid Index Event							
28,448,483	142,678,957	28,448,483	142,678,957	20,377,523	150,749,917	20,377,523	150,749,917
28,448,378	105	28,448,378	105	20,377,492	31	20,377,492	31
28,448,378	0	28,448,378	0	20,377,492	0	20,377,492	0
Members with Required Pre-Index History							
25,668,326	2,780,052	25,668,326	2,780,052	18,586,631	1,790,861	18,586,631	1,790,861
21,480,531	4,187,795	21,480,531	4,187,795	15,409,521	3,177,110	15,409,521	3,177,110
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	4,187,795	N/A	4,187,795	N/A	3,177,110	N/A	3,177,110
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
21,480,531	0	21,480,531	0	15,409,521	0	15,409,521	0
Members with Required Post-Index Follow-Up							
21,480,531	0	21,480,531	0	15,409,521	0	15,409,521	0
21,480,531	0	21,480,531	0	15,409,521	0	15,409,521	0
21,480,531	0	21,480,531	0	15,409,521	0	15,409,521	0
21,480,531	0	21,480,531	0	15,409,521	0	15,409,521	0
Final Cohort							

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

21,480,531	N/A	21,480,531	N/A	15,409,521	N/A	15,409,521	N/A
21,480,531	N/A	21,480,531	N/A	15,409,521	N/A	15,409,521	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)		With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)		With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements							
231,611,185	N/A	231,611,185	N/A	231,611,185	N/A	231,611,185	N/A
171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118
171,179,418	25,649	171,179,418	25,649	171,179,418	25,649	171,179,418	25,649
171,179,418	0	171,179,418	0	171,179,418	0	171,179,418	0
171,127,440	51,978	171,127,440	51,978	171,127,440	51,978	171,127,440	51,978
Members with a Valid Index Event							
2,008,294	169,119,146	2,008,294	169,119,146	2,008,294	169,119,146	252,316	170,875,124
*****	*****	*****	*****	*****	*****	*****	*****
*****	*****	*****	*****	*****	*****	*****	*****
Members with Required Pre-Index History							
1,755,937	252,352	1,755,937	252,352	1,755,937	252,352	230,671	21,643
1,694,574	61,363	1,694,574	61,363	1,694,574	61,363	106,283	124,388
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	61,363	N/A	61,363	N/A	61,363	N/A	124,388
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
1,694,574	0	1,694,574	0	1,694,574	0	106,283	0
Members with Required Post-Index Follow-Up							
1,694,574	0	1,694,574	0	1,694,574	0	106,283	0
1,694,574	0	1,694,574	0	1,694,574	0	106,283	0
1,694,574	0	1,694,574	0	1,694,574	0	106,283	0
1,694,574	0	1,694,574	0	1,694,574	0	106,283	0
Final Cohort							
1,694,574	N/A	1,694,574	N/A	1,694,574	N/A	106,283	N/A

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

1,694,574	N/A	1,694,574	N/A	1,694,574	N/A	106,283	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)		With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)		With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements							
231,611,185	N/A	231,611,185	N/A	231,611,185	N/A	231,611,185	N/A
171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118
171,179,418	25,649	171,179,418	25,649	171,179,418	25,649	171,179,418	25,649
171,179,418	0	171,179,418	0	171,179,418	0	171,179,418	0
171,127,440	51,978	171,127,440	51,978	171,127,440	51,978	171,127,440	51,978
Members with a Valid Index Event							
252,316	170,875,124	252,316	170,875,124	43,566,086	127,561,354	10,792,021	160,335,419
*****	*****	*****	*****	43,565,962	124	10,791,960	61
*****	*****	*****	*****	43,565,962	0	10,791,960	0
Members with Required Pre-Index History							
230,671	21,643	230,671	21,643	39,595,751	3,970,211	9,423,424	1,368,536
106,283	124,388	106,283	124,388	30,221,690	9,374,061	1,947,898	7,475,526
N/A	N/A	N/A	N/A	N/A	N/A	N/A	7,310,959
N/A	N/A	N/A	N/A	N/A	8,733,368	N/A	6,843,206
N/A	N/A	N/A	N/A	N/A	7,336,407	N/A	N/A
N/A	124,388	N/A	124,388	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
106,283	0	106,283	0	30,221,690	0	1,947,898	0
Members with Required Post-Index Follow-Up							
106,283	0	106,283	0	30,221,690	0	1,947,898	0
106,283	0	106,283	0	30,221,690	0	1,947,898	0
106,283	0	106,283	0	30,221,690	0	1,947,898	0
106,283	0	106,283	0	30,221,690	0	1,947,898	0
Final Cohort							

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

106,283	N/A	106,283	N/A	30,221,690	N/A	1,947,898	N/A
106,283	N/A	106,283	N/A	30,221,690	N/A	1,947,898	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)		With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)		With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)		With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements							
231,611,185	N/A	231,611,185	N/A	231,611,185	N/A	231,611,185	N/A
171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118
171,179,418	25,649	171,179,418	25,649	171,179,418	25,649	171,179,418	25,649
171,179,418	0	171,179,418	0	171,179,418	0	171,179,418	0
171,127,440	51,978	171,127,440	51,978	171,127,440	51,978	171,127,440	51,978
Members with a Valid Index Event							
43,566,086	127,561,354	10,792,021	160,335,419	43,566,086	127,561,354	10,792,021	160,335,419
43,565,962	124	10,791,960	61	43,565,962	124	10,791,960	61
43,565,962	0	10,791,960	0	43,565,962	0	10,791,960	0
Members with Required Pre-Index History							
39,595,751	3,970,211	9,423,424	1,368,536	39,595,751	3,970,211	9,423,424	1,368,536
30,547,553	9,048,198	3,669,473	5,753,951	30,547,553	9,048,198	3,669,473	5,753,951
N/A	N/A	N/A	5,406,052	N/A	N/A	N/A	5,406,052
N/A	8,431,405	N/A	5,165,951	N/A	8,431,405	N/A	5,165,951
N/A	6,650,092	N/A	N/A	N/A	6,650,092	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
30,547,553	0	3,669,473	0	30,547,553	0	3,669,473	0
Members with Required Post-Index Follow-Up							
30,547,553	0	3,669,473	0	30,547,553	0	3,669,473	0
30,547,553	0	3,669,473	0	30,547,553	0	3,669,473	0
30,547,553	0	3,669,473	0	30,547,553	0	3,669,473	0
30,547,553	0	3,669,473	0	30,547,553	0	3,669,473	0
Final Cohort							

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

30,547,553	N/A	3,669,473	N/A	30,547,553	N/A	3,669,473	N/A
30,547,553	N/A	3,669,473	N/A	30,547,553	N/A	3,669,473	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)		With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)		With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	
Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
Members Meeting Enrollment and Demographic Requirements					
231,611,185	N/A	231,611,185	N/A	231,611,185	N/A
171,205,067	60,406,118	171,205,067	60,406,118	171,205,067	60,406,118
171,179,418	25,649	171,179,418	25,649	171,179,418	25,649
171,179,418	0	171,179,418	0	171,179,418	0
171,127,440	51,978	171,127,440	51,978	171,127,440	51,978
Members with a Valid Index Event					
43,566,086	127,561,354	43,566,086	127,561,354	43,566,086	127,561,354
43,565,962	124	43,565,962	124	43,565,962	124
43,565,962	0	43,565,962	0	43,565,962	0
Members with Required Pre-Index History					
39,595,751	3,970,211	39,595,751	3,970,211	39,595,751	3,970,211
4,358,350	35,237,401	4,358,350	35,237,401	4,358,350	35,237,401
N/A	N/A	N/A	N/A	N/A	N/A
N/A	27,818,890	N/A	27,818,890	N/A	27,818,890
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	33,187,524	N/A	33,187,524	N/A	33,187,524
4,358,350	0	4,358,350	0	4,358,350	0
Members with Required Post-Index Follow-Up					
4,358,350	0	4,358,350	0	4,358,350	0
4,358,350	0	4,358,350	0	4,358,350	0
4,358,350	0	4,358,350	0	4,358,350	0
4,358,350	0	4,358,350	0	4,358,350	0
Final Cohort					

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine1 in the Sentinel Distributed Database (SDD from November 1, 2020 to January 31, 2024

4,358,350	N/A	4,358,350	N/A	4,358,350	N/A
4,358,350	N/A	4,358,350	N/A	4,358,350	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r04. Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD)		
	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[2]	
	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements		
Enrolled at any point during the query period	150,211,854	N/A
Had required coverage type (medical and/or drug coverage)	96,117,308	54,094,546
Enrolled during specified age range	96,116,624	684
Had requestable medical charts	96,116,624	0
Met demographic requirements (sex, race, and Hispanic origin)	96,068,809	47,815
Members with a Valid Index Event		
Had any cohort-defining claim during the query period	35,248,651	60,820,158
Claim recorded during specified age range	35,248,568	83
Episode defining index claim recorded during the query period	35,248,568	0
Members with Required Pre-Index History		
Had sufficient pre-index continuous enrollment	32,290,986	2,957,582
Met inclusion andexclusion criteria[7]	19,510,553	12,780,433
Evidence of immunocompromised ***(excludes individuals meeting this criterion from non-immunocompromised cohort)***	N/A	N/A
No evidence of two previous COVID-19 vaccine codes ***(excludes individuals meeting this criterion from non-immunocompromised cohort)***	N/A	N/A
No evidence of three previous COVID-19 vaccine codes and immunocompromised ***(excludes individuals meeting this criterion from immunocompromised cohort)***	N/A	N/A
No evidence of two previous COVID-19 vaccine codes ***(excludes individuals meeting this criterion from the overall booster cohort)***	N/A	12,780,433
Met event incidence criteria	19,510,553	0
Members with Required Post-Index Follow-Up		
Had sufficient post-index continuous enrollment	19,510,553	0
Had index episode of at least required length	19,510,553	0
Had index episode longer than blackout period	19,510,553	0
Did not have an event during blackout period	19,510,553	0
Final Cohort		

Table 6 r04. Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Sentinel Distributed Database (SDD)		
Number of members	19,510,553	N/A
Number of episodes	19,510,553	N/A

[1]The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:

- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[3]Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[4]The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[5]The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[6]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

[7]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

N/A: Not Applicable

Table 6 r04. Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines)1 in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024

With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[3,4]		With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[3,5]		With Booster COVID-19 Vaccine (Booster Specific Code)[6]	
Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
Members Meeting Enrollment and Demographic Requirements					
150,211,854	N/A	150,211,854	N/A	150,211,854	N/A
96,117,308	54,094,546	96,117,308	54,094,546	96,117,308	54,094,546
96,116,624	684	96,116,624	684	96,116,624	684
96,116,624	0	96,116,624	0	96,116,624	0
96,068,809	47,815	96,068,809	47,815	96,068,809	47,815
Members with a Valid Index Event					
35,248,651	60,820,158	35,248,651	60,820,158	22,907,121	73,161,688
35,248,568	83	35,248,568	83	22,907,087	34
35,248,568	0	35,248,568	0	22,907,087	0
Members with Required Pre-Index History					
32,290,986	2,957,582	32,290,986	2,957,582	21,414,387	1,492,700
5,976,552	26,314,434	7,772,502	24,518,484	21,414,387	0
N/A	N/A	N/A	18,318,301	N/A	N/A
N/A	N/A	N/A	15,004,838	N/A	N/A
N/A	26,314,434	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
5,976,552	0	7,772,502	0	21,414,387	0
Members with Required Post-Index Follow-Up					
5,976,552	0	7,772,502	0	21,414,387	0
5,976,552	0	7,772,502	0	21,414,387	0
5,976,552	0	7,772,502	0	21,414,387	0
5,976,552	0	7,772,502	0	21,414,387	0
Final Cohort					
5,976,552	N/A	7,772,502	N/A	21,414,387	N/A
5,976,552	N/A	7,772,502	N/A	21,414,387	N/A

Table 6 r04. Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines)1 in the Sentinel Distributed Database (SDD) from September 1, 2021 to January 31, 2024

[1]The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:

- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[3]Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[4]The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[5]The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[6]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

[7]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

N/A: Not Applicable

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 17, 2024)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2000	01/31/2024
DP02	01/01/2000	01/31/2024
DP03	01/01/2008	04/30/2023
DP04	01/01/2006	10/31/2023
DP05	01/01/2005	07/31/2022
DP06	01/01/2000	12/31/2021
DP07	01/01/2000	04/30/2023
DP08	01/01/2004	07/31/2023
DP09	01/01/2000	10/31/2022
DP10	01/01/2007	10/31/2023
DP11	01/01/2000	08/31/2022
DP12	01/01/2014	12/31/2020
DP13	01/01/2008	09/30/2023
DP14	01/01/2010	06/30/2023

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-proprietary Name	Proprietary Name
Pfizer	
30 mcg/0.3 mL for adult 16+ (original formula)	Comirnaty
COVID-19 vac mRNA,tris(Pfizer)/PF	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose	Pfizer-BioNTech Covid-19 Vaccine, Bivalent
COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Pfizer-BioNTech Covid-19 Vaccine, Bivalent
COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose	Pfizer-BioNTech Covid-19 Vaccine, Bivalent
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose	Pfizer-BioNTech Covid-19 Vaccine
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Comirnaty
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, reconstituted, 30 mcg/0.3mL dose	Pfizer-BioNTech Covid-19 Vaccine
Moderna	
0.5 mL dose (same as original EUA formula)	Spikevax
0.5 mL dose of Original and Omicron COVID-19 strains	Moderna COVID-19 Vaccine, Bivalent

Appendix B. List of Non-proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-proprietary Name	Proprietary Name
COVID-19 vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose	Moderna COVID-19 Vaccine

Moderna	
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Moderna COVID-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Spikevax
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose	Moderna COVID-19 Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose, 6mo-<6yr	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose, 6yr-<12yr	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL	Moderna COVID-19 Vaccine, Bivalent
COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	Moderna COVID-19 Vaccine, Bivalent
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose	Moderna COVID-19 Vaccine
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL or 50mcg/0.25mL dose	Moderna COVID-19 Vaccine

Appendix B. List of Non-proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-proprietary Name	Proprietary Name
Novavax	
SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	NOVAVAX COVID-19 Vaccine, Adjuvanted
Jannsen	
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	Janssen COVID-19 Vaccine

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
	Pfizer		
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, first dose	Procedure	CPT-4
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, second dose	Procedure	CPT-4
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, third dose	Procedure	CPT-4
0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, booster dose	Procedure	CPT-4
00069100001	30 mcg/0.3 mL for adult 16+ (original formula)	Procedure	NDC
00069100002	30 mcg/0.3 mL for adult 16+ (original formula)	Procedure	NDC
00069100003	30 mcg/0.3 mL for adult 16+ (original formula)	Procedure	NDC
00069202501	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Procedure	NDC
00069202510	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Procedure	NDC
00069202525	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, first dose	Procedure	CPT-4
0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, second dose	Procedure	CPT-4
0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	Procedure	CPT-4
0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	Procedure	CPT-4
0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, first dose	Procedure	CPT-4
0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, second dose	Procedure	CPT-4
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	Procedure	CPT-4
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, first dose	Procedure	CPT-4
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, second dose	Procedure	CPT-4
0083A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	Procedure	CPT-4
0124A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation booster dose	Procedure	CPT-4
0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation booster dose	Procedure	CPT-4
208	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose; FDA EUA (12+ yrs) and BLA (16+ yrs), Pfizer adult primary series and IC dose original formulation. EUA 8/31/2022 rescinded monovalent booster dose. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty)	Procedure	CV

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
217	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose; FDA EUA (12+ yrs) and BLA (16+ yrs), Pfizer adult primary series and IC dose tris-sucrose formulation. EUA 8/31/2022 rescinded monovalent booster dose	Procedure	CV
218	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose; FDA EUA (5 yrs through 11 yrs), Pfizer tris-sucrose pediatric primary series, IC, and booster	Procedure	CV
219	COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose; FDA EUA (6 mo through 4 yrs), Pfizer tris-sucrose pediatric primary series	Procedure	CV
300	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose; EUA authorized Pfizer adult bivalent booster ages 12+ yrs, original strain + omicron BA.4/BA.5	Procedure	CV
301	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose; EUA authorized (5 yrs through 11 yrs) Pfizer bivalent booster, original strain + omicron BA.4/BA.5	Procedure	CV
302	COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose; Pre-EUA Pfizer bivalent (ages 6 mo through 4 yrs), original strain + omicron BA.4/BA.5	Procedure	CV
59267007801	COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267007802	COVID-19 vac mRNA,tris(Pfizer)/PF	Procedure	NDC
59267007804	COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267030401	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
59267030402	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
59267056501	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
59267056502	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose	Procedure	NDC
59267060901	COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose	Procedure	NDC
59267060902	COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose	Procedure	NDC
59267100001	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose	Procedure	NDC
59267100002	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, reconstituted, 30 mcg/0.3mL dose	Procedure	NDC
59267100003	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, reconstituted, 30 mcg/0.3mL dose	Procedure	NDC
59267102501	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC
59267102502	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC
59267102503	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC
59267102504	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC
59267105501	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267105502	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267105504	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
59267140401	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
59267140402	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	Procedure	CPT-4
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
	Moderna		
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 100mcg/0.5mL dosage, first dose	Procedure	CPT-4
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 100mcg/0.5mL dosage, second dose	Procedure	CPT-4
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 100mcg/0.5mL dosage, third dose	Procedure	CPT-4
0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 50mcg/0.25mL dosage, booster dose	Procedure	CPT-4
0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, first dose	Procedure	CPT-4
0092A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, second dose	Procedure	CPT-4
0093A	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, third dose	Procedure	CPT-4
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, booster dose	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25mcg/0.25mL dosage, for intramuscular use, first dose	Procedure	CPT-4
0112A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25mcg/0.25mL dosage, for intramuscular use, second dose	Procedure	CPT-4
0113A	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25mcg/0.25mL dosage, for intramuscular use, third dose	Procedure	CPT-4
0134A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 50mcg/0.5mL dosage, booster dose	Procedure	CPT-4
0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25mcg/0.25mL dosage, booster dose	Procedure	CPT-4
0164A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2mL dosage, booster dose	Procedure	CPT-4
207	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose; FDA EUA and BLA (18+ yrs), Moderna adult primary series and IC dose. EUA 8/31/2022 rescinded monovalent booster dose. Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax)	Procedure	CV
221	COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose; FDA EUA Moderna, EUA 8/31/2022 rescinded use of this product for adult monovalent booster dose. Vaccine now only authorized for 6 yrs through 11 primary series and IC doses	Procedure	CV

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
227	COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose; Temporarily inactivated - Use CVX code 221 for EUA Moderna Pediatric 6yr to<12 yr vaccine 2.5 mL vial, 50 mcg/0.5 mL dose	Procedure	CV
228	COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose; FDA EUA Authorized (6 mo through 5 yrs), Moderna pediatric primary series and IC dose	Procedure	CV
229	COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose; EUA authorized Moderna bivalent booster 2 dose levels: ages 6 yrs thru 11 yrs 0.25mL dose; 12 years and older 0.5mL dose	Procedure	CV
230	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL; Pre-EUA Moderna bivalent booster (ages 6 mo through 5 yrs), original strain + omicron BA.4/BA.5	Procedure	CV
80777010011	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777010015	0.5 mL dose (same as original EUA formula)	Procedure	NDC
80777010098	0.5 mL dose (same as original EUA formula)	Procedure	NDC
80777010099	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777027310	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777027315	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777027398	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose	Procedure	NDC
80777027399	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL or 50mcg/0.25mL dose	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
80777027505	COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose	Procedure	NDC
80777027599	COVID-19 vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose	Procedure	NDC
80777027705	COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose	Procedure	NDC
80777027799	COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose, 6yr-<12yr	Procedure	NDC
80777027905	COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose	Procedure	NDC
80777027999	COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose, 6mo-<6yr	Procedure	NDC
80777028005	0.5 mL dose of Original and Omicron COVID-19 strains	Procedure	NDC
80777028099	0.5 mL dose of Original and Omicron COVID-19 strains	Procedure	NDC
80777028205	COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	Procedure	NDC
80777028299	COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	Procedure	NDC
80777028302	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL	Procedure	NDC
80777028399	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL	Procedure	NDC
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Procedure	CPT-4
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	Procedure	CPT-4
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	Procedure	CPT-4
91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2mL dosage, for intramuscular use	Procedure	CPT-4
	Novavax		
0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5mcg/0.5mL dosage; first dose	Procedure	CPT-4
0042A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5mcg/0.5mL dosage; seconod dose	Procedure	CPT-4
0044A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5mcg/0.5mL dosage; booster	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
211	COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL; FDA EUA Authorized, Novavax primary series adult dose	Procedure	CV
80631010001	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC
80631010010	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC
80631010201	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC
80631010210	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
	Jannsen		
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; single dose	Procedure	CPT-4
0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; booster	Procedure	CPT-4
212	COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL; FDA EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations	Procedure	CV
59676058005	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
59676058015	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	Procedure	NDC
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
	Unknown Vaccination Brand		
213	SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED; Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product not known. CVX code 500 should be used to record Non-US vaccine where product is not known.	Procedure	CV
M0201	COVID-19 vaccine home admin	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
	Reactive Airway and Lung Diseases		
J66.0	Byssinosis	Diagnosis	ICD-10-CM
J66.1	Flax-dressers' disease	Diagnosis	ICD-10-CM
J66.2	Cannabinosis	Diagnosis	ICD-10-CM
J66.8	Airway disease due to other specific organic dusts	Diagnosis	ICD-10-CM
J67.0	Farmer's lung	Diagnosis	ICD-10-CM
J67.1	Bagassosis	Diagnosis	ICD-10-CM
J67.2	Bird fancier's lung	Diagnosis	ICD-10-CM
J67.3	Suberosis	Diagnosis	ICD-10-CM
J67.4	Maltworker's lung	Diagnosis	ICD-10-CM
J67.5	Mushroom-worker's lung	Diagnosis	ICD-10-CM
J67.6	Maple-bark-stripper's lung	Diagnosis	ICD-10-CM
J67.7	Air conditioner and humidifier lung	Diagnosis	ICD-10-CM
J67.8	Hypersensitivity pneumonitis due to other organic dusts	Diagnosis	ICD-10-CM
J67.9	Hypersensitivity pneumonitis due to unspecified organic dust	Diagnosis	ICD-10-CM
J68.0	Bronchitis and pneumonitis due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
J68.4	Chronic respiratory conditions due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
J68.8	Other respiratory conditions due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
J68.9	Unspecified respiratory condition due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
	Other Chronic Respiratory Diseases (Pneumonia and Bronchitis)		
B44.81	Allergic bronchopulmonary aspergillosis	Diagnosis	ICD-10-CM
G47.34	Idiopathic sleep related nonobstructive alveolar hypoventilation	Diagnosis	ICD-10-CM
G47.36	Sleep related hypoventilation in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43	Emphysema	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44	Other chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J61	Pneumoconiosis due to asbestos and other mineral fibers	Diagnosis	ICD-10-CM
J62	Pneumoconiosis due to dust containing silica	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J62.8	Pneumoconiosis due to other dust containing silica	Diagnosis	ICD-10-CM
J63	Pneumoconiosis due to other inorganic dusts	Diagnosis	ICD-10-CM
J63.6	Pneumoconiosis due to other specified inorganic dusts	Diagnosis	ICD-10-CM
J65	Pneumoconiosis associated with tuberculosis	Diagnosis	ICD-10-CM
J70	Respiratory conditions due to other external agents	Diagnosis	ICD-10-CM
J70.1	Chronic and other pulmonary manifestations due to radiation	Diagnosis	ICD-10-CM
J70.3	Chronic drug-induced interstitial lung disorders	Diagnosis	ICD-10-CM
J70.4	Drug-induced interstitial lung disorders, unspecified	Diagnosis	ICD-10-CM
J70.5	Respiratory conditions due to smoke inhalation	Diagnosis	ICD-10-CM
J70.8	Respiratory conditions due to other specified external agents	Diagnosis	ICD-10-CM
J70.9	Respiratory conditions due to unspecified external agent	Diagnosis	ICD-10-CM
J82	Pulmonary eosinophilia, not elsewhere classified	Diagnosis	ICD-10-CM
J82.8	Pulmonary eosinophilia, not elsewhere classified	Diagnosis	ICD-10-CM
J82.89	Other pulmonary eosinophilia, not elsewhere classified	Diagnosis	ICD-10-CM
J84	Other interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.0	Alveolar and parieto-alveolar conditions	Diagnosis	ICD-10-CM
J84.09	Other alveolar and parieto-alveolar conditions	Diagnosis	ICD-10-CM
J84.1	Other interstitial pulmonary diseases with fibrosis	Diagnosis	ICD-10-CM
J84.10	Pulmonary fibrosis, unspecified	Diagnosis	ICD-10-CM
J84.111	Idiopathic interstitial pneumonia, not otherwise specified	Diagnosis	ICD-10-CM
J84.113	Idiopathic non-specific interstitial pneumonitis	Diagnosis	ICD-10-CM
J84.115	Respiratory bronchiolitis interstitial lung disease	Diagnosis	ICD-10-CM
J84.117	Desquamative interstitial pneumonia	Diagnosis	ICD-10-CM
J84.17	Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere	Diagnosis	ICD-10-CM
J84.170	Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere	Diagnosis	ICD-10-CM
J84.178	Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere	Diagnosis	ICD-10-CM
J84.8	Other specified interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.82	Adult pulmonary Langerhans cell histiocytosis	Diagnosis	ICD-10-CM
J84.84	Other interstitial lung diseases of childhood	Diagnosis	ICD-10-CM
J84.841	Neuroendocrine cell hyperplasia of infancy	Diagnosis	ICD-10-CM
J84.842	Pulmonary interstitial glycogenosis	Diagnosis	ICD-10-CM
J84.843	Alveolar capillary dysplasia with vein misalignment	Diagnosis	ICD-10-CM
J84.848	Other interstitial lung diseases of childhood	Diagnosis	ICD-10-CM
J84.89	Other specified interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.9	Interstitial pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J91	Pleural effusion in conditions classified elsewhere	Diagnosis	ICD-10-CM
J92.0	Pleural plaque with presence of asbestos	Diagnosis	ICD-10-CM
J96.1	Chronic respiratory failure	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
J98.4	Other disorders of lung	Diagnosis	ICD-10-CM
J98.9	Respiratory disorder, unspecified	Diagnosis	ICD-10-CM
P27	Chronic respiratory disease originating in the perinatal period	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

P27.0	Wilson-Mikity syndrome	Diagnosis	ICD-10-CM
P27.1	Bronchopulmonary dysplasia originating in the perinatal period	Diagnosis	ICD-10-CM
P27.8	Other chronic respiratory diseases originating in the perinatal period	Diagnosis	ICD-10-CM
P27.9	Unspecified chronic respiratory disease originating in the perinatal period	Diagnosis	ICD-10-CM
	Sickle Cell Disease		
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
	Liver Disease (Severe/Moderate)		
B18	Chronic viral hepatitis	Diagnosis	ICD-10-CM
B18.0	Chronic viral hepatitis B with delta-agent	Diagnosis	ICD-10-CM
B18.1	Chronic viral hepatitis B without delta-agent	Diagnosis	ICD-10-CM
B18.2	Chronic viral hepatitis C	Diagnosis	ICD-10-CM
B18.8	Other chronic viral hepatitis	Diagnosis	ICD-10-CM
B18.9	Chronic viral hepatitis, unspecified	Diagnosis	ICD-10-CM
E83.01	Wilson's disease	Diagnosis	ICD-10-CM
E83.110	Hereditary hemochromatosis	Diagnosis	ICD-10-CM
E88.01	Alpha-1-antitrypsin deficiency	Diagnosis	ICD-10-CM
I85	Esophageal varices	Diagnosis	ICD-10-CM
I85.0	Esophageal varices	Diagnosis	ICD-10-CM
I85.00	Esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.01	Esophageal varices with bleeding	Diagnosis	ICD-10-CM
I85.1	Secondary esophageal varices	Diagnosis	ICD-10-CM
I85.10	Secondary esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.11	Secondary esophageal varices with bleeding	Diagnosis	ICD-10-CM
I86.4	Gastric varices	Diagnosis	ICD-10-CM
K65.2	Spontaneous bacterial peritonitis	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K83.01	Primary sclerosing cholangitis	Diagnosis	ICD-10-CM
K91.83	Postprocedural hepatorenal syndrome	Diagnosis	ICD-10-CM
R18	Ascites	Diagnosis	ICD-10-CM
R18.8	Other ascites	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
	Tuberculosis		
A15	Respiratory tuberculosis	Diagnosis	ICD-10-CM
A15.5	Tuberculosis of larynx, trachea and bronchus	Diagnosis	ICD-10-CM
A15.6	Tuberculous pleurisy	Diagnosis	ICD-10-CM
A15.7	Primary respiratory tuberculosis	Diagnosis	ICD-10-CM
A15.8	Other respiratory tuberculosis	Diagnosis	ICD-10-CM
A15.9	Respiratory tuberculosis unspecified	Diagnosis	ICD-10-CM
A19	Miliary tuberculosis	Diagnosis	ICD-10-CM
A19.0	Acute miliary tuberculosis of a single specified site	Diagnosis	ICD-10-CM
A19.1	Acute miliary tuberculosis of multiple sites	Diagnosis	ICD-10-CM
A19.2	Acute miliary tuberculosis, unspecified	Diagnosis	ICD-10-CM
A19.8	Other miliary tuberculosis	Diagnosis	ICD-10-CM
A19.9	Miliary tuberculosis, unspecified	Diagnosis	ICD-10-CM
B90	Sequelae of tuberculosis	Diagnosis	ICD-10-CM
B90.9	Sequelae of respiratory and unspecified tuberculosis	Diagnosis	ICD-10-CM
J65	Pneumoconiosis associated with tuberculosis	Diagnosis	ICD-10-CM
Z22.7	Latent tuberculosis	Diagnosis	ICD-10-CM
Z86.11	Personal history of tuberculosis	Diagnosis	ICD-10-CM
Z86.15	Personal history of latent tuberculosis infection	Diagnosis	ICD-10-CM
	Cystic fibrosis		
E84	Cystic fibrosis	Diagnosis	ICD-10-CM
E84.0	Cystic fibrosis with pulmonary manifestations	Diagnosis	ICD-10-CM
E84.1	Cystic fibrosis with intestinal manifestations	Diagnosis	ICD-10-CM
E84.11	Meconium ileus in cystic fibrosis	Diagnosis	ICD-10-CM
E84.19	Cystic fibrosis with other intestinal manifestations	Diagnosis	ICD-10-CM
E84.8	Cystic fibrosis with other manifestations	Diagnosis	ICD-10-CM
E84.9	Cystic fibrosis, unspecified	Diagnosis	ICD-10-CM
P09.4	Abnormal findings on neonatal screening for cystic fibrosis	Diagnosis	ICD-10-CM
Z14.1	Cystic fibrosis carrier	Diagnosis	ICD-10-CM
	Congenital or Acquired Heart Disease		
02Q50ZZ	Repair Atrial Septum, Open Approach	Procedure	ICD-10-PCS
02QM0ZZ	Repair Ventricular Septum, Open Approach	Procedure	ICD-10-PCS
02U507Z	Supplement Atrial Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02U50JZ	Supplement Atrial Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02U53JZ	Supplement Atrial Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02UM07Z	Supplement Ventricular Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

02UM0JZ	Supplement Ventricular Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02UM3JZ	Supplement Ventricular Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
33647	Repair of atrial septal defect and ventricular septal defect, with direct or patch closure	Procedure	CPT-4
33720	Repair sinus of Valsalva aneurysm, with cardiopulmonary bypass	Procedure	CPT-4
33741	Transcatheter atrial septostomy (TAS) for congenital cardiac anomalies to create effective atrial flow, including all imaging guidance by the proceduralist, when performed, any method (eg, Rashkind, Sang-Park, balloon, cutting balloon, blade)	Procedure	CPT-4
33745	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); initial intracardiac shunt	Procedure	CPT-4
33746	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); each additional intracardiac shunt location (List separately in addition to code for primary procedure)	Procedure	CPT-4
33924	Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in conjunction with a congenital heart procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)	Procedure	CPT-4
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)	Procedure	CPT-4
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete	Procedure	CPT-4
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report	Procedure	CPT-4
93316	Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only	Procedure	CPT-4
93317	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only	Procedure	CPT-4
93530	Right heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93531	Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93532	Combined right heart catheterization and transseptal left heart catheterization through intact septum with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93533	Combined right heart catheterization and transseptal left heart catheterization through existing septal opening, with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93563	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization (List separately in addition to code for primary procedure)	Procedure	CPT-4
93564	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
93580	Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant	Procedure	CPT-4
93581	Percutaneous transcatheter closure of a congenital ventricular septal defect with implant	Procedure	CPT-4
P29.38	Other persistent fetal circulation	Diagnosis	ICD-10-CM
Q20.0	Common arterial trunk	Diagnosis	ICD-10-CM
Q20.1	Double outlet right ventricle	Diagnosis	ICD-10-CM
Q20.2	Double outlet left ventricle	Diagnosis	ICD-10-CM
Q20.3	Discordant ventriculoarterial connection	Diagnosis	ICD-10-CM
Q20.4	Double inlet ventricle	Diagnosis	ICD-10-CM
Q20.5	Discordant atrioventricular connection	Diagnosis	ICD-10-CM
Q20.6	Isomerism of atrial appendages	Diagnosis	ICD-10-CM
Q20.8	Other congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Q20.9	Congenital malformation of cardiac chambers and connections, unspecified	Diagnosis	ICD-10-CM
Q21.0	Ventricular septal defect	Diagnosis	ICD-10-CM
Q21.1	Atrial septal defect	Diagnosis	ICD-10-CM
Q21.2	Atrioventricular septal defect	Diagnosis	ICD-10-CM
Q21.3	Tetralogy of Fallot	Diagnosis	ICD-10-CM
Q21.4	Aortopulmonary septal defect	Diagnosis	ICD-10-CM
Q21.8	Other congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.9	Congenital malformation of cardiac septum, unspecified	Diagnosis	ICD-10-CM
Q22.0	Pulmonary valve atresia	Diagnosis	ICD-10-CM
Q22.1	Congenital pulmonary valve stenosis	Diagnosis	ICD-10-CM
Q22.2	Congenital pulmonary valve insufficiency	Diagnosis	ICD-10-CM
Q22.3	Other congenital malformations of pulmonary valve	Diagnosis	ICD-10-CM
Q22.4	Congenital tricuspid stenosis	Diagnosis	ICD-10-CM
Q22.5	Ebstein's anomaly	Diagnosis	ICD-10-CM
Q22.6	Hypoplastic right heart syndrome	Diagnosis	ICD-10-CM
Q22.8	Other congenital malformations of tricuspid valve	Diagnosis	ICD-10-CM
Q22.9	Congenital malformation of tricuspid valve, unspecified	Diagnosis	ICD-10-CM
Q23.0	Congenital stenosis of aortic valve	Diagnosis	ICD-10-CM
Q23.1	Congenital insufficiency of aortic valve	Diagnosis	ICD-10-CM
Q23.2	Congenital mitral stenosis	Diagnosis	ICD-10-CM
Q23.3	Congenital mitral insufficiency	Diagnosis	ICD-10-CM
Q23.4	Hypoplastic left heart syndrome	Diagnosis	ICD-10-CM
Q23.8	Other congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.9	Congenital malformation of aortic and mitral valves, unspecified	Diagnosis	ICD-10-CM
Q24.0	Dextrocardia	Diagnosis	ICD-10-CM
Q24.1	Levocardia	Diagnosis	ICD-10-CM
Q24.2	Cor triatriatum	Diagnosis	ICD-10-CM
Q24.3	Pulmonary infundibular stenosis	Diagnosis	ICD-10-CM
Q24.4	Congenital subaortic stenosis	Diagnosis	ICD-10-CM
Q24.5	Malformation of coronary vessels	Diagnosis	ICD-10-CM
Q24.6	Congenital heart block	Diagnosis	ICD-10-CM
Q24.8	Other specified congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.9	Congenital malformation of heart, unspecified	Diagnosis	ICD-10-CM
Q25.0	Patent ductus arteriosus	Diagnosis	ICD-10-CM
Q25.1	Coarctation of aorta	Diagnosis	ICD-10-CM
Q25.21	Interruption of aortic arch	Diagnosis	ICD-10-CM
Q25.29	Other atresia of aorta	Diagnosis	ICD-10-CM
Q25.3	Supravalvular aortic stenosis	Diagnosis	ICD-10-CM
Q25.40	Congenital malformation of aorta unspecified	Diagnosis	ICD-10-CM
Q25.41	Absence and aplasia of aorta	Diagnosis	ICD-10-CM
Q25.42	Hypoplasia of aorta	Diagnosis	ICD-10-CM
Q25.43	Congenital aneurysm of aorta	Diagnosis	ICD-10-CM
Q25.44	Congenital dilation of aorta	Diagnosis	ICD-10-CM
Q25.45	Double aortic arch	Diagnosis	ICD-10-CM
Q25.46	Tortuous aortic arch	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Q25.47	Right aortic arch	Diagnosis	ICD-10-CM
Q25.48	Anomalous origin of subclavian artery	Diagnosis	ICD-10-CM
Q25.49	Other congenital malformations of aorta	Diagnosis	ICD-10-CM
Q25.5	Atresia of pulmonary artery	Diagnosis	ICD-10-CM
Q25.6	Stenosis of pulmonary artery	Diagnosis	ICD-10-CM
Q25.71	Coarctation of pulmonary artery	Diagnosis	ICD-10-CM
Q25.72	Congenital pulmonary arteriovenous malformation	Diagnosis	ICD-10-CM
Q25.79	Other congenital malformations of pulmonary artery	Diagnosis	ICD-10-CM
Q25.8	Other congenital malformations of other great arteries	Diagnosis	ICD-10-CM
Q25.9	Congenital malformation of great arteries, unspecified	Diagnosis	ICD-10-CM
Q26.0	Congenital stenosis of vena cava	Diagnosis	ICD-10-CM
Q26.1	Persistent left superior vena cava	Diagnosis	ICD-10-CM
Q26.2	Total anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.3	Partial anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.4	Anomalous pulmonary venous connection, unspecified	Diagnosis	ICD-10-CM
Q87.40	Marfan's syndrome, unspecified	Diagnosis	ICD-10-CM
Q87.410	Marfan's syndrome with aortic dilation	Diagnosis	ICD-10-CM
Q87.418	Marfan's syndrome with other cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.82	Arterial tortuosity syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM
Q91.0	Trisomy 18, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.1	Trisomy 18, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.2	Trisomy 18, translocation	Diagnosis	ICD-10-CM
Q91.3	Trisomy 18, unspecified	Diagnosis	ICD-10-CM
Q91.4	Trisomy 13, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.5	Trisomy 13, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.6	Trisomy 13, translocation	Diagnosis	ICD-10-CM
Q91.7	Trisomy 13, unspecified	Diagnosis	ICD-10-CM
Q93.81	Velo-cardio-facial syndrome	Diagnosis	ICD-10-CM
Q93.82	Williams syndrome	Diagnosis	ICD-10-CM
	Lung Cancer		
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
	Breast Cancer		
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
	Colorectal Cancer		
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
	Prostate Cancer		
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
	Endometrial Cancer		
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
	Other Cancer		
C00.0	Malignant neoplasm of external upper lip	Diagnosis	ICD-10-CM
C00.1	Malignant neoplasm of external lower lip	Diagnosis	ICD-10-CM
C00.2	Malignant neoplasm of external lip, unspecified	Diagnosis	ICD-10-CM
C00.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-10-CM
C00.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-10-CM
C00.5	Malignant neoplasm of lip, unspecified, inner aspect	Diagnosis	ICD-10-CM
C00.6	Malignant neoplasm of commissure of lip, unspecified	Diagnosis	ICD-10-CM
C00.8	Malignant neoplasm of overlapping sites of lip	Diagnosis	ICD-10-CM
C00.9	Malignant neoplasm of lip, unspecified	Diagnosis	ICD-10-CM
C01	Malignant neoplasm of base of tongue	Diagnosis	ICD-10-CM
C02.0	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-10-CM
C02.1	Malignant neoplasm of border of tongue	Diagnosis	ICD-10-CM
C02.2	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-10-CM
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-10-CM
C02.4	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-10-CM
C02.8	Malignant neoplasm of overlapping sites of tongue	Diagnosis	ICD-10-CM
C02.9	Malignant neoplasm of tongue, unspecified	Diagnosis	ICD-10-CM
C03.0	Malignant neoplasm of upper gum	Diagnosis	ICD-10-CM
C03.1	Malignant neoplasm of lower gum	Diagnosis	ICD-10-CM
C03.9	Malignant neoplasm of gum, unspecified	Diagnosis	ICD-10-CM
C04.0	Malignant neoplasm of anterior floor of mouth	Diagnosis	ICD-10-CM
C04.1	Malignant neoplasm of lateral floor of mouth	Diagnosis	ICD-10-CM
C04.8	Malignant neoplasm of overlapping sites of floor of mouth	Diagnosis	ICD-10-CM
C04.9	Malignant neoplasm of floor of mouth, unspecified	Diagnosis	ICD-10-CM
C05.0	Malignant neoplasm of hard palate	Diagnosis	ICD-10-CM
C05.1	Malignant neoplasm of soft palate	Diagnosis	ICD-10-CM
C05.2	Malignant neoplasm of uvula	Diagnosis	ICD-10-CM
C05.8	Malignant neoplasm of overlapping sites of palate	Diagnosis	ICD-10-CM
C05.9	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-10-CM
C06.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-10-CM
C06.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-10-CM
C06.2	Malignant neoplasm of retromolar area	Diagnosis	ICD-10-CM
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth	Diagnosis	ICD-10-CM
C06.9	Malignant neoplasm of mouth, unspecified	Diagnosis	ICD-10-CM
C07	Malignant neoplasm of parotid gland	Diagnosis	ICD-10-CM
C08.0	Malignant neoplasm of submandibular gland	Diagnosis	ICD-10-CM
C08.1	Malignant neoplasm of sublingual gland	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C08.9	Malignant neoplasm of major salivary gland, unspecified	Diagnosis	ICD-10-CM
C09.0	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-10-CM
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)	Diagnosis	ICD-10-CM
C09.8	Malignant neoplasm of overlapping sites of tonsil	Diagnosis	ICD-10-CM
C09.9	Malignant neoplasm of tonsil, unspecified	Diagnosis	ICD-10-CM
C10.0	Malignant neoplasm of vallecula	Diagnosis	ICD-10-CM
C10.1	Malignant neoplasm of anterior surface of epiglottis	Diagnosis	ICD-10-CM
C10.2	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-10-CM
C10.3	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-10-CM
C10.4	Malignant neoplasm of branchial cleft	Diagnosis	ICD-10-CM
C10.8	Malignant neoplasm of overlapping sites of oropharynx	Diagnosis	ICD-10-CM
C10.9	Malignant neoplasm of oropharynx, unspecified	Diagnosis	ICD-10-CM
C11.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-10-CM
C11.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.8	Malignant neoplasm of overlapping sites of nasopharynx	Diagnosis	ICD-10-CM
C11.9	Malignant neoplasm of nasopharynx, unspecified	Diagnosis	ICD-10-CM
C12	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-10-CM
C13.0	Malignant neoplasm of postcricoid region	Diagnosis	ICD-10-CM
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-10-CM
C13.2	Malignant neoplasm of posterior wall of hypopharynx	Diagnosis	ICD-10-CM
C13.8	Malignant neoplasm of overlapping sites of hypopharynx	Diagnosis	ICD-10-CM
C13.9	Malignant neoplasm of hypopharynx, unspecified	Diagnosis	ICD-10-CM
C14.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-10-CM
C14.2	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-10-CM
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM
C16.0	Malignant neoplasm of cardia	Diagnosis	ICD-10-CM
C16.1	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-10-CM
C16.2	Malignant neoplasm of body of stomach	Diagnosis	ICD-10-CM
C16.3	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-10-CM
C16.4	Malignant neoplasm of pylorus	Diagnosis	ICD-10-CM
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.8	Malignant neoplasm of overlapping sites of stomach	Diagnosis	ICD-10-CM
C16.9	Malignant neoplasm of stomach, unspecified	Diagnosis	ICD-10-CM
C17.0	Malignant neoplasm of duodenum	Diagnosis	ICD-10-CM
C17.1	Malignant neoplasm of jejunum	Diagnosis	ICD-10-CM
C17.2	Malignant neoplasm of ileum	Diagnosis	ICD-10-CM
C17.3	Meckel's diverticulum, malignant	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C17.8	Malignant neoplasm of overlapping sites of small intestine	Diagnosis	ICD-10-CM
C17.9	Malignant neoplasm of small intestine, unspecified	Diagnosis	ICD-10-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C21.0	Malignant neoplasm of anus, unspecified	Diagnosis	ICD-10-CM
C21.1	Malignant neoplasm of anal canal	Diagnosis	ICD-10-CM
C21.2	Malignant neoplasm of cloacogenic zone	Diagnosis	ICD-10-CM
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Diagnosis	ICD-10-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
C22.9	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-10-CM
C23	Malignant neoplasm of gallbladder	Diagnosis	ICD-10-CM
C24.0	Malignant neoplasm of extrahepatic bile duct	Diagnosis	ICD-10-CM
C24.1	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-10-CM
C24.8	Malignant neoplasm of overlapping sites of biliary tract	Diagnosis	ICD-10-CM
C24.9	Malignant neoplasm of biliary tract, unspecified	Diagnosis	ICD-10-CM
C25.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-10-CM
C25.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-10-CM
C25.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-10-CM
C25.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-10-CM
C25.4	Malignant neoplasm of endocrine pancreas	Diagnosis	ICD-10-CM
C25.7	Malignant neoplasm of other parts of pancreas	Diagnosis	ICD-10-CM
C25.8	Malignant neoplasm of overlapping sites of pancreas	Diagnosis	ICD-10-CM
C25.9	Malignant neoplasm of pancreas, unspecified	Diagnosis	ICD-10-CM
C26.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-10-CM
C26.1	Malignant neoplasm of spleen	Diagnosis	ICD-10-CM
C26.9	Malignant neoplasm of ill-defined sites within the digestive system	Diagnosis	ICD-10-CM
C30.0	Malignant neoplasm of nasal cavity	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C30.1	Malignant neoplasm of middle ear	Diagnosis	ICD-10-CM
C31.0	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-10-CM
C31.1	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-10-CM
C31.2	Malignant neoplasm of frontal sinus	Diagnosis	ICD-10-CM
C31.3	Malignant neoplasm of sphenoid sinus	Diagnosis	ICD-10-CM
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses	Diagnosis	ICD-10-CM
C31.9	Malignant neoplasm of accessory sinus, unspecified	Diagnosis	ICD-10-CM
C32.0	Malignant neoplasm of glottis	Diagnosis	ICD-10-CM
C32.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-10-CM
C32.2	Malignant neoplasm of subglottis	Diagnosis	ICD-10-CM
C32.3	Malignant neoplasm of laryngeal cartilage	Diagnosis	ICD-10-CM
C32.8	Malignant neoplasm of overlapping sites of larynx	Diagnosis	ICD-10-CM
C32.9	Malignant neoplasm of larynx, unspecified	Diagnosis	ICD-10-CM
C33	Malignant neoplasm of trachea	Diagnosis	ICD-10-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
C37	Malignant neoplasm of thymus	Diagnosis	ICD-10-CM
C38.0	Malignant neoplasm of heart	Diagnosis	ICD-10-CM
C38.1	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-10-CM
C38.2	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-10-CM
C38.3	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-10-CM
C38.4	Malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb	Diagnosis	ICD-10-CM

C40.01	Malignant neoplasm of scapula and long bones of right upper limb	Diagnosis	ICD-10-CM
C40.02	Malignant neoplasm of scapula and long bones of left upper limb	Diagnosis	ICD-10-CM
C40.10	Malignant neoplasm of short bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.11	Malignant neoplasm of short bones of right upper limb	Diagnosis	ICD-10-CM
C40.12	Malignant neoplasm of short bones of left upper limb	Diagnosis	ICD-10-CM
C40.20	Malignant neoplasm of long bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.21	Malignant neoplasm of long bones of right lower limb	Diagnosis	ICD-10-CM
C40.22	Malignant neoplasm of long bones of left lower limb	Diagnosis	ICD-10-CM
C40.30	Malignant neoplasm of short bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.31	Malignant neoplasm of short bones of right lower limb	Diagnosis	ICD-10-CM
C40.32	Malignant neoplasm of short bones of left lower limb	Diagnosis	ICD-10-CM
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb	Diagnosis	ICD-10-CM
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb	Diagnosis	ICD-10-CM
C41.0	Malignant neoplasm of bones of skull and face	Diagnosis	ICD-10-CM
C41.1	Malignant neoplasm of mandible	Diagnosis	ICD-10-CM
C41.2	Malignant neoplasm of vertebral column	Diagnosis	ICD-10-CM
C41.3	Malignant neoplasm of ribs, sternum and clavicle	Diagnosis	ICD-10-CM
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx	Diagnosis	ICD-10-CM
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified	Diagnosis	ICD-10-CM
C43.0	Malignant melanoma of lip	Diagnosis	ICD-10-CM
C43.10	Malignant melanoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C43.11	Malignant melanoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C43.111	Malignant melanoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.112	Malignant melanoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.12	Malignant melanoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C43.121	Malignant melanoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.122	Malignant melanoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.20	Malignant melanoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C43.21	Malignant melanoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C43.22	Malignant melanoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C43.30	Malignant melanoma of unspecified part of face	Diagnosis	ICD-10-CM
C43.31	Malignant melanoma of nose	Diagnosis	ICD-10-CM
C43.39	Malignant melanoma of other parts of face	Diagnosis	ICD-10-CM
C43.4	Malignant melanoma of scalp and neck	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C43.51	Malignant melanoma of anal skin	Diagnosis	ICD-10-CM
C43.52	Malignant melanoma of skin of breast	Diagnosis	ICD-10-CM
C43.59	Malignant melanoma of other part of trunk	Diagnosis	ICD-10-CM
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.61	Malignant melanoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.62	Malignant melanoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.70	Malignant melanoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C43.71	Malignant melanoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C43.72	Malignant melanoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C43.8	Malignant melanoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C43.9	Malignant melanoma of skin, unspecified	Diagnosis	ICD-10-CM
C45.0	Mesothelioma of pleura	Diagnosis	ICD-10-CM
C45.1	Mesothelioma of peritoneum	Diagnosis	ICD-10-CM
C45.2	Mesothelioma of pericardium	Diagnosis	ICD-10-CM
C45.7	Mesothelioma of other sites	Diagnosis	ICD-10-CM
C45.9	Mesothelioma, unspecified	Diagnosis	ICD-10-CM
C46.0	Kaposi's sarcoma of skin	Diagnosis	ICD-10-CM
C46.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-10-CM
C46.2	Kaposi's sarcoma of palate	Diagnosis	ICD-10-CM
C46.3	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-10-CM
C46.4	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-10-CM
C46.50	Kaposi's sarcoma of unspecified lung	Diagnosis	ICD-10-CM
C46.51	Kaposi's sarcoma of right lung	Diagnosis	ICD-10-CM
C46.52	Kaposi's sarcoma of left lung	Diagnosis	ICD-10-CM
C46.7	Kaposi's sarcoma of other sites	Diagnosis	ICD-10-CM
C46.9	Kaposi's sarcoma, unspecified	Diagnosis	ICD-10-CM
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck	Diagnosis	ICD-10-CM
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip	Diagnosis	ICD-10-CM
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip	Diagnosis	ICD-10-CM
C47.3	Malignant neoplasm of peripheral nerves of thorax	Diagnosis	ICD-10-CM
C47.4	Malignant neoplasm of peripheral nerves of abdomen	Diagnosis	ICD-10-CM
C47.5	Malignant neoplasm of peripheral nerves of pelvis	Diagnosis	ICD-10-CM
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified	Diagnosis	ICD-10-CM
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified	Diagnosis	ICD-10-CM
C48.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-10-CM
C48.1	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-10-CM
C48.2	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-10-CM
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck	Diagnosis	ICD-10-CM
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip	Diagnosis	ICD-10-CM
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip	Diagnosis	ICD-10-CM
C49.3	Malignant neoplasm of connective and soft tissue of thorax	Diagnosis	ICD-10-CM
C49.4	Malignant neoplasm of connective and soft tissue of abdomen	Diagnosis	ICD-10-CM
C49.5	Malignant neoplasm of connective and soft tissue of pelvis	Diagnosis	ICD-10-CM
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified	Diagnosis	ICD-10-CM
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	Diagnosis	ICD-10-CM
C49.9	Malignant neoplasm of connective and soft tissue, unspecified	Diagnosis	ICD-10-CM
C49.A0	Gastrointestinal stromal tumor, unspecified site	Diagnosis	ICD-10-CM
C49.A1	Gastrointestinal stromal tumor of esophagus	Diagnosis	ICD-10-CM
C49.A2	Gastrointestinal stromal tumor of stomach	Diagnosis	ICD-10-CM
C49.A3	Gastrointestinal stromal tumor of small intestine	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
C49.A9	Gastrointestinal stromal tumor of other sites	Diagnosis	ICD-10-CM
C4A.0	Merkel cell carcinoma of lip	Diagnosis	ICD-10-CM
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.11	Merkel cell carcinoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.12	Merkel cell carcinoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C4A.21	Merkel cell carcinoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.30	Merkel cell carcinoma of unspecified part of face	Diagnosis	ICD-10-CM
C4A.31	Merkel cell carcinoma of nose	Diagnosis	ICD-10-CM
C4A.39	Merkel cell carcinoma of other parts of face	Diagnosis	ICD-10-CM
C4A.4	Merkel cell carcinoma of scalp and neck	Diagnosis	ICD-10-CM
C4A.51	Merkel cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C4A.52	Merkel cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C4A.59	Merkel cell carcinoma of other part of trunk	Diagnosis	ICD-10-CM
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C4A.71	Merkel cell carcinoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C4A.72	Merkel cell carcinoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C4A.8	Merkel cell carcinoma of overlapping sites	Diagnosis	ICD-10-CM
C4A.9	Merkel cell carcinoma, unspecified	Diagnosis	ICD-10-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C51.0	Malignant neoplasm of labium majus	Diagnosis	ICD-10-CM
C51.1	Malignant neoplasm of labium minus	Diagnosis	ICD-10-CM
C51.2	Malignant neoplasm of clitoris	Diagnosis	ICD-10-CM
C51.8	Malignant neoplasm of overlapping sites of vulva	Diagnosis	ICD-10-CM
C51.9	Malignant neoplasm of vulva, unspecified	Diagnosis	ICD-10-CM
C52	Malignant neoplasm of vagina	Diagnosis	ICD-10-CM
C53.0	Malignant neoplasm of endocervix	Diagnosis	ICD-10-CM
C53.1	Malignant neoplasm of exocervix	Diagnosis	ICD-10-CM
C53.8	Malignant neoplasm of overlapping sites of cervix uteri	Diagnosis	ICD-10-CM
C53.9	Malignant neoplasm of cervix uteri, unspecified	Diagnosis	ICD-10-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
C55	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-10-CM
C56.1	Malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C56.2	Malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C56.9	Malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C57.00	Malignant neoplasm of unspecified fallopian tube	Diagnosis	ICD-10-CM
C57.01	Malignant neoplasm of right fallopian tube	Diagnosis	ICD-10-CM
C57.02	Malignant neoplasm of left fallopian tube	Diagnosis	ICD-10-CM
C57.10	Malignant neoplasm of unspecified broad ligament	Diagnosis	ICD-10-CM
C57.11	Malignant neoplasm of right broad ligament	Diagnosis	ICD-10-CM
C57.12	Malignant neoplasm of left broad ligament	Diagnosis	ICD-10-CM
C57.20	Malignant neoplasm of unspecified round ligament	Diagnosis	ICD-10-CM
C57.21	Malignant neoplasm of right round ligament	Diagnosis	ICD-10-CM
C57.22	Malignant neoplasm of left round ligament	Diagnosis	ICD-10-CM
C57.3	Malignant neoplasm of parametrium	Diagnosis	ICD-10-CM
C57.4	Malignant neoplasm of uterine adnexa, unspecified	Diagnosis	ICD-10-CM
C57.7	Malignant neoplasm of other specified female genital organs	Diagnosis	ICD-10-CM
C57.8	Malignant neoplasm of overlapping sites of female genital organs	Diagnosis	ICD-10-CM
C57.9	Malignant neoplasm of female genital organ, unspecified	Diagnosis	ICD-10-CM
C58	Malignant neoplasm of placenta	Diagnosis	ICD-10-CM
C60.0	Malignant neoplasm of prepuce	Diagnosis	ICD-10-CM
C60.1	Malignant neoplasm of glans penis	Diagnosis	ICD-10-CM
C60.2	Malignant neoplasm of body of penis	Diagnosis	ICD-10-CM
C60.8	Malignant neoplasm of overlapping sites of penis	Diagnosis	ICD-10-CM
C60.9	Malignant neoplasm of penis, unspecified	Diagnosis	ICD-10-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
C62.00	Malignant neoplasm of unspecified undescended testis	Diagnosis	ICD-10-CM
C62.01	Malignant neoplasm of undescended right testis	Diagnosis	ICD-10-CM
C62.02	Malignant neoplasm of undescended left testis	Diagnosis	ICD-10-CM
C62.10	Malignant neoplasm of unspecified descended testis	Diagnosis	ICD-10-CM
C62.11	Malignant neoplasm of descended right testis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C62.12	Malignant neoplasm of descended left testis	Diagnosis	ICD-10-CM
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C63.00	Malignant neoplasm of unspecified epididymis	Diagnosis	ICD-10-CM
C63.01	Malignant neoplasm of right epididymis	Diagnosis	ICD-10-CM
C63.02	Malignant neoplasm of left epididymis	Diagnosis	ICD-10-CM
C63.10	Malignant neoplasm of unspecified spermatic cord	Diagnosis	ICD-10-CM
C63.11	Malignant neoplasm of right spermatic cord	Diagnosis	ICD-10-CM
C63.12	Malignant neoplasm of left spermatic cord	Diagnosis	ICD-10-CM
C63.2	Malignant neoplasm of scrotum	Diagnosis	ICD-10-CM
C63.7	Malignant neoplasm of other specified male genital organs	Diagnosis	ICD-10-CM
C63.8	Malignant neoplasm of overlapping sites of male genital organs	Diagnosis	ICD-10-CM
C63.9	Malignant neoplasm of male genital organ, unspecified	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C66.1	Malignant neoplasm of right ureter	Diagnosis	ICD-10-CM
C66.2	Malignant neoplasm of left ureter	Diagnosis	ICD-10-CM
C66.9	Malignant neoplasm of unspecified ureter	Diagnosis	ICD-10-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
C68.0	Malignant neoplasm of urethra	Diagnosis	ICD-10-CM
C68.1	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-10-CM
C68.8	Malignant neoplasm of overlapping sites of urinary organs	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
C69.00	Malignant neoplasm of unspecified conjunctiva	Diagnosis	ICD-10-CM
C69.01	Malignant neoplasm of right conjunctiva	Diagnosis	ICD-10-CM
C69.02	Malignant neoplasm of left conjunctiva	Diagnosis	ICD-10-CM
C69.10	Malignant neoplasm of unspecified cornea	Diagnosis	ICD-10-CM
C69.11	Malignant neoplasm of right cornea	Diagnosis	ICD-10-CM
C69.12	Malignant neoplasm of left cornea	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C69.20	Malignant neoplasm of unspecified retina	Diagnosis	ICD-10-CM
C69.21	Malignant neoplasm of right retina	Diagnosis	ICD-10-CM
C69.22	Malignant neoplasm of left retina	Diagnosis	ICD-10-CM
C69.30	Malignant neoplasm of unspecified choroid	Diagnosis	ICD-10-CM
C69.31	Malignant neoplasm of right choroid	Diagnosis	ICD-10-CM
C69.32	Malignant neoplasm of left choroid	Diagnosis	ICD-10-CM
C69.40	Malignant neoplasm of unspecified ciliary body	Diagnosis	ICD-10-CM
C69.41	Malignant neoplasm of right ciliary body	Diagnosis	ICD-10-CM
C69.42	Malignant neoplasm of left ciliary body	Diagnosis	ICD-10-CM
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.51	Malignant neoplasm of right lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.52	Malignant neoplasm of left lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.60	Malignant neoplasm of unspecified orbit	Diagnosis	ICD-10-CM
C69.61	Malignant neoplasm of right orbit	Diagnosis	ICD-10-CM
C69.62	Malignant neoplasm of left orbit	Diagnosis	ICD-10-CM
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa	Diagnosis	ICD-10-CM
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa	Diagnosis	ICD-10-CM
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa	Diagnosis	ICD-10-CM
C69.90	Malignant neoplasm of unspecified site of unspecified eye	Diagnosis	ICD-10-CM
C69.91	Malignant neoplasm of unspecified site of right eye	Diagnosis	ICD-10-CM
C69.92	Malignant neoplasm of unspecified site of left eye	Diagnosis	ICD-10-CM
C70.0	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C70.1	Malignant neoplasm of spinal meninges	Diagnosis	ICD-10-CM
C70.9	Malignant neoplasm of meninges, unspecified	Diagnosis	ICD-10-CM
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-10-CM
C71.1	Malignant neoplasm of frontal lobe	Diagnosis	ICD-10-CM
C71.2	Malignant neoplasm of temporal lobe	Diagnosis	ICD-10-CM
C71.3	Malignant neoplasm of parietal lobe	Diagnosis	ICD-10-CM
C71.4	Malignant neoplasm of occipital lobe	Diagnosis	ICD-10-CM
C71.5	Malignant neoplasm of cerebral ventricle	Diagnosis	ICD-10-CM
C71.6	Malignant neoplasm of cerebellum	Diagnosis	ICD-10-CM
C71.7	Malignant neoplasm of brain stem	Diagnosis	ICD-10-CM
C71.8	Malignant neoplasm of overlapping sites of brain	Diagnosis	ICD-10-CM
C71.9	Malignant neoplasm of brain, unspecified	Diagnosis	ICD-10-CM
C72.0	Malignant neoplasm of spinal cord	Diagnosis	ICD-10-CM
C72.1	Malignant neoplasm of cauda equina	Diagnosis	ICD-10-CM
C72.20	Malignant neoplasm of unspecified olfactory nerve	Diagnosis	ICD-10-CM
C72.21	Malignant neoplasm of right olfactory nerve	Diagnosis	ICD-10-CM
C72.22	Malignant neoplasm of left olfactory nerve	Diagnosis	ICD-10-CM
C72.30	Malignant neoplasm of unspecified optic nerve	Diagnosis	ICD-10-CM
C72.31	Malignant neoplasm of right optic nerve	Diagnosis	ICD-10-CM
C72.32	Malignant neoplasm of left optic nerve	Diagnosis	ICD-10-CM
C72.40	Malignant neoplasm of unspecified acoustic nerve	Diagnosis	ICD-10-CM
C72.41	Malignant neoplasm of right acoustic nerve	Diagnosis	ICD-10-CM
C72.42	Malignant neoplasm of left acoustic nerve	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C72.50	Malignant neoplasm of unspecified cranial nerve	Diagnosis	ICD-10-CM
C72.59	Malignant neoplasm of other cranial nerves	Diagnosis	ICD-10-CM
C72.9	Malignant neoplasm of central nervous system, unspecified	Diagnosis	ICD-10-CM
C73	Malignant neoplasm of thyroid gland	Diagnosis	ICD-10-CM
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.01	Malignant neoplasm of cortex of right adrenal gland	Diagnosis	ICD-10-CM
C74.02	Malignant neoplasm of cortex of left adrenal gland	Diagnosis	ICD-10-CM
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.11	Malignant neoplasm of medulla of right adrenal gland	Diagnosis	ICD-10-CM
C74.12	Malignant neoplasm of medulla of left adrenal gland	Diagnosis	ICD-10-CM
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.91	Malignant neoplasm of unspecified part of right adrenal gland	Diagnosis	ICD-10-CM
C74.92	Malignant neoplasm of unspecified part of left adrenal gland	Diagnosis	ICD-10-CM
C75.0	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-10-CM
C75.1	Malignant neoplasm of pituitary gland	Diagnosis	ICD-10-CM
C75.2	Malignant neoplasm of craniopharyngeal duct	Diagnosis	ICD-10-CM
C75.3	Malignant neoplasm of pineal gland	Diagnosis	ICD-10-CM
C75.4	Malignant neoplasm of carotid body	Diagnosis	ICD-10-CM
C75.5	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-10-CM
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified	Diagnosis	ICD-10-CM
C75.9	Malignant neoplasm of endocrine gland, unspecified	Diagnosis	ICD-10-CM
C76.0	Malignant neoplasm of head, face and neck	Diagnosis	ICD-10-CM
C76.1	Malignant neoplasm of thorax	Diagnosis	ICD-10-CM
C76.2	Malignant neoplasm of abdomen	Diagnosis	ICD-10-CM
C76.3	Malignant neoplasm of pelvis	Diagnosis	ICD-10-CM
C76.40	Malignant neoplasm of unspecified upper limb	Diagnosis	ICD-10-CM
C76.41	Malignant neoplasm of right upper limb	Diagnosis	ICD-10-CM
C76.42	Malignant neoplasm of left upper limb	Diagnosis	ICD-10-CM
C76.50	Malignant neoplasm of unspecified lower limb	Diagnosis	ICD-10-CM
C76.51	Malignant neoplasm of right lower limb	Diagnosis	ICD-10-CM
C76.52	Malignant neoplasm of left lower limb	Diagnosis	ICD-10-CM
C76.8	Malignant neoplasm of other specified ill-defined sites	Diagnosis	ICD-10-CM
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Diagnosis	ICD-10-CM
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes	Diagnosis	ICD-10-CM
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes	Diagnosis	ICD-10-CM
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions	Diagnosis	ICD-10-CM
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified	Diagnosis	ICD-10-CM
C78.00	Secondary malignant neoplasm of unspecified lung	Diagnosis	ICD-10-CM
C78.01	Secondary malignant neoplasm of right lung	Diagnosis	ICD-10-CM
C78.02	Secondary malignant neoplasm of left lung	Diagnosis	ICD-10-CM
C78.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-10-CM
C78.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C78.30	Secondary malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
C78.39	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-10-CM
C78.4	Secondary malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C78.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-10-CM
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct	Diagnosis	ICD-10-CM
C78.80	Secondary malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
C78.89	Secondary malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.10	Secondary malignant neoplasm of unspecified urinary organs	Diagnosis	ICD-10-CM
C79.11	Secondary malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C79.19	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-10-CM
C79.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-10-CM
C79.31	Secondary malignant neoplasm of brain	Diagnosis	ICD-10-CM
C79.32	Secondary malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C79.40	Secondary malignant neoplasm of unspecified part of nervous system	Diagnosis	ICD-10-CM
C79.49	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-10-CM
C79.51	Secondary malignant neoplasm of bone	Diagnosis	ICD-10-CM
C79.52	Secondary malignant neoplasm of bone marrow	Diagnosis	ICD-10-CM
C79.60	Secondary malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C79.61	Secondary malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C79.62	Secondary malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C79.70	Secondary malignant neoplasm of unspecified adrenal gland	Diagnosis	ICD-10-CM
C79.71	Secondary malignant neoplasm of right adrenal gland	Diagnosis	ICD-10-CM
C79.72	Secondary malignant neoplasm of left adrenal gland	Diagnosis	ICD-10-CM
C79.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-10-CM
C79.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
C79.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.9	Secondary malignant neoplasm of unspecified site	Diagnosis	ICD-10-CM
C7A.00	Malignant carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
C7A.010	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
C7A.011	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C7A.012	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.020	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
C7A.021	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
C7A.022	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
C7A.023	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
C7A.024	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
C7A.025	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
C7A.026	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.090	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
C7A.091	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
C7A.092	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
C7A.093	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
C7A.094	Malignant carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
C7A.095	Malignant carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
C7A.098	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.1	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.8	Other malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B.00	Secondary carcinoid tumors, unspecified site	Diagnosis	ICD-10-CM
C7B.01	Secondary carcinoid tumors of distant lymph nodes	Diagnosis	ICD-10-CM
C7B.02	Secondary carcinoid tumors of liver	Diagnosis	ICD-10-CM
C7B.03	Secondary carcinoid tumors of bone	Diagnosis	ICD-10-CM
C7B.04	Secondary carcinoid tumors of peritoneum	Diagnosis	ICD-10-CM
C7B.09	Secondary carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7B.1	Secondary Merkel cell carcinoma	Diagnosis	ICD-10-CM
C7B.8	Other secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C80.0	Disseminated malignant neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.1	Malignant (primary) neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-10-CM
D37.01	Neoplasm of uncertain behavior of lip	Diagnosis	ICD-10-CM
D37.02	Neoplasm of uncertain behavior of tongue	Diagnosis	ICD-10-CM
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands	Diagnosis	ICD-10-CM
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands	Diagnosis	ICD-10-CM
D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands	Diagnosis	ICD-10-CM
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified	Diagnosis	ICD-10-CM
D37.04	Neoplasm of uncertain behavior of the minor salivary glands	Diagnosis	ICD-10-CM
D37.05	Neoplasm of uncertain behavior of pharynx	Diagnosis	ICD-10-CM
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity	Diagnosis	ICD-10-CM
D37.5	Neoplasm of uncertain behavior of rectum	Diagnosis	ICD-10-CM

D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D37.8	Neoplasm of uncertain behavior of other specified digestive organs	Diagnosis	ICD-10-CM
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	Diagnosis	ICD-10-CM
D38.0	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-10-CM
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	Diagnosis	ICD-10-CM
D38.2	Neoplasm of uncertain behavior of pleura	Diagnosis	ICD-10-CM
D38.3	Neoplasm of uncertain behavior of mediastinum	Diagnosis	ICD-10-CM
D38.4	Neoplasm of uncertain behavior of thymus	Diagnosis	ICD-10-CM
D38.5	Neoplasm of uncertain behavior of other respiratory organs	Diagnosis	ICD-10-CM
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified	Diagnosis	ICD-10-CM
D39.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-10-CM
D39.10	Neoplasm of uncertain behavior of unspecified ovary	Diagnosis	ICD-10-CM
D39.11	Neoplasm of uncertain behavior of right ovary	Diagnosis	ICD-10-CM
D39.12	Neoplasm of uncertain behavior of left ovary	Diagnosis	ICD-10-CM
D39.2	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-10-CM
D39.8	Neoplasm of uncertain behavior of other specified female genital organs	Diagnosis	ICD-10-CM
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified	Diagnosis	ICD-10-CM
D40.0	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-10-CM
D40.10	Neoplasm of uncertain behavior of unspecified testis	Diagnosis	ICD-10-CM
D40.11	Neoplasm of uncertain behavior of right testis	Diagnosis	ICD-10-CM
D40.12	Neoplasm of uncertain behavior of left testis	Diagnosis	ICD-10-CM
D40.8	Neoplasm of uncertain behavior of other specified male genital organs	Diagnosis	ICD-10-CM
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D41.3	Neoplasm of uncertain behavior of urethra	Diagnosis	ICD-10-CM
D41.4	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-10-CM
D41.8	Neoplasm of uncertain behavior of other specified urinary organs	Diagnosis	ICD-10-CM
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ	Diagnosis	ICD-10-CM
D42.0	Neoplasm of uncertain behavior of cerebral meninges	Diagnosis	ICD-10-CM
D42.1	Neoplasm of uncertain behavior of spinal meninges	Diagnosis	ICD-10-CM
D42.9	Neoplasm of uncertain behavior of meninges, unspecified	Diagnosis	ICD-10-CM
D43.0	Neoplasm of uncertain behavior of brain, supratentorial	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D43.1	Neoplasm of uncertain behavior of brain, infratentorial	Diagnosis	ICD-10-CM
D43.2	Neoplasm of uncertain behavior of brain, unspecified	Diagnosis	ICD-10-CM
D43.3	Neoplasm of uncertain behavior of cranial nerves	Diagnosis	ICD-10-CM
D43.4	Neoplasm of uncertain behavior of spinal cord	Diagnosis	ICD-10-CM
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system	Diagnosis	ICD-10-CM
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified	Diagnosis	ICD-10-CM
D44.0	Neoplasm of uncertain behavior of thyroid gland	Diagnosis	ICD-10-CM
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland	Diagnosis	ICD-10-CM
D44.11	Neoplasm of uncertain behavior of right adrenal gland	Diagnosis	ICD-10-CM
D44.12	Neoplasm of uncertain behavior of left adrenal gland	Diagnosis	ICD-10-CM
D44.2	Neoplasm of uncertain behavior of parathyroid gland	Diagnosis	ICD-10-CM
D44.3	Neoplasm of uncertain behavior of pituitary gland	Diagnosis	ICD-10-CM
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct	Diagnosis	ICD-10-CM
D44.5	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-10-CM
D44.6	Neoplasm of uncertain behavior of carotid body	Diagnosis	ICD-10-CM
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia	Diagnosis	ICD-10-CM
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland	Diagnosis	ICD-10-CM
D47.01	Cutaneous mastocytosis	Diagnosis	ICD-10-CM
D47.02	Systemic mastocytosis	Diagnosis	ICD-10-CM
D47.09	Other mast cell neoplasms of uncertain behavior	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-10-CM
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-10-CM
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
D48.3	Neoplasm of uncertain behavior of retroperitoneum	Diagnosis	ICD-10-CM
D48.4	Neoplasm of uncertain behavior of peritoneum	Diagnosis	ICD-10-CM
D48.5	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-10-CM
D48.60	Neoplasm of uncertain behavior of unspecified breast	Diagnosis	ICD-10-CM
D48.61	Neoplasm of uncertain behavior of right breast	Diagnosis	ICD-10-CM
D48.62	Neoplasm of uncertain behavior of left breast	Diagnosis	ICD-10-CM
D48.7	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-10-CM
D48.9	Neoplasm of uncertain behavior, unspecified	Diagnosis	ICD-10-CM
D49.0	Neoplasm of unspecified behavior of digestive system	Diagnosis	ICD-10-CM
D49.1	Neoplasm of unspecified behavior of respiratory system	Diagnosis	ICD-10-CM
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin	Diagnosis	ICD-10-CM
D49.3	Neoplasm of unspecified behavior of breast	Diagnosis	ICD-10-CM
D49.4	Neoplasm of unspecified behavior of bladder	Diagnosis	ICD-10-CM
D49.511	Neoplasm of unspecified behavior of right kidney	Diagnosis	ICD-10-CM
D49.512	Neoplasm of unspecified behavior of left kidney	Diagnosis	ICD-10-CM
D49.519	Neoplasm of unspecified behavior of unspecified kidney	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D49.59	Neoplasm of unspecified behavior of other genitourinary organ	Diagnosis	ICD-10-CM
D49.6	Neoplasm of unspecified behavior of brain	Diagnosis	ICD-10-CM
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system	Diagnosis	ICD-10-CM
D49.81	Neoplasm of unspecified behavior of retina and choroid	Diagnosis	ICD-10-CM
D49.89	Neoplasm of unspecified behavior of other specified sites	Diagnosis	ICD-10-CM
D49.9	Neoplasm of unspecified behavior of unspecified site	Diagnosis	ICD-10-CM
Q85.00	Neurofibromatosis, unspecified	Diagnosis	ICD-10-CM
Q85.01	Neurofibromatosis, type 1	Diagnosis	ICD-10-CM
Q85.02	Neurofibromatosis, type 2	Diagnosis	ICD-10-CM
Q85.03	Schwannomatosis	Diagnosis	ICD-10-CM
Q85.09	Other neurofibromatosis	Diagnosis	ICD-10-CM
	Asthma		
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
	COPD and Bronchiectasis		
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
	Diabetes (Type 1 and 2)		
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM

E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
	Hypertension		
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
	Acute Myocardial Infarction		
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
	Atrial Fibrillation		
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
	Heart Failure		
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
	Ischemic Heart Disease		
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM

I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
	Stroke/Transient Ischemic Attack(TIA)		
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
	History of Cardiac Arrest		
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
	History of Coronary Angioplasty or Bypass		
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
	Alzheimer's Disease and related conditions		
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Depression			
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
	Bipolar or Other Depressive Mood Disorders		
F30.10	Manic episode without psychotic symptoms, unspecified	Diagnosis	ICD-10-CM
F30.11	Manic episode without psychotic symptoms, mild	Diagnosis	ICD-10-CM
F30.12	Manic episode without psychotic symptoms, moderate	Diagnosis	ICD-10-CM
F30.13	Manic episode, severe, without psychotic symptoms	Diagnosis	ICD-10-CM
F30.2	Manic episode, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F30.3	Manic episode in partial remission	Diagnosis	ICD-10-CM
F30.4	Manic episode in full remission	Diagnosis	ICD-10-CM
F30.8	Other manic episodes	Diagnosis	ICD-10-CM
F30.9	Manic episode, unspecified	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.74	Bipolar disorder, in full remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F34.81	Disruptive mood dysregulation disorder	Diagnosis	ICD-10-CM
F34.89	Other specified persistent mood disorders	Diagnosis	ICD-10-CM
F34.9	Persistent mood [affective] disorder, unspecified	Diagnosis	ICD-10-CM
F39	Unspecified mood [affective] disorder	Diagnosis	ICD-10-CM
	ADHD		
F63.0	Pathological gambling	Diagnosis	ICD-10-CM
F63.1	Pyromania	Diagnosis	ICD-10-CM
F63.2	Kleptomania	Diagnosis	ICD-10-CM
F63.3	Trichotillomania	Diagnosis	ICD-10-CM
F63.81	Intermittent explosive disorder	Diagnosis	ICD-10-CM
F63.89	Other impulse disorders	Diagnosis	ICD-10-CM
F63.9	Impulse disorder, unspecified	Diagnosis	ICD-10-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
F91	Conduct disorders	Diagnosis	ICD-10-CM
F91.0	Conduct disorder confined to family context	Diagnosis	ICD-10-CM
F91.1	Conduct disorder, childhood-onset type	Diagnosis	ICD-10-CM
F91.2	Conduct disorder, adolescent-onset type	Diagnosis	ICD-10-CM
F91.3	Oppositional defiant disorder	Diagnosis	ICD-10-CM
F91.8	Other conduct disorders	Diagnosis	ICD-10-CM
F91.9	Conduct disorder, unspecified	Diagnosis	ICD-10-CM
	Cerebral Palsy		
G80	Cerebral palsy	Diagnosis	ICD-10-CM
G80.0	Spastic quadriplegic cerebral palsy	Diagnosis	ICD-10-CM
G80.1	Spastic diplegic cerebral palsy	Diagnosis	ICD-10-CM
G80.2	Spastic hemiplegic cerebral palsy	Diagnosis	ICD-10-CM
G80.3	Athetoid cerebral palsy	Diagnosis	ICD-10-CM
G80.4	Ataxic cerebral palsy	Diagnosis	ICD-10-CM
G80.8	Other cerebral palsy	Diagnosis	ICD-10-CM
G80.9	Cerebral palsy, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G81	Hemiplegia and hemiparesis	Diagnosis	ICD-10-CM
G81.0	Flaccid hemiplegia	Diagnosis	ICD-10-CM
G81.00	Flaccid hemiplegia affecting unspecified side	Diagnosis	ICD-10-CM
G81.01	Flaccid hemiplegia affecting right dominant side	Diagnosis	ICD-10-CM
G81.02	Flaccid hemiplegia affecting left dominant side	Diagnosis	ICD-10-CM
G81.03	Flaccid hemiplegia affecting right nondominant side	Diagnosis	ICD-10-CM
G81.04	Flaccid hemiplegia affecting left nondominant side	Diagnosis	ICD-10-CM
G81.1	Spastic hemiplegia	Diagnosis	ICD-10-CM
G81.10	Spastic hemiplegia affecting unspecified side	Diagnosis	ICD-10-CM
G81.11	Spastic hemiplegia affecting right dominant side	Diagnosis	ICD-10-CM
G81.12	Spastic hemiplegia affecting left dominant side	Diagnosis	ICD-10-CM
G81.13	Spastic hemiplegia affecting right nondominant side	Diagnosis	ICD-10-CM
G81.14	Spastic hemiplegia affecting left nondominant side	Diagnosis	ICD-10-CM
G81.9	Hemiplegia, unspecified	Diagnosis	ICD-10-CM
G81.90	Hemiplegia, unspecified affecting unspecified side	Diagnosis	ICD-10-CM
G81.91	Hemiplegia, unspecified affecting right dominant side	Diagnosis	ICD-10-CM
G81.92	Hemiplegia, unspecified affecting left dominant side	Diagnosis	ICD-10-CM
G81.93	Hemiplegia, unspecified affecting right nondominant side	Diagnosis	ICD-10-CM
G81.94	Hemiplegia, unspecified affecting left nondominant side	Diagnosis	ICD-10-CM
G82	Paraplegia (paraparesis) and quadriplegia (quadriparesis)	Diagnosis	ICD-10-CM
G82.2	Paraplegia	Diagnosis	ICD-10-CM
G82.20	Paraplegia, unspecified	Diagnosis	ICD-10-CM
G82.21	Paraplegia, complete	Diagnosis	ICD-10-CM
G82.22	Paraplegia, incomplete	Diagnosis	ICD-10-CM
G82.5	Quadriplegia	Diagnosis	ICD-10-CM
G82.50	Quadriplegia, unspecified	Diagnosis	ICD-10-CM
G82.51	Quadriplegia, C1-C4 complete	Diagnosis	ICD-10-CM
G82.52	Quadriplegia, C1-C4 incomplete	Diagnosis	ICD-10-CM
G82.53	Quadriplegia, C5-C7 complete	Diagnosis	ICD-10-CM
G82.54	Quadriplegia, C5-C7 incomplete	Diagnosis	ICD-10-CM
G83	Other paralytic syndromes	Diagnosis	ICD-10-CM
G83.0	Diplegia of upper limbs	Diagnosis	ICD-10-CM
G83.1	Monoplegia of lower limb	Diagnosis	ICD-10-CM
G83.10	Monoplegia of lower limb affecting unspecified side	Diagnosis	ICD-10-CM
G83.11	Monoplegia of lower limb affecting right dominant side	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G83.12	Monoplegia of lower limb affecting left dominant side	Diagnosis	ICD-10-CM
G83.13	Monoplegia of lower limb affecting right nondominant side	Diagnosis	ICD-10-CM
G83.14	Monoplegia of lower limb affecting left nondominant side	Diagnosis	ICD-10-CM
G83.2	Monoplegia of upper limb	Diagnosis	ICD-10-CM
G83.20	Monoplegia of upper limb affecting unspecified side	Diagnosis	ICD-10-CM
G83.21	Monoplegia of upper limb affecting right dominant side	Diagnosis	ICD-10-CM
G83.22	Monoplegia of upper limb affecting left dominant side	Diagnosis	ICD-10-CM
G83.23	Monoplegia of upper limb affecting right nondominant side	Diagnosis	ICD-10-CM
G83.24	Monoplegia of upper limb affecting left nondominant side	Diagnosis	ICD-10-CM
G83.3	Monoplegia, unspecified	Diagnosis	ICD-10-CM
G83.30	Monoplegia, unspecified affecting unspecified side	Diagnosis	ICD-10-CM
G83.31	Monoplegia, unspecified affecting right dominant side	Diagnosis	ICD-10-CM
G83.32	Monoplegia, unspecified affecting left dominant side	Diagnosis	ICD-10-CM
G83.33	Monoplegia, unspecified affecting right nondominant side	Diagnosis	ICD-10-CM
G83.34	Monoplegia, unspecified affecting left nondominant side	Diagnosis	ICD-10-CM
G83.4	Cauda equina syndrome	Diagnosis	ICD-10-CM
G83.5	Locked-in state	Diagnosis	ICD-10-CM
G83.8	Other specified paralytic syndromes	Diagnosis	ICD-10-CM
G83.81	Brown-Sequard syndrome	Diagnosis	ICD-10-CM
G83.82	Anterior cord syndrome	Diagnosis	ICD-10-CM
G83.83	Posterior cord syndrome	Diagnosis	ICD-10-CM
G83.84	Todd's paralysis (postepileptic)	Diagnosis	ICD-10-CM
G83.89	Other specified paralytic syndromes	Diagnosis	ICD-10-CM
G83.9	Paralytic syndrome, unspecified	Diagnosis	ICD-10-CM
	Spinal Cord Injuries		
G96.11	Dural tear	Diagnosis	ICD-10-CM
S12.000A	Unspecified displaced fracture of first cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.000B	Unspecified displaced fracture of first cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.001A	Unspecified nondisplaced fracture of first cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S12.001B	Unspecified nondisplaced fracture of first cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.100A	Unspecified displaced fracture of second cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.100B	Unspecified displaced fracture of second cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.101A	Unspecified nondisplaced fracture of second cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.101B	Unspecified nondisplaced fracture of second cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.200A	Unspecified displaced fracture of third cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.200B	Unspecified displaced fracture of third cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.201A	Unspecified nondisplaced fracture of third cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.201B	Unspecified nondisplaced fracture of third cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.300A	Unspecified displaced fracture of fourth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.300B	Unspecified displaced fracture of fourth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.301A	Unspecified nondisplaced fracture of fourth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.301B	Unspecified nondisplaced fracture of fourth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.400A	Unspecified displaced fracture of fifth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.400B	Unspecified displaced fracture of fifth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.401A	Unspecified nondisplaced fracture of fifth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.401B	Unspecified nondisplaced fracture of fifth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.500A	Unspecified displaced fracture of sixth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S12.500B	Unspecified displaced fracture of sixth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.501A	Unspecified nondisplaced fracture of sixth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.501B	Unspecified nondisplaced fracture of sixth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.600A	Unspecified displaced fracture of seventh cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.600B	Unspecified displaced fracture of seventh cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.601A	Unspecified nondisplaced fracture of seventh cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.601B	Unspecified nondisplaced fracture of seventh cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.9XXA	Fracture of neck, unspecified, initial encounter	Diagnosis	ICD-10-CM
S14.0XXA	Concussion and edema of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.0XXS	Concussion and edema of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.101A	Unspecified injury at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.101S	Unspecified injury at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.102A	Unspecified injury at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.102S	Unspecified injury at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.103A	Unspecified injury at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.103S	Unspecified injury at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.104A	Unspecified injury at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.104S	Unspecified injury at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.105A	Unspecified injury at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM

S14.105S	Unspecified injury at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.106A	Unspecified injury at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.106S	Unspecified injury at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.107A	Unspecified injury at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.107S	Unspecified injury at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.108A	Unspecified injury at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.108S	Unspecified injury at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.109A	Unspecified injury at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.109S	Unspecified injury at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.111A	Complete lesion at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.111S	Complete lesion at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.112A	Complete lesion at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.112S	Complete lesion at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.113S	Complete lesion at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.114A	Complete lesion at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.114S	Complete lesion at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.115A	Complete lesion at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.115S	Complete lesion at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

S14.116A	Complete lesion at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.116S	Complete lesion at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.117A	Complete lesion at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.117S	Complete lesion at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.118A	Complete lesion at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.118S	Complete lesion at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.119A	Complete lesion at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.119S	Complete lesion at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.121A	Central cord syndrome at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.121S	Central cord syndrome at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.122A	Central cord syndrome at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.122S	Central cord syndrome at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.123A	Central cord syndrome at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.123S	Central cord syndrome at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.124A	Central cord syndrome at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.124S	Central cord syndrome at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.125A	Central cord syndrome at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.125S	Central cord syndrome at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

S14.126A	Central cord syndrome at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.126S	Central cord syndrome at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.127A	Central cord syndrome at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.127S	Central cord syndrome at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.128A	Central cord syndrome at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.128S	Central cord syndrome at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.129A	Central cord syndrome at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.129S	Central cord syndrome at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.131A	Anterior cord syndrome at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.131S	Anterior cord syndrome at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.132A	Anterior cord syndrome at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.132S	Anterior cord syndrome at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.133A	Anterior cord syndrome at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.133S	Anterior cord syndrome at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.134A	Anterior cord syndrome at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.134S	Anterior cord syndrome at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.135A	Anterior cord syndrome at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.135S	Anterior cord syndrome at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

S14.136A	Anterior cord syndrome at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.136S	Anterior cord syndrome at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.137A	Anterior cord syndrome at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.137S	Anterior cord syndrome at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.138A	Anterior cord syndrome at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.138S	Anterior cord syndrome at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.139A	Anterior cord syndrome at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.139S	Anterior cord syndrome at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.141A	Brown-Sequard syndrome at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.141S	Brown-Sequard syndrome at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.142A	Brown-Sequard syndrome at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.142S	Brown-Sequard syndrome at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.143A	Brown-Sequard syndrome at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.143S	Brown-Sequard syndrome at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.144A	Brown-Sequard syndrome at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.144S	Brown-Sequard syndrome at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.145A	Brown-Sequard syndrome at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.145S	Brown-Sequard syndrome at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

S14.146A	Brown-Sequard syndrome at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.146S	Brown-Sequard syndrome at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.147A	Brown-Sequard syndrome at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.147S	Brown-Sequard syndrome at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.148A	Brown-Sequard syndrome at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.148S	Brown-Sequard syndrome at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.149A	Brown-Sequard syndrome at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.149S	Brown-Sequard syndrome at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.151A	Other incomplete lesion at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.151S	Other incomplete lesion at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.152A	Other incomplete lesion at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.152S	Other incomplete lesion at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.153A	Other incomplete lesion at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.153S	Other incomplete lesion at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.154A	Other incomplete lesion at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.154S	Other incomplete lesion at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.155A	Other incomplete lesion at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.155S	Other incomplete lesion at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S14.156A	Other incomplete lesion at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.156S	Other incomplete lesion at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.157A	Other incomplete lesion at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.157S	Other incomplete lesion at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.158A	Other incomplete lesion at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.158S	Other incomplete lesion at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.159A	Other incomplete lesion at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.159S	Other incomplete lesion at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S22.009A	Unspecified fracture of unspecified thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.009B	Unspecified fracture of unspecified thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.019A	Unspecified fracture of first thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.019B	Unspecified fracture of first thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.029A	Unspecified fracture of second thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.029B	Unspecified fracture of second thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.039A	Unspecified fracture of third thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.039B	Unspecified fracture of third thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.049A	Unspecified fracture of fourth thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.049B	Unspecified fracture of fourth thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S22.059A	Unspecified fracture of T5-T6 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.059B	Unspecified fracture of T5-T6 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.069A	Unspecified fracture of T7-T8 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.069B	Unspecified fracture of T7-T8 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.079A	Unspecified fracture of T9-T10 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.079B	Unspecified fracture of T9-T10 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.089A	Unspecified fracture of T11-T12 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.089B	Unspecified fracture of T11-T12 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S24.0XXA	Concussion and edema of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.0XXS	Concussion and edema of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.101A	Unspecified injury at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.101S	Unspecified injury at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.102A	Unspecified injury at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.102S	Unspecified injury at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.103A	Unspecified injury at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.103S	Unspecified injury at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.104A	Unspecified injury at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.104S	Unspecified injury at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM

S24.109A	Unspecified injury at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.109S	Unspecified injury at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.111A	Complete lesion at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.111S	Complete lesion at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.112A	Complete lesion at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.112S	Complete lesion at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.113A	Complete lesion at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.113S	Complete lesion at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.114A	Complete lesion at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.114S	Complete lesion at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.119A	Complete lesion at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.119S	Complete lesion at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.131A	Anterior cord syndrome at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.131S	Anterior cord syndrome at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.132A	Anterior cord syndrome at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.132S	Anterior cord syndrome at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.133A	Anterior cord syndrome at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.133S	Anterior cord syndrome at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S24.134A	Anterior cord syndrome at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.134S	Anterior cord syndrome at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.139A	Anterior cord syndrome at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.139S	Anterior cord syndrome at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.141A	Brown-Sequard syndrome at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.141S	Brown-Sequard syndrome at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.142A	Brown-Sequard syndrome at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.142S	Brown-Sequard syndrome at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.143A	Brown-Sequard syndrome at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.143S	Brown-Sequard syndrome at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.144A	Brown-Sequard syndrome at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.144S	Brown-Sequard syndrome at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.149A	Brown-Sequard syndrome at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.149S	Brown-Sequard syndrome at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.151A	Other incomplete lesion at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.151S	Other incomplete lesion at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.152A	Other incomplete lesion at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.152S	Other incomplete lesion at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S24.153A	Other incomplete lesion at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.153S	Other incomplete lesion at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.154A	Other incomplete lesion at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.154S	Other incomplete lesion at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.159A	Other incomplete lesion at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.159S	Other incomplete lesion at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S32.009A	Unspecified fracture of unspecified lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.009B	Unspecified fracture of unspecified lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.019A	Unspecified fracture of first lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.019B	Unspecified fracture of first lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.029A	Unspecified fracture of second lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.029B	Unspecified fracture of second lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.039A	Unspecified fracture of third lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.039B	Unspecified fracture of third lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.049A	Unspecified fracture of fourth lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.049B	Unspecified fracture of fourth lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.059A	Unspecified fracture of fifth lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.059B	Unspecified fracture of fifth lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.10XA	Unspecified fracture of sacrum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.10XB	Unspecified fracture of sacrum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.2XXA	Fracture of coccyx, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.2XXB	Fracture of coccyx, initial encounter for open fracture	Diagnosis	ICD-10-CM
S34.01XA	Concussion and edema of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.01XS	Concussion and edema of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.02XA	Concussion and edema of sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.02XS	Concussion and edema of sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.101A	Unspecified injury to L1 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.101S	Unspecified injury to L1 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.102A	Unspecified injury to L2 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.102S	Unspecified injury to L2 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.103A	Unspecified injury to L3 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.103S	Unspecified injury to L3 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.104A	Unspecified injury to L4 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.104S	Unspecified injury to L4 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.105A	Unspecified injury to L5 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.105S	Unspecified injury to L5 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.109A	Unspecified injury to unspecified level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.109S	Unspecified injury to unspecified level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM

S34.111A	Complete lesion of L1 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.111S	Complete lesion of L1 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.112A	Complete lesion of L2 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.112S	Complete lesion of L2 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.113A	Complete lesion of L3 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.113S	Complete lesion of L3 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.114A	Complete lesion of L4 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.114S	Complete lesion of L4 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.115A	Complete lesion of L5 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.115S	Complete lesion of L5 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.119A	Complete lesion of unspecified level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.119S	Complete lesion of unspecified level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.121A	Incomplete lesion of L1 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.121S	Incomplete lesion of L1 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.122A	Incomplete lesion of L2 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.122S	Incomplete lesion of L2 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.123A	Incomplete lesion of L3 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.123S	Incomplete lesion of L3 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S34.124A	Incomplete lesion of L4 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.124S	Incomplete lesion of L4 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.125A	Incomplete lesion of L5 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.125S	Incomplete lesion of L5 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.129A	Incomplete lesion of unspecified level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.129S	Incomplete lesion of unspecified level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.131A	Complete lesion of sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.131S	Complete lesion of sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.132A	Incomplete lesion of sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.132S	Incomplete lesion of sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.139A	Unspecified injury to sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.139S	Unspecified injury to sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.3XXA	Injury of cauda equina, initial encounter	Diagnosis	ICD-10-CM
	Down Syndrome		
Q90	Down syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM
	Alcohol Abuse or Dependence		
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM

F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM

F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
	Obesity: Diagnosed or Identified by Weight Management Procedure		
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
	Overweight		
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
	Smoking: Diagnosed or Identified by Smoking Cessation Procedure		
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
	HIV/AIDS		
B20	Human immunodeficiency virus [HIV] disease	Diagnosis	ICD-10-CM
B97.35	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere	Diagnosis	ICD-10-CM
O98.7	Human immunodeficiency virus [HIV] disease complicating pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O98.71	Human immunodeficiency virus [HIV] disease complicating pregnancy	Diagnosis	ICD-10-CM
O98.711	Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98.712	Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98.713	Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O98.719	Human immunodeficiency virus [HIV] disease complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O98.72	Human immunodeficiency virus [HIV] disease complicating childbirth	Diagnosis	ICD-10-CM
O98.73	Human immunodeficiency virus [HIV] disease complicating the puerperium	Diagnosis	ICD-10-CM
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status	Diagnosis	ICD-10-CM
	Hematological Malignancy		
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.27	Mixed cellularity Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.70	Other Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.77	Other Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.90	Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.97	Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.00	Follicular lymphoma grade I, unspecified site	Diagnosis	ICD-10-CM
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.07	Follicular lymphoma grade I, spleen	Diagnosis	ICD-10-CM
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.10	Follicular lymphoma grade II, unspecified site	Diagnosis	ICD-10-CM
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.17	Follicular lymphoma grade II, spleen	Diagnosis	ICD-10-CM
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.20	Follicular lymphoma grade III, unspecified, unspecified site	Diagnosis	ICD-10-CM

C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.27	Follicular lymphoma grade III, unspecified, spleen	Diagnosis	ICD-10-CM
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.30	Follicular lymphoma grade IIIa, unspecified site	Diagnosis	ICD-10-CM
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.37	Follicular lymphoma grade IIIa, spleen	Diagnosis	ICD-10-CM
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.40	Follicular lymphoma grade IIIb, unspecified site	Diagnosis	ICD-10-CM
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.47	Follicular lymphoma grade IIIb, spleen	Diagnosis	ICD-10-CM
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.50	Diffuse follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.57	Diffuse follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.60	Cutaneous follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.67	Cutaneous follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.80	Other types of follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.87	Other types of follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.90	Follicular lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.97	Follicular lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.00	Small cell B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.07	Small cell B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.10	Mantle cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.17	Mantle cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.19	Mantle cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.30	Diffuse large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.37	Diffuse large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.57	Lymphoblastic (diffuse) lymphoma, spleen	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.70	Burkitt lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.72	Burkitt lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.76	Burkitt lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.77	Burkitt lymphoma, spleen	Diagnosis	ICD-10-CM
C83.78	Burkitt lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.79	Burkitt lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.80	Other non-follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.87	Other non-follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.00	Mycosis fungoides, unspecified site	Diagnosis	ICD-10-CM
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.02	Mycosis fungoides, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.03	Mycosis fungoides, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.06	Mycosis fungoides, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.07	Mycosis fungoides, spleen	Diagnosis	ICD-10-CM
C84.08	Mycosis fungoides, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.09	Mycosis fungoides, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.10	Sezary disease, unspecified site	Diagnosis	ICD-10-CM
C84.11	Sezary disease, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.12	Sezary disease, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.13	Sezary disease, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.14	Sezary disease, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.16	Sezary disease, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.17	Sezary disease, spleen	Diagnosis	ICD-10-CM
C84.18	Sezary disease, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.19	Sezary disease, extranodal and solid organ sites	Diagnosis	ICD-10-CM

C84.40	Peripheral T-cell lymphoma, not classified, unspecified site	Diagnosis	ICD-10-CM
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.47	Peripheral T-cell lymphoma, not classified, spleen	Diagnosis	ICD-10-CM
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site	Diagnosis	ICD-10-CM
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen	Diagnosis	ICD-10-CM
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site	Diagnosis	ICD-10-CM
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen	Diagnosis	ICD-10-CM
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site	Diagnosis	ICD-10-CM
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.Z7	Other mature T/NK-cell lymphomas, spleen	Diagnosis	ICD-10-CM

C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.10	Unspecified B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.17	Unspecified B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.87	Other specified types of non-Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.97	Non-Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C86.0	Extranodal NK/T-cell lymphoma, nasal type	Diagnosis	ICD-10-CM
C86.1	Hepatosplenic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.2	Enteropathy-type (intestinal) T-cell lymphoma	Diagnosis	ICD-10-CM
C86.3	Subcutaneous panniculitis-like T-cell lymphoma	Diagnosis	ICD-10-CM
C86.4	Blastic NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.5	Angioimmunoblastic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.6	Primary cutaneous CD30-positive T-cell proliferations	Diagnosis	ICD-10-CM
C88.0	Waldenstrom macroglobulinemia	Diagnosis	ICD-10-CM
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	Diagnosis	ICD-10-CM
C88.8	Other malignant immunoproliferative diseases	Diagnosis	ICD-10-CM
C90.00	Multiple myeloma not having achieved remission	Diagnosis	ICD-10-CM
C90.01	Multiple myeloma in remission	Diagnosis	ICD-10-CM
C90.02	Multiple myeloma in relapse	Diagnosis	ICD-10-CM
C90.10	Plasma cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C90.12	Plasma cell leukemia in relapse	Diagnosis	ICD-10-CM
C90.20	Extramedullary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.22	Extramedullary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C90.30	Solitary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.32	Solitary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C91.00	Acute lymphoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.02	Acute lymphoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse	Diagnosis	ICD-10-CM
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.32	Prolymphocytic leukemia of B-cell type, in relapse	Diagnosis	ICD-10-CM
C91.40	Hairy cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.42	Hairy cell leukemia, in relapse	Diagnosis	ICD-10-CM
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission	Diagnosis	ICD-10-CM

C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse	Diagnosis	ICD-10-CM
C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.62	Prolymphocytic leukemia of T-cell type, in relapse	Diagnosis	ICD-10-CM
C91.90	Lymphoid leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C91.92	Lymphoid leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission	Diagnosis	ICD-10-CM
C91.A2	Mature B-cell leukemia Burkitt-type, in relapse	Diagnosis	ICD-10-CM
C91.Z0	Other lymphoid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.Z2	Other lymphoid leukemia, in relapse	Diagnosis	ICD-10-CM
C92.00	Acute myeloblastic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.02	Acute myeloblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	Diagnosis	ICD-10-CM
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse	Diagnosis	ICD-10-CM
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	Diagnosis	ICD-10-CM
C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse	Diagnosis	ICD-10-CM
C92.30	Myeloid sarcoma, not having achieved remission	Diagnosis	ICD-10-CM
C92.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-10-CM
C92.40	Acute promyelocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.42	Acute promyelocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.50	Acute myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.52	Acute myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission	Diagnosis	ICD-10-CM
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse	Diagnosis	ICD-10-CM
C92.90	Myeloid leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C92.92	Myeloid leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission	Diagnosis	ICD-10-CM
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse	Diagnosis	ICD-10-CM
C92.Z0	Other myeloid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C92.Z2	Other myeloid leukemia, in relapse	Diagnosis	ICD-10-CM
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.02	Acute monoblastic/monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.12	Chronic myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.32	Juvenile myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.92	Monocytic leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z2	Other monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.02	Acute erythroid leukemia, in relapse	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.22	Acute megakaryoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.32	Mast cell leukemia, in relapse	Diagnosis	ICD-10-CM
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	Diagnosis	ICD-10-CM
C94.42	Acute panmyelosis with myelofibrosis, in relapse	Diagnosis	ICD-10-CM
C94.6	Myelodysplastic disease, not classified	Diagnosis	ICD-10-CM
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.82	Other specified leukemias, in relapse	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.92	Leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C96.20	Malignant mast cell neoplasm, unspecified	Diagnosis	ICD-10-CM
C96.21	Aggressive systemic mastocytosis	Diagnosis	ICD-10-CM
C96.22	Mast cell sarcoma	Diagnosis	ICD-10-CM
C96.29	Other malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.6	Unifocal Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.A	Histiocytic sarcoma	Diagnosis	ICD-10-CM
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D45	Polycythemia vera	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D47.1	Chronic myeloproliferative disease	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Treatment-Independent Immune Deficiencies			
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D70.0	Congenital agranulocytosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D70.4	Cyclic neutropenia	Diagnosis	ICD-10-CM
D71	Functional disorders of polymorphonuclear neutrophils	Diagnosis	ICD-10-CM
D76.1	Hemophagocytic lymphohistiocytosis	Diagnosis	ICD-10-CM
D76.2	Hemophagocytic syndrome, infection-associated	Diagnosis	ICD-10-CM
D76.3	Other histiocytosis syndromes	Diagnosis	ICD-10-CM
D80.0	Hereditary hypogammaglobulinemia	Diagnosis	ICD-10-CM
D80.1	Nonfamilial hypogammaglobulinemia	Diagnosis	ICD-10-CM
D80.2	Selective deficiency of immunoglobulin A [IgA]	Diagnosis	ICD-10-CM
D80.3	Selective deficiency of immunoglobulin G [IgG] subclasses	Diagnosis	ICD-10-CM
D80.4	Selective deficiency of immunoglobulin M [IgM]	Diagnosis	ICD-10-CM
D80.5	Immunodeficiency with increased immunoglobulin M [IgM]	Diagnosis	ICD-10-CM
D80.6	Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia	Diagnosis	ICD-10-CM
D80.8	Other immunodeficiencies with predominantly antibody defects	Diagnosis	ICD-10-CM
D80.9	Immunodeficiency with predominantly antibody defects, unspecified	Diagnosis	ICD-10-CM
D81.0	Severe combined immunodeficiency [SCID] with reticular dysgenesis	Diagnosis	ICD-10-CM
D81.1	Severe combined immunodeficiency [SCID] with low T- and B-cell numbers	Diagnosis	ICD-10-CM
D81.2	Severe combined immunodeficiency [SCID] with low or normal B-cell numbers	Diagnosis	ICD-10-CM
D81.3	Adenosine deaminase [ADA] deficiency	Diagnosis	ICD-10-CM
D81.30	Adenosine deaminase deficiency, unspecified	Diagnosis	ICD-10-CM
D81.31	Severe combined immunodeficiency due to adenosine deaminase deficiency	Diagnosis	ICD-10-CM
D81.32	Adenosine deaminase 2 deficiency	Diagnosis	ICD-10-CM
D81.39	Other adenosine deaminase deficiency	Diagnosis	ICD-10-CM
D81.4	Nezelof's syndrome	Diagnosis	ICD-10-CM
D81.5	Purine nucleoside phosphorylase [PNP] deficiency	Diagnosis	ICD-10-CM
D81.6	Major histocompatibility complex class I deficiency	Diagnosis	ICD-10-CM
D81.7	Major histocompatibility complex class II deficiency	Diagnosis	ICD-10-CM
D81.89	Other combined immunodeficiencies	Diagnosis	ICD-10-CM
D81.9	Combined immunodeficiency, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D82.0	Wiskott-Aldrich syndrome	Diagnosis	ICD-10-CM
D82.1	Di George's syndrome	Diagnosis	ICD-10-CM
D82.2	Immunodeficiency with short-limbed stature	Diagnosis	ICD-10-CM
D82.3	Immunodeficiency following hereditary defective response to Epstein-Barr virus	Diagnosis	ICD-10-CM
D82.4	Hyperimmunoglobulin E [IgE] syndrome	Diagnosis	ICD-10-CM
D82.8	Immunodeficiency associated with other specified major defects	Diagnosis	ICD-10-CM
D82.9	Immunodeficiency associated with major defect, unspecified	Diagnosis	ICD-10-CM
D83.0	Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function	Diagnosis	ICD-10-CM
D83.1	Common variable immunodeficiency with predominant immunoregulatory T-cell disorders	Diagnosis	ICD-10-CM
D83.2	Common variable immunodeficiency with autoantibodies to B- or T-cells	Diagnosis	ICD-10-CM
D83.8	Other common variable immunodeficiencies	Diagnosis	ICD-10-CM
D83.9	Common variable immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D84.0	Lymphocyte function antigen-1 [LFA-1] defect	Diagnosis	ICD-10-CM
D84.1	Defects in the complement system	Diagnosis	ICD-10-CM
D84.8	Other specified immunodeficiencies	Diagnosis	ICD-10-CM
D84.9	Immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D89.82	Autoimmune lymphoproliferative syndrome [ALPS]	Diagnosis	ICD-10-CM
E40	Kwashiorkor	Diagnosis	ICD-10-CM
E41	Nutritional marasmus	Diagnosis	ICD-10-CM
E42	Marasmic kwashiorkor	Diagnosis	ICD-10-CM
E43	Unspecified severe protein-calorie malnutrition	Diagnosis	ICD-10-CM
E80.3	Defects of catalase and peroxidase	Diagnosis	ICD-10-CM
Q89.01	Asplenia (congenital)	Diagnosis	ICD-10-CM
Q89.09	Congenital malformations of spleen	Diagnosis	ICD-10-CM
	Dialysis		
3E1M39Z	Irrigation of Peritoneal Cavity using Dialysate, Percutaneous Approach	Procedure	ICD-10-PCS
5A1D00Z	Performance of Urinary Filtration, Single	Procedure	ICD-10-PCS
5A1D60Z	Performance of Urinary Filtration, Multiple	Procedure	ICD-10-PCS
5A1D70Z	Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

5A1D80Z	Performance of Urinary Filtration, Prolonged Intermittent, 6-18 hours Per Day	Procedure	ICD-10-PCS
5A1D90Z	Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day	Procedure	ICD-10-PCS
A4653	Peritoneal dialysis catheter anchoring device, belt, each	Procedure	HCPCS
A4671	Disposable cycler set used with cycler dialysis machine, each	Procedure	HCPCS
A4672	Drainage extension line, sterile, for dialysis, each	Procedure	HCPCS
A4673	Extension line with easy lock connectors, used with dialysis	Procedure	HCPCS
A4674	Chemicals/antiseptics solution used to clean/sterilize dialysis equipment, per 8 oz	Procedure	HCPCS
A4680	Activated carbon filter for hemodialysis, each	Procedure	HCPCS
A4690	Dialyzer (artificial kidneys), all types, all sizes, for hemodialysis, each	Procedure	HCPCS
A4700	Standard dialysate solution, each	Procedure	HCPCS
A4705	Bicarbonate dialysate solution, each	Procedure	HCPCS
A4706	Bicarbonate concentrate, solution, for hemodialysis, per gallon	Procedure	HCPCS
A4707	Bicarbonate concentrate, powder, for hemodialysis, per packet	Procedure	HCPCS
A4708	Acetate concentrate solution, for hemodialysis, per gallon	Procedure	HCPCS
A4709	Acid concentrate, solution, for hemodialysis, per gallon	Procedure	HCPCS
A4712	Water, sterile, for injection, per 10 ml	Procedure	HCPCS
A4714	Treated water (deionized, distilled, or reverse osmosis) for peritoneal dialysis, per gallon	Procedure	HCPCS
A4719	"Y set" tubing for peritoneal dialysis	Procedure	HCPCS
A4720	Dialysate solution, any concentration of dextrose, fluid volume greater than 249 cc, but less than or equal to 999 cc, for peritoneal dialysis	Procedure	HCPCS
A4721	Dialysate solution, any concentration of dextrose, fluid volume greater than 999 cc but less than or equal to 1999 cc, for peritoneal dialysis	Procedure	HCPCS
A4722	Dialysate solution, any concentration of dextrose, fluid volume greater than 1999 cc but less than or equal to 2999 cc, for peritoneal dialysis	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

A4723	Dialysate solution, any concentration of dextrose, fluid volume greater than 2999 cc but less than or equal to 3999 cc, for peritoneal dialysis	Procedure	HCPCS
A4724	Dialysate solution, any concentration of dextrose, fluid volume greater than 3999 cc but less than or equal to 4999 cc, for peritoneal dialysis	Procedure	HCPCS
A4725	Dialysate solution, any concentration of dextrose, fluid volume greater than 4999 cc but less than or equal to 5999 cc, for peritoneal dialysis	Procedure	HCPCS
A4726	Dialysate solution, any concentration of dextrose, fluid volume greater than 5999 cc, for peritoneal dialysis	Procedure	HCPCS
A4728	Dialysate solution, nondextrose containing, 500 ml	Procedure	HCPCS
A4730	Fistula cannulation set for hemodialysis, each	Procedure	HCPCS
A4735	Local/topical anesthetics for dialysis only	Procedure	HCPCS
A4736	Topical anesthetic, for dialysis, per g	Procedure	HCPCS
A4737	Injectable anesthetic, for dialysis, per 10 ml	Procedure	HCPCS
A4740	Shunt accessory, for hemodialysis, any type, each	Procedure	HCPCS
A4750	Blood tubing, arterial or venous, for hemodialysis, each	Procedure	HCPCS
A4755	Blood tubing, arterial and venous combined, for hemodialysis, each	Procedure	HCPCS
A4760	Dialysate solution test kit, for peritoneal dialysis, any type, each	Procedure	HCPCS
A4765	Dialysate concentrate, powder, additive for peritoneal dialysis, per packet	Procedure	HCPCS
A4766	Dialysate concentrate, solution, additive for peritoneal dialysis, per 10 ml	Procedure	HCPCS
A4802	Protamine sulfate, for hemodialysis, per 50 mg	Procedure	HCPCS
A4820	Hemodialysis kit supplies	Procedure	HCPCS
A4850	Hemostats with rubber tips for dialysis	Procedure	HCPCS
A4860	Disposable catheter tips for peritoneal dialysis, per 10	Procedure	HCPCS
A4870	Plumbing and/or electrical work for home hemodialysis equipment	Procedure	HCPCS
A4880	Storage tanks utilized in connection with water purification system, replacement tanks for dialysis	Procedure	HCPCS
A4890	Contracts, repair and maintenance, for hemodialysis equipment	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

A4900	Continuous ambulatory peritoneal dialysis (capd) supply kit	Procedure	HCPCS
A4901	Continuous cycling peritoneal dialysis (ccpd) supply kit	Procedure	HCPCS
A4905	Intermittent peritoneal dialysis (ipd) supply kit	Procedure	HCPCS
A4910	Non-medical supplies for dialysis, (i.e., scale, scissors, stopwatch, etc.)	Procedure	HCPCS
A4911	Drain bag/bottle, for dialysis, each	Procedure	HCPCS
A4912	Gomco drain bottle	Procedure	HCPCS
A4913	Miscellaneous dialysis supplies, not otherwise specified	Procedure	HCPCS
A4914	Preparation kits	Procedure	HCPCS
A4918	Venous pressure clamp, for hemodialysis, each	Procedure	HCPCS
E1500	Centrifuge, for dialysis	Procedure	HCPCS
E1510	Kidney, dialysate delivery system kidney machine, pump recirculating, air removal system, flowrate meter, power off, heater and temperature control with alarm, IV poles, pressure gauge, concentrate container	Procedure	HCPCS
E1520	Heparin infusion pump for hemodialysis	Procedure	HCPCS
E1530	Air bubble detector for hemodialysis, each, replacement	Procedure	HCPCS
E1540	Pressure alarm for hemodialysis, each, replacement	Procedure	HCPCS
E1550	Bath conductivity meter for hemodialysis, each	Procedure	HCPCS
E1560	Blood leak detector for hemodialysis, each, replacement	Procedure	HCPCS
E1570	Adjustable chair, for ESRD patients	Procedure	HCPCS
E1575	Transducer protectors/fluid barriers, for hemodialysis, any size, per 10	Procedure	HCPCS
E1580	Unipuncture control system for hemodialysis	Procedure	HCPCS
E1590	Hemodialysis machine	Procedure	HCPCS
E1592	Automatic intermittent peritoneal dialysis system	Procedure	HCPCS
E1594	Cycler dialysis machine for peritoneal dialysis	Procedure	HCPCS
E1600	Delivery and/or installation charges for hemodialysis equipment	Procedure	HCPCS
E1610	Reverse osmosis water purification system, for hemodialysis	Procedure	HCPCS
E1615	Deionizer water purification system, for hemodialysis	Procedure	HCPCS
E1620	Blood pump for hemodialysis, replacement	Procedure	HCPCS
E1625	Water softening system, for hemodialysis	Procedure	HCPCS
E1630	Reciprocating peritoneal dialysis system	Procedure	HCPCS
E1632	Wearable artificial kidney, each	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E1634	Peritoneal dialysis clamps, each	Procedure	HCPCS
E1635	Compact (portable) travel hemodialyzer system	Procedure	HCPCS
E1636	Sorbent cartridges, for hemodialysis, per 10	Procedure	HCPCS
Z49	Encounter for care involving renal dialysis	Diagnosis	ICD-10-CM
Z49.01	Encounter for fitting and adjustment of extracorporeal dialysis catheter	Diagnosis	ICD-10-CM
Z49.02	Encounter for fitting and adjustment of peritoneal dialysis catheter	Diagnosis	ICD-10-CM
Z49.31	Encounter for adequacy testing for hemodialysis	Diagnosis	ICD-10-CM
Z49.32	Encounter for adequacy testing for peritoneal dialysis	Diagnosis	ICD-10-CM
Z99.2	Dependence on renal dialysis	Diagnosis	ICD-10-CM
	Chemo Therapeutic Agents/Diagnoses and Procedures		
3E00X05	Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E00X0M	Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E01305	Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E0130M	Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E02305	Introduction of Other Antineoplastic into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E0230M	Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E03002	Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03003	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03005	Introduction of Other Antineoplastic into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300P	Introduction of Clofarabine into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03302	Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330P	Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04002	Introduction of High-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04003	Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04005	Introduction of Other Antineoplastic into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400P	Introduction of Clofarabine into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04302	Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0430M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0430P	Introduction of Clofarabine into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E05002	Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05003	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05005	Introduction of Other Antineoplastic into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0500P	Introduction of Clofarabine into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05302	Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05303	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05305	Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530P	Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06002	Introduction of High-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06003	Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06005	Introduction of Other Antineoplastic into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600P	Introduction of Clofarabine into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06302	Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06303	Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06305	Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630P	Introduction of Clofarabine into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E09305	Introduction of Other Antineoplastic into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E0930M	Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E09705	Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0970M	Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E09X05	Introduction of Other Antineoplastic into Nose, External Approach	Procedure	ICD-10-PCS
3E09X0M	Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach	Procedure	ICD-10-PCS
3E0A305	Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0A30M	Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B305	Introduction of Other Antineoplastic into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B30M	Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B705	Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0B70M	Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0BX05	Introduction of Other Antineoplastic into Ear, External Approach	Procedure	ICD-10-PCS
3E0BX0M	Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach	Procedure	ICD-10-PCS
3E0C305	Introduction of Other Antineoplastic into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C30M	Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C705	Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0C70M	Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0CX05	Introduction of Other Antineoplastic into Eye, External Approach	Procedure	ICD-10-PCS
3E0CX0M	Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0D305	Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D30M	Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D705	Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0D70M	Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0DX05	Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0DX0M	Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0E305	Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E30M	Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E705	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E70M	Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E805	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0E80M	Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F305	Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F30M	Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F705	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F70M	Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F805	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0F80M	Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G305	Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G30M	Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G705	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G70M	Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G805	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G80M	Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H305	Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H30M	Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H705	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H70M	Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H805	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H80M	Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J305	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J30M	Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J705	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0J70M	Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J805	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J80M	Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K305	Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K30M	Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K705	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K70M	Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K805	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K80M	Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0L305	Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L30M	Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L705	Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0L70M	Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0M305	Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M30M	Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M705	Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0M70M	Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N305	Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N30M	Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N705	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N70M	Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N805	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0N80M	Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P305	Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P30M	Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P705	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P70M	Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P805	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P80M	Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0Q005	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q00M	Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q305	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0Q30M	Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q705	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0Q70M	Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0R302	Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R303	Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R305	Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R30M	Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S302	Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S303	Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S305	Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S30M	Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U305	Introduction of Other Antineoplastic into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U30M	Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V305	Introduction of Other Antineoplastic into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V30M	Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W305	Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W30M	Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0Y305	Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y30M	Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y705	Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0Y70M	Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Procedure	CPT-4
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	Procedure	CPT-4
96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug	Procedure	CPT-4
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)	Procedure	CPT-4
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Procedure	CPT-4
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	Procedure	CPT-4
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96420	CHEMOTX ADMIN INTRA-ART; PUSH TECH	Procedure	CPT-4
96422	CHEMOTX ADMIN INTRA-ART; INFUSION TECH TO 1 HR	Procedure	CPT-4
96423	Chemotherapy administration, intra-arterial; infusion technique, each additional hour up to 8 hours (List separately in addition to code for primary procedure)	Procedure	CPT-4

96425	Chemotherapy administration, intra-arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump	Procedure	CPT-4
96440	CHEMOTX-PLEURAL CAVITY-REQ & INCL THORACENTESIS	Procedure	CPT-4
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter	Procedure	CPT-4
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture	Procedure	CPT-4
96542	CHEMOTX INJ SUBARACH/INTRAVENTRIC-1/MX AGENTS	Procedure	CPT-4
96549	UNLISTED CHEMOTX PROC	Procedure	CPT-4
A9545	Iodine I-131 tositumomab, therapeutic, per treatment dose	Procedure	HCPCS
C1084	Denileukin diftitox, 300 mcg, ontak iv	Procedure	HCPCS
C1086	Temozolomide, 5 mg, temodar	Procedure	HCPCS
C1166	Injection, cytarabine liposome, per 10 mg	Procedure	HCPCS
C1167	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
C1178	Injection, busulfan, per 6 mg	Procedure	HCPCS
C9004	Injection, gemtuzumab ozogamicin, per 5 mg	Procedure	HCPCS
C9012	Injection, arsenic trioxide, per 1 mg/kg	Procedure	HCPCS
C9017	Lomustine, 10 mg	Procedure	HCPCS
C9021	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
C9024	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
C9042	Injection, bendamustine HCl (Belrapzo), 1 mg	Procedure	HCPCS
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
C9049	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
C9050	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
C9110	Injection, alemtuzumab, per 10 mg/ ml	Procedure	HCPCS
C9127	Injection, paclitaxel protein-bound particles, per 1 mg	Procedure	HCPCS
C9129	Injection, clofarabine, per 1 mg	Procedure	HCPCS
C9205	Injection, oxaliplatin, per 5 mg	Procedure	HCPCS
C9207	Injection, bortezomib, per 3.5 mg	Procedure	HCPCS
C9213	Injection, pemetrexed, per 10 mg	Procedure	HCPCS
C9214	Injection, bevacizumab, per 10 mg	Procedure	HCPCS

C9215	Injection, cetuximab, per 10 mg	Procedure	HCPCS
C9218	Injection, azacitidine, per 1 mg	Procedure	HCPCS
C9231	Injection, decitabine, per 1 mg	Procedure	HCPCS
C9235	Injection, panitumumab, 10 mg	Procedure	HCPCS
C9239	Injection, temsirolimus, 1 mg	Procedure	HCPCS
C9240	Injection, ixabepilone, 1 mg	Procedure	HCPCS
C9243	Injection, bendamustine hcl, 1 mg	Procedure	HCPCS
C9253	Injection, temozolomide, 1mg	Procedure	HCPCS
C9259	Injection, pralatrexate, 1 mg	Procedure	HCPCS
C9260	Injection, ofatumumab, 10 mg	Procedure	HCPCS
C9262	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
C9265	Injection, romidepsin, 1 mg	Procedure	HCPCS
C9273	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
C9276	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
C9280	Injection, eribulin mesylate, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9287	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
C9289	Injection, asparaginase Erwinia chrysanthemi, 1,000 IU	Procedure	HCPCS
C9292	Injection, pertuzumab, 10 mg	Procedure	HCPCS
C9295	Injection, carfilzomib, 1 mg	Procedure	HCPCS
C9297	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
C9414	Etoposide; oral, 50 mg, brand name	Procedure	HCPCS
C9415	Doxorubicin HCl, 10 mg, brand name	Procedure	HCPCS
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
C9418	Cisplatin, powder or solution, per 10 mg, brand name	Procedure	HCPCS
C9419	Injection, cladribine, per 1 mg, brand name	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
C9422	Cytarabine, 100 mg, brand name	Procedure	HCPCS
C9423	Dacarbazine, 100 mg, brand name	Procedure	HCPCS
C9424	Daunorubicin, 10 mg	Procedure	HCPCS
C9425	Etoposide, 10 mg, brand name	Procedure	HCPCS
C9426	Floxuridine, 500 mg, brand name	Procedure	HCPCS
C9427	Ifosfamide, 1 gm, brand name	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C9429	Idarubicin HCl, 5 mg, brand name	Procedure	HCPCS
C9431	Paclitaxel, 30 mg, brand name	Procedure	HCPCS
C9432	Mitomycin, 5 mg, brand name	Procedure	HCPCS
C9433	Thiotepa, 15 mg, brand name	Procedure	HCPCS
C9437	Carmustine, brand name, 100 mg	Procedure	HCPCS
C9440	Vinorelbine tartrate, brand name, per 10 mg	Procedure	HCPCS
C9474	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D70.1	Agranulocytosis secondary to cancer chemotherapy	Diagnosis	ICD-10-CM
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	Procedure	HCPCS
G3001	Administration and supply of tositumomab, 450 mg	Procedure	HCPCS
G9835	Trastuzumab administered within 12 months of diagnosis	Procedure	HCPCS
G9837	Trastuzumab not administered within 12 months of diagnosis	Procedure	HCPCS
J0202	Injection, alemtuzumab, 1 mg	Procedure	HCPCS
J0207	Injection, amifostine, 500 mg	Procedure	HCPCS
J0594	Injection, busulfan, 1 mg	Procedure	HCPCS
J0894	Injection, decitabine, 1 mg	Procedure	HCPCS
J7527	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8510	Busulfan; oral, 2 mg	Procedure	HCPCS
J8520	Capecitabine, oral, 150 mg	Procedure	HCPCS
J8521	Capecitabine, oral, 500 mg	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J8560	Etoposide, oral, 50 mg	Procedure	HCPCS
J8561	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8562	Fludarabine phosphate, oral, 10 mg	Procedure	HCPCS
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
J8600	Melphalan, oral 2 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J8700	Temozolomide, oral, 5 mg	Procedure	HCPCS
J8705	Topotecan, oral, 0.25 mg	Procedure	HCPCS
J8999	Prescription drug, oral, chemotherapeutic, nos	Procedure	HCPCS
J9000	Injection, doxorubicin HCl, 10 mg	Procedure	HCPCS
J9001	Injection, doxorubicin HCl, all lipid formulations, 10 mg	Procedure	HCPCS
J9002	Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg	Procedure	HCPCS
J9010	Injection, alemtuzumab, 10 mg	Procedure	HCPCS
J9015	Injection, aldesleukin, per single use vial	Procedure	HCPCS
J9017	Injection, arsenic trioxide, 1 mg	Procedure	HCPCS
J9019	Injection, asparaginase (Erwinaze), 1,000 IU	Procedure	HCPCS
J9020	Injection, asparaginase, not otherwise specified, 10,000 units	Procedure	HCPCS
J9025	Injection, azacitidine, 1 mg	Procedure	HCPCS
J9027	Injection, clofarabine, 1 mg	Procedure	HCPCS
J9033	Injection, bendamustine HCl (Treanda), 1 mg	Procedure	HCPCS
J9034	Injection, bendamustine HCl (Bendeka), 1 mg	Procedure	HCPCS
J9035	Injection, bevacizumab, 10 mg	Procedure	HCPCS
J9036	Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
J9041	Injection, bortezomib (Velcade), 0.1 mg	Procedure	HCPCS
J9042	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
J9043	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
J9045	Injection, carboplatin, 50 mg	Procedure	HCPCS
J9047	Injection, carfilzomib, 1 mg	Procedure	HCPCS
J9050	Injection, carmustine, 100 mg	Procedure	HCPCS
J9055	Injection, cetuximab, 10 mg	Procedure	HCPCS
J9057	Injection, copanlisib, 1 mg	Procedure	HCPCS
J9060	Injection, cisplatin, powder or solution, 10 mg	Procedure	HCPCS
J9062	Cisplatin, 50 mg	Procedure	HCPCS
J9065	Injection, cladribine, per 1 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS
J9098	Injection, cytarabine liposome, 10 mg	Procedure	HCPCS
J9100	Cytarabine, 100 mg	Procedure	HCPCS
J9110	Injection, cytarabine, 500 mg	Procedure	HCPCS
J9118	Injection, calaspargase pegol-mknl, 10 units	Procedure	HCPCS
J9120	Injection, dactinomycin, 0.5 mg	Procedure	HCPCS
J9130	Dacarbazine, 100 mg	Procedure	HCPCS
J9140	Dacarbazine, 200 mg	Procedure	HCPCS
J9150	Injection, daunorubicin, 10 mg	Procedure	HCPCS
J9151	Injection, daunorubicin citrate, liposomal formulation, 10 mg	Procedure	HCPCS
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
J9160	Injection, denileukin diftitox, 300 mcg	Procedure	HCPCS
J9170	Injection, docetaxel, 20 mg	Procedure	HCPCS
J9171	Injection, docetaxel, 1 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9178	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
J9179	Injection, eribulin mesylate, 0.1 mg	Procedure	HCPCS
J9180	Epirubicin HCl, 50 mg	Procedure	HCPCS
J9181	Injection, etoposide, 10 mg	Procedure	HCPCS
J9182	Etoposide, 100 mg	Procedure	HCPCS
J9185	Injection, fludarabine phosphate, 50 mg	Procedure	HCPCS
J9190	Injection, fluorouracil, 500 mg	Procedure	HCPCS
J9200	Floxuridine, 500 mg	Procedure	HCPCS
J9201	Injection, gemcitabine HCl, not otherwise specified, 200 mg	Procedure	HCPCS
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9205	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
J9206	Injection, irinotecan, 20 mg	Procedure	HCPCS
J9207	Injection, ixabepilone, 1 mg	Procedure	HCPCS
J9208	Injection, ifosfamide, 1 g	Procedure	HCPCS

J9211	Idarubicin HCl, 5 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9229	Injection, inotuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9230	Injection, mechlorethamine HCl, (nitrogen mustard), 10 mg	Procedure	HCPCS
J9245	Injection, melphalan hydrochloride, not otherwise specified, 50 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
J9261	Injection, nelarabine, 50 mg	Procedure	HCPCS
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
J9263	Injection, oxaliplatin, 0.5 mg	Procedure	HCPCS
J9264	Injection, paclitaxel protein-bound particles, 1 mg	Procedure	HCPCS
J9265	Injection, paclitaxel, 30 mg	Procedure	HCPCS
J9266	Injection, pegaspargase, per single dose vial	Procedure	HCPCS
J9267	Injection, paclitaxel, 1 mg	Procedure	HCPCS
J9268	Pentostatin, per 10 mg	Procedure	HCPCS
J9269	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
J9270	Plicamycin, 2.5 mg	Procedure	HCPCS
J9280	Mitomycin, 5 mg	Procedure	HCPCS
J9290	Mitomycin, 20 mg	Procedure	HCPCS
J9291	Mitomycin, 40 mg	Procedure	HCPCS
J9293	Injection, mitoxantrone HCl, per 5 mg	Procedure	HCPCS
J9300	Injection, gemtuzumab ozogamicin, 5 mg	Procedure	HCPCS
J9301	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
J9302	Injection, ofatumumab, 10 mg	Procedure	HCPCS
J9303	Injection, panitumumab, 10 mg	Procedure	HCPCS
J9305	Injection, pemetrexed, NOS, 10 mg	Procedure	HCPCS
J9306	Injection, pertuzumab, 1 mg	Procedure	HCPCS
J9307	Injection, pralatrexate, 1 mg	Procedure	HCPCS
J9310	Injection, rituximab, 100 mg	Procedure	HCPCS
J9311	Injection, rituximab 10 mg and hyaluronidase	Procedure	HCPCS
J9312	Injection, rituximab, 10 mg	Procedure	HCPCS
J9315	Injection, romidepsin, 1 mg	Procedure	HCPCS
J9320	Streptozocin, 1 g	Procedure	HCPCS
J9328	Injection, temozolomide, 1 mg	Procedure	HCPCS
J9330	Injection, temsirolimus, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J9340	Thiotepa, 15 mg	Procedure	HCPCS
J9350	Injection, topotecan, 4 mg	Procedure	HCPCS
J9351	Injection, topotecan, 0.1 mg	Procedure	HCPCS
J9355	Injection, trastuzumab, 10 mg	Procedure	HCPCS
J9356	Injection, trastuzumab, 10 mg and hyaluronidase-oysk	Procedure	HCPCS
J9360	Injection, vinblastine sulfate, 1 mg	Procedure	HCPCS
J9370	Vincristine sulfate, 1 mg	Procedure	HCPCS
J9371	Injection, vincristine sulfate liposome, 1 mg	Procedure	HCPCS
J9375	Vincristine sulfate, 2 mg	Procedure	HCPCS
J9380	Vincristine sulfate, 5 mg	Procedure	HCPCS
J9390	Vinorelbine tartrate, per 10 mg	Procedure	HCPCS
J9999	Not otherwise classified, antineoplastic drugs	Procedure	HCPCS
Q2025	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
Q2043	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
Q2048	Injection, doxorubicin hydrochloride, liposomal, DOXIL, 10 mg	Procedure	HCPCS
Q2049	Injection, doxorubicin HCl, liposomal, imported Lipodox, 10 mg	Procedure	HCPCS
Q2050	Injection, doxorubicin HCl, liposomal, not otherwise specified, 10 mg	Procedure	HCPCS
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Procedure	HCPCS
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Procedure	HCPCS
Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Procedure	HCPCS
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Procedure	HCPCS
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	Procedure	HCPCS
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg	Procedure	HCPCS
Q9979	Injection, Alemtuzumab, 1 mg	Procedure	HCPCS
S0087	Injection, alemtuzumab, 30 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS
S0108	Mercaptopurine, oral, 50 mg	Procedure	HCPCS
S0115	Bortezomib, 3.5 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S0116	Bevacizumab, 100 mg	Procedure	HCPCS
S0168	Injection, azacitidine, 100 mg	Procedure	HCPCS
S0172	Chlorambucil, oral, 2 mg	Procedure	HCPCS
S0176	Hydroxyurea, oral, 500 mg	Procedure	HCPCS
S0178	Lomustine, oral, 10 mg	Procedure	HCPCS
S0182	Procarbazine HCl, oral, 50 mg	Procedure	HCPCS
T80.810	Extravasation of vesicant antineoplastic chemotherapy	Diagnosis	ICD-10-CM
T80.810A	Extravasation of vesicant antineoplastic chemotherapy, initial encounter	Diagnosis	ICD-10-CM
T80.810D	Extravasation of vesicant antineoplastic chemotherapy, subsequent encounter	Diagnosis	ICD-10-CM
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW033B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW033S5	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW04351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW043B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043S5	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXR5	Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXT5	Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
Z51.1	Encounter for antineoplastic chemotherapy and immunotherapy	Diagnosis	ICD-10-CM
Z51.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-10-CM
Z51.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-10-CM
Immunosuppressant Therapeutic Agents			
3E030WL	Introduction of Immunosuppressive into Peripheral Vein, Open	Procedure	ICD-10-PCS
3E033WL	Introduction of Immunosuppressive into Peripheral Vein, Percutaneous	Procedure	ICD-10-PCS
3E040WL	Introduction of Immunosuppressive into Central Vein, Open	Procedure	ICD-10-PCS
3E043WL	Introduction of Immunosuppressive into Central Vein, Percutaneous	Procedure	ICD-10-PCS
3E050WL	Introduction of Immunosuppressive into Peripheral Artery, Open	Procedure	ICD-10-PCS
3E053WL	Introduction of Immunosuppressive into Peripheral Artery, Percutaneous	Procedure	ICD-10-PCS
3E060WL	Introduction of Immunosuppressive into Central Artery, Open	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E063WL	Introduction of Immunosuppressive into Central Artery, Percutaneous	Procedure	ICD-10-PCS
4153F	Combination peginterferon and ribavirin therapy prescribed (HEP-C)	Procedure	CPT-2
90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each	Procedure	CPT-4
C9006	Injection, tacrolimus, per 5 mg (1 amp)	Procedure	HCPCS
C9020	Sirolimus tablet, 1 mg	Procedure	HCPCS
C9029	Injection, guselkumab, 1 mg	Procedure	HCPCS
C9042	Injection, bendamustine HCl (Belrapzo), 1 mg	Procedure	HCPCS
C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
C9106	Sirolimus, per 1 mg/ml	Procedure	HCPCS
C9126	Injection natalizumab per 5 mg	Procedure	HCPCS
C9211	Injection, alefacept, for intravenous use, per 7.5 mg	Procedure	HCPCS
C9212	Injection, alefacept, for intramuscular use, per 7.5 mg	Procedure	HCPCS
C9230	Injection, abatacept, per 10 mg	Procedure	HCPCS
C9236	Injection, eculizumab, 10 mg	Procedure	HCPCS
C9249	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
C9261	Injection, ustekinumab, 1 mg	Procedure	HCPCS
C9264	Injection, tocilizumab, 1 mg	Procedure	HCPCS
C9286	Injection, belatacept, 1 mg	Procedure	HCPCS
C9436	Azathioprine, parenteral, brand name, per 100 mg	Procedure	HCPCS
C9438	Cyclosporine, oral, 100 mg, brand name	Procedure	HCPCS
C9487	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
J0129	Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J0135	Injection, adalimumab, 20 mg	Procedure	HCPCS
J0215	Injection, alefacept, 0.5 mg	Procedure	HCPCS
J0480	Injection, basiliximab, 20 mg	Procedure	HCPCS
J0485	Injection, belatacept, 1 mg	Procedure	HCPCS
J0490	Injection, belimumab, 10 mg	Procedure	HCPCS
J0593	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS

J0638	Injection, canakinumab, 1 mg	Procedure	HCPCS
J0717	Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J0718	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
J0897	Injection, denosumab, 1 mg	Procedure	HCPCS
J1300	Injection, eculizumab, 10 mg	Procedure	HCPCS
J1303	Injection, ravulizumab-cwvz, 10 mg	Procedure	HCPCS
J1438	Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J1595	Injection, glatiramer acetate, 20 mg	Procedure	HCPCS
J1600	Injection, gold sodium thiomalate, up to 50 mg	Procedure	HCPCS
J1602	Injection, golimumab, 1 mg, for intravenous use	Procedure	HCPCS
J1628	Injection, guselkumab, 1 mg	Procedure	HCPCS
J1745	Injection, infliximab, excludes biosimilar, 10 mg	Procedure	HCPCS
J1825	Injection, interferon beta-1a, 33 mcg	Procedure	HCPCS
J1826	Injection, interferon beta-1a, 30 mcg	Procedure	HCPCS
J1830	Injection interferon beta-1b, 0.25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J2323	Injection, natalizumab, 1 mg	Procedure	HCPCS
J2350	Injection, ocrelizumab, 1 mg	Procedure	HCPCS
J2504	Injection, pegademase bovine, 25 IU	Procedure	HCPCS
J2793	Injection, rilonacept, 1 mg	Procedure	HCPCS
J2860	Injection, siltuximab, 10 mg	Procedure	HCPCS
J2910	Injection, aurothioglucose, up to 50 mg	Procedure	HCPCS
J3031	Injection, fremanezumab-vfrm, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J3111	Injection, romosozumab-aqqg, 1 mg	Procedure	HCPCS
J3245	Injection, tildrakizumab, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J3262	Injection, tocilizumab, 1 mg	Procedure	HCPCS
J3357	Ustekinumab, for subcutaneous injection, 1 mg	Procedure	HCPCS
J3358	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
J3380	Injection, vedolizumab, 1 mg	Procedure	HCPCS
J7500	Azathioprine, oral, 50 mg	Procedure	HCPCS
J7501	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
J7502	Cyclosporine, oral, 100 mg	Procedure	HCPCS
J7503	Tacrolimus, extended release, (Envarsus XR), oral, 0.25 mg	Procedure	HCPCS
J7505	Muromonab-CD3, parenteral, 5 mg	Procedure	HCPCS
J7507	Tacrolimus, oral, per 1 mg	Procedure	HCPCS
J7508	Tacrolimus, extended release, (Astagraf XL), oral, 0.1 mg	Procedure	HCPCS
J7513	Daclizumab, parenteral, 25 mg	Procedure	HCPCS
J7515	Cyclosporine, oral, 25 mg	Procedure	HCPCS
J7516	Cyclosporine, parenteral, 250 mg	Procedure	HCPCS
J7517	Mycophenolate mofetil, oral, 250 mg	Procedure	HCPCS
J7520	Sirolimus, oral, 1 mg	Procedure	HCPCS
J7525	Tacrolimus, parenteral, 5 mg	Procedure	HCPCS
J7599	Immunosuppressive drug, not otherwise classified	Procedure	HCPCS
J9119	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
J9204	Injection, mogamulizumab-kpkc, 1 mg	Procedure	HCPCS
J9210	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
J9212	Injection, interferon alfacon-1, recombinant, 1 mcg	Procedure	HCPCS
J9213	Injection, interferon, alfa-2a, recombinant, 3 million units	Procedure	HCPCS
J9214	Injection, interferon, alfa-2b, recombinant, 1 million units	Procedure	HCPCS
J9215	Injection, interferon, alfa-N3, (human leukocyte derived), 250,000 IU	Procedure	HCPCS
J9216	Injection, interferon, gamma 1-b, 3 million units	Procedure	HCPCS
J9271	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
K0119	Azathioprine, oral, tab, 50 mg	Procedure	HCPCS
K0120	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
K0122	Cyclosporine, parenteral, 250 mg	Procedure	HCPCS
K0412	Mycophenolate mofetil, oral, 250 mg (CellCept)	Procedure	HCPCS
Q2010	Injection, glatiramer acetate, per dose	Procedure	HCPCS
Q2012	Injection, pegademase bovine, 25 IU	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Q2019	Injection, basiliximab, 20 mg	Procedure	HCPCS
Q2044	Injection, belimumab, 10 mg	Procedure	HCPCS
Q3025	Injection, interferon beta-1a, 11 mcg for intramuscular use	Procedure	HCPCS
Q3026	Injection, interferon beta-1a, 11 mcg for subcutaneous use	Procedure	HCPCS
Q3027	Injection, interferon beta-1a, 1 mcg for intramuscular use	Procedure	HCPCS
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use	Procedure	HCPCS
Q4079	Injection, natalizumab, 1 mg	Procedure	HCPCS
Q5102	Injection, infliximab, biosimilar, 10 mg	Procedure	HCPCS
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg	Procedure	HCPCS
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg	Procedure	HCPCS
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg	Procedure	HCPCS
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg	Procedure	HCPCS
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Procedure	HCPCS
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Procedure	HCPCS
Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Procedure	HCPCS
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Procedure	HCPCS
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	Procedure	HCPCS
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg	Procedure	HCPCS
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg	Procedure	HCPCS
Q5119	Injection, rituximab-pvvr, biosimilar, (RUXIENCE), 10 mg	Procedure	HCPCS
Q5121	Injection, infliximab-axxq, biosimilar, (AVSOLA), 10 mg	Procedure	HCPCS
Q9989	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
S0145	Injection, PEGylated interferon alfa-2A, 180 mcg per ml	Procedure	HCPCS
S0146	Injection, pegylated interferon alfa-2b, 10 mcg per 0.5 ml	Procedure	HCPCS
S0148	Injection, PEGylated interferon alfa-2B, 10 mcg	Procedure	HCPCS
S0162	Injection, efalizumab, 125 mg	Procedure	HCPCS
S0193	Injection alefacept, 7.5 mg (includes dose packaging)	Procedure	HCPCS
Steroid/Corticosteroid Diagnoses and Procedures and Dispensi			
J7509	Methylprednisolone, oral, per 4 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J7510	Prednisolone, oral, per 5 mg	Procedure	HCPCS
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	Procedure	HCPCS
J8540	Dexamethasone, oral, 0.25 mg	Procedure	HCPCS
Z79.52	Long term (current) use of systemic steroids	Diagnosis	ICD-10-CM
Z92.241	Personal history of systemic steroid therapy	Diagnosis	ICD-10-CM
Organ Transplant Diagnoses and Procedures			
02Y	Heart and Great Vessels, Transplantation	Procedure	ICD-10-PCS
02YA	Transplantation / Heart	Procedure	ICD-10-PCS
02YA0Z0	Transplantation of Heart, Allogeneic, Open Approach	Procedure	ICD-10-PCS
02YA0Z1	Transplantation of Heart, Syngeneic, Open Approach	Procedure	ICD-10-PCS
02YA0Z2	Transplantation of Heart, Zooplastic, Open Approach	Procedure	ICD-10-PCS
07Y	Lymphatic and Hemic Systems, Transplantation	Procedure	ICD-10-PCS
07YP	Transplantation / Spleen	Procedure	ICD-10-PCS
07YP0Z0	Transplantation of Spleen, Allogeneic, Open Approach	Procedure	ICD-10-PCS
07YP0Z1	Transplantation of Spleen, Syngeneic, Open Approach	Procedure	ICD-10-PCS
07YP0Z2	Transplantation of Spleen, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BY	Respiratory System, Transplantation	Procedure	ICD-10-PCS
0BYC	Transplantation / Upper Lung Lobe, Right	Procedure	ICD-10-PCS
0BYC0Z0	Transplantation of Right Upper Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYC0Z1	Transplantation of Right Upper Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYC0Z2	Transplantation of Right Upper Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYD	Transplantation / Middle Lung Lobe, Right	Procedure	ICD-10-PCS
0BYD0Z0	Transplantation of Right Middle Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYD0Z1	Transplantation of Right Middle Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYD0Z2	Transplantation of Right Middle Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYF	Transplantation / Lower Lung Lobe, Right	Procedure	ICD-10-PCS
0BYF0Z0	Transplantation of Right Lower Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYF0Z1	Transplantation of Right Lower Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0BYF0Z2	Transplantation of Right Lower Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYG	Transplantation / Upper Lung Lobe, Left	Procedure	ICD-10-PCS
0BYG0Z0	Transplantation of Left Upper Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYG0Z1	Transplantation of Left Upper Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYG0Z2	Transplantation of Left Upper Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYH	Transplantation / Lung Lingula	Procedure	ICD-10-PCS
0BYH0Z0	Transplantation of Lung Lingula, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYH0Z1	Transplantation of Lung Lingula, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYH0Z2	Transplantation of Lung Lingula, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYJ	Transplantation / Lower Lung Lobe, Left	Procedure	ICD-10-PCS
0BYJ0Z0	Transplantation of Left Lower Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYJ0Z1	Transplantation of Left Lower Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYJ0Z2	Transplantation of Left Lower Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYK	Transplantation / Lung, Right	Procedure	ICD-10-PCS
0BYK0Z0	Transplantation of Right Lung, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYK0Z1	Transplantation of Right Lung, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYK0Z2	Transplantation of Right Lung, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYL	Transplantation / Lung, Left	Procedure	ICD-10-PCS
0BYL0Z0	Transplantation of Left Lung, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYL0Z1	Transplantation of Left Lung, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYL0Z2	Transplantation of Left Lung, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYM	Transplantation / Lungs, Bilateral	Procedure	ICD-10-PCS
0BYM0Z0	Transplantation of Bilateral Lungs, Allogeneic, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0BYM0Z1	Transplantation of Bilateral Lungs, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYM0Z2	Transplantation of Bilateral Lungs, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DY	Gastrointestinal System, Transplantation	Procedure	ICD-10-PCS
0DY5	Transplantation / Esophagus	Procedure	ICD-10-PCS
0DY50Z0	Transplantation of Esophagus, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DY50Z1	Transplantation of Esophagus, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0DY50Z2	Transplantation of Esophagus, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DY6	Transplantation / Stomach	Procedure	ICD-10-PCS
0DY60Z0	Transplantation of Stomach, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DY60Z1	Transplantation of Stomach, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0DY60Z2	Transplantation of Stomach, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DY8	Transplantation / Small Intestine	Procedure	ICD-10-PCS
0DY80Z0	Transplantation of Small Intestine, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DY80Z1	Transplantation of Small Intestine, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0DY80Z2	Transplantation of Small Intestine, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DYE	Transplantation / Large Intestine	Procedure	ICD-10-PCS
0DYE0Z0	Transplantation of Large Intestine, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DYE0Z1	Transplantation of Large Intestine, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0DYE0Z2	Transplantation of Large Intestine, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0FY	Hepatobiliary System and Pancreas, Transplantation	Procedure	ICD-10-PCS
0FY0	Transplantation / Liver	Procedure	ICD-10-PCS
0FY00Z0	Transplantation of Liver, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0FY00Z1	Transplantation of Liver, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0FY00Z2	Transplantation of Liver, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0FYG	Transplantation / Pancreas	Procedure	ICD-10-PCS
0FYG0Z0	Transplantation of Pancreas, Allogeneic, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0FYG0Z1	Transplantation of Pancreas, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0FYG0Z2	Transplantation of Pancreas, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0TY	Urinary System, Transplantation	Procedure	ICD-10-PCS
0TY0	Transplantation / Kidney, Right	Procedure	ICD-10-PCS
0TY00Z0	Transplantation of Right Kidney, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0TY00Z1	Transplantation of Right Kidney, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0TY00Z2	Transplantation of Right Kidney, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0TY1	Transplantation / Kidney, Left	Procedure	ICD-10-PCS
0TY10Z0	Transplantation of Left Kidney, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0TY10Z1	Transplantation of Left Kidney, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0TY10Z2	Transplantation of Left Kidney, Zooplastic, Open Approach	Procedure	ICD-10-PCS
30230AZ	Transfusion of Embryonic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G1	Transfusion of Nonautologous Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G2	Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G3	Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G4	Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30230Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30233AZ	Transfusion of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G1	Transfusion of Nonautologous Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G2	Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G3	Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G4	Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30240AZ	Transfusion of Embryonic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240G1	Transfusion of Nonautologous Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30240G2	Transfusion of Allogeneic Related Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240G3	Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240G4	Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y0	Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30243AZ	Transfusion of Embryonic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243G1	Transfusion of Nonautologous Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243G2	Transfusion of Allogeneic Related Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243G3	Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243G4	Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30243X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30250G1	Transfusion of Nonautologous Bone Marrow into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
30250X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
30250Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
30253G1	Transfusion of Nonautologous Bone Marrow into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30253X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30253Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30260G1	Transfusion of Nonautologous Bone Marrow into Central Artery, Open Approach	Procedure	ICD-10-PCS
30260X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Artery, Open Approach	Procedure	ICD-10-PCS
30260Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Artery, Open Approach	Procedure	ICD-10-PCS
30263G1	Transfusion of Nonautologous Bone Marrow into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30263X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30263Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
32851	Lung transplant, single; without cardiopulmonary bypass	Procedure	CPT-4
32852	Lung transplant, single; with cardiopulmonary bypass	Procedure	CPT-4
32853	Lung transplant, double (bilateral sequential or en bloc); without cardiopulmonary bypass	Procedure	CPT-4
32854	Lung transplant, double (bilateral sequential or en bloc); with cardiopulmonary bypass	Procedure	CPT-4
33935	Heart-lung transplant with recipient cardiectomy-pneumonectomy	Procedure	CPT-4
33945	Heart transplant, with or without recipient cardiectomy	Procedure	CPT-4
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor	Procedure	CPT-4
38242	Allogeneic lymphocyte infusions	Procedure	CPT-4
38243	Hematopoietic progenitor cell (HPC); HPC boost	Procedure	CPT-4
44135	Intestinal allotransplantation; from cadaver donor	Procedure	CPT-4
44136	Intestinal allotransplantation; from living donor	Procedure	CPT-4
47135	Liver allotransplantation, orthotopic, partial or whole, from cadaver or living donor, any age	Procedure	CPT-4
47136	Liver allotransplantation; heterotopic, partial or whole, from cadaver or living donor, any age	Procedure	CPT-4
48554	Transplantation of pancreatic allograft	Procedure	CPT-4
50360	Renal allotransplantation, implantation of graft; excluding donor and recipient nephrectomy	Procedure	CPT-4
50365	Renal allotransplantation, implantation of graft; with recipient nephrectomy	Procedure	CPT-4
50366	Renal Homotransplantation, Implantation Of Graft	Procedure	CPT-4
50370	Removal of transplanted renal allograft	Procedure	CPT-4
BT29	Computerized Tomography (CT Scan) / Kidney Transplant	Procedure	ICD-10-PCS
BT2900Z	Computerized Tomography (CT Scan) of Kidney Transplant using High Osmolar Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT290ZZ	Computerized Tomography (CT Scan) of Kidney Transplant using High Osmolar Contrast	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

BT2910Z	Computerized Tomography (CT Scan) of Kidney Transplant using Low Osmolar Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT291ZZ	Computerized Tomography (CT Scan) of Kidney Transplant using Low Osmolar Contrast	Procedure	ICD-10-PCS
BT29Y0Z	Computerized Tomography (CT Scan) of Kidney Transplant using Other Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT29YZZ	Computerized Tomography (CT Scan) of Kidney Transplant using Other Contrast	Procedure	ICD-10-PCS
BT29ZZZ	Computerized Tomography (CT Scan) of Kidney Transplant	Procedure	ICD-10-PCS
BT39	Magnetic Resonance Imaging (MRI) / Kidney Transplant	Procedure	ICD-10-PCS
BT39Y0Z	Magnetic Resonance Imaging (MRI) of Kidney Transplant using Other Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT39YZZ	Magnetic Resonance Imaging (MRI) of Kidney Transplant using Other Contrast	Procedure	ICD-10-PCS
BT39ZZZ	Magnetic Resonance Imaging (MRI) of Kidney Transplant	Procedure	ICD-10-PCS
BT49	Ultrasonography / Kidney Transplant	Procedure	ICD-10-PCS
BT49ZZZ	Ultrasonography of Kidney Transplant	Procedure	ICD-10-PCS
D89.810	Acute graft-versus-host disease	Diagnosis	ICD-10-CM
D89.811	Chronic graft-versus-host disease	Diagnosis	ICD-10-CM
D89.812	Acute on chronic graft-versus-host disease	Diagnosis	ICD-10-CM
D89.813	Graft-versus-host disease, unspecified	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
S2053	Transplantation of small intestine and liver allografts	Procedure	HCPCS
S2054	Transplantation of multivisceral organs	Procedure	HCPCS
S2060	Lobar lung transplantation	Procedure	HCPCS
S2065	Simultaneous pancreas kidney transplantation	Procedure	HCPCS
S2142	Cord blood-derived stem-cell transplantation, allogeneic	Procedure	HCPCS
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition	Procedure	HCPCS
S2152	Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor(s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre- and posttransplant care in the global definition	Procedure	HCPCS
T86.00	Unspecified complication of bone marrow transplant	Diagnosis	ICD-10-CM
T86.01	Bone marrow transplant rejection	Diagnosis	ICD-10-CM
T86.02	Bone marrow transplant failure	Diagnosis	ICD-10-CM
T86.03	Bone marrow transplant infection	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

T86.09	Other complications of bone marrow transplant	Diagnosis	ICD-10-CM
T86.10	Unspecified complication of kidney transplant	Diagnosis	ICD-10-CM
T86.11	Kidney transplant rejection	Diagnosis	ICD-10-CM
T86.12	Kidney transplant failure	Diagnosis	ICD-10-CM
T86.13	Kidney transplant infection	Diagnosis	ICD-10-CM
T86.19	Other complication of kidney transplant	Diagnosis	ICD-10-CM
T86.20	Unspecified complication of heart transplant	Diagnosis	ICD-10-CM
T86.21	Heart transplant rejection	Diagnosis	ICD-10-CM
T86.22	Heart transplant failure	Diagnosis	ICD-10-CM
T86.23	Heart transplant infection	Diagnosis	ICD-10-CM
T86.290	Cardiac allograft vasculopathy	Diagnosis	ICD-10-CM
T86.298	Other complications of heart transplant	Diagnosis	ICD-10-CM
T86.30	Unspecified complication of heart-lung transplant	Diagnosis	ICD-10-CM
T86.31	Heart-lung transplant rejection	Diagnosis	ICD-10-CM
T86.32	Heart-lung transplant failure	Diagnosis	ICD-10-CM
T86.33	Heart-lung transplant infection	Diagnosis	ICD-10-CM
T86.39	Other complications of heart-lung transplant	Diagnosis	ICD-10-CM
T86.40	Unspecified complication of liver transplant	Diagnosis	ICD-10-CM
T86.41	Liver transplant rejection	Diagnosis	ICD-10-CM
T86.42	Liver transplant failure	Diagnosis	ICD-10-CM
T86.43	Liver transplant infection	Diagnosis	ICD-10-CM
T86.49	Other complications of liver transplant	Diagnosis	ICD-10-CM
T86.810	Lung transplant rejection	Diagnosis	ICD-10-CM
T86.811	Lung transplant failure	Diagnosis	ICD-10-CM
T86.812	Lung transplant infection	Diagnosis	ICD-10-CM
T86.818	Other complications of lung transplant	Diagnosis	ICD-10-CM
T86.819	Unspecified complication of lung transplant	Diagnosis	ICD-10-CM
T86.850	Intestine transplant rejection	Diagnosis	ICD-10-CM
T86.851	Intestine transplant failure	Diagnosis	ICD-10-CM
T86.852	Intestine transplant infection	Diagnosis	ICD-10-CM
T86.858	Other complications of intestine transplant	Diagnosis	ICD-10-CM
T86.859	Unspecified complication of intestine transplant	Diagnosis	ICD-10-CM
T86.890	Other transplanted tissue rejection	Diagnosis	ICD-10-CM
T86.891	Other transplanted tissue failure	Diagnosis	ICD-10-CM
T86.892	Other transplanted tissue infection	Diagnosis	ICD-10-CM
T86.898	Other complications of other transplanted tissue	Diagnosis	ICD-10-CM
T86.899	Unspecified complication of other transplanted tissue	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

T86.90	Unspecified complication of unspecified transplanted organ and tissue	Diagnosis	ICD-10-CM
T86.91	Unspecified transplanted organ and tissue rejection	Diagnosis	ICD-10-CM
T86.92	Unspecified transplanted organ and tissue failure	Diagnosis	ICD-10-CM
T86.93	Unspecified transplanted organ and tissue infection	Diagnosis	ICD-10-CM
T86.99	Other complications of unspecified transplanted organ and tissue	Diagnosis	ICD-10-CM
Y83.0	Surgical operation with transplant of whole organ as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure	Diagnosis	ICD-10-CM
Z48.21	Encounter for aftercare following heart transplant	Diagnosis	ICD-10-CM
Z48.22	Encounter for aftercare following kidney transplant	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z48.24	Encounter for aftercare following lung transplant	Diagnosis	ICD-10-CM
Z48.280	Encounter for aftercare following heart-lung transplant	Diagnosis	ICD-10-CM
Z48.288	Encounter for aftercare following multiple organ transplant	Diagnosis	ICD-10-CM
Z48.290	Encounter for aftercare following bone marrow transplant	Diagnosis	ICD-10-CM
Z48.298	Encounter for aftercare following other organ transplant	Diagnosis	ICD-10-CM
Z94.0	Kidney transplant status	Diagnosis	ICD-10-CM
Z94.1	Heart transplant status	Diagnosis	ICD-10-CM
Z94.2	Lung transplant status	Diagnosis	ICD-10-CM
Z94.3	Heart and lungs transplant status	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Z94.81	Bone marrow transplant status	Diagnosis	ICD-10-CM
Z94.82	Intestine transplant status	Diagnosis	ICD-10-CM
Z94.83	Pancreas transplant status	Diagnosis	ICD-10-CM
Z94.84	Stem cells transplant status	Diagnosis	ICD-10-CM
Z94.89	Other transplanted organ and tissue status	Diagnosis	ICD-10-CM
Z94.9	Transplanted organ and tissue status, unspecified	Diagnosis	ICD-10-CM
	Hyperlipidemia		
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
	Rheumatoid Arthritis/Osteoarthritis		
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM

M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM

M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM

M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM

M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM

M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM

M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM

M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM

M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM

M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM

M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM

M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM

M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM

M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM

M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM

M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM

M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM

M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM

M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM

M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Acquired Hypothyroidism			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
	Glaucoma		
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM

H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
	Osteoporosis		
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
	Benign Prostatic Hyperplasia		
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
	Hip/Pelvic Fracture		
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.350A	Stress fracture, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.351A	Stress fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.352A	Stress fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.353A	Stress fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.359A	Stress fracture, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.451A	Pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.452A	Pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.453A	Pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.459A	Pathological fracture, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.550A	Pathological fracture in neoplastic disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M84.551A	Pathological fracture in neoplastic disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.552A	Pathological fracture in neoplastic disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.553A	Pathological fracture in neoplastic disease, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.559A	Pathological fracture in neoplastic disease, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.650A	Pathological fracture in other disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.651A	Pathological fracture in other disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.652A	Pathological fracture in other disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.653A	Pathological fracture in other disease, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.659A	Pathological fracture in other disease, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M97.01XA	Periprosthetic fracture around internal prosthetic right hip joint, initial encounter	Diagnosis	ICD-10-CM
M97.02XA	Periprosthetic fracture around internal prosthetic left hip joint, initial encounter	Diagnosis	ICD-10-CM
S32.301A	Unspecified fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.301B	Unspecified fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.302A	Unspecified fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.302B	Unspecified fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.309A	Unspecified fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.309B	Unspecified fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.311A	Displaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.311B	Displaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.312A	Displaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.312B	Displaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.313A	Displaced avulsion fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.313B	Displaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.314A	Nondisplaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.314B	Nondisplaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.315A	Nondisplaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.315B	Nondisplaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.316A	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.316B	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.391A	Other fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.391B	Other fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.392A	Other fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.392B	Other fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.399A	Other fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.399B	Other fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.401A	Unspecified fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.401B	Unspecified fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.402A	Unspecified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.402B	Unspecified fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.409A	Unspecified fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.409B	Unspecified fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.411A	Displaced fracture of anterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.411B	Displaced fracture of anterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.412A	Displaced fracture of anterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.412B	Displaced fracture of anterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.413A	Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.413B	Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.414A	Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.414B	Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.415A	Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.415B	Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.416A	Nondisplaced fracture of anterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.416B	Nondisplaced fracture of anterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.421A	Displaced fracture of posterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.421B	Displaced fracture of posterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.422A	Displaced fracture of posterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.422B	Displaced fracture of posterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.423A	Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.423B	Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.424A	Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.424B	Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.425A	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.425B	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.426A	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.426B	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.431A	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.431B	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.432A	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.432B	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.433A	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.433B	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.434A	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.434B	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.435A	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.435B	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.436A	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.436B	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.441A	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.441B	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.442A	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.442B	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.443A	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.443B	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.444A	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.444B	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.445A	Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.445B	Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.446A	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.446B	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.451A	Displaced transverse fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.451B	Displaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.452A	Displaced transverse fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.452B	Displaced transverse fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.453A	Displaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.453B	Displaced transverse fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.454A	Nondisplaced transverse fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.454B	Nondisplaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.455A	Nondisplaced transverse fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.455B	Nondisplaced transverse fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.456A	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.456B	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.461A	Displaced associated transverse-posterior fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.461B	Displaced associated transverse-posterior fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.462A	Displaced associated transverse-posterior fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

S32.462B	Displaced associated transverse-posterior fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.463A	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.463B	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.464A	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.464B	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.465A	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.465B	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.466A	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.466B	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.471A	Displaced fracture of medial wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.471B	Displaced fracture of medial wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.472A	Displaced fracture of medial wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.472B	Displaced fracture of medial wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.473A	Displaced fracture of medial wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.473B	Displaced fracture of medial wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.474A	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.474B	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.475A	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.475B	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.476A	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.476B	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.481A	Displaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.481B	Displaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.482A	Displaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.482B	Displaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.483A	Displaced dome fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.483B	Displaced dome fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.484A	Nondisplaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.484B	Nondisplaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.485A	Nondisplaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.485B	Nondisplaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.486A	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.486B	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.491A	Other specified fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

S32.491B	Other specified fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.492A	Other specified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.492B	Other specified fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.499A	Other specified fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.499B	Other specified fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.501A	Unspecified fracture of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.501B	Unspecified fracture of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.502A	Unspecified fracture of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.502B	Unspecified fracture of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.509A	Unspecified fracture of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.509B	Unspecified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.511A	Fracture of superior rim of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.511B	Fracture of superior rim of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.512A	Fracture of superior rim of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.512B	Fracture of superior rim of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.519A	Fracture of superior rim of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.519B	Fracture of superior rim of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.591A	Other specified fracture of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM

S32.591B	Other specified fracture of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.592A	Other specified fracture of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.592B	Other specified fracture of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.599A	Other specified fracture of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.599B	Other specified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.601A	Unspecified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.601B	Unspecified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.602A	Unspecified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.602B	Unspecified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.609A	Unspecified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.609B	Unspecified fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.611A	Displaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.611B	Displaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.612A	Displaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.612B	Displaced avulsion fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.613A	Displaced avulsion fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.613B	Displaced avulsion fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.614A	Nondisplaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.614B	Nondisplaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.615A	Nondisplaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.615B	Nondisplaced avulsion fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.616A	Nondisplaced avulsion fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.616B	Nondisplaced avulsion fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.691A	Other specified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.691B	Other specified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.692A	Other specified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.692B	Other specified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.699A	Other specified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.699B	Other specified fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.810A	Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.810B	Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.811A	Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.811B	Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.82XA	Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.82XB	Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.89XA	Fracture of other parts of pelvis, initial encounter for closed fracture	Diagnosis	ICD-10-CM

S32.89XB	Fracture of other parts of pelvis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.9XXA	Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.9XXB	Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S72.001A	Fracture of unspecified part of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.001B	Fracture of unspecified part of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.001C	Fracture of unspecified part of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.002A	Fracture of unspecified part of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.002B	Fracture of unspecified part of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.002C	Fracture of unspecified part of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.009A	Fracture of unspecified part of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.009B	Fracture of unspecified part of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.009C	Fracture of unspecified part of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.011A	Unspecified intracapsular fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.011B	Unspecified intracapsular fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.011C	Unspecified intracapsular fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.012A	Unspecified intracapsular fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.012B	Unspecified intracapsular fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.012C	Unspecified intracapsular fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.019A	Unspecified intracapsular fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.019B	Unspecified intracapsular fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.019C	Unspecified intracapsular fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.021A	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.021B	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.021C	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.022A	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.022B	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.022C	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.023A	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.023B	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.023C	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.024A	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.024B	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.024C	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.025A	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.025B	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.025C	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.026A	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.026B	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.026C	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.031A	Displaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.031B	Displaced midcervical fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.031C	Displaced midcervical fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.032A	Displaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.032B	Displaced midcervical fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.032C	Displaced midcervical fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.033A	Displaced midcervical fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.033B	Displaced midcervical fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.033C	Displaced midcervical fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.034A	Nondisplaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.034B	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.034C	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.035A	Nondisplaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.035B	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.035C	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.036A	Nondisplaced midcervical fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.036B	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.036C	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.041A	Displaced fracture of base of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.041B	Displaced fracture of base of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.041C	Displaced fracture of base of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.042A	Displaced fracture of base of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.042B	Displaced fracture of base of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.042C	Displaced fracture of base of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.043A	Displaced fracture of base of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.043B	Displaced fracture of base of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.043C	Displaced fracture of base of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.044A	Nondisplaced fracture of base of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.044B	Nondisplaced fracture of base of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.044C	Nondisplaced fracture of base of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.045A	Nondisplaced fracture of base of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.045B	Nondisplaced fracture of base of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.045C	Nondisplaced fracture of base of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.046A	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.046B	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.046C	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.051A	Unspecified fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.051B	Unspecified fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.051C	Unspecified fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.052A	Unspecified fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.052B	Unspecified fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.052C	Unspecified fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.059A	Unspecified fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.059B	Unspecified fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.059C	Unspecified fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.061A	Displaced articular fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.061B	Displaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.061C	Displaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.062A	Displaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.062B	Displaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.062C	Displaced articular fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.063A	Displaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.063B	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.063C	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.064A	Nondisplaced articular fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.064B	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.064C	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.065A	Nondisplaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.065B	Nondisplaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.065C	Nondisplaced articular fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

S72.066A	Nondisplaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.066B	Nondisplaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.066C	Nondisplaced articular fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.091A	Other fracture of head and neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.091B	Other fracture of head and neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.091C	Other fracture of head and neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.092A	Other fracture of head and neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.092B	Other fracture of head and neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.092C	Other fracture of head and neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.099A	Other fracture of head and neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.099B	Other fracture of head and neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.099C	Other fracture of head and neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.101A	Unspecified trochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.101B	Unspecified trochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.101C	Unspecified trochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.102A	Unspecified trochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.102B	Unspecified trochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

S72.102C	Unspecified trochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.109A	Unspecified trochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.109B	Unspecified trochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.109C	Unspecified trochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.111A	Displaced fracture of greater trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.111B	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.111C	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.112A	Displaced fracture of greater trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.112B	Displaced fracture of greater trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.112C	Displaced fracture of greater trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.113A	Displaced fracture of greater trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.113B	Displaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.113C	Displaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.114A	Nondisplaced fracture of greater trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.114B	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.114C	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.115A	Nondisplaced fracture of greater trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

S72.115B	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.115C	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.116A	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.116B	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.116C	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.121A	Displaced fracture of lesser trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.121B	Displaced fracture of lesser trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.121C	Displaced fracture of lesser trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.122A	Displaced fracture of lesser trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.122B	Displaced fracture of lesser trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.122C	Displaced fracture of lesser trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.123A	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.123B	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.123C	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.124A	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.124B	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

S72.124C	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.125A	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.125B	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.125C	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.126A	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.126B	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.126C	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.131A	Displaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.131B	Displaced apophyseal fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.131C	Displaced apophyseal fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.132A	Displaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.132B	Displaced apophyseal fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.132C	Displaced apophyseal fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.133A	Displaced apophyseal fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.133B	Displaced apophyseal fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.133C	Displaced apophyseal fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.134A	Nondisplaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.134B	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.134C	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.135A	Nondisplaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.135B	Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.135C	Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.136A	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.136B	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.136C	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.141A	Displaced intertrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.141B	Displaced intertrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.141C	Displaced intertrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.142A	Displaced intertrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.142B	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.142C	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.143A	Displaced intertrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.143B	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.143C	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.144A	Nondisplaced intertrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.144B	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.144C	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.145A	Nondisplaced intertrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.145B	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.145C	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.146A	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.146B	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.146C	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.21XA	Displaced subtrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.21XB	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.21XC	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.22XA	Displaced subtrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.22XB	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.22XC	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.23XA	Displaced subtrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.23XB	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.23XC	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.24XA	Nondisplaced subtrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.24XB	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.24XC	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.25XA	Nondisplaced subtrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.25XB	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.25XC	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.26XA	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.26XB	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.26XC	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S79.001A	Unspecified physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.002A	Unspecified physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.009A	Unspecified physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.011A	Salter-Harris Type I physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.012A	Salter-Harris Type I physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.019A	Salter-Harris Type I physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.091A	Other physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S79.092A	Other physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.099A	Other physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Cataract		
			10
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.031	Anterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.032	Anterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.033	Anterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.039	Anterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.091	Other age-related incipient cataract, right eye	Diagnosis	ICD-10-CM
H25.092	Other age-related incipient cataract, left eye	Diagnosis	ICD-10-CM
H25.093	Other age-related incipient cataract, bilateral	Diagnosis	ICD-10-CM
H25.099	Other age-related incipient cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.10	Age-related nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H25.11	Age-related nuclear cataract, right eye	Diagnosis	ICD-10-CM
H25.12	Age-related nuclear cataract, left eye	Diagnosis	ICD-10-CM
H25.13	Age-related nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H25.20	Age-related cataract, morgagnian type, unspecified eye	Diagnosis	ICD-10-CM
H25.21	Age-related cataract, morgagnian type, right eye	Diagnosis	ICD-10-CM
H25.22	Age-related cataract, morgagnian type, left eye	Diagnosis	ICD-10-CM
H25.23	Age-related cataract, morgagnian type, bilateral	Diagnosis	ICD-10-CM
H25.811	Combined forms of age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.812	Combined forms of age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.813	Combined forms of age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.819	Combined forms of age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.89	Other age-related cataract	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.001	Unspecified infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.002	Unspecified infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.003	Unspecified infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.009	Unspecified infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye	Diagnosis	ICD-10-CM
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye	Diagnosis	ICD-10-CM
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral	Diagnosis	ICD-10-CM
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.031	Infantile and juvenile nuclear cataract, right eye	Diagnosis	ICD-10-CM
H26.032	Infantile and juvenile nuclear cataract, left eye	Diagnosis	ICD-10-CM
H26.033	Infantile and juvenile nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H26.039	Infantile and juvenile nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM

H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.062	Combined forms of infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.063	Combined forms of infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.102	Unspecified traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.103	Unspecified traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.109	Unspecified traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, right eye	Diagnosis	ICD-10-CM
H26.112	Localized traumatic opacities, left eye	Diagnosis	ICD-10-CM
H26.113	Localized traumatic opacities, bilateral	Diagnosis	ICD-10-CM
H26.119	Localized traumatic opacities, unspecified eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.122	Partially resolved traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.123	Partially resolved traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.129	Partially resolved traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.132	Total traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.133	Total traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.139	Total traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H26.212	Cataract with neovascularization, left eye	Diagnosis	ICD-10-CM
H26.213	Cataract with neovascularization, bilateral	Diagnosis	ICD-10-CM
H26.219	Cataract with neovascularization, unspecified eye	Diagnosis	ICD-10-CM
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye	Diagnosis	ICD-10-CM
H26.222	Cataract secondary to ocular disorders (degenerative) (inflammatory), left eye	Diagnosis	ICD-10-CM
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral	Diagnosis	ICD-10-CM
H26.229	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified eye	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
H26.411	Soemmering's ring, right eye	Diagnosis	ICD-10-CM
H26.412	Soemmering's ring, left eye	Diagnosis	ICD-10-CM
H26.413	Soemmering's ring, bilateral	Diagnosis	ICD-10-CM
H26.419	Soemmering's ring, unspecified eye	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM
H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
Q12.0	Congenital cataract	Diagnosis	ICD-10-CM
	Parkinsons Disease and Secondary Parkinsonism		
G20	Parkinson's disease	Diagnosis	ICD-10-CM
G21.11	Neuroleptic induced parkinsonism	Diagnosis	ICD-10-CM
G21.19	Other drug induced secondary parkinsonism	Diagnosis	ICD-10-CM
G21.3	Postencephalitic parkinsonism	Diagnosis	ICD-10-CM
G21.4	Vascular parkinsonism	Diagnosis	ICD-10-CM
G21.8	Other secondary parkinsonism	Diagnosis	ICD-10-CM
G21.9	Secondary parkinsonism, unspecified	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
	COVID-19 Diagnosis		

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

B97.29	Other coronavirus as the cause of diseases classified elsewhere	Diagnosis	ICD-10-CM
U07.1	COVID-19	Diagnosis	ICD-10-CM
	Remdesivir		
XW033E5	Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043E5	Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
	Chloroquine		
J0390	Injection, chloroquine HCl, up to 250 mg	Procedure	HCPCS
	Azithromycin		
J0456	Injection, azithromycin, 500 mg	Procedure	HCPCS
Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 g	Procedure	HCPCS
	Dexamethasone		
J1094	Injection, dexamethasone acetate, 1 mg	Procedure	HCPCS
J1100	Injection, dexamethasone sodium phosphate, 1 mg	Procedure	HCPCS
J8540	Dexamethasone, oral, 0.25 mg	Procedure	HCPCS
S0173	Dexamethasone, oral, 4 mg	Procedure	HCPCS
	Other Corticosteroids		
C9469	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Procedure	HCPCS
G2112	Patient receiving <=5 mg daily prednisone (or equivalent), or RA activity is worsening, or glucocorticoid use is for less than 6 months	Procedure	HCPCS
G2113	Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity	Procedure	HCPCS
G9467	Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills within the last twelve months	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G9468	Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills	Procedure	HCPCS
G9469	Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 90 or greater consecutive days or a single prescription equating to 900 mg prednisone or greater for all fills	Procedure	HCPCS
G9470	Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills	Procedure	HCPCS
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	Procedure	HCPCS
J0704	Injection, betamethasone sodium phosphate, per 4 mg	Procedure	HCPCS
J1020	Injection, methylprednisolone acetate, 20 mg	Procedure	HCPCS
J1030	Injection, methylprednisolone acetate, 40 mg	Procedure	HCPCS
J1040	Injection, methylprednisolone acetate, 80 mg	Procedure	HCPCS
J1700	Injection, hydrocortisone acetate, up to 25 mg	Procedure	HCPCS
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg	Procedure	HCPCS
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	Procedure	HCPCS
J2650	Injection, prednisolone acetate, up to 1 ml	Procedure	HCPCS
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	Procedure	HCPCS
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	Procedure	HCPCS
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	Procedure	HCPCS
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	Procedure	HCPCS
J3302	Injection, triamcinolone diacetate, per 5 mg	Procedure	HCPCS
J3303	Injection, triamcinolone hexacetonide, per 5 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J3304	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Procedure	HCPCS
J7506	Prednisone, oral, per 5 mg	Procedure	HCPCS
J7509	Methylprednisolone, oral, per 4 mg	Procedure	HCPCS
J7510	Prednisolone, oral, per 5 mg	Procedure	HCPCS
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	Procedure	HCPCS
	Inhaled Corticosteroids		
J7622	Beclomethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
J7624	Bethamethasone, inhalation solution administered through DME, unit dose form, per mg	Procedure	HCPCS
J7626	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7627	Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7633	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS
J7634	Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS
J7637	Dexamethasone, inhalation solution, compounded product, administered through DME, concentrated form, per mg	Procedure	HCPCS
J7638	Dexamethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
J7641	Flunisolide, inhalation solution, compounded product, administered through DME, unit dose, per mg	Procedure	HCPCS
J7683	Triamcinolone, inhalation solution, compounded product, administered through DME, concentrated form, per mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J7684	Triamcinolone, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
K0527	Triamcinolone, inhalation solution administered through DME, concentrated form, per milligram	Procedure	HCPCS
K0528	Triamcinolone, inhalation solution administered through DME, unit dose form, per milligram	Procedure	HCPCS
	Baricitinib		
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
	Tocilizumab		
C9264	Injection, tocilizumab, 1 mg	Procedure	HCPCS
J3262	Injection, tocilizumab, 1 mg	Procedure	HCPCS
	Bamlanivimab		
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	Procedure	HCPCS
Q0239	Injection, bamlanivimab, 700 mg	Procedure	HCPCS
XW033F6	Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
XW043F6	Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
	Casirivimab/Imdevimab		
M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion and post administration monitoring, subsequent repeat doses	Procedure	HCPCS
M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M0243	intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	Procedure	HCPCS
M0244	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	Procedure	HCPCS
Q0240	Injection, casirivimab and imdevimab, 600 mg	Procedure	HCPCS
Q0243	Injection, casirivimab and imdevimab, 2400 mg	Procedure	HCPCS
Q0244	Injection, casirivimab and imdevimab, 1200 mg	Procedure	HCPCS
XW033G6	Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
XW043G6	Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
	Bamlanivimab/Etesevimab		
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	Procedure	HCPCS
M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	Procedure	HCPCS
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	Procedure	HCPCS
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
	Sotrovimab		
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence	Procedure	HCPCS
Q0247	Injection, sotrovimab, 500 mg	Procedure	HCPCS
	Antidepressants		
4064F	Antidepressant pharmacotherapy prescribed (MDD, MDD ADOL)	Procedure	CPT-2
C9055	Injection, brexanolone, 1 mg	Procedure	HCPCS
G8126	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase	Procedure	HCPCS
G8129	Patient documented as being treated with antidepressant medication for at least 6 months continuous treatment phase	Procedure	HCPCS
G9194	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase	Procedure	HCPCS
J1320	Injection, amitriptyline HCl, up to 20 mg	Procedure	HCPCS
J1632	Injection, brexanolone, 1 mg	Procedure	HCPCS
J3270	Injection, imipramine hcl, up to 25 mg	Procedure	HCPCS
S0106	Bupropion HCl sustained release tablet, 150 mg, per bottle of 60 tablets	Procedure	HCPCS

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Sickle Cell Disease	
crizanlizumab-tmca	Adakveo
voxelotor	Oxbryta
Cystic Fibrosis	
aztreonam lysine	Cayston
elexacaftor/tezacaftor/ivacaftor	Trikafta
ivacaftor	Kalydeco
lumacaftor/ivacaftor	Orkambi
mannitol	Bronchitol
tezacaftor/ivacaftor	Symdeko
tobramycin	Bethkis
tobramycin	Tobi Podhaler
tobramycin	tobramycin
tobramycin in 0.225 % sodium chloride	Tobi
tobramycin in 0.225 % sodium chloride	tobramycin in 0.225 % NaCl
tobramycin/nebulizer	Kitabis Pak
tobramycin/nebulizer	tobramycin with nebulizer
Obesity: Identified by Weight Management-Related Prescription	
amino acids/multivit-minerals/dietary supplement/protein sup	Optifast 70
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	Bontril PDM
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	Suprenza
phentermine HCl	phentermine

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
phentermine HCl/topiramate	Qsymia
resveratrol/chromium pico/green tea/EGCG/caffeine/digestive3	Resveratrol Diet
Smoking: Identified by Smoking-Related Prescriptions	
nicotine	NTS Step 1
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorelief
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline
Chemo Therapeutic Agents/ Prescription	
ABEMACICLIB	VERZENIO
ACALABRUTINIB	CALQUENCE
ADO-TRASTUZUMAB EMTANSINE	KADCYLA
AFATINIB DIMALEATE	GILOTRIF
ALDESLEUKIN	PROLEUKIN
ALECTINIB HCL	ALECENSA
ALEMTUZUMAB	CAMPATH
ALEMTUZUMAB	LEMTRADA
ALPELISIB	PIQRAY 200MG DAILY DOSE
ALPELISIB	PIQRAY 250MG DAILY DOSE
ALPELISIB	PIQRAY 300MG DAILY DOSE
ALTRETAMINE	HEXALEN
ARSENIC TRIOXIDE	ARSENIC TRIOXIDE
ARSENIC TRIOXIDE	TRISENOX
ASPARAGINASE	ELSPAR

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ASPARAGINASE ERWINIA CHRYSANTHEMI	ERWINAZE
ATEZOLIZUMAB	TECENTRIQ
AVAPRITINIB	AYVAKIT
AVELUMAB	BAVENCIO
AXICABTAGENE CILOLEUCEL	YESCARTA
AXITINIB	INLYTA
AZACITIDINE	AZACITIDINE
AZACITIDINE	ONUREG
AZACITIDINE	VIDAZA
BELANTAMAB MAFODOTIN/BLMF	BLENREP
BELINOSTAT	BELEODAQ
BENDAMUSTINE HCL	BELRAPZO
BENDAMUSTINE HCL	BENDAMUSTINE HYDROCHLORIDE
BENDAMUSTINE HCL	BENDEKA
BENDAMUSTINE HCL	TREANDA
BEVACIZUMAB	AVASTIN
BEVACIZUMAB/AWWB	MVASI
BEVACIZUMAB/BVZR	ZIRABEV
BEXAROTENE	BEXAROTENE
BEXAROTENE	TARGRETIN
BINIMETINIB	MEKTOVI
BLEOMYCIN SULF	BLEO 15K
BLEOMYCIN SULFATE	BLENOXANE
BLEOMYCIN SULFATE	BLEOMYCIN
BLEOMYCIN SULFATE	BLEOMYCIN SULFATE
BLINATUMOMAB	BLINCYTO
BORTEZOMIB	BORTEZOMIB
BORTEZOMIB	VELCADE
BOSUTINIB	BOSULIF
BRENTUXIMAB VEDOTIN	ADCETRIS
BREXUCABTAGENE AUTOLEUCEL	TECARTUS
BRIGATINIB	ALUNBRIG
BUSULFAN	BUSULFAN
BUSULFAN	BUSULFEX
BUSULFAN	MYLERAN
CABAZITAXEL	JEVTANA
CABOZANTINIB S-MALATE	CABOMETYX
CABOZANTINIB S-MALATE	COMETRIQ

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
CALASPARGASE PEGOL/MKNL	ASPARLAS
CAPECI	CAPECITABINE
CAPECITABINE	CAPECITABINE
CAPECITABINE	XELODA
CAPMATINIB HCL	TABRECTA
CARBOPLATIN	CARBOPLATIN
CARBOPLATIN	PARAPLATIN
CARFILZOMIB	KYPROLIS
CARMUSTINE	BICNU
CARMUSTINE	BICNU W/DILUENT ABSOLUTEETHANOL
CARMUSTINE	BiCNU
CARMUSTINE	CARMUSTINE
CARMUSTINE IN POLIFEPROSAN INTRACRANIAL IMPLANT WAFER	GLIADEL WAFER
CEMIPLIMAB-RWLC	LIBTAYO
CERITINIB	ZYKADIA
CETUXIMAB	ERBITUX
CHLORAMBUCIL	LEUKERAN
CISPLATIN	CISPLATIN
CISPLATIN	CISPLATIN AQ
CISPLATIN	PLATINOL AQ
CLADRIBINE	CLADRIBINE
CLADRIBINE	LEUSTATIN
CLOFARABINE	CLOFARABINE
CLOFARABINE	CLOLAR
COBIMETINIB FUMARATE	COTELLIC
COPANLISIB HCL	ALIQOPA
CRIZOTINIB	XALKORI
CYCLOPHOSPHAMIDE	CYCLOPHOSPHAMIDE
CYCLOPHOSPHAMIDE	CYTOXAN
CYCLOPHOSPHAMIDE	NEOSAR
CYTARABINE	CYTARABINE
CYTARABINE	CYTARABINEAQUEOUS
CYTARABINE	CYTOSAR-U
CYTARABINE	TARABINE PFS
CYTARABINE LIPOSOME	DEPOCYT
DABRAFENIB MESYLATE	TAFINLAR

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
DACARBAZINE	DACARBAZINE
DACARBAZINE	DTIC-DOME
DACOMITINIB	VIZIPDCO
DACTINOMYCIN	COSMEGEN
DACTINOMYCIN	DACTINOMYCIN
DARATUMUMAB	DARZALEX
DARATUMUMAB/HYALURONIDASE/FIHJ	DARZALEX FASPRO
DASATINIB	SPRYCEL
DAUNORUBICIN CITRATE LIPOSOME	DAUNOXOME
DAUNORUBICIN HCL	CERUBIDINE
DAUNORUBICIN HCL	DAUNORUBICIN HCL
DAUNORUBICIN HCL	DAUNORUBICIN HYDROCHLORIDE
DAUNORUBICIN-CYTARABINE LIPOSOME	VYXEOS
DECI	INQOVI
DECITABINE	DACOGEN
DECITABINE	DECITABINE
DENILEUKIN DIFTITOX	ONTAK
DINUTUXIMAB	UNITUXIN
DOCETAXEL	DOCEFREZ
DOCETAXEL	DOCETAXEL
DOCETAXEL	DOCETAXEL (NON- ALCOHOL FORMULA)
DOCETAXEL	DOCETAXEL (NON-ALCOHOL FORMULA)
DOCETAXEL	TAXOTERE
DOXORUBICIN HCL	ADRIAMYCIN
DOXORUBICIN HCL	ADRIAMYCIN PFS
DOXORUBICIN HCL	ADRIAMYCIN RDF
DOXORUBICIN HCL	DOXORUBICIN HCL
DOXORUBICIN HCL	DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HCL	RUBEX
DOXORUBICIN HCL	doxorubicin
DOXORUBICIN HCL LIPOSOMAL	DOXIL
DOXORUBICIN HCL LIPOSOMAL	DOXORUBICIN HCL LIPOSOME
DOXORUBICIN HCL LIPOSOMAL	DOXORUBICIN HYDROCHLORIDELIPOSOMAL
DOXORUBICIN HCL LIPOSOMAL	DOXORUBICIN HYDROCHLORIDELIPOSOME
DOXORUBICIN HCL LIPOSOMAL	LIPODOX
DOXORUBICIN HCL LIPOSOMAL	LIPODOX 50
DURVALUMAB	IMFINZI
DUVELISIB	COPIKTRA

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ELOTUZUMAB	EMPLICITI
ENASIDENIB MESYLATE	IDHIFA
ENCORAFENIB	BRAFTOVI
ENFORTUMAB VEDOTIN/EJFV	PADCEV
ENTRECTINIB	ROZLYTREK
EPIRUBICIN HCL	ELLENCE
EPIRUBICIN HCL	EPIRUBICIN HCL
EPIRUBICIN HCL	EPIRUBICIN HYDROCHLORIDE
ERDAFITINIB	BALVERSA
ERIBULIN MESYLATE	HALAVEN
ERLOTINIB	TARCEVA
ERLOTINIB HCL	ERLOTINIB HYDROCHLORIDE
ETOPOSIDE	ETOPOSIDE
ETOPOSIDE	TOPOSAR
ETOPOSIDE	VEPESID
ETOPOSIDE PHOSPHATE	ETOPOPHOS
EVEROLIMUS	AFINITOR
EVEROLIMUS	AFINITOR DISPERZ
EVEROLIMUS	EVEROLIMUS
FAM/TRASTUZUMAB DERUXTECAN/NXKI	ENHERTU
FEDRATINIB HCL	INREBIC
FLOXURIDINE	FLOXURIDINE
FLOXURIDINE	FUDR
FLUDARABINE PHOSPHATE	FLUDARA
FLUDARABINE PHOSPHATE	FLUDARABINE
FLUDARABINE PHOSPHATE	FLUDARABINE PHOSPHATE
FLUDARABINE PHOSPHATE	OFORTA
FLUOROURACIL	ADRUCIL
FLUOROURACIL	FLUOROURACIL
FOSTAMATINIB DISODIUM	TAVALISSE
GEFITINIB	IRESSA
GEMCITABINE HCL	GEMCITABINE
GEMCITABINE HCL	GEMCITABINE HCL
GEMCITABINE HCL	GEMCITABINE HYDROCHLORIDE
GEMCITABINE HCL	GEMZAR
GEMCITABINE HCL-NACL	INFUGEM
GEMTUZUMAB OZOGAMICIN	MYLOTARG
GILTERITINIB FUMARATE	XOSPATA

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
GLASDEGIB MALEATE	DAURISMO
GLUCARPIDASE	VORAXAZE
HYDROXYUREA	HYDREA
HYDROXYUREA	HYDROXYUREA
HYDROXYUREA	MYLOCEL
IBRITUMOMAB TIUXETAN FOR INDIUM-111 (IN-111)	ZEVALIN IN-111
IBRITUMOMAB TIUXETAN FOR YTTRIUM/90 (Y/90)	ZEVALIN Y-90
IBRUTINIB	IMBRUVICA
IDARUBICIN HCL	IDAMYCIN PFS
IDARUBICIN HCL	IDARUBICIN
IDARUBICIN HCL	IDARUBICIN HCL
IDARUBICIN HCL	IDARUBICIN HYDROCHLORIDE
IDELALISIB	ZYDELIG
IFOSFAMIDE	IFEX
IFOSFAMIDE	IFOSFAMIDE
IFOSFAMIDE/MESNA	IFEX/MESNEX COMBO PACK
IFOSFAMIDE/MESNA	IFOSFAMIDE/MESNA
IMATINIB MESYLATE	GLEEVEC
IMATINIB MESYLATE	IMATINIB MESYLATE
INOTUZUMAB OZOGAMICIN	BESPONSA
INTERFERON ALFA-2A	ROFERON-A
INTERFERON ALFA-2B	INTRON A
INTERFERON ALFA-2B	INTRON-A
INTERFERON ALFA-2B	INTRON-A W/DILUENT
INTERFERON ALFA-N3	ALFERON N
INTERFERON GAMMA-1B	ACTIMMUNE
IPILIMUMAB	YERVOY
IRINOTECAN HCL	CAMPTOSAR
IRINOTECAN HCL	IRINOTECAN
IRINOTECAN HCL	IRINOTECAN HCL
IRINOTECAN HCL	IRINOTECAN HYDROCHLORIDE
IRINOTECAN HCL LIPOSOME	ONIVYDE
ISATUXIMAB/IRFC	SARCLISA
IVOSIDENIB	TIBSOVO
IXABEPILONE	IXEPDCA

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
IXABEPILONE	IXEPDCA KIT
IXAZOMIB CITRATE	NINLARO
LAPATINIB DITOSYLATE	LAPATINIB DITOSYLATE
LAPATINIB DITOSYLATE	TYKERB
LAROTRECTINIB SULFATE	VITRAKVI
LENVATINIB	LENVIMA 10MG DAILY DOSE
LENVATINIB	LENVIMA 12MG DAILY DOSE
LENVATINIB	LENVIMA 14MG DAILY DOSE
LENVATINIB	LENVIMA 18MG DAILY DOSE
LENVATINIB	LENVIMA 20MG DAILY DOSE
LENVATINIB	LENVIMA 24MG DAILY DOSE
LENVATINIB	LENVIMA 4 MG DAILY DOSE
LENVATINIB	LENVIMA 8MG DAILY DOSE
LISOCABTAGENE MARALEUCEL	BREYANZI
LOMUSTINE	CEENU
LOMUSTINE	GLEOSTINE
LOMUSTINE	LOMUSTINE
LORLATINIB	LORBRENA
LURBINECTEDIN	ZEPZELCA
MECHLORETHAMINE HCL	MUSTARGEN
MELPHALAN	ALKERAN
MELPHALAN	MELPHALAN
MELPHALAN HCL	ALKERAN
MELPHALAN HCL	EVOMELA
MELPHALAN HCL	MELPHALAN HCL
MELPHALAN HCL	MELPHALAN HYDROCHLORIDE
MERCAPTOPURINE	MERCAPTOPURINE
MERCAPTOPURINE	PURINETHOL
MERCAPTOPURINE	PURIXAN
METHOTREXATE	METHOTREXATE
METHOTREXATE	XATMEP
METHOTREXATE SODIUM	METHOTREXATE
METHOTREXATE SODIUM	METHOTREXATE SODIUM
METHOTREXATE SODIUM	METHOTREXATE SODIUM LPF
METHOTREXATE SODIUM	RHEUMATREX
METHOTREXATE SODIUM	TREXALL
METHOTREXATE SODIUM/PF	METHOTREXATE SODIUM (PF)
METHOTREXATE/PF	OTREXUP (PF)

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
METHOTREXATE/PF	RASUVO (PF)
MIDOSTAURIN	RYDAPT
MITOMYCIN	MITOMYCIN
MITOMYCIN	MUTAMYCIN
MITOXANTRONE	MITOXANTRONE HCL
MITOXANTRONE	NOVANTRONE
MOGAMULIZUMAB-KPKC	POTELIGEO
MOXETUMOMAB PASUDOTOX-TDFK	LUMOXITI
NAXITAMAB/GQGK	DANYELZA
NECITUMUMAB	PORTRAZZA
NELARABINE	ARRANON
NERATINIB MALEATE	NERLYNX
NILOTINIB	TASIGNA
NIRAPARIB TOSYLATE	ZEJULA
NIVOLUMAB	OPDIVO
OBINUTUZUMAB	GAZYVA
OFATUMUMAB	ARZERRA
OLAPARIB	LYNPARZA
OLARATUMAB	LARTRUVO
OMACETAXINE MEPESUCCINATE	SYNRIBO
OSIMERTINIB MESYLATE	TAGRISSO
OXALIPLATIN	ELOXATIN
OXALIPLATIN	OXALIPLATIN
PACLITAXEL	ABRAXANE
PACLITAXEL	ONXOL
PACLITAXEL	PACLITAXEL
PACLITAXEL	TAXOL
PALBOCICLIB	IBRANCE
PANITUMUMAB	VECTIBIX
PANOBINOSTAT LACTATE	FARYDAK
PAZOPANIB HCL	VOTRIENT
PEGASPARGASE	ONCASPAR
PEGINTERFERON ALFA-2B	SYLATRON
PEMBROLIZUMAB	KEYTRUDA
PEMETREXED DISODIUM	ALIMTA
PEMIGATINIB	PEMAZYRE
PENTOSTATIN	NIPENT
PENTOSTATIN	PENTOSTATIN

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
PERTUZUMAB	PERJETA
PERTUZUMAB/TRASTUZ/HYALURON/ZZXF	PHESGO
PEXIDARTINIB HCL	TURALIO
PLICAMYCIN	MITHRACIN
POLATUZUMAB VEDOTIN-PIIQ	POLIVY
POMALIDOMIDE	POMALYST
PONATINIB HCL	ICLUSIG
PRALATREXATE	FOLOTYN
PRALSETINIB	GAVRETO
PROCARBAZINE HCL	MATULANE
RAMUCIRUMAB	CYRAMZA
REGORAFENIB	STIVARGA
RIBOCICLIB SUCCINATE	KISQALI
RIBOCICLIB/LETROZOLE	KISQALI FEMARA 200 DOSE
RIBOCICLIB/LETROZOLE	KISQALI FEMARA 400 DOSE
RIBOCICLIB/LETROZOLE	KISQALI FEMARA 600 DOSE
RIPRETINIB	QINLOCK
RITUXIMAB	RITUXAN
RITUXIMAB-HYALURONIDASE HUMAN	RITUXAN HYCELA
RITUXIMAB/ABBS	TRUXIMA
RITUXIMAB/ARRX	RIABNI
RITUXIMAB/PVVR	RUXIENCE
ROMIDEPSIN	ISTODAX
ROMIDEPSIN	ISTODAX (OVERFILL)
ROMIDEPSIN	ROMIDEPSIN
RUCAPARIB CAMSYLATE	RUBRACA
RUXOLITINIB PHOSPHATE	JAKAFI
SACITUZUMAB GOVITECAN/HZIY	TRODELVY
SELINEXOR	XPOVIO 100 MG ONCE WEEKLY
SELINEXOR	XPOVIO 40 MG ONCE WEEKLY
SELINEXOR	XPOVIO 40 MG TWICE WEEKLY
SELINEXOR	XPOVIO 60 MG ONCE WEEKLY
SELINEXOR	XPOVIO 60 MG TWICE WEEKLY
SELINEXOR	XPOVIO 80 MG ONCE WEEKLY
SELINEXOR	XPOVIO 80 MG TWICE WEEKLY
SELPERCATINIB	RETEVMO
SELUMETINIB SULFATE	KOSELUGO
SIPULEUCEL-T	PROVENGE

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
SONIDEGIB PHOSPHATE	ODOMZO
SORAFENIB TOSYLATE	NEXAVAR
STREPTOZOCIN	ZANOSAR
SUNITINIB MALATE	SUTENT
TAFASITAMAB/CXIX	MONJUVI
TAGRAXOFUSP-ERZS	ELZONRIS
TALAZOPARIB TOSYLATE	TALZENNA
TALIMOGENE LAHERPAREPVEC	IMLYGIC
TAZEMETOSTAT HBR	TAZVERIK
TEMOZOLOMIDE	TEMODAR
TEMOZOLOMIDE	TEMOZOLOMIDE
TEMSIROLIMUS	TEMSIROLIMUS
TEMSIROLIMUS	TORISEL
TENIPOSIDE	TENIPOSIDE
TENIPOSIDE	VUMON
TEPOTINIB HCL	TEPMETKO
THIOGUANINE	TABLOID
THIOTEPA	TEPADINA
THIOTEPA	THIOPLEX
THIOTEPA	THIOTEPA
TISAGENLECLEUCEL-T	KYMRIAH
TOPOTECAN HCL	HYCAMTIN
TOPOTECAN HCL	TOPOTECAN HCL
TOPOTECAN HCL	TOPOTECAN HYDROCHLORIDE
TOPOTECAN HCL	TOPOTECAN HYDROCLORIDE
TOSITUMOMAB	BEXXAR
TRABECTEDIN	YONDELIS
TRAMETINIB DIMETHYL SULFOXIDE	MEKINIST
TRASTUZUMAB	HERCEPTIN
TRASTUZUMAB-HYALURONIDASE-OYSK	HERCPTIN HYLECTA
TRASTUZUMAB/ANNS	KANJINTI
TRASTUZUMAB/DKST	OGIVRI
TRASTUZUMAB/DTTB	ONTRUZANT
TRASTUZUMAB/PKRB	HERZUMA
TRASTUZUMAB/QYYP	TRAZIMERA
TRIFLURIDINE-TIPIRACIL	LONSURF
TRILACICLIB DIHYDROCHLORIDE	COSELA
TUCATINIB	TUKYSA

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
UMBRALISIB TOSYLATE	UKONIQ
URACIL MUSTARD	URACIL MUSTARD
VALRUBICIN	VALRUBICIN
VALRUBICIN	VALSTAR
VANDETANIB	CAPRELSA
VANDETANIB	VANDETANIB
VEMURAFENIB	ZELBORAF
VENETOCLAX	VENCLEXTA
VENETOCLAX	VENCLEXTA STARTING PACK
VINBLASTINE SULFATE	VINBLASTINE SULFATE
VINCRISTINE SULFATE	VINCASAR PFS
VINCRISTINE SULFATE	VINCRISTINE SULFATE
VINCRISTINE SULFATE LIPOSOME	MARQIBO
VINORELBINE TARTRATE	NAVELBINE
VINORELBINE TARTRATE	VINORELBINE TARTRATE
VISMODEGIB	ERIVEDGE
VORINOSTAT	ZOLINZA
ZANUBRUTINIB	BRUKINSA
ZIV-AFLIBERCEPT	ZALTRAP
Immunosuppressant Therapeutic Agents	
ABATACEPT	ORENCIA
ABATACEPT	ORENCIA CLICKJET
ADALIMUMAB	HUMIRA
ADALIMUMAB	HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK
ADALIMUMAB	HUMIRA PEN
ADALIMUMAB	HUMIRA PEN-CD/UC/HS STARTER
ADALIMUMAB	HUMIRA PEN-PSORIASIS STARTER
ANAKINRA	KINERET
ANTI/THYMOCYTE	THYMOGLOBULIN
APREMILAST	OTEZLA
AURANOFIN	RIDAURA
AUROTHIOGLUCOSE	AUROTHIOGLUCOSE
AUROTHIOGLUCOSE	SOLGANAL
AZATHIOPRINE	AZASAN
AZATHIOPRINE	AZATHIOPRINE
AZATHIOPRINE	AZATHIOPRINE SODIUM

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
AZATHIOPRINE	IMURAN
BARICITINIB	OLUMIANT
BASILIXIMAB	SIMULECT
BELATACEPT	NULOJIX
BELIMUMAB	BENLYSTA
CANAKINUMAB	ILARIS
CYCLOSPORINE	CYCLOSPORINE
CYCLOSPORINE	SANDIMMUNE
CYCLOSPORINE MODIFIED	CYCLOSPORINE MODIFIED
CYCLOSPORINE MODIFIED	GENGRAF
CYCLOSPORINE MODIFIED	NEORAL
DACLIZUMAB	ZENAPAX
EMAPALUMAB/LZSG	GAMIFANT
ETANERCEPT	ENBREL
ETANERCEPT	ENBREL MINI
ETANERCEPT	ENBREL SURECLICK
EVEROLIMUS	EVEROLIMUS
EVEROLIMUS	ZORTRESS
FINGOLIMOD HYDROCHLORIDE	GILENYA
GOLD SODIUM THIOMALATE	GOLD SODIUM THIOMALATE
GOLD SODIUM THIOMALATE	MYOCHRYSINE
GOLIMUMAB	SIMPONI
GOLIMUMAB	SIMPONI ARIA
INEBILIZUMAB/CDON	UPLIZNA
LEFLUNOMIDE	ARAVA
LEFLUNOMIDE	LEFLUNOMIDE
LENALIDOMIDE	REVLIMID
LYMPHOCYTE IMMUNE GLOBULIN ANTI/THYMOCYTE G	ATGAM
METHOTREXATE	RASUVO
METHOTREXATE	REDITREX
METHOTREXATE SODIUM	METHOTREXATE
METHOTREXATE SODIUM	RHEUMATREX
METHOTREXATE/PF	OTREXUP
MUROMONAB CD3	ORTHOCLONE OKT3
MYCOPHENOLATE MOFETIL	CELLCEPT
MYCOPHENOLATE MOFETIL	MYCOPHENOLATE MOFETIL

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
MYCOPHENOLATE MOFETIL HCL	CELLCEPT INTRAVENOUS
MYCOPHENOLATE MOFETIL HCL	MYCOPHENOLATE MOFETIL
MYCOPHENOLATE SODIUM	MYCOPHENOLIC ACID DR
MYCOPHENOLATE SODIUM	MYFORTIC
RILONACEPT	ARCALYST
SARILUMAB SUBCUTANEOUS	KEVZARA
SATRALIZUMAB/MWGE	ENSPRYNG
SIROLIMUS	RAPAMUNE
SIROLIMUS	SIROLIMUS
TACROLIMUS	ASTAGRAF XL
TACROLIMUS	ENVARSUS XR
TACROLIMUS	HECORIA
TACROLIMUS	PROGRAF
TACROLIMUS	TACROLIMUS
THALIDOMIDE	THALOMID
TOCILIZUMAB IV	ACTEMRA
TOCILIZUMAB SUBCUTANEOUS	ACTEMRA
TOCILIZUMAB SUBCUTANEOUS	ACTEMRA ACTPEN
TOFACITINIB CITRATE	XELJANZ
TOFACITINIB CITRATE	XELJANZ XR
TOFACITINIB CITRATE ORAL	XELJANZ
UPADACITINIB	RINVOQ
VOCLOSPORIN	LUPKYNIS
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/TETRACYCLINE HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
betamethasone acetate and sodium phos in sterile water/PF	betameth ac,sod phos(PF)-water
betamethasone acetate/betamethasone sodium phosphate	BSP-0820
betamethasone acetate/betamethasone sodium phosphate	Beta-1
betamethasone acetate/betamethasone sodium phosphate	Celestone Soluspan

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
betamethasone acetate/betamethasone sodium phosphate	Pod-Care 100C
betamethasone acetate/betamethasone sodium phosphate	ReadySharp Betamethasone
betamethasone acetate/betamethasone sodium phosphate	betamethasone acet,sod phos
betamethasone acetate/betamethasone sodium phosphate/water	betamethasone ace,sod phos-wtr
betamethasone sodium phosph in sterile water for injection	betamethasone sod phosph-water
budesonide	Entocort EC
budesonide	Ortikos
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	Tarpeyo
budesonide	Uceris
budesonide	budesonide
budesonide/formoterol fumarate	Symbicort
budesonide/formoterol fumarate	budesonide-formoterol
budesonide/glycopyrrolate/formoterol fumarate	Breztri Aerosphere
bupivacaine HCl/dexamethasone sodium phos in sterile water	bupivacaine-dexameth in water
cortisone acetate	cortisone
deflazacort	Emflaza
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dexabliss
dexamethasone	Dexamethasone Intensol
dexamethasone	Dxevo
dexamethasone	Hemady
dexamethasone	HiDex
dexamethasone	TaperDex
dexamethasone	ZCort
dexamethasone	dexamethasone

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
dexamethasone acetate and sodium phosphate in sterile water	dexamethasone ac, sod ph-water
dexamethasone acetate in sodium chloride, iso-osmotic	dexamethasone ace-NaCl,iso-osm
dexamethasone sodium phosphate	Dexonto
dexamethasone sodium phosphate	ReadySharp dexamethasone
dexamethasone sodium phosphate	dexamethasone sodium phosphate
dexamethasone sodium phosphate in 0.9 % sodium chloride	dexamethasone-0.9 % sod. chlor
dexamethasone sodium phosphate/PF	Active Injection Kit D (PF)
dexamethasone sodium phosphate/PF	DoubleDex (PF)
dexamethasone sodium phosphate/PF	MAS Care-Pak (PF)
dexamethasone sodium phosphate/PF	dexamethasone sodium phos (PF)
dexamethasone sodium phosphate/lidocaine HCl	Lidocidex-I
fludrocortisone acetate	fludrocortisone
hydrocortisone	Alkindi Sprinkle
hydrocortisone	Cortef
hydrocortisone	hydrocortisone
hydrocortisone sodium succinate	A-Hydrocort
hydrocortisone sodium succinate	Solu-Cortef
hydrocortisone sodium succinate/PF	Solu-Cortef Act-O-Vial (PF)
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
methylprednisolone acetate	Depo-Medrol
methylprednisolone acetate	P-Care D40
methylprednisolone acetate	P-Care D80
methylprednisolone acetate	methylprednisolone acetate
methylprednisolone acetate in sodium chloride,iso-osmotic/PF	methylpred ac(PF)-NaCl,iso-osm
methylprednisolone acetate in sterile water for injection	methylprednisolone acet-water
methylprednisolone acetate/bupivacaine HCl in sterile water	methylprednisol ac-bupivac-wat
methylprednisolone sodium succinate	Solu-Medrol

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
methylprednisolone sodium succinate	methylprednisolone sodium succ
methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	prednisolone
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	prednisone
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Kenalog-80
triamcinolone acetonide	P-Care K40
triamcinolone acetonide	P-Care K80
triamcinolone acetonide	Pod-Care 100K
triamcinolone acetonide	Pro-C-Dure 5
triamcinolone acetonide	Pro-C-Dure 6
triamcinolone acetonide	Zilretta
triamcinolone acetonide	triamcinolone acetonide
triamcinolone acetonide in 0.9 % sodium chloride	triamcinolone aceton-0.9% NaCl
triamcinolone acetonide/0.9% sodium chloride/PF	triamcinol ac (PF) in 0.9%NaCl
triamcinolone acetonide/bupivacaine/in 0.9% sodium chloride	triamcinol ace-bupiv-0.9% NaCl
triamcinolone acetonide/lidocaine HCl	Lidocilone I
triamcinolone diacetate in 0.9 % sodium chloride	triamcinolone diacet-0.9% NaCl
triamcinolone diacetate in 0.9 % sodium chloride/PF	triamcinolone dia(PF)-0.9%NaCl
triamcinolone hexacetonide	Aristospan Intra-Articular
triamcinolone hexacetonide	Aristospan Intralesional
triamcinolone hexacetonide	Hexatrione
Lopinavir/Ritonavir	
LOPINAVIR/RITONAVIR	

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Remdesivir	
REMDESIVIR	
REMDESIVIR (EMERGENCY USE AUTHORIZATION)	
REMDESIVIR FOR IV	
remdesivir	
Hydroxychloroquine	
hydroxychloroquine sulfate	Plaquenil
hydroxychloroquine sulfate	hydroxychloroquine
Chloroquine	
chloroquine phosphate	chloroquine phosphate
Azithromycin	
AZITHROMYCIN	
AZITHROMYCIN HYDROGEN CITRATE	
Ivermectin	
IVERMECTIN	
Dexamethasone	
BUPIVACAINE HCL/DEXAMETHASONE SODIUM PHOSPHATE IN STERILE WATER	
DEXAMETHASONE	
DEXAMETHASONE ACETATE	
DEXAMETHASONE ACETATE AND SODIUM PHOSPHATE IN STERILE WATER	
DEXAMETHASONE ACETATE IN SODIUM CHLORIDE, ISO/OSMOTIC	
DEXAMETHASONE ACETATE/SODIUM PHOSPHATE	
DEXAMETHASONE SODIUM PHOSPHATE	
DEXAMETHASONE SODIUM PHOSPHATE IN 0.9 % SODIUM CHLORIDE	
DEXAMETHASONE SODIUM PHOSPHATE PF/BUPIVACAINE 0.25%	
DEXAMETHASONE SODIUM PHOSPHATE/DEXTROSE	
DEXAMETHASONE SODIUM PHOSPHATE/LIDOCAINE HCL	

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
DEXAMETHASONE SODIUM PHOSPHATE/NACL	
DEXAMETHASONE SODIUM PHOSPHATE/PF	
DEXAMETHASONE/BUPIVACAINE HCL/EPINEPHRINE	
DEXAMETHASONE/SALIVA COLLECTION DEVICE	
dexamethasone	
dexamethasone sodium phosphate	
dexamethasone sodium phosphate/PF	
Other Corticosteroids	
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/TETRACYCLINE HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
betamethasone acetate and sodium phos in sterile water/PF	betameth ac,sod phos(PF)-water
betamethasone acetate/betamethasone sodium phosphate	BSP-0820
betamethasone acetate/betamethasone sodium phosphate	Beta-1
betamethasone acetate/betamethasone sodium phosphate	Celestone Soluspan
betamethasone acetate/betamethasone sodium phosphate	Pod-Care 100C
betamethasone acetate/betamethasone sodium phosphate	ReadySharp Betamethasone
betamethasone acetate/betamethasone sodium phosphate	betamethasone acet,sod phos
betamethasone acetate/betamethasone sodium phosphate/water	betamethasone ace,sod phos-wtr
betamethasone sodium phosph in sterile water for injection	betamethasone sod phosph-water
cortisone acetate	cortisone
fludrocortisone acetate	fludrocortisone
hydrocortisone	Alkindi Sprinkle

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
hydrocortisone	Cortef
hydrocortisone	hydrocortisone
hydrocortisone sodium succinate	A-Hydrocort
hydrocortisone sodium succinate	Solu-Cortef
hydrocortisone sodium succinate/PF	Solu-Cortef Act-O-Vial (PF)
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
methylprednisolone acetate	Depo-Medrol
methylprednisolone acetate	P-Care D40
methylprednisolone acetate	P-Care D80
methylprednisolone acetate	methylprednisolone acetate
methylprednisolone acetate in sodium chloride,iso-osmotic/PF	methylpred ac(PF)-NaCl,iso-osm
methylprednisolone acetate in sterile water for injection	methylprednisolone acet-water
methylprednisolone acetate/bupivacaine HCl in sterile water	methylprednisol ac-bupivac-wat
methylprednisolone sodium succinate	Solu-Medrol
methylprednisolone sodium succinate	methylprednisolone sodium succ
methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	prednisolone
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	prednisone
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Kenalog-80
triamcinolone acetonide	P-Care K40
triamcinolone acetonide	P-Care K80
triamcinolone acetonide	Pod-Care 100K

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
triamcinolone acetonide	Pro-C-Dure 5
triamcinolone acetonide	Pro-C-Dure 6
triamcinolone acetonide	Zilretta
triamcinolone acetonide	triamcinolone acetonide
triamcinolone acetonide in 0.9 % sodium chloride	triamcinolone aceton-0.9% NaCl
triamcinolone acetonide/0.9% sodium chloride/PF	triamcinol ac (PF) in 0.9%NaCl
triamcinolone acetonide/bupivacaine/in 0.9% sodium chloride	triamcinol ace-bupiv-0.9% NaCl
triamcinolone acetonide/lidocaine HCl	Lidocilone I
triamcinolone diacetate in 0.9 % sodium chloride	triamcinolone diacet-0.9% NaCl
triamcinolone diacetate in 0.9 % sodium chloride/PF	triamcinolone dia(PF)-0.9%NaCl
triamcinolone hexacetonide	Aristospan Intra-Articular
triamcinolone hexacetonide	Aristospan Intralesional
triamcinolone hexacetonide	Hexatrione
Inhaled Corticosteroids	
beclomethasone dipropionate	Qvar RediHaler
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	budesonide
budesonide/formoterol fumarate	Symbicort
budesonide/formoterol fumarate	budesonide-formoterol
budesonide/glycopyrrolate/formoterol fumarate	Breztri Aerosphere
ciclesonide	Alvesco
fluticasone furoate	Arnuity Ellipta
fluticasone furoate/umeclidinium bromide/vilanterol trifenat	Trelegy Ellipta
fluticasone furoate/vilanterol trifenatate	Breo Ellipta
fluticasone furoate/vilanterol trifenatate	fluticasone furoate-vilanterol
fluticasone propionate	ArmonAir Digihaler
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA
fluticasone propionate	fluticasone propionate

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Advair HFA
fluticasone propionate/salmeterol xinafoate	AirDuo Digihaler
fluticasone propionate/salmeterol xinafoate	AirDuo RespiClick
fluticasone propionate/salmeterol xinafoate	Wixela Inhub
fluticasone propionate/salmeterol xinafoate	fluticasone propion-salmeterol
mometasone furoate	Asmanex HFA
mometasone furoate	Asmanex Twisthaler
mometasone furoate/formoterol fumarate	Dulera
Paxlovid	
nirmatrelvir/ritonavir	Paxlovid (EUA)
Baricitinib	
BARICITINIB	
Tocilizumab	
tocilizumab	Actemra
tocilizumab	Actemra ACTPen
Bamlanivimab	
Bamlanivimab	Bamlanivimab
Casirivimab/Imdevimab	
Casirivimab	
Casirivimab/Imdevimab	
Imdevimab	
casirivimab-imdevimab	
Bamlanivimab/Etesevimab	
Bamlanivimab	Bamlanivimab
Etesevimab	etesevimab
Sotrovimab	
Sotrovimab injection 500mg/8ml	sotrovimab
NSAIDs	
NAPROXEN	Napro
NAPROXEN	Naproderm
amlodipine besylate/celecoxib	Consensi
bromfenac sodium	BromSite
bromfenac sodium	Prolensa
bromfenac sodium	bromfenac
bupivacaine/ketorolac/ketamine	bupivacaine-ketorolac-ketamine
bupivacaine/meloxicam	Zynrelef
celecoxib	Celebrex

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
celecoxib	Elyxyb
celecoxib	celecoxib
celecoxib/capsaicin/methyl salicylate/menthol	NuDroxiPAK
chlorpheniramine maleate/phenylephrine HCl/ibuprofen	Advil Allergy-Congestion Rlf
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Allergy Sinus
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
diclofenac epolamine	Flector
diclofenac epolamine	Licart
diclofenac epolamine	diclofenac epolamine
diclofenac potassium	Cambia
diclofenac potassium	Cataflam
diclofenac potassium	Lofena
diclofenac potassium	Zipsor
diclofenac potassium	diclofenac potassium
diclofenac sodium	Arthritis Pain (diclofenac)
diclofenac sodium	Diclo Gel
diclofenac sodium	Diclofono
diclofenac sodium	Dicloprep-100
diclofenac sodium	Diclozor
diclofenac sodium	Pennsaid
diclofenac sodium	Solaraze
diclofenac sodium	VennGel One
diclofenac sodium	Voltaren
diclofenac sodium	Voltaren Arthritis Pain
diclofenac sodium	Voltaren-XR
diclofenac sodium	diclofenac sodium
diclofenac sodium/capsaicin	CapsFenac Pak
diclofenac sodium/capsaicin	Dicloheal-60
diclofenac sodium/capsaicin	Diclopak
diclofenac sodium/capsaicin	Flexipak
diclofenac sodium/capsaicin	Inavix
diclofenac sodium/capsaicin	NuDiclo SoluPAK
diclofenac sodium/capsaicin	NuDiclo TabPAK

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
diclofenac sodium/capsaicin	Pennsaicin
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-50
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-75
diclofenac sodium/capsicum oleoresin	Capsinac
diclofenac sodium/capsicum oleoresin	DermacinRx Lexitral
diclofenac sodium/capsicum oleoresin	Diclofex DC
diclofenac sodium/capsicum oleoresin	Diclosaicin
diclofenac sodium/capsicum oleoresin	Diclotral
diclofenac sodium/capsicum oleoresin	Iclofenac CP
diclofenac sodium/capsicum oleoresin	Inflammacin
diclofenac sodium/capsicum oleoresin	Kapzin DC
diclofenac sodium/capsicum oleoresin	Lexitral PharmaPak II
diclofenac sodium/capsicum oleoresin	Sure Result DSS Premium Pack
diclofenac sodium/capsicum oleoresin	Xelitral
diclofenac sodium/capsicum oleoresin	Xenaflamm
diclofenac sodium/capsicum oleoresin	Ziclopro
diclofenac sodium/hyaluronate sodium/niacinamide	Roaoxia
diclofenac sodium/hyaluronate sodium/niacinamide	diclofenac-hyaluronate-niacin
diclofenac sodium/kinesiology tape	Clofenax
diclofenac sodium/kinesiology tape	Diclo Gel-Xrylix Sheet
diclofenac sodium/kinesiology tape	Lexixryl
diclofenac sodium/kinesiology tape	Profinac
diclofenac sodium/kinesiology tape	Xrylix (diclofenac-kines tape)
diclofenac sodium/kinesiology tape	Xrylix II
diclofenac sodium/lidocaine	Lidovix
diclofenac sodium/lidocaine HCl/kinesiology tape	TriXylitral
diclofenac sodium/lidocaine/methyl salicylate/camphor	Diclovix
diclofenac sodium/menthol	DiThol
diclofenac sodium/menthol/camphor	Diclotrex
diclofenac sodium/menthol/camphor	Diclotrex II
diclofenac sodium/menthol/camphor	Inflatherm(diclofenac-menthol)

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
diclofenac sodium/menthol/kinesiology tape	DiMentho
diclofenac sodium/menthol/kinesiology tape	Diclovix M
diclofenac sodium/methyl salicylate/menthol	DicloPR
diclofenac sodium/methyl salicylate/menthol	Varophen (diclofenac)
diclofenac sodium/methyl salicylate/menthol/camphor	Inflamma-K
diclofenac sodium/misoprostol	Arthrotec 50
diclofenac sodium/misoprostol	Arthrotec 75
diclofenac sodium/misoprostol	diclofenac-misoprostol
diclofenac sodium/silicone, adhesive	Solaravix
diclofenac sodium/trolamine salicylate	Inflatherm (diclofenac-trolam)
diclofenac submicronized	Zorvolex
diclofenac submicronized	diclofenac submicronized
etodolac	Lodine
etodolac	etodolac
etodolac/capsaicin/methyl salicylate/menthol	NuDroxiPAK E-400
fenoprofen calcium	Fenortho
fenoprofen calcium	Nalfon
fenoprofen calcium	ProFeno
fenoprofen calcium	fenoprofen
flurbiprofen	flurbiprofen
flurbiprofen sodium	flurbiprofen sodium
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	hydrocodone-ibuprofen
ibuprofen	Addaprin
ibuprofen	Advil
ibuprofen	Advil Junior Strength
ibuprofen	Advil Liqui-Gel
ibuprofen	Advil Migraine
ibuprofen	Caldolor
ibuprofen	Children's Advil
ibuprofen	Children's Ibuprofen

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ibuprofen	Children's Motrin
ibuprofen	Children's Motrin Jr Strength
ibuprofen	Children's Profen IB
ibuprofen	I-Prin
ibuprofen	IBU
ibuprofen	IBU-200
ibuprofen	Ibuprofen IB
ibuprofen	Ibuprofen Jr Strength
ibuprofen	Infant's Advil
ibuprofen	Infant's Ibuprofen
ibuprofen	Infant's Motrin
ibuprofen	Infants ProfenIB
ibuprofen	Motrin IB
ibuprofen	Provil
ibuprofen	Wal-Profen
ibuprofen	ibuprofen
ibuprofen lysine/PF	NeoProfen (ibuprofen lysn)(PF)
ibuprofen lysine/PF	ibuprofen lysine (PF)
ibuprofen/acetaminophen	Advil Dual Action
ibuprofen/capsaicin/methyl salicylate/menthol	NuDroxiPAK I-800
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen/diphenhydramine HCl	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Motrin PM
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
ibuprofen/glycerin	Ibupak
ibuprofen/irritants counter-irritants combination no.2	Comfort Pac-Ibuprofen
ibuprofen/oxycodone HCl	ibuprofen-oxycodone
ibuprofen/phenylephrine HCl	Advil Sinus Congestion-Pain
ibuprofen/phenylephrine HCl	Congestion Relief (ibuprof-PE)
ibuprofen/phenylephrine HCl	Sudafed PE Head Congestn-Pain
ibuprofen/pseudoephedrine HCl	Advil Cold and Sinus
ibuprofen/pseudoephedrine HCl	Cold and Sinus Pain Relief

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief (ibuprofen)
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold-Sinus(with PSE)
ibuprofen/pseudoephedrine HCl	Wal-Profen Cold-Sinus
ibuprofen/pseudoephedrine HCl	Wal-Profen D Cold and Sinus
indomethacin	Indocin
indomethacin	indomethacin
indomethacin sodium	indomethacin sodium
indomethacin, submicronized	Tivorbex
indomethacin, submicronized	indomethacin submicronized
ketoprofen	Frotek
ketoprofen	ketoprofen
ketoprofen, micronized	Frotek
ketorolac tromethamine	Acular
ketorolac tromethamine	Acular LS
ketorolac tromethamine	ReadySharp ketorolac
ketorolac tromethamine	Sprix
ketorolac tromethamine	ketorolac
ketorolac tromethamine/PF	Acuvail (PF)
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova II SUIK
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova SUIK
meclofenamate sodium	meclofenamate
mefenamic acid	mefenamic acid
meloxicam	Anjeso
meloxicam	Mobic
meloxicam	Qmiiz ODT
meloxicam	meloxicam
meloxicam, submicronized	Vivlodex
meloxicam, submicronized	meloxicam submicronized
meloxicam/irritants counter-irritants combination no.2	Comfort Pac-Meloxicam
nabumetone	Relafen
nabumetone	Relafen DS
nabumetone	nabumetone

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
nabumetone/capsaicin/methyl salicylate/menthol	NuDroxiPAK N-500
naproxen	EC-Naprosyn
naproxen	EC-Naproxen
naproxen	Naprosyn
naproxen	naproxen
naproxen sodium	Aleve
naproxen sodium	All Day Pain Relief
naproxen sodium	All Day Relief
naproxen sodium	Anaprox DS
naproxen sodium	Flanax (naproxen)
naproxen sodium	Mediproxen
naproxen sodium	Midol (naproxen)
naproxen sodium	Naprelan CR
naproxen sodium	Wal-Proxen
naproxen sodium	naproxen sodium
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen sodium/diphenhydramine HCl	Naproxen PM
naproxen sodium/pseudoephedrine HCl	Aleve Cold and Sinus
naproxen sodium/pseudoephedrine HCl	Aleve Sinus and Headache
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Cold
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Headache
naproxen sodium/pseudoephedrine HCl	All Day Pain Relief Sinus,Cold
naproxen sodium/pseudoephedrine HCl	Sinus and Cold-D
naproxen sodium/pseudoephedrine HCl	Sudafed Sinus 12Hr Pressr-Pain
naproxen/esomeprazole magnesium	Vimovo
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/irritant counter-irritant combination no.2	Comfort Pac-Naproxen
nepafenac	Ilevro
nepafenac	Nevanac
oxaprozin	Daypro
oxaprozin	oxaprozin
phenylephrine HCl/ketorolac tromethamine	Omidria
piroxicam	Feldene
piroxicam	piroxicam
prednisolone acetate/bromfenac sodium	prednisolone acetate-bromfenac

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone acetate/nepafenac	prednisolone acetate-nepafenac
prednisolone sodium phosphate/bromfenac sodium	prednisolone sod ph-bromfenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
ropivacaine HCl/clonidine HCl/ketorolac tromethamine	ropivacaine-clonidin-ketorolac
ropivacaine HCl/epinephrine/clonidine HCl/ketorolac trometh	ropivacaine-epi-clonid-ketorol
ropivacaine/ketorolac/ketamine	ropivacaine-ketorolac-ketamine
sulindac	sulindac
sumatriptan succinate/naproxen sodium	Treximet
sumatriptan succinate/naproxen sodium	sumatriptan-naproxen
tolmetin sodium	tolmetin
tramadol HCl/celecoxib	Seglentis
tropicamide/proparacaine/phenylephrine/ketorolac in water	Mydriatic4(trop-prop-PE-ktrlc)
tropicamide/proparacaine/phenylephrine/ketorolac in water	tropic-proparacai-pe-ketor-wat
Antidepressants	
St. John's wort	Alterra
St. John's wort	Centrum Herbals St Johns Wort
St. John's wort	Kira St. John's Wort
St. John's wort	Movana
St. John's wort	Quanterra Emotional
St. John's wort	St. John's wort
amitriptyline HCl	Elavil
amitriptyline HCl	Vanatrip
amitriptyline HCl	amitriptyline

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
amitriptyline HCl/chlordiazepoxide	Limbitrol
amitriptyline HCl/chlordiazepoxide	Limbitrol DS
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amoxapine	Asendin
amoxapine	amoxapine
brexanolone	Zulresso
bupropion HBr	Aplenzin
bupropion HCl	Budeprion SR
bupropion HCl	Budeprion XL
bupropion HCl	Forfivo XL
bupropion HCl	Wellbutrin
bupropion HCl	Wellbutrin SR
bupropion HCl	Wellbutrin XL
bupropion HCl	bupropion HCl
bupropion HCl/dietary supplement combination no.15	Appbutamone-D
bupropion HCl/dietary supplement combination no.16	Appbutamone
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clomipramine HCl	Anafranil
clomipramine HCl	clomipramine
desipramine HCl	Norpramin
desipramine HCl	desipramine
desvenlafaxine	Khedezla
desvenlafaxine	desvenlafaxine
desvenlafaxine fumarate	desvenlafaxine fumarate
desvenlafaxine succinate	Pristiq
desvenlafaxine succinate	desvenlafaxine succinate
dextromethorphan HBr/bupropion HCl	Auvelity
doxepin HCl	Adapin
doxepin HCl	Silenor
doxepin HCl	Sinequan
doxepin HCl	doxepin
duloxetine HCl	Cymbalta
duloxetine HCl	Drizalma Sprinkle
duloxetine HCl	Irenka

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
duloxetine HCl	duloxetine
escitalopram oxalate	Lexapro
escitalopram oxalate	escitalopram oxalate
esketamine HCl	Spravato
fluoxetine HCl	Prozac
fluoxetine HCl	Prozac Weekly
fluoxetine HCl	Rapiflux
fluoxetine HCl	Sarafem
fluoxetine HCl	Selfemra
fluoxetine HCl	fluoxetine
fluoxetine HCl/dietary supplement no.17	Gaboxetine
fluoxetine HCl/dietary supplement no.8	Sentroxatine
fluvoxamine maleate	Luvox
fluvoxamine maleate	Luvox CR
fluvoxamine maleate	fluvoxamine
imipramine HCl	Tofranil
imipramine HCl	imipramine HCl
imipramine pamoate	Tofranil-PM
imipramine pamoate	imipramine pamoate
isocarboxazid	Marplan
levomilnacipran HCl	Fetzima
maprotiline HCl	Ludiomil
maprotiline HCl	maprotiline
milnacipran HCl	Savella
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mirtazapine	mirtazapine
nefazodone HCl	Serzone
nefazodone HCl	nefazodone
nortriptyline HCl	Aventyl
nortriptyline HCl	Pamelor
nortriptyline HCl	nortriptyline
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine HCl	paroxetine HCl
paroxetine mesylate	Pexeva

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
perphenazine/amitriptyline HCl	Etrafon 2-10
perphenazine/amitriptyline HCl	Etrafon 2-25
perphenazine/amitriptyline HCl	Etrafon Forte 4-25
perphenazine/amitriptyline HCl	Triavil 2-10
perphenazine/amitriptyline HCl	Triavil 2-25
perphenazine/amitriptyline HCl	Triavil 4-25
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenelzine sulfate	Nardil
phenelzine sulfate	phenelzine
protriptyline HCl	Vivactil
protriptyline HCl	protriptyline
selegiline	Emsam
sertraline HCl	Zoloft
sertraline HCl	sertraline
tranylcypromine sulfate	Parnate
tranylcypromine sulfate	tranylcypromine
trazodone HCl	Desyrel
trazodone HCl	Oleptro ER
trazodone HCl	trazodone
trazodone HCl/dietary supplement no.8	Trazamine
trimipramine maleate	Surmontil
trimipramine maleate	trimipramine
venlafaxine HCl	Effexor
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
venlafaxine besylate	venlafaxine besylate
vilazodone HCl	Viibryd
vilazodone HCl	vilazodone
vortioxetine hydrobromide	Brintellix
vortioxetine hydrobromide	Trintellix

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

	Run	Scenario	Group	Query Period	Stratifications	Distribution of Index	Exposure: Index Exposure	Exposure: Cohort definition	Exposure: Incident exposure washout period
With at least one COVID-19 vaccine	r01	1	firstvac	11/01/2020 - latest available data	-Sex -Year -Year month -Agegroup - Geographic region (states) -agegroup*Year Month	Y	First dose of COVID-19 vaccine (Any brand)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

With at least two COVID-19 vaccine	r02	2	firstsecvac	11/01/2020 - latest available data	- agegroup*Calendar Month -Sex - Geographic region (states)	Y	First dose of COVID-19 vaccine (Any brand)	First valid exposure episodes during query period	0
	r03	3	pfizerpfizer	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0
	r03	4	modernamoderna	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0
	r03	5	janssenjanssen	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen_Jannsen)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

	r03	6	otherother	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0
	r03	7	pfizermodern a	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0
	r03	8	modernapfize r	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0
	r03	9	pfizerother	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

Brand combination for first and second COVID-19 vaccine	r03	10	pfizerjanssen	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0
	r03	11	modernajanssen	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0
	r03	12	modernaother	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0
	r03	13	janssenmoderna	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

	r03	14	janssenpfizer	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen)	First valid exposure episodes during query period	0
	r03	15	janssenother	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen)	First valid exposure episodes during query period	0
	r03	16	othermoderna	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0
	r03	17	otherpfizer	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

	r03	18	otherjanssen	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0
	r03	19	oclaimsoclaims	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims: NDC and PX codes)	First valid exposure episodes during query period	0
	r03	20	oiisoiis	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (IIS: CVX codes)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

	r03	21	oclaimsoiis	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims: NDC and PX codes)	First valid exposure episodes during query period	0
	r03	22	oiisoclaims	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (IIS: CVX codes)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

Data source combination for first and second COVID-19 vaccine	r03	23	oclaims_claimsiis	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims: NDC and PX codes)	First valid exposure episodes during query period	0
	r03	24	oiis_iisclaims	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (IIS: CVX codes)	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

	r03	25	claimsiis_oiis	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims)	First valid exposure episodes during query period	0
	r03	26	iisclaims_oclaims	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims)	First valid exposure episodes during query period	0
	r03	27	iisclaims_iisclaims	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims)	First valid exposure episodes during query period	0

	r04	28	3rddose_all	09/01/2021 - latest available data	- Sex - Geographic State region -**agegroup*Calendar Month**	-	3rd dose of the pfizer and moderna COVID-19 vaccine that qualifies as a booster for non-immunocompromised individuals	First valid exposure episodes during query period	0
Booster (we define based on order of codes)	r04	29	4thdose_immuno	09/01/2021 - latest available data	-	-	4th dose of the pfizer and moderna COVID-19 vaccine that qualifies as a booster including immunocompromised individuals	First valid exposure episodes during query period	0

Appendix F. Technical Specifications Used for this Request

	r04	30	3rddose_nonimmuno	09/01/2021 - latest available data	-	-	3rd dose of the pfizer and moderna COVID-19 vaccine that qualifies as a booster excluding immunocompromised individuals	First valid exposure episodes during query period	0
Booster defined by code description	r04	31	boosterbivalent	09/01/2021 - latest available data	- Sex - Geographic State region -**agegroup*Calendar Month**	-	Evidence of one COVID vaccine codes of any brand that specifies "booster" or "bivalent"	First valid exposure episodes during query period	0

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.
N/A: Not Applicable

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

Exposure

Incident w/ respect to:	Build Episodes on Point Exposure?	Treatment episode gap	Exposure episode extension	Minimum exposure episode duration	Minimum days supplied	Maximum exposure episode duration	Care setting	Principal diagnosis position	Forced supply to attach to dispensings	Output Baseline Table	Censor treatment episode at evidence of:	Follow-Up Time Categories:
n/a	Y						Any care setting	N/A	N/A	Y	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

n/a	Y		Any care setting	N/A	N/A	Y	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y	Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y	Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y	Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y			Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y	Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y	Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y	Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days
n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days

Appendix F. Technical Specifications Used for this Request

n/a	Y		Any care setting	N/A	N/A	Y	*Death; *Disenrollment; * DP end date; *Query end date;	-
n/a	Y		Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	-

n/a	Y				Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	
n/a	Y				Any care setting	N/A	N/A	N	*Death; *Disenrollment; * DP end date; *Query end date;	-

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

Inclusion/Exclusion Criteria

Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	1	4	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Inclusion	Any	Any	5	latest value (i.e., the end of enrollment)	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
			OR				

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (IIS)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	latest value (i.e., the end of enrollment)	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
			OR				
COVID-19 vaccine (Claims)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	latest value (i.e., the end of enrollment)	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

			OR				
COVID-19 vaccine (IIS)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
			OR				
COVID-19 vaccine (Claims)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
			OR				
COVID-19 vaccine (IIS)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
			OR				

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (Claims)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (IIS)	Inclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

COVID-19 vaccine (IIS)	Inclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
COVID-19 vaccine (IIS)	Inclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
Evidence of **two** COVID				Earlier			

vaccine codes of any brand that are 4 days apart **[Booster_twoprev]**	inclusion	Any	Any	value (i.e., the start of enrollment)	-4	Yes - looking at dispensing date only, not days supply	1
Immunocompromised (including, HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, Solid Malignancies)	inclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	
AND							
Evidence of **three** COVID vaccine codes of any brand that are 4 days apart **[Booster_threeprev]**	inclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-4		

Appendix F. Technical Specifications Used for this Request

Immunocompromised (including, HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, Solid Malignancies)	**exclusion**	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply
Evidence of **two** COVID vaccine codes of any brand that are 4 days apart **[Booster_twoprev]**	inclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-4	

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

Event Outcome

Event	Incident event washout period	Incident w/ respect to:	Care setting	Principal diagnosis position	Exclude evidence of days supply if event washout includes dispensings	Event de-duplication	Risk Evaluation Window Start

Appendix F. Technical Specifications Used for this Request

Second dose of COVID-19 vaccine (Combo: SecondCovid_Vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of COVID-19 vaccine (Combo: SecondCovid_Vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Pfizer COVID-19 vaccine (pfizertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

Second dose of Moderna COVID-19 vaccine (modernatwo_vax	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Jannsen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Moderna COVID-19 vaccine	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

Second dose of Pfizer COVID-19 vaccine	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Jannsen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Jannsen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Moderna COVID-19 vaccine (modernatwo_ vax	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Pfizer COVID-19 vaccine (pfizertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

Second dose of Moderna COVID-19 vaccine (modernatwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Pfizer COVID-19 vaccine (pfizertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Janssen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of Claims only COVID-19 vaccine (claimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

Second dose of IIS only COVID-19 vaccine (iisclaims_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of COVID-19 vaccine (IIS) (iisclaims_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of COVID-19 vaccine (Claims) (claimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

Second dose of COVID-19 vaccine (Claims and IIS) (bothclaimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of COVID-19 vaccine (IIS and Claims) (bothclaimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of COVID-19 vaccine (IIS) (iisclaims_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

Second dose of COVID-19 vaccine (Claims) (claimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
Second dose of COVID-19 vaccine (IIS and Claims) (bothclaimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

		Baseline Characteristics		
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
Demographics				
Age (continuous, and categorical)	-	02	N/A	N/A
Sex	-	02	N/A	N/A
Race	-	02	N/A	N/A
Ethnicity	-	02	N/A	N/A
Year	-	02	N/A	N/A
COVID-19 Vaccination				
Duplicated COVID-19 vaccines (having evidence of days with COVID-19 vaccine codes within ≤4 days of first code)				
Duplicated	COVAR1	02	N/A	Any
COVID vaccine brand for the first observed record				
Pfizer at index	COVAR2	02	N/A	Any
Moderna at index	COVAR3	02	N/A	Any
Jannsen at index	COVAR4	02	N/A	Any
Novavax at index	COVAR5	02	N/A	Any
Unspecified at index	COVAR6	02	N/A	Any
Other (including Janssen, Novavax, and Unspecified) at index	COVAR7	02	N/A	N/A
Pfizer 1-4 days after the index date	COVAR8	02	N/A	Any
Moderna 1-4 days after the index date	COVAR9	02	N/A	Any
Jannsen 1-4 days after the index date	COVAR10	02	N/A	Any
Novavax 1-4 days after the index date	COVAR11	02	N/A	Any
Unspecified 1-4 days after the index date	COVAR12	02	N/A	Any
Other (including Janssen, Novavax, and Unspecified) 1-4 days after the index date	COVAR13	02	N/A	N/A
Having both Pfizer and Moderna at the index	COVAR14	02	COVAR2 and COVAR3	N/A
Having both Pfizer and Other at the index	COVAR15	02	COVAR2 and COVAR7	N/A
Having both Moderna and Other at the index	COVAR16	02	COVAR3 and COVAR7	N/A
Having both Pfizer and Moderna 1-4 days after the index date	COVAR17	02	COVAR8 and COVAR9	N/A
Having both Pfizer and Other 1-4 days after the index date	COVAR18	02	COVAR8 and COVAR13	N/A
Having both Moderna and Other 1-4 days after the index date	COVAR19	02	COVAR9 and COVAR13	N/A
COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day				

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Only Pfizer at index	COVAR20	02	COVAR2 AND NOT (COVAR3 or COVAR4 or COVAR5 or COVAR6)	N/A
Only Moderna at index	COVAR21	02	COVAR3 AND NOT (COVAR2 or COVAR4 or COVAR5 or COVAR6)	N/A
Only Jannsen at index	COVAR22	02	COVAR4 AND NOT (COVAR2 or COVAR3 or COVAR5 or COVAR6)	N/A
Only Novavax at index	COVAR23	02	COVAR5 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR6)	N/A
Only Unspecified at index	COVAR24	02	COVAR6 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR5)	N/A
Only Other (including Janssen, Novavax, and Unspecified) at index	COVAR25	02	COVAR7 AND NOT (COVAR2 or COVAR3)	N/A
COVID vaccine code type for the first observed record				
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR26	02	N/A	Any
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR27	02	N/A	Any
Insurance claims data (NDC/CPT/HCPCS codes) 1-4 days after the index date	COVAR28	02	N/A	Any
State-based Immunization Information Systems (IIS) (CVX codes) 1-4 days after the index date	COVAR29	02	N/A	Any
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) at the index date	COVAR30	02	COVAR26 and COVAR27	N/A
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) 1-4 days after the index date	COVAR31	02	COVAR28 and COVAR29	N/A
COVID vaccine code type for the first observed record, With no evidence of having other types of code				

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Only Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR32	02	COVAR26 AND NOT COVAR27	N/A
Only State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR33	02	COVAR27 AND NOT COVAR26	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)				
Monovalent at index date	COVAR34	02	N/A	Any
Bivalent at index date	COVAR35	02	N/A	Any
Monovalent 1-4 days after the index date	COVAR36	02	N/A	Any
Bivalent 1-4 days after the index date	COVAR37	02	N/A	Any
Having both Monovalent and Bivalent at index date	COVAR38	02	COVAR34 and COVAR35	N/A
Having Monovalent and Bivalent 1-4 days after the index date	COVAR39	02	COVAR36 and COVAR37	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine				
Only Monovalent at index date	COVAR40	02	COVAR34 AND NOT COVAR35	N/A
Only Bivalent at index date	COVAR41	02	COVAR35 AND NOT COVAR34	N/A
COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description				
CovVax_dose1	COVAR42	02	N/A	Any
COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description				
CovVax_dose2	COVAR43	02	N/A	Any
COVID vaccine Numbers (unique days with a code associated with a vaccine)				
With at least one COVID-19 vaccine codes	COVAR44	02	N/A	Any
With at least two COVID-19 vaccine codes in two separate days	COVAR45	02	N/A	Any
With at least three COVID-19 vaccine codes in three separate days	COVAR46	02	N/A	Any
With at least four COVID-19 vaccine codes in four separate days	COVAR47	02	N/A	Any
With one COVID-19 vaccine	COVAR48	02	COVAR44 AND NOT COVAR45	N/A
With two COVID-19 vaccine in two separate days	COVAR49	02	COVAR45 AND NOT COVAR46	N/A
With three COVID-19 vaccine in three separate days	COVAR50	02	COVAR46 AND NOT COVAR47	N/A
High-risk comorbidities for severe COVID-19 infection [2]				
Pre-index				
Reactive Airway and Lung Diseases	COVAR51	02	N/A	Any

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR52	02	N/A	Any
Sickle Cell Disease	COVAR53	02	N/A	Any
Liver disease (severe/moderate)	COVAR54	02	N/A	Any
Tuberculosis	COVAR55	02	N/A	Any
Cystic fibrosis	COVAR56	02	N/A	Any
Congenital or Acquired Heart Disease	COVAR57	02	N/A	Any
Lung Cancer (ccw)	COVAR58	02	N/A	IP*, IS* or
	COVAR59	02	N/A	AV*, ED* OA*
	COVAR60	02	COVAR58 or COVAR59	N/A
Breast Cancer (ccw)	COVAR61	02	N/A	IP*, IS* or
	COVAR62	02	N/A	AV*, ED* OA*
	COVAR63	02	COVAR61 or COVAR62	N/A
Colorectal Cancer (ccw)	COVAR64	02	N/A	IP*, IS* or
	COVAR65	02	N/A	AV*, ED* OA*
	COVAR66	02	COVAR64 or COVAR65	N/A
Prostate Cancer (ccw)	COVAR67	02	N/A	IP*, IS* or
	COVAR68	02	N/A	AV*, ED* OA*
	COVAR69	02	COVAR67 or COVAR68	N/A
Endometrial Cancer (ccw)	COVAR70	02	N/A	IP*, IS* or
	COVAR71	02	N/A	AV*, ED* OA*
	COVAR72	02	COVAR70 or COVAR71	N/A
Other cancer	COVAR73	02	N/A	Any
Asthma (ccw)	COVAR74	02	N/A	IP*, IS*, or
	COVAR75	02	N/A	AV*, ED* OA*
	COVAR76	02	COVAR74 or COVAR75	N/A
COPD and Bronchiectasis (ccw)	COVAR77	02	N/A	IP*, IS*, or
	COVAR78	02	N/A	AV*, ED* OA*
	COVAR79	02	COVAR77 or COVAR78	N/A
Diabetes (types 1 and 2) (ccw)	COVAR80	02	N/A	IP*, IS* or

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	COVAR81	02	N/A	AV*, ED*, OA*
	COVAR82	02	COVAR80 or COVAR81	N/A
Chronic Kidney Disease (ccw)	COVAR83	02	N/A	IP*, IS*, or
	COVAR84	02	N/A	AV*, ED* OA*
	COVAR85	02	COVAR83 or COVAR84	N/A
Hypertension (ccw)	COVAR86	02	N/A	IP*, IS* or
	COVAR87	02	N/A	AV*, ED*, OA*
	COVAR88	02	COVAR86 or COVAR87	N/A
Acute Myocardial Infarction (ccw)	COVAR89	02	N/A	IPP, IPS
Atrial Fibrillation (ccw)	COVAR90	02	N/A	IPP, IPS or
	COVAR91	02	N/A	AV*, ED*, OA*
	COVAR92	02	COVAR90 or COVAR91	N/A
Heart Failure (ccw)	COVAR93	02	N/A	IP*, AV*, ED*, OA*
Ischemic Heart Disease (ccw)	COVAR94	02	N/A	Any
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR95	02	N/A	IP*
	COVAR96	02	N/A	AV*, ED*, OA*
	COVAR97	02	COVAR95 or COVAR96	N/A
History of Cardiac Arrest	COVAR98	02	N/A	Any
History of Coronary Angioplasty or Bypass	COVAR99	02	N/A	Any
Alzheimer's disease, dementia, and conditions (ccw)	COVAR100	02	N/A	Any
Depression (ccw)	COVAR101	02	N/A	Any
Bipolar, or Other Depressive Mood Disorders	COVAR102	02	N/A	Any
ADHD	COVAR103	02	N/A	Any
Cerebral palsy	COVAR104	02	N/A	Any
Spinal cord injuries	COVAR105	02	N/A	Any
Down syndrome	COVAR106	02	N/A	Any
Alcohol Abuse or Dependence	COVAR107	02	N/A	Any
Drug Abuse or Dependence	COVAR108	02	N/A	Any
Obesity: diagnosed or identified by weight management procedures	COVAR109	02	N/A	Any

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Obesity: identified by weight management-related prescriptions	COVAR110	02	N/A	Any
Overweight	COVAR111	02	N/A	Any
Obesity/overweight	COVAR112	02	COVAR109 or COVAR110 or COVAR111	N/A
Smoking: diagnosed or identified by smoking cessation procedures	COVAR113	02	N/A	Any
Smoking: identified by smoking-related prescriptions	COVAR114	02	N/A	Any
Smoking	COVAR115	02	COVAR113 or COVAR114	N/A
HIV/AIDS	COVAR116	02	N/A	Any
Hematological Malignancy	COVAR117	02	N/A	Any
Treatment-Independent Immune Deficiencies	COVAR118	02	N/A	Any
Dialysis	COVAR119	02	N/A	Any
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR120	02	N/A	Any
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR121	02	N/A	Any
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR122	02	N/A	Any
Organ Transplant Diagnoses and Procedures	COVAR123	02	N/A	Any
Solid Malignancies	COVAR124	02	N/A	Any
Immunocompromised	COVAR125	02	COVAR116 or COVAR117 or COVAR118 or COVAR119 or COVAR120 or COVAR121 or COVAR122 or COVAR123 or COVAR124	N/A
Other general Health Indicators [2]				
Pre-index				
Hyperlipidemia (ccw)	COVAR126	02	N/A	IP*, IS* or
	COVAR127	02	N/A	AV*, ED*, OA*
	COVAR128	02	COVAR126 or COVAR127	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR129	02	N/A	Any
Acquired Hypothyroidism (ccw)	COVAR130	02	N/A	IP*, IS*, or

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	COVAR131	02	N/A	AV*, ED* OA*
	COVAR132	02	COVAR130 or COVAR131	N/A
Glaucoma (ccw)	COVAR133	02	N/A	AV*, ED*, OA*
Osteoporosis (ccw)	COVAR134	02	N/A	IP*, IS*, or
	COVAR135	02	N/A	AV*, ED* OA*
	COVAR136	02	COVAR134 or COVAR135	N/A
Anemia (ccw)	COVAR137	02	N/A	Any
Benign Prostatic Hyperplasia (ccw)	COVAR138	02	N/A	IP*, IS*, or
	COVAR139	02	N/A	AV*, ED* OA*
	COVAR140	02	COVAR138 or COVAR139	N/A
Hip/Pelvic Fracture (ccw)	COVAR141	02	N/A	Any
Cataract (ccw)	COVAR142	02	N/A	AV*, ED*, OA*
Parkinson's Disease and Secondary Parkinsonism (ccw)	COVAR143	02	N/A	IP*, IS*, or
	COVAR144	02	N/A	AV*, ED* OA*
	COVAR145	02	COVAR143 or COVAR144	N/A
COVID-19 diagnosis/Treatments				
Pre-index				
COVID-19 diagnosis	COVAR146	02	N/A	Any
Lopinavir/Ritonavir	COVAR147	02	N/A	Any
Remdesivir	COVAR148	02	N/A	Any
Hydroxychloroquine	COVAR149	02	N/A	Any
Chloroquine	COVAR150	02	N/A	Any
Azithromycin	COVAR151	02	N/A	Any
Ivermectin	COVAR152	02	N/A	Any
Dexamethasone	COVAR153	02	N/A	Any
Other Corticosteroids	COVAR154	02	N/A	Any
Inhaled Corticosteroids	COVAR155	02	N/A	Any
Paxlovid	COVAR156	02	N/A	Any
Baricitinib	COVAR157	02	N/A	Any
Tocilizumab	COVAR158	02	N/A	Any
Bamlanivimab	COVAR159	02	N/A	Any
Casirivimab/Imdevimab	COVAR160	02	N/A	Any

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Bamlanivimab/Etesevimab	COVAR161	02	N/A	Any
Sotrovimab	COVAR162	02	N/A	Any
NSAIDs	COVAR163	02	N/A	Any
Antidepressants	COVAR164	02	N/A	Any
Post-index				
COVID-19 diagnosis	COVAR165	02	N/A	Any
Lopinavir/Ritonavir	COVAR166	02	N/A	Any
Remdesivir	COVAR167	02	N/A	Any
Hydroxychloroquine	COVAR168	02	N/A	Any
Chloroquine	COVAR169	02	N/A	Any
Azithromycin	COVAR170	02	N/A	Any
Ivermectin	COVAR171	02	N/A	Any
Dexamethasone	COVAR172	02	N/A	Any
Other Corticosteroids	COVAR173	02	N/A	Any
Inhaled Corticosteroids	COVAR174	02	N/A	Any
Paxlovid	COVAR175	02	N/A	Any
Baricitinib	COVAR176	02	N/A	Any
Tocilizumab	COVAR177	02	N/A	Any
Bamlanivimab	COVAR178	02	N/A	Any
Casirivimab/Imdevimab	COVAR179	02	N/A	Any
Bamlanivimab/Etesevimab	COVAR180	02	N/A	Any
Sotrovimab	COVAR181	02	N/A	Any
NSAIDs	COVAR182	02	N/A	Any
Antidepressants	COVAR183	02	N/A	Any
Comorbidity score				
Charlson/Elixhauser comorbidity scores		02	N/A	Any
Health Service Utilization Intensity Metrics				
Mean number of ambulatory encounters	-	02	N/A	AV*
Mean number of emergency room encounters	-	02	N/A	ED*
Mean number of inpatient hospital encounters	-	02	N/A	IP*
Mean number of non-acute institutional encounters	-	02	N/A	IS*
Mean number of other ambulatory encounters	-	02	N/A	OA*
Mean number of filled prescriptions	-	02	N/A	N/A
Mean number of generics dispensed	-	02	N/A	N/A
Mean number of unique drug classes dispensed	-	02	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**
The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

[1]Caresetting/ Principal Diagnosis
Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.

Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

N/A: Not Applicable

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics				
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
Duplicated COVID-19 vaccines (having evidence of days with COVID-19 vaccine codes within ≤4 days of first code)					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	No	1	N/A
COVID vaccine brand for the first observed record					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
N/A	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
N/A	1	4	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day					
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
COVID vaccine code type for the first observed record					
*Drug Code	0	0	N/A	1	N/A
*Procedure Code (CPT/HCPCS codes)					
*Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code	1	4	N/A	1	N/A
*Procedure Code (CPT/HCPCS codes)					
*Procedure Code (CVX)	1	4	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
COVID vaccine code type for the first observed record, With no evidence of having other types of code					
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

N/A	N/A	N/A	N/A	N/A	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine					
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	5	latest available data	N/A	1	N/A
*Procedure Code (CPT/HCPCS codes)					
*Procedure Code (CVX)	0	latest available data	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data	N/A	2	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data	N/A	3	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data	N/A	4	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

High-risk comorbidities for severe COVID-19 infection [2]					
Pre-index					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	Earliest available data	0	N/A	1	N/A
*Diagnosis/procedure Codes	Earliest available data	0	N/A	1	N/A
*Diagnosis/procedure Codes	Earliest available data	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug Code	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug codes	-183	0	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug codes					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug codes					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug codes					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
Other general Health Indicators [2]					
Pre-index					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

COVID-19 diagnosis/Treatments					
Pre-index					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
Post-index					
*Diagnosis/procedure Codes	1	183	N/A	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
Comorbidity score					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
Health Service Utilization Intensity Metrics					
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**
The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

[1]Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.
Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories
N/A: Not Applicable

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Demographics						
Age (continuous, and categorical)	-	02	N/A	N/A	N/A	0
Sex	-	02	N/A	N/A	N/A	0
Race	-	02	N/A	N/A	N/A	0
Ethnicity	-	02	N/A	N/A	N/A	0
Year	-	02	N/A	N/A	N/A	0
COVID-19 Vaccination						
Duplicated COVID-19 vaccines (having evidence of days with COVID-19 vaccine codes within ≤4 days of first code)						
Duplicated	COVAR1	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1
COVID vaccine brand for the first observed record						
Pfizer at index	COVAR2	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
Moderna at index	COVAR3	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
Jannsen at index	COVAR4	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
Novavax at index	COVAR5	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
Unspecified at index	COVAR6	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
Other (including Janssen, Novavax, and Unspecified) at index	COVAR7	02	N/A	N/A	N/A	0

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

	Baseline Characteristics								
Evaluation period end	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
	Demographics								
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
	COVID-19 Vaccination								
4	No	1	N/A						
0	N/A	1	N/A	Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Pfizer 1-4 days after the index date	COVAR8	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1
Moderna 1-4 days after the index date	COVAR9	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1
Jannsen 1-4 days after the index date	COVAR10	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1
Novavax 1-4 days after the index date	COVAR11	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1
Unspecified 1-4 days after the index date	COVAR12	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1
Other (including Janssen, Novavax, and Unspecified) 1-4 days after the index date	COVAR13	02	N/A	N/A	N/A	1
Having both Pfizer and Moderna at the index	COVAR14	02	COVAR2 and COVAR3	N/A	N/A	N/A
Having both Pfizer and Other at the index	COVAR15	02	COVAR2 and COVAR7	N/A	N/A	N/A
Having both Moderna and Other at the index	COVAR16	02	COVAR3 and COVAR7	N/A	N/A	N/A
Having both Pfizer and Moderna 1-4 days after the index date	COVAR17	02	COVAR8 and COVAR9	N/A	N/A	N/A
Having both Pfizer and Other 1-4 days after the index date	COVAR18	02	COVAR8 and COVAR13	N/A	N/A	N/A
Having both Moderna and Other 1-4 days after the index date	COVAR19	02	COVAR9 and COVAR13	N/A	N/A	N/A
COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day						
Only Pfizer at index	COVAR20	02	COVAR2 AND NOT (COVAR3 or COVAR4 or COVAR5 or COVAR6)	N/A	N/A	N/A

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

		Baseline Characteristics							
Evaluation period end	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
4	N/A	1	N/A						
4	N/A	1	N/A						
4	N/A	1	N/A						
4	N/A	1	N/A						
4	N/A	1	N/A						
4	N/A	1	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
	COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day			Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
N/A	N/A	N/A	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Only Moderna at index	COVAR21	02	COVAR3 AND NOT (COVAR2 or COVAR4 or COVAR5 or COVAR6)	N/A	N/A	N/A
Only Jannsen at index	COVAR22	02	COVAR4 AND NOT (COVAR2 or COVAR3 or COVAR5 or COVAR6)	N/A	N/A	N/A
Only Novavax at index	COVAR23	02	COVAR5 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR6)	N/A	N/A	N/A
Only Unspecified at index	COVAR24	02	COVAR6 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR5)	N/A	N/A	N/A
Only Other (including Janssen, Novavax, and Unspecified) at index	COVAR25	02	COVAR7 AND NOT (COVAR2 or COVAR3)	N/A	N/A	N/A
COVID vaccine code type for the first observed record						
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR26	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes)	0
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR27	02	N/A	Any	*Procedure Code (CVX)	0
Insurance claims data (NDC/CPT/HCPCS codes) 1-4 days after the index date	COVAR28	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes)	1
State-based Immunization Information Systems (IIS) (CVX codes) 1-4 days after the index date	COVAR29	02	N/A	Any	*Procedure Code (CVX)	1

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

		Baseline Characteristics							
Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
	COVID vaccine code type for the first observed record			Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
0	N/A	1	N/A						
0	N/A	1	N/A						
4	N/A	1	N/A						
4	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) at the index date	COVAR30	02	COVAR26 and COVAR27	N/A	N/A	N/A
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) 1-4 days after the index date	COVAR31	02	COVAR28 and COVAR29	N/A	N/A	N/A
COVID vaccine code type for the first observed record, With no evidence of having other types of code						
Only Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR32	02	COVAR26 AND NOT COVAR27	N/A	N/A	N/A
Only State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR33	02	COVAR27 AND NOT COVAR26	N/A	N/A	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)						
Monovalent at index date	COVAR34	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
Bivalent at index date	COVAR35	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
Monovalent 1-4 days after the index date	COVAR36	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

		Baseline Characteristics							
Evaluation period end	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
	COVID vaccine code type for the first observed record, With no evidence of having other types of code			Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
	COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)			Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
0	N/A	1	N/A						
0	N/A	1	N/A						
4	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Bivalent 1-4 days after the index date	COVAR37	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1
Having both Monovalent and Bivalent at index date	COVAR38	02	COVAR34 and COVAR35	N/A	N/A	N/A
Having Monovalent and Bivalent 1-4 days after the index date	COVAR39	02	COVAR36 and COVAR37	N/A	N/A	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine						
Only Monovalent at index date	COVAR40	02	COVAR34 AND NOT COVAR35	N/A	N/A	N/A
Only Bivalent at index date	COVAR41	02	COVAR35 AND NOT COVAR34	N/A	N/A	N/A
COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description						
CovVax_dose1	COVAR42	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

	Baseline Characteristics								
Evaluation period end	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
4	N/A	1	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
	COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine			Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
	COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description			Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
0	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics						
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**
COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description						
CovVax_dose2	COVAR43	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	5
COVID vaccine Numbers (unique days with a code associated with a vaccine)					*Procedure Code (CPT/HCPCS codes)	
With at least one COVID-19 vaccine codes	COVAR44	02	N/A	Any	*Procedure Code (CVX)	0
With at least two COVID-19 vaccine codes in two separate days	COVAR45	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
With at least three COVID-19 vaccine codes in three separate days	COVAR46	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
With at least four COVID-19 vaccine codes in four separate days	COVAR47	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0
With one COVID-19 vaccine	COVAR48	02	COVAR44 AND NOT COVAR45	N/A	N/A	N/A
With two COVID-19 vaccine in two separate days	COVAR49	02	COVAR45 AND NOT COVAR46	N/A	N/A	N/A
With three COVID-19 vaccine in three separate days	COVAR50	02	COVAR46 AND NOT COVAR47	N/A	N/A	N/A
High-risk comorbidities for severe COVID-19 infection [2]						
Pre-index						
Reactive Airway and Lung Diseases	COVAR51	02	N/A	Any	*Diagnosis/procedure Codes	-183
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR52	02	N/A	Any	*Diagnosis/procedure Codes	-183

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

	Baseline Characteristics								
Evaluation period end	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
	COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description			Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
latest available data	N/A	1	N/A						
	COVID vaccine Numbers (unique days with a code associated with a vaccine)								
latest available data	N/A	1	N/A						
latest available data	N/A	2	N/A						
latest available data	N/A	3	N/A						
latest available data	N/A	4	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
N/A	N/A	N/A	N/A						
	High-risk comorbidities for severe COVID-19 infection [2]								
	Pre-index								
0	N/A	1	N/A						
0	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Sickle Cell Disease	COVAR53	02	N/A	Any	*Diagnosis/procedure Codes	-183
Liver disease (severe/moderate)	COVAR54	02	N/A	Any	*Diagnosis/procedure Codes	-183
Tuberculosis	COVAR55	02	N/A	Any	*Diagnosis/procedure Codes	-183
Cystic fibrosis	COVAR56	02	N/A	Any	*Diagnosis/procedure Codes	-183
Congenital or Acquired Heart Disease	COVAR57	02	N/A	Any	*Diagnosis/procedure Codes	-183
Lung Cancer (ccw)	COVAR58	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR59	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR60	02	COVAR58 or COVAR59	N/A	N/A	N/A
Breast Cancer (ccw)	COVAR61	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR62	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR63	02	COVAR61 or COVAR62	N/A	N/A	N/A
Colorectal Cancer (ccw)	COVAR64	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR65	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR66	02	COVAR64 or COVAR65	N/A	N/A	N/A
Prostate Cancer (ccw)	COVAR67	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR68	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR69	02	COVAR67 or COVAR68	N/A	N/A	N/A
Endometrial Cancer (ccw)	COVAR70	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR71	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR72	02	COVAR70 or COVAR71	N/A	N/A	N/A
Other cancer	COVAR73	02	N/A	Any	*Diagnosis/procedure Codes	-183
Asthma (ccw)	COVAR74	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183
	COVAR75	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR76	02	COVAR74 or COVAR75	N/A	N/A	N/A
COPD and Bronchiectasis (ccw)	COVAR77	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183
	COVAR78	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR79	02	COVAR77 or COVAR78	N/A	N/A	N/A

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

	Baseline Characteristics								
Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Diabetes (types 1 and 2) (ccw)	COVAR80	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR81	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
	COVAR82	02	COVAR80 or COVAR81	N/A	N/A	N/A
Chronic Kidney Disease (ccw)	COVAR83	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183
	COVAR84	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR85	02	COVAR83 or COVAR84	N/A	N/A	N/A
Hypertension (ccw)	COVAR86	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR87	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
	COVAR88	02	COVAR86 or COVAR87	N/A	N/A	N/A
Acute Myocardial Infarction (ccw)	COVAR89	02	N/A	IPP, IPS	*Diagnosis/procedure Codes	-183
Atrial Fibrillation (ccw)	COVAR90	02	N/A	IPP, IPS or	*Diagnosis/procedure Codes	-183
	COVAR91	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
	COVAR92	02	COVAR90 or COVAR91	N/A	N/A	N/A
Heart Failure (ccw)	COVAR93	02	N/A	IP*, AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
Ischemic Heart Disease (ccw)	COVAR94	02	N/A	Any	*Diagnosis/procedure Codes	-183
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR95	02	N/A	IP*	*Diagnosis/procedure Codes	-183
	COVAR96	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
	COVAR97	02	COVAR95 or COVAR96	N/A	N/A	N/A
History of Cardiac Arrest	COVAR98	02	N/A	Any	*Diagnosis/procedure Codes	-183
History of Coronary Angioplasty or Bypass	COVAR99	02	N/A	Any	*Diagnosis/procedure Codes	-183
Alzheimer's disease, dementia, and conditions (ccw)	COVAR100	02	N/A	Any	*Diagnosis/procedure Codes	-183
Depression (ccw)	COVAR101	02	N/A	Any	*Diagnosis/procedure Codes	-183
Bipolar, or Other Depressive Mood Disorders	COVAR102	02	N/A	Any	*Diagnosis/procedure Codes	-183
ADHD	COVAR103	02	N/A	Any	*Diagnosis/procedure Codes	-183
Cerebral palsy	COVAR104	02	N/A	Any	*Diagnosis/procedure Codes	Earliest available data
Spinal cord injuries	COVAR105	02	N/A	Any	*Diagnosis/procedure Codes	Earliest available data

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

	Baseline Characteristics								
Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Down syndrome	COVAR106	02	N/A	Any	*Diagnosis/procedure Codes	Earliest available data
Alcohol Abuse or Dependence	COVAR107	02	N/A	Any	*Diagnosis/procedure Codes	-183
Drug Abuse or Dependence	COVAR108	02	N/A	Any	*Diagnosis/procedure Codes	-183
Obesity: diagnosed or identified by weight management procedures	COVAR109	02	N/A	Any	*Diagnosis/procedure Codes	-183
Obesity: identified by weight management-related prescriptions	COVAR110	02	N/A	Any	*Drug Code	-183
Overweight	COVAR111	02	N/A	Any	*Diagnosis/procedure Codes	-183
Obesity/overweight	COVAR112	02	COVAR109 or COVAR110 or COVAR111	N/A	N/A	N/A
Smoking: diagnosed or identified by smoking cessation procedures	COVAR113	02	N/A	Any	*Diagnosis/procedure Codes	-183
Smoking: identified by smoking-related prescriptions	COVAR114	02	N/A	Any	*Drug codes	-183
Smoking	COVAR115	02	COVAR113 or COVAR114	N/A	N/A	N/A
HIV/AIDS	COVAR116	02	N/A	Any	*Diagnosis/procedure Codes	-183
Hematological Malignancy	COVAR117	02	N/A	Any	*Diagnosis/procedure Codes	-183
Treatment-Independent Immune Deficiencies	COVAR118	02	N/A	Any	*Diagnosis/procedure Codes	-183
Dialysis	COVAR119	02	N/A	Any	*Diagnosis/procedure Codes	-183
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR120	02	N/A	Any	*Diagnosis/procedure Codes	-183
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR121	02	N/A	Any	*Diagnosis/procedure Codes *Drug codes	-183
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR122	02	N/A	Any	*Diagnosis/procedure Codes *Drug codes	-183
Organ Transplant Diagnoses and Procedures	COVAR123	02	N/A	Any	*Diagnosis/procedure Codes *Drug codes	-183
Solid Malignancies	COVAR124	02	N/A	Any	*Diagnosis/procedure Codes	-183
Immunocompromised	COVAR125	02	COVAR116 or COVAR117 or COVAR118 or COVAR119 or COVAR120 or COVAR121 or COVAR122 or COVAR123 or COVAR124	N/A	N/A	N/A
Other general Health Indicators [2]						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

	Baseline Characteristics								
Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
N/A	N/A	N/A	N/A						
	Other general Health Indicators [2]								

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Pre-index						
Hyperlipidemia (ccw)	COVAR126	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183
	COVAR127	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
	COVAR128	02	COVAR126 or COVAR127	N/A	N/A	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR129	02	N/A	Any	*Diagnosis/procedure Codes	-183
Acquired Hypothyroidism (ccw)	COVAR130	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183
	COVAR131	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR132	02	COVAR130 or COVAR131	N/A	N/A	N/A
Glaucoma (ccw)	COVAR133	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
Osteoporosis (ccw)	COVAR134	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183
	COVAR135	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR136	02	COVAR134 or COVAR135	N/A	N/A	N/A
Anemia (ccw)	COVAR137	02	N/A	Any	*Diagnosis/procedure Codes	-183
Benign Prostatic Hyperplasia (ccw)	COVAR138	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183
	COVAR139	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR140	02	COVAR138 or COVAR139	N/A	N/A	N/A
Hip/Pelvic Fracture (ccw)	COVAR141	02	N/A	Any	*Diagnosis/procedure Codes	-183
Cataract (ccw)	COVAR142	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183
Parkinson's Disease and Secondary Parkinsonism (ccw)	COVAR143	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183
	COVAR144	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183
	COVAR145	02	COVAR143 or COVAR144	N/A	N/A	N/A
COVID-19 diagnosis/Treatments						
Pre-index						
COVID-19 diagnosis	COVAR146	02	N/A	Any	*Diagnosis/procedure Codes	-183
Lopinavir/Ritonavir	COVAR147	02	N/A	Any	*Drug/procedure Codes	-183
Remdesivir	COVAR148	02	N/A	Any	*Drug/procedure Codes	-183
Hydroxychloroquine	COVAR149	02	N/A	Any	*Drug/procedure Codes	-183
Chloroquine	COVAR150	02	N/A	Any	*Drug/procedure Codes	-183
Azithromycin	COVAR151	02	N/A	Any	*Drug/procedure Codes	-183
Ivermectin	COVAR152	02	N/A	Any	*Drug/procedure Codes	-183

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
	Pre-index								
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0	N/A	2	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	1	N/A						
0	N/A	2	N/A						
N/A	N/A	N/A	N/A						
	COVID-19 diagnosis/Treatments								
	Pre-index								
0	N/A	1	N/A	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
0	No	1	N/A						
0	No	1	N/A						
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Dexamethasone	COVAR153	02	N/A	Any	*Drug/procedure Codes	-183
Other Corticosteroids	COVAR154	02	N/A	Any	*Drug/procedure Codes	-183
Inhaled Corticosteroids	COVAR155	02	N/A	Any	*Drug/procedure Codes	-183
Paxlovid	COVAR156	02	N/A	Any	*Drug/procedure Codes	-183
Baricitinib	COVAR157	02	N/A	Any	*Drug/procedure Codes	-183
Tocilizumab	COVAR158	02	N/A	Any	*Drug/procedure Codes	-183
Bamlanivimab	COVAR159	02	N/A	Any	*Drug/procedure Codes	-183
Casirivimab/Imdevimab	COVAR160	02	N/A	Any	*Drug/procedure Codes	-183
Bamlanivimab/Etesevimab	COVAR161	02	N/A	Any	*Drug/procedure Codes	-183
Sotrovimab	COVAR162	02	N/A	Any	*Drug/procedure Codes	-183
NSAIDs	COVAR163	02	N/A	Any	*Drug/procedure Codes	-183
Antidepressants	COVAR164	02	N/A	Any	*Drug/procedure Codes	-183
Post-index						
COVID-19 diagnosis	COVAR165	02	N/A	Any	*Diagnosis/procedure Codes	1
Lopinavir/Ritonavir	COVAR166	02	N/A	Any	*Drug/procedure Codes	1
Remdesivir	COVAR167	02	N/A	Any	*Drug/procedure Codes	1
Hydroxychloroquine	COVAR168	02	N/A	Any	*Drug/procedure Codes	1
Chloroquine	COVAR169	02	N/A	Any	*Drug/procedure Codes	1
Azithromycin	COVAR170	02	N/A	Any	*Drug/procedure Codes	1
Ivermectin	COVAR171	02	N/A	Any	*Drug/procedure Codes	1
Dexamethasone	COVAR172	02	N/A	Any	*Drug/procedure Codes	1
Other Corticosteroids	COVAR173	02	N/A	Any	*Drug/procedure Codes	1
Inhaled Corticosteroids	COVAR174	02	N/A	Any	*Drug/procedure Codes	1
Paxlovid	COVAR175	02	N/A	Any	*Drug/procedure Codes	1
Baricitinib	COVAR176	02	N/A	Any	*Drug/procedure Codes	1
Tocilizumab	COVAR177	02	N/A	Any	*Drug/procedure Codes	1
Bamlanivimab	COVAR178	02	N/A	Any	*Drug/procedure Codes	1
Casirivimab/Imdevimab	COVAR179	02	N/A	Any	*Drug/procedure Codes	1
Bamlanivimab/Etesevimab	COVAR180	02	N/A	Any	*Drug/procedure Codes	1
Sotrovimab	COVAR181	02	N/A	Any	*Drug/procedure Codes	1
NSAIDs	COVAR182	02	N/A	Any	*Drug/procedure Codes	1
Antidepressants	COVAR183	02	N/A	Any	*Drug/procedure Codes	1
Comorbidity Score						
Charlson/Elixhauser comorbidity scores		02	N/A	Any	*Diagnosis/procedure Codes	-183
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	-	02	N/A	AV*	N/A	-183
Mean number of emergency room encounters	-	02	N/A	ED*	N/A	-183
Mean number of inpatient hospital encounters	-	02	N/A	IP*	N/A	-183
Mean number of non-acute institutional encounters	-	02	N/A	IS*	N/A	-183
Mean number of other ambulatory encounters	-	02	N/A	OA*	N/A	-183
Mean number of filled prescriptions	-	02	N/A	N/A	N/A	-183
Mean number of generics dispensed	-	02	N/A	N/A	N/A	-183

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A						
0	No	1	N/A						
0	No	1	N/A						
0	No	1	N/A						
0	No	1	N/A	N/A	N/A	N/A	N/A		
0	No	1	N/A	N/A	N/A	N/A	N/A		
	Post-index								
183	N/A	1	N/A	N/A	N/A	N/A	N/A		
183	No	1	N/A						
183	No	1	N/A	N/A	N/A	N/A	N/A		
183	No	1	N/A	N/A	N/A	N/A	N/A		
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
183	No	1	N/A						
	Comorbidity Score								
0	N/A	1	N/A						
	Health Service Utilization Intensity Metrics								
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
0	N/A	N/A	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start
Mean number of unique drug classes dispensed	-	02	N/A	N/A	N/A	-183

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**

[1]Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.

Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

N/A: Not Applicable

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
0	N/A	N/A	N/A						

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**

[1]Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.

Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

N/A: Not Appl

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Demographics										
Age (continuous, and categorical)	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Sex	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Race	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Ethnicity	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Year	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
COVID-19 Vaccination										
COVID vaccine brand for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts)										
Pfizer at index	COVAR1	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
Moderna at index	COVAR2	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
COVID vaccine code type for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts)										
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR3	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes)	0	0	N/A	1	N/A
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR4	04	N/A	Any	*Procedure Code (CVX)	0	0	N/A	1	N/A
COVID vaccine for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts); monovalent or bivalent (only Pfizer and Moderna)										

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Monovalent at index date	COVAR5	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
Bivalent at index date	COVAR6	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
COVID vaccine for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts); whether the "Booster" or "Bivalent" is mentioned in the code description										
CovVax_Booster_1	COVAR7	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
COVID vaccine for the observed record after the third or fourth record (depends on if they are from immunocompromised or non-immunocompromised cohorts); whether the "Booster" or "Bivalent" is mentioned in the code description										
CovVax_Booster_2	COVAR8	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	4	latest available data	N/A	1	N/A
COVID vaccine Numbers (unique days with a code associated with a vaccine) for scenario 31 to see how many codes are recorded before booster/bivalnet vaccine										
With at least one COVID-19 vaccine codes	COVAR9	04	N/A	Any	*Procedure Code (CVX)	Earliest available data	-4	N/A	1	N/A
With at least two COVID-19 vaccine codes in two separate days	COVAR10	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	Earliest available data	-4	N/A	2	N/A
With at least three COVID-19 vaccine codes in three separate days	COVAR11	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	Earliest available data	-4	N/A	3	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
With at least four COVID-19 vaccine codes in four separate days	COVAR12	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	Earliest available data	-4	N/A	4	N/A
With one COVID-19 vaccine	COVAR13	04	COVAR9 AND NOT COVAR10	N/A	N/A	N/A	N/A	N/A	N/A	N/A
With two COVID-19 vaccine in two separate days	COVAR14	04	COVAR10 AND NOT COVAR11	N/A	N/A	N/A	N/A	N/A	N/A	N/A
With three COVID-19 vaccine in three separate days	COVAR15	04	COVAR11 AND NOT COVAR12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
High-risk comorbidities for severe COVID-19 infection [2]										
Pre-index										
Reactive Airway and Lung Diseases	COVAR16	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR17	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Sickle Cell Disease	COVAR18	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Liver disease (severe/moderate)	COVAR19	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Tuberculosis	COVAR20	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Cystic fibrosis	COVAR21	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Congenital or Acquired Heart Disease	COVAR22	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Lung Cancer (ccw)	COVAR23	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR24	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR25	04	COVAR23 or COVAR24	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Breast Cancer (ccw)	COVAR26	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR27	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR28	04	COVAR26 or COVAR27	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Colorectal Cancer (ccw)	COVAR29	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR30	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR31	04	COVAR29 or COVAR30	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Prostate Cancer (ccw)	COVAR32	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR33	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR34	04	COVAR32 or COVAR33	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Endometrial Cancer (ccw)	COVAR35	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR36	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
	COVAR37	04	COVAR35 or COVAR36	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other cancer	COVAR38	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Asthma (ccw)	COVAR39	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR40	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR41	04	COVAR39 or COVAR40	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COPD and Bronchiectasis (ccw)	COVAR42	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR43	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR44	04	COVAR42 or COVAR43	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diabetes (types 1 and 2) (ccw)	COVAR45	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR46	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR47	04	COVAR45 or COVAR46	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic Kidney Disease (ccw)	COVAR48	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR49	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR50	04	COVAR48 or COVAR49	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hypertension (ccw)	COVAR51	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
	COVAR52	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR53	04	COVAR51 or COVAR52	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Acute Myocardial Infarction (ccw)	COVAR54	04	N/A	IPP, IPS	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Atrial Fibrillation (ccw)	COVAR55	04	N/A	IPP, IPS or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR56	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR57	04	COVAR55 or COVAR56	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Heart Failure (ccw)	COVAR58	04	N/A	IP*, AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Ischemic Heart Disease (ccw)	COVAR59	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR60	04	N/A	IP*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR61	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR62	04	COVAR60 or COVAR61	N/A	N/A	N/A	N/A	N/A	N/A	N/A
History of Cardiac Arrest	COVAR63	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
History of Coronary Angioplasty or Bypass	COVAR64	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Alzheimer's disease, dementia, an	COVAR65	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Depression (ccw)	COVAR66	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Bipolar, or Other Depressive Mood Disorders	COVAR67	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
ADHD	COVAR68	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Cerebral palsy	COVAR69	04	N/A	Any	*Diagnosis/ procedure Codes	Earliest available data	0	N/A	1	N/A
Spinal cord injuries	COVAR70	04	N/A	Any	*Diagnosis/ procedure Codes	Earliest available data	0	N/A	1	N/A
Down syndrome	COVAR71	04	N/A	Any	*Diagnosis/ procedure Codes	Earliest available data	0	N/A	1	N/A
Alcohol Abuse or Dependence	COVAR72	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Drug Abuse or Dependence	COVAR73	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Obesity: diagnosed or identified by weight management procedures	COVAR74	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Obesity: identified by weight management-related prescriptions	COVAR75	04	N/A	Any	*Drug Code	-183	0	N/A	1	N/A
Overweight	COVAR76	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Obesity/overweight	COVAR77	04	COVAR74 or COVAR75 or COVAR76	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Smoking: diagnosed or identified by smoking cessation procedures	COVAR78	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Smoking: identified by smoking-related prescriptions	COVAR79	04	N/A	Any	*Drug codes	-183	0	N/A	1	N/A
Smoking	COVAR80	04	COVAR78 or COVAR79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HIV/AIDS	COVAR81	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Hematological Malignancy	COVAR82	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Treatment-Independent Immune Deficiencies	COVAR83	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Dialysis	COVAR84	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR85	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR86	04	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR87	04	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A
Organ Transplant Diagnoses and Procedures	COVAR88	04	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Solid Malignancies	COVAR89	02	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A
Immunocompromised	COVAR90	01	COVAR81 or COVAR82 or COVAR83 or COVAR84 or COVAR85 or COVAR86 or COVAR87 or COVAR88 or COVAR89	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other general Health Indicators										
Pre-index										
Hyperlipidemia (ccw)	COVAR91	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR92	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR93	04	COVAR91 or COVAR92	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR94	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
Acquired Hypothyroidism (ccw)	COVAR95	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR96	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR97	04	COVAR95 or COVAR96	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Glaucoma (ccw)	COVAR98	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Osteoporosis (ccw)	COVAR99	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR100	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR101	04	COVAR99 or COVAR100	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Anemia (ccw)	COVAR102	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Benign Prostatic Hyperplasia (ccw)	COVAR103	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR104	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR105	04	COVAR103 or COVAR104	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hip/Pelvic Fracture (ccw)	COVAR106	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Cataract (ccw)	COVAR107	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Parkinson's Disease and Secondary Parkinsonism (ccw)	COVAR108	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR109	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR110	04	COVAR108 or COVAR109	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COVID-19 diagnosis/Treatments										
Pre-index										

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
COVID-19 diagnosis	COVAR111	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Lopinavir/Ritonavir	COVAR112	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Remdesivir	COVAR113	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Hydroxychloroquine	COVAR114	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Chloroquine	COVAR115	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Azithromycin	COVAR116	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Ivermectin	COVAR117	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Dexamethasone	COVAR118	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Other Corticosteroids	COVAR119	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Inhaled Corticosteroids	COVAR120	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Paxlovid	COVAR121	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Baricitinib	COVAR122	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Tocilizumab	COVAR123	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Bamlanivimab	COVAR124	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Casirivimab/Imdevimab	COVAR125	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Bamlanivimab/Etesevimab	COVAR126	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Sotrovimab	COVAR127	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
NSAIDs	COVAR128	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Antidepressants	COVAR129	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Post-index										
COVID-19 diagnosis	COVAR130	04	N/A	Any	*Diagnosis/ procedure Codes	1	183	N/A	1	N/A
Lopinavir/Ritonavir	COVAR131	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Remdesivir	COVAR132	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Hydroxychloroquine	COVAR133	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Chloroquine	COVAR134	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Azithromycin	COVAR135	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Ivermectin	COVAR136	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Dexamethasone	COVAR137	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Other Corticosteroids	COVAR138	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Inhaled Corticosteroids	COVAR139	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Paxlovid	COVAR140	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Baricitinib	COVAR141	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Tocilizumab	COVAR142	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Bamlanivimab	COVAR143	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Casirivimab/Imdevimab	COVAR144	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Bamlanivimab/Etesevimab	COVAR145	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Sotrovimab	COVAR146	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
NSAIDs	COVAR147	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Antidepressants	COVAR148	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Comorbidity score										
Charlson/Elixhauser comorbidity scores		04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Health Service Utilization Intensity Metrics										
Mean number of ambulatory encounters	-	04	N/A	AV*	N/A	-183	0	N/A	N/A	N/A
Mean number of emergency room encounters	-	04	N/A	ED*	N/A	-183	0	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
N/A	N/A	N/A	N/A		

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Mean number of inpatient hospital encounters	-	04	N/A	IP*	N/A	-183	0	N/A	N/A	N/A
Mean number of non-acute institutional encounters	-	04	N/A	IS*	N/A	-183	0	N/A	N/A	N/A
Mean number of other ambulatory encounters	-	04	N/A	OA*	N/A	-183	0	N/A	N/A	N/A
Mean number of filled prescriptions	-	04	N/A	N/A	N/A	-183	0	N/A	N/A	N/A
Mean number of generics dispensed	-	04	N/A	N/A	N/A	-183	0	N/A	N/A	N/A
Mean number of unique drug clas	-	04	N/A	N/A	N/A	-183	0	N/A	N/A	N/A

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**
The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		
N/A	N/A	N/A	N/A		

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes. The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.**

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied

[1]Caresetting/ Principal Diagnosis
- Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.
Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories
N/A: Not Applicable

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics					
Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values

[1]Caresetting/ Principal Diagnosis
- Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.
Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories
N/A: Not Applicable

Appendix H. Design Diagram Used for this Request



***Covariates:

Window I: Age, year, race, sex, ethnicity, COVID-19 vaccine brand/type of code, etc.

Window II: High-risk comorbidities for severe COVID-19 infection, General Health Indicators, and COVID-19 diagnosis/Treatment

Window III: COVID-19 diagnosis/Treatment

Appendix H. Design Diagram Used for this Request



Appendix H. Design Diagram Used for this Request



***Covariates:

Window I: Age, year, race, sex, ethnicity, COVID-19 vaccine brand/type of code, etc.

Window II: High-risk comorbidities for severe COVID-19 infection, General Health Indicators, and COVID-19 diagnosis/Treatment

Window III: COVID-19 diagnosis/Treatment

Appendix H. Design Diagram Used for this Request



Immunocompromised: including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

Appendix H. Design Diagram Used for this Request



Immunocompromised: including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

Appendix H. Design Diagram Used for this Request